APOLIPOPROTEIN E (APOE) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted electronically in XML file format and is hereby incorporated by reference in its entirety. Said XML copy, created on Jan. 23, 2023, is named 121301-11202_SL.xml and is 4,471,402 bytes in size.

BACKGROUND OF THE INVENTION

The apolipoprotein E gene encodes the Apolipoprotein E (APOE) protein, a glycoprotein that, following cleavage of an 18 amino acid signal peptide, is composed of 299 amino acids. There are three common isoforms of APOE, APOE2, APOE3, and APOE4, encoded by three corresponding alleles. The three APOE isoforms, ApoE ε2 (APOE2), ApoE ε3 (APOE3), ApoE ε4 (APOE4), differ from one another only at amino acid positions 112 and 158; APOE2 has a Cys112 and a Cys158, APOE3 has a Cys112 and an Arg 158, and APOE4 has an Arg112 and an Arg158. APOE is widely expressed, but is primarily expressed peripherally in liver hepatocytes and in glial cells in the central nervous system (CNS).

In the periphery, APOE functions in lipid homeostasis. These lipoprotein particles cannot cross the blood-brain barrier; studies have shown that apoE-containing particles released by astrocytes and microglia are the main sources of brain apoE (Bjorkhem I, et al. (1998) J Lipid Research 39(8):1594-1600; Pitas R E, et al. (1987) Biochimica Biophysica Acta. 13; 917(1):148-161; Krasemann S, et al. (2017) Immunity. 47(3):566-581.e9. doi:10.1016/j.immuni.2017.08.008). In the brain, APOE modulates multiple pathways including lipid transport, synaptic integrity and plasticity, glucose metabolism, neuroinflammation, and cerebrovascular integrity. For example, once APOE is secreted from cells, several transporters (e.g., ATB-binding cssestte transporters) transfer cholesterol and phospholipids to nascent APOE to form lipoprotein particles which APOE subsequently distributes to neurons through binding to APOE receptors, such as LDL receptor (LDLR) family members. Furthermore, it has been observed that the serum APOE phenotype but not the cerebrospinal fluid (CSF) ApoE phenotype of a recipient completely converted to that of donor following liver transplantation. In addition, astrocytes produce APOE in high-density lipoprotein (HDL)-like particles that have distinct properties from APOE derived from other sources (see, e.g., Morikawa, et al., Neurobiol Dis. June-July 2005; 19(1-2): 66-76). Therefore, the APOE in CSF cannot be derived from the plasma pool and therefore must be synthesized locally (Linton M F, et al. (1991) J Clin Invest. 88(1):270-281. doi:10.1172/JCI115288).

Polymorphism in the APOE gene has been associated with multiple proteinopathies. The best established link between APOE polymorphism and disease is between APOE genotype and Alzheimer's disease (AD) which has been shown to be a major risk determinant of late-onset Alzheimer's disease, the symptoms of which develop after age 65. Additionally, recent work from Haltzman lab described that possession of the ε4 allele significantly accelerated disease progression (p=0.02), with one ε4 allele increasing progression rate by 14% and two ε4 alleles increasing the rate by 23% compared to non-carriers (Holtzman, et al. (2017) Nature 549:523). AD is the leading cause of dementia in elderly individuals and its pathological hallmarks include the deposition of extracellular amyloid-β (Aβ) aggregates as amyloid plaques and intracellular hyperphosphorylated tau aggregates as neurofibrillary tangles along with neuronal loss and glial activation. As individuals with late-onset AD account for 95% or more of the total AD population, various efforts to elucidate the role of APOE in AD are ongoing.

More specifically, it has been shown that subjects having one copy of APOE4 have a greater than three-fold risk of developing AD and subjects having two copies of APOE4 have a greater than 12-fold increased risk of developing AD, while two copies of APOE2 are protective in subjects from AD development (Reiman E M, et al. (2020) Nature Communications 11 (1); 667). In addition, there have been three APOE knockout human cases reported and none of these subjects experienced dementia at the time of hospital visit (age 40-60) (Ghiselli, et al. (1981) Science 214(4526):1239; Mak, et al. (2014) JAMA Neurol 71:1228; and Lohse, et al. (1992) J Lipid Res. (11):1583). In one of the three cases (40 years old male), MRI and Cerebral Spinal Fluid (CSF) biomarker tests demonstrated no signs of neurodegenerations with intact brain structure and normal range of Tau and p-Tau levels. Furthermore, a recent case study, has shown that the Christchurch mutation in ApoE3 may be protective again presenilin 1 driven dementia as evident by preserved cognitive function and limited Taupathy by PET. The presence of the Christchurch mutation led to loss of function of ApoE3 binding to HSPGs and LDL receptors and the patient has hyperlipoproteinemia type III but no cardiovascular disease (Arboleda-Velasquez, et al. (2019) Nature Medicien 25:1680).

It has also been demonstrated in ApoE inducible amyloid mouse models that increased expression of ApoE4 accelerates amyloid accumulation and neuritic dystrophy (Liu, et al. (2017) Neuron 96:1024) and Huynh, et al. (Neuron (2017) 96:1013) and that antisense inhibition of APOE4 is protective in transgenic amyloid precursor protein (APP)/presenillin 1 (PS1-21) mice. In addition, it has been shown that deletion of ApoE4 in a tauopathy mouse model was protective of neurodegeneration (Holtzman, et al. (2017) Nature 549:523) and that reintroduction of APOE4 expression in human neurons derived from induced pluripotent stem cells that expressed APOE4 but were made APOE null results in a gain of toxic effect from APOE4 (Wang, et al. (2018) Nat Medicine 24:647). Furthermore, it has been shown that restricting expression of APOE4 to the liver of mice can still have an effect on cognitive abilities and can compromise the blood brain barrier and increase neuroinflammation (alzforum.org/news/research-news/apoe-has-hand-Alzheimer'ss-beyond-av-beyond-brain).

Currently, there are no cures or preventative treatments for subjects having an APOE-associated neurodegenerative disease, such as AD, and supportive and symptomatic management is the mainstay of treatment. Therefore, there is a need in the art for compositions and methods for the treatment of subjects that have or are at risk of developing a neurodegenerative disease.

BRIEF SUMMARY OF THE INVENTION

The present disclosure provides RNAi agent compositions which effect the RNA-induced silencing complex (RISC)-mediated cleavage of RNA transcripts of an apolipoprotein E (APOE) gene. The APOE gene may be within a cell, e.g., a cell within a subject, such as a human. The present disclosure also provides methods of using the RNAi agent compositions of the disclosure for inhibiting the expression of an APOE gene or for treating a subject who would benefit from inhibiting or reducing the expression of an APOE gene, e.g., a pathogenic APOE allele, i.e., APOE4, e.g., a subject suffering or prone to suffering from an APOE-associated neurodegenerative disease, such as an amyloid-p-mediated disease or a tau-mediated disease. In particular, the RNAi agent compositions herein are capable of affecting the unique APOE expression by astrocytes within the CNS for the treatment of APOE-associated neurodegenerative disease.

Accordingly, in one aspect, the instant disclosure provides a double stranded ribonucleic acid (RNAi) agent for inhibiting expression of an apolipoprotein E (APOE) gene, where the RNAi agent includes a sense strand and an antisense strand, and where the antisense strand includes a region of complementarity which includes at least 15 contiguous nucleotides differing by no more than 3 nucleotides (i.e., differing by 3, 2, 1, or 0 nucleotides) from any one of the antisense sequences listed in any one of Tables 2-5 and 7-10. In certain embodiments, the antisense strand includes a region of complementarity which includes at least 15 contiguous nucleotides of any one of the antisense sequences listed in any one of Tables 2-5 and 7-10. In certain embodiments, the antisense strand includes a region of complementarity which includes at least 15 contiguous nucleotides of any one of the antisense sequences listed in any one of Tables 7 and 8. In certain embodiments, the antisense strand includes a region of complementarity which includes at least 15 contiguous nucleotides of any one of the antisense sequences listed in any one of Tables 9 and 10. In certain embodiments, the antisense strand includes a region of complementarity which includes at least 19 contiguous nucleotides differing by no more than 3 nucleotides (i.e., differing by 3, 2, 1, or 0 nucleotides) from any one of the antisense sequences listed in any one of Tables 2-5 and 7-10. In certain embodiments, the antisense strand includes a region of complementarity which includes at least 19 contiguous nucleotide (i.e., differing by 3, 2, 1, or 0 nucleotides) of any one of the antisense sequences listed in any one of Tables 7 and 8. In certain embodiments, the antisense strand includes a region of complementarity which includes at least 19 contiguous nucleotide (i.e., differing by 3, 2, 1, or 0 nucleotides) of any one of the antisense sequences listed in any one of Tables 9 and 10. In certain embodiments, the antisense strand includes a region of complementarity which includes at least 19 contiguous nucleotides of any one of the antisense sequences listed in any one of Tables 2-5 and 7-10. In certain embodiments, the antisense strand includes a region of complementarity which includes at least 19 contiguous nucleotides of any one of the antisense sequences listed in any one of Tables 7 and 8. In certain embodiments, the antisense strand includes a region of complementarity which includes at least 19 contiguous nucleotides of any one of the antisense sequences listed in any one of Tables 9 and 10. In certain embodiments, thymine-to-uracil or uracil-to-thymine differences between aligned (compared) sequences are not counted as nucleotides that differ between the aligned (compared) sequences.

In some embodiments, the agents include one or more lipophilic moieties conjugated to one or more internal nucleotide positions, optionally via a linker or carrier.

In other embodiments, the agent further comprises a targeting ligand that targets a liver tissue, e.g., one or more GalNAc derivatives, optionally conjugated to the double stranded RNAi agent via a linker or carrier.

In yet other embodiments, the agents further comprise one or more lipophilic moieties conjugated to one or more internal nucleotide positions, optionally via a linker or carrier and a targeting ligand that targets a liver tissue, e.g., one or more GalNAc derivatives, optionally conjugated to the double stranded RNAi agent via a linker or carrier.

In certain embodiments, the double stranded RNAi agents inhibit the expression of an APOE2 allele, an APOE3 allele, and an APOE4 allele. In other embodiments, the double stranded RNAi agents inhibit the expression of APOE4 but do not substantially inhibit the expression of APOE2 and APOE3, e.g., the expression of APOE2 and APOE3 is inhibited by no more than about 10%.

Another aspect of the instant disclosure provides a double stranded RNAi agent for inhibiting expression of a apolipoprotein E (APOE) gene, where the dsRNA agent includes a sense strand and an antisense strand, where the sense strand includes at least 15 contiguous nucleotides differing by no more than 3 nucleotides (i.e., differing by 3, 2, 1, or 0 nucleotides) from any one of the sense strand sequences presented in Tables 2-5 and 7-10; and where the antisense strand includes at least 15 contiguous nucleotides differing by no more than 3 nucleotides from any one of antisense strand nucleotide sequences presented in Tables 2-5 and 7-10. In certain embodiments, the sense strand includes at least 15 contiguous nucleotides of any one of the sense strand sequences presented in Tables 2-5 and 7-10; and where the antisense strand includes at least 15 contiguous nucleotides of any one of antisense strand nucleotide sequences presented in Tables 2-5 and 7-10. In certain embodiments, the sense strand includes at least 15 contiguous nucleotides of any one of the sense strand sequences presented in Tables 7 and 8; and where the antisense strand includes at least 15 contiguous nucleotides of any one of antisense strand nucleotide sequences presented in Tables 7 and 8. In certain embodiments, the sense strand includes at least 15 contiguous nucleotides of any one of the sense strand sequences presented in Tables 9 and 10; and where the antisense strand includes at least 15 contiguous nucleotides of any one of antisense strand nucleotide sequences presented in Tables 9 and 10. In certain embodiments, the sense strand includes at least 19 contiguous nucleotides (i.e., differing by 3, 2, 1, or 0 nucleotides) of any one of the sense strand sequences presented in Tables 2-5 and 7-10; and where the antisense strand includes at least 19 contiguous nucleotides of any one of antisense strand nucleotide sequences presented in Tables 2-5 and 7-10 (i.e., differing by 3, 2, 1, or 0 nucleotides) from any one of antisense strand nucleotide sequences presented in Tables 2-5 and 7-10. In certain embodiments, the sense strand includes at least 19 contiguous nucleotides (i.e., differing by 3, 2, 1, or 0 nucleotides) of any one of the sense strand sequences presented in Tables 7 and 8; and where the antisense strand includes at least 19 contiguous nucleotides (i.e., differing by 3, 2, 1, or 0 nucleotides) of any one of antisense strand nucleotide sequences presented in Tables 7 and 8. In certain embodiments, the sense strand includes at least 19 contiguous nucleotides (i.e., differing by 3, 2, 1, or 0 nucleotides) of any one of the sense strand sequences presented in Tables 9 and 10; and where the antisense strand includes at least 19 contiguous nucleotides (i.e., differing by 3, 2, 1, or 0 nucleotides) of any one of antisense strand nucleotide sequences presented in Tables 9 and 10.

In some embodiments, the agents include one or more lipophilic moieties conjugated to one or more internal nucleotide positions, optionally via a linker or carrier.

An additional aspect of the disclosure provides a double stranded RNAi agent for inhibiting expression of an apolipoprotein E (APOE) gene, where the dsRNA agent includes a sense strand and an antisense strand, where the sense strand includes at least 15 contiguous nucleotides differing by no more than 3 nucleotides (i.e., differing by 3, 2, 1, or 0 nucleotides) from any one of the nucleotide sequences of SEQ ID NOs: 1, 3, 5, 7, or 9, or a nucleotide sequence having at least 90% nucleotide sequence identity, e.g. 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity, to the entire nucleotide sequence of any one of SEQ ID NOs: 1, 3, 5, 7, or 9, where a substitution of a uracil for any thymine of SEQ ID NOs: 1, 3, 5, 7, and 9 (when comparing aligned sequences) does not count as a difference that contributes to the differing by no more than 3 nucleotides (i.e., differing by 3, 2, 1, or 0 nucleotides) from any one of the nucleotide sequences of SEQ ID NOs: 1, 3, 5, 7, and 9 or the nucleotide sequence having at least 90% nucleotide sequence identity, e.g. 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity, to the entire nucleotide sequence of any one of SEQ ID NOs: 1, 3, 5, 7, or 9; and where the antisense strand includes at least 15 contiguous nucleotides differing by no more than 3 nucleotides from any one of the nucleotide sequences of SEQ ID NOs: 2, 4, 6, 8, or 10 or a nucleotide sequence having at least 90% nucleotide sequence identity, e.g. 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity, to the entire nucleotide sequence of any one of SEQ ID NOs: 2, 4, 6, 8, or 10, where a substitution of a uracil for any thymine of SEQ ID NOs: 2, 4, 6, 8, and 10, (when comparing aligned sequences) does not count as a difference that contributes to the differing by no more than 3 nucleotides from any one of the nucleotide sequences of SEQ ID NOs: 2, 4, 6, 8, and 10, or the nucleotide sequence having at least 90% nucleotide sequence identity, e.g. 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity, to the entire nucleotide sequence of any one of SEQ ID NOs: 2, 4, 6, 8, or 10, where at least one of the sense strand and the antisense strand includes one or more lipophilic moieties conjugated to one or more internal nucleotide positions, optionally via a linker or carrier.

In one embodiment, the double stranded RNAi agent targeted to APOE comprises a sense strand which includes at least 15 contiguous nucleotides differing by no more than 3 nucleotides (i.e., differing by 3, 2, 1, or 0 nucleotides) from the nucleotide sequence of the sense strand nucleotide sequence of a duplex in Tables 2-5 and 7-10. In one embodiment, the double stranded RNAi agent targeted to APOE comprises a sense strand which includes at least 15 contiguous nucleotides differing by no more than 3 nucleotides (i.e., differing by 3, 2, 1, or 0 nucleotides) from the nucleotide sequence of the sense strand nucleotide sequence of a duplex in Tables 7 and 8. In one embodiment, the double stranded RNAi agent targeted to APOE comprises a sense strand which includes at least 15 contiguous nucleotides differing by no more than 3 nucleotides (i.e., differing by 3, 2, 1, or 0 nucleotides) from the nucleotide sequence of the sense strand nucleotide sequence of a duplex in Tables 9 and 10.

In one embodiment, the double stranded RNAi agent targeted to APOE comprises an antisense strand which includes at least 15 contiguous nucleotides differing by no more than 3 nucleotides (i.e., differing by 3, 2, 1, or 0 nucleotides) from the antisense nucleotide sequence of any one of the duplexes in one of Tables 2-5 and 7-10. In one embodiment, the double stranded RNAi agent targeted to APOE comprises an antisense strand which includes at least 15 contiguous nucleotides differing by no more than 3 nucleotides (i.e., differing by 3, 2, 1, or 0 nucleotides) from the antisense nucleotide sequence of duplex in one of Tables 7 and 8. In one embodiment, the double stranded RNAi agent targeted to APOE comprises an antisense strand which includes at least 15 contiguous nucleotides differing by no more than 3 nucleotides (i.e., differing by 3, 2, 1, or 0 nucleotides) from the antisense nucleotide sequence of duplex in one of Tables 9 and 10.

In one embodiment, the double stranded RNAi agent targeted to APOE comprises a sense strand which includes at least 15 contiguous nucleotides differing by no more than 3 nucleotides (i.e., differing by 3, 2, 1, or 0 nucleotides) from any one of the nucleotide sequences of nucleotides 50-113, 59-97, 59-90, 107-177, 107-153, 124-153, 198-240, 203-240, 209-240, 283-378, 283-312, 307-378, 322-369, 330-357, 394-419, 568-600, 568-594, 841-879, 900-926, 997-1055, 1002-1044, 1014-1044, 1019-1044, 1120-1166, 1130-1166, 1130-1155 of SEQ ID NO: 1, and the antisense strand comprises at least 15 contiguous nucleotides from the corresponding nucleotide sequence of SEQ ID NO: 2.

In one embodiment, the double stranded RNAi agent targeted to APOE comprises a sense strand which includes at least 15 contiguous nucleotides differing by no more than 3 nucleotides (i.e., differing by 3, 2, 1, or 0 nucleotides) from any one of the nucleotide sequences of nucleotides 59-90, 330-357, 568-594, 1019-1044, 1130-1155 of SEQ ID NO: 1, and the antisense strand comprises at least 15 contiguous nucleotides from the corresponding nucleotide sequence of SEQ ID NO: 2.

In one embodiment, the double stranded RNAi agent targeted to APOE comprises a sense strand which includes at least 15 contiguous nucleotides differing by no more than 3 nucleotides (i.e., differing by 3, 2, 1, or 0 nucleotides) from any one of the nucleotide sequences of nucleotides 57-79, 62-84, 75-97, 86-108, 207-229, 213-235, 218-240, 898-920, 1128-1150, 637-659 of SEQ ID NO: 1, and the antisense strand comprises at least 15 contiguous nucleotides from the corresponding nucleotide sequence of SEQ ID NO: 2.

In another embodiment, the double stranded RNAi agent targeted to APOE comprises a sense strand which includes at least 15 contiguous nucleotides differing by no more than 3 nucleotides (i.e., differing by 3, 2, 1, or 0 nucleotides) from any one of the nucleotide sequences of nucleotides 57-79, 62-84, 207-229, 1128-1150 of SEQ ID NO: 1, and the antisense strand comprises at least 15 contiguous nucleotides from the corresponding nucleotide sequence of SEQ ID NO: 2.

In some embodiments, the agent further comprises a targeting ligand that targets a liver tissue, e.g., one or more GalNAc derivatives, optionally conjugated to the double stranded RNAi agent via a linker or carrier.

In certain embodiments of the invention, the double stranded RNAi agents inhibit the expression of an APOE2 allele, an APOE3 allele, and an APOE4 allele. In other embodiments, the double stranded RNAi agents inhibit the expression of APOE4 but do not substantially inhibit the expression of APOE2 and APOE3, e.g., the expression of APOE2 and APOE3 is inhibited by no more than about 10%.

Optionally, the double stranded RNAi agent includes at least one modified nucleotide.

In certain embodiments, the lipophilicity of the lipophilic moiety, measured by log K_ow, exceeds 0.

In some embodiments, the hydrophobicity of the double-stranded RNAi agent, measured by the unbound fraction in a plasma protein binding assay of the double-stranded RNAi agent, exceeds 0.2. In a related embodiment, the plasma protein binding assay is an electrophoretic mobility shift assay using human serum albumin protein.

In certain embodiments, substantially of the nucleotides of the sense strand are modified nucleotides. Optionally, all of the nucleotides of the sense strand are modified nucleotides.

In some embodiments, substantially all of the nucleotides of the antisense strand are modified nucleotides. Optionally, all of the nucleotides of the antisense strand are modified nucleotides.

Optionally, all of the nucleotides of the sense strand and all of the nucleotides of the antisense strand are modified nucleotides.

In one embodiment, at least one of the modified nucleotides is a deoxy-nucleotide, a 3′-terminal deoxy-thymidine (dT) nucleotide, a 2′-O-methyl modified nucleotide, a 2′-fluoro modified nucleotide, a 2′-deoxy-modified nucleotide, a locked nucleotide, an unlocked nucleotide, a conformationally restricted nucleotide, a constrained ethyl nucleotide, an abasic nucleotide, a 2′-amino-modified nucleotide, a 2′-O-allyl-modified nucleotide, 2′-C-alkyl-modified nucleotide, 2′-hydroxyl-modified nucleotide, a 2′-methoxyethyl modified nucleotide, a 2′-O-alkyl-modified nucleotide, a morpholino nucleotide, a phosphoramidate, a non-natural base comprising nucleotide, a tetrahydropyran modified nucleotide, a 1,5-anhydrohexitol modified nucleotide, a cyclohexenyl modified nucleotide, a nucleotide comprising a 5′-phosphorothioate group, a nucleotide comprising a 5′-methylphosphonate group, a nucleotide comprising a 5′ phosphate or 5′ phosphate mimic, a nucleotide comprising vinyl phosphonate, a nucleotide comprising adenosine-glycol nucleic acid (GNA), a nucleotide comprising thymidine-glycol nucleic acid (GNA) S-Isomer, a nucleotide comprising 2-hydroxymethyl-tetrahydrofurane-5-phosphate, a nucleotide comprising 2′-deoxythymidine-3′phosphate, a nucleotide comprising 2′-deoxyguanosine-3′-phosphate, or a terminal nucleotide linked to a cholesteryl derivative or a dodecanoic acid bisdecylamide group.

In a related embodiment, the modified nucleotide is a 2′-deoxy-2′-fluoro modified nucleotide, a 2′-deoxy-modified nucleotide, 3′-terminal deoxy-thymidine nucleotides (dT), a locked nucleotide, an abasic nucleotide, a 2′-amino-modified nucleotide, a 2′-alkyl-modified nucleotide, a morpholino nucleotide, a phosphoramidate, or a non-natural base comprising nucleotide.

In one embodiment, the modified nucleotide includes a short sequence of 3′-terminal deoxy-thymidine nucleotides (dT).

In another embodiment, the modifications on the nucleotides are 2′-O-methyl, 2′fluoro and GNA modifications.

In an additional embodiment, the double stranded RNAi agent includes at least one phosphorothioate internucleotide linkage. Optionally, the double stranded RNAi agent includes 6-8 (e.g., 6, 7, or 8) phosphorothioate internucleotide linkages.

In certain embodiments, the region of complementarity is at least 17 nucleotides in length. Optionally, the region of complementarity is 19-23 nucleotides in length. Optionally, the region of complementarity is 19 nucleotides in length.

In one embodiment, each strand is no more than 30 nucleotides in length.

In another embodiment, at least one strand includes a 3′ overhang of at least 1 nucleotide. Optionally, at least one strand includes a 3′ overhang of at least 2 nucleotides.

In certain embodiments, the double stranded RNAi agent further includes a lipophilic ligand, e.g., a C16 ligand, conjugated to the 3′ end of the sense strand through a monovalent or branched bivalent or trivalent linker. In certain embodiments, the double stranded RNAi agent further includes a lipophilic ligand, e.g., a C16 ligand, conjugated to an internal nucleotide positon, e.g., through a monovalent or branched bivalent or trivalent linker.

In one embodiment, the ligand is

embedded image

where B is a nucleotide base or a nucleotide base analog, optionally where B is adenine, guanine, cytosine, thymine or uracil.

In yet other embodiments, the agents further comprise a lipophilic ligand, e.g., a C16 ligand, conjugated to an internal nucleotide position, e.g., through a monovalent or branched bivalent or trivalent linker, and a targeting ligand that targets a liver tissue, e.g., one or more GalNAc derivatives conjugated to the 3′ end of the sense strand through a monovalent or branched bivalent or trivalent linker.

In another embodiment, the region of complementarity to APOE includes any one of the antisense sequences in any one of Tables 2-5 and 7-10. In certain embodiments, the region of complementarity to APOE includes any one of the antisense sequences in any one of Tables 7 and 8. In certain embodiments, the region of complementarity to APOE includes any one of the antisense sequences in any one of Tables 9 and 10.

In an additional embodiment, the region of complementarity to APOE is that of any one of the antisense sequences in any one of Tables 2-5 and 7-10. In certain embodiments, the region of complementarity to APOE is that of any one of the antisense sequences in any one of Tables 7 and 8. In some embodiments, the internal nucleotide positions include all positions except the terminal two positions from each end of the strand. In certain embodiments, the region of complementarity to APOE is that of any one of the antisense sequences in any one of Tables 9 and 10. In some embodiments, the internal nucleotide positions include all positions except the terminal two positions from each end of the strand.

In a related embodiment, the internal positions include all positions except terminal three positions from each end of the strand. Optionally, the internal positions exclude the cleavage site region of the sense strand.

In some embodiments, the internal positions exclude positions 9-12, counting from the 5′-end of the sense strand. In certain embodiments, the sense strand is 21 nucleotides in length.

In other embodiments, the internal positions exclude positions 11-13, counting from the 3′-end of the sense strand. Optionally, the internal positions exclude the cleavage site region of the antisense strand. In certain embodiments, the sense strand is 21 nucleotides in length.

In some embodiments, the internal positions exclude positions 12-14, counting from the 5′-end of the antisense strand. In certain embodiments, the antisense strand is 23 nucleotides in length.

In another embodiment, the internal positions excluding positions 11-13 on the sense strand, counting from the 3′-end, and positions 12-14 on the antisense strand, counting from the 5′-end. In certain embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.

In an additional embodiment, one or more lipophilic moieties are conjugated to one or more of the following internal positions: positions 4-8 and 13-18 on the sense strand, and positions 6-10 and 15-18 on the antisense strand, counting from the 5′end of each strand. Optionally, one or more lipophilic moieties are conjugated to one or more of the following internal positions: positions 5, 6, 7, 15, and 17 on the sense strand, and positions 15 and 17 on the antisense strand, counting from the 5′-end of each strand. In certain embodiments, the sense strand is 21 nucleotides in length and the antisense strand is 23 nucleotides in length.

In certain embodiments, the lipophilic moiety is an aliphatic, alicyclic, or polyalicyclic compound. Optionally, the lipophilic moiety is lipid, cholesterol, retinoic acid, cholic acid, adamantane acetic acid, 1-pyrene butyric acid, dihydrotestosterone, 1,3-bis-O(hexadecyl)glycerol, geranyloxyhexyanol, hexadecylglycerol, borneol, menthol, 1,3-propanediol, heptadecyl group, palmitic acid, myristic acid, O3-(oleoyl)lithocholic acid, O3-(oleoyl)cholenic acid, dimethoxytrityl, or phenoxazine.

In some embodiments, the lipophilic moiety contains a saturated or unsaturated C₄-C₃₀hydrocarbon chain, and an optional functional group selected that is hydroxyl, amine, carboxylic acid, sulfonate, phosphate, thiol, azide, or alkyne.

In certain embodiments, the lipophilic moiety contains a saturated or unsaturated C₆-C₁₈hydrocarbon chain. Optionally, the lipophilic moiety contains a saturated or unsaturated C₁₆hydrocarbon chain. In a related embodiment, the lipophilic moiety is conjugated via a carrier that replaces one or more nucleotide(s) in the internal position(s). In certain embodiments, the carrier is a cyclic group that is pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, [1,3]dioxolanyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, quinoxalinyl, pyridazinonyl, tetrahydrofuranyl, or decalinyl; or is an acyclic moiety based on a serinol backbone or a diethanolamine backbone.

In some embodiments, the lipophilic moiety is conjugated to the double-stranded RNAi agent via a linker containing an ether, thioether, urea, carbonate, amine, amide, maleimide-thioether, disulfide, phosphodiester, sulfonamide linkage, a product of a click reaction, or carbamate.

In one embodiment, the lipophilic moiety is conjugated to a nucleobase, sugar moiety, or internucleosidic linkage.

In another embodiment, the double-stranded RNAi agent further includes a phosphate or phosphate mimic at the 5′-end of the antisense strand. Optionally, the phosphate mimic is a 5′-vinyl phosphonate (VP).

In certain embodiments, the double-stranded RNAi agent further includes a targeting ligand that targets a receptor which mediates delivery to a CNS tissue, e.g., a hydrophilic ligand. In certain embodiments, the targeting ligand is a C16 ligand.

In some embodiments, the double-stranded RNAi agent further includes a targeting ligand that targets a brain tissue, e.g., striatum.

In some embodiments, the double-stranded RNAi agent further includes a targeting ligand that targets a liver tissue, e.g., hepatocytes.

In one embodiment, the lipophilic moeity or targeting ligand is conjugated via a bio-cleavable linker that is DNA, RNA, disulfide, amide, functionalized monosaccharides or oligosaccharides of galactosamine, glucosamine, glucose, galactose, mannose, or a combination thereof.

In a related embodiment, the 3′ end of the sense strand is protected via an end cap which is a cyclic group having an amine, the cyclic group being pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, [1,3]dioxolanyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, quinoxalinyl, pyridazinonyl, tetrahydrofuranyl, or decalinyl.

In one embodiment, the RNAi agent includes at least one modified nucleotide that is a 2′-O-methyl modified nucleotide, a 2′-fluoro modified nucleotide, a nucleotide that includes a glycol nucleic acid (GNA) or a nucleotide that includes a vinyl phosphonate. Optionally, the RNAi agent includes at least one of each of the following modifications: 2′-O-methyl modified nucleotide, a 2′-fluoro modified nucleotide, a nucleotide comprising a glycol nucleic acid (GNA) and a nucleotide comprising vinyl phosphonate.

In another embodiment, the RNAi agent includes a pattern of modified nucleotides as provided below in Tables 2-5 and 7-10 where locations of 2′-C16, 2′-O-methyl, GNA, phosphorothioate and 2′-fluoro modifications, irrespective of the individual nucleotide base sequences of the displayed RNAi agents. In one embodiment, the RNAi agent includes a pattern of modified nucleotides as provided below in Tables 7 and 8 where locations of 2′-C16, 2′-O-methyl, GNA, phosphorothioate and 2′-fluoro modifications, irrespective of the individual nucleotide base sequences of the displayed RNAi agents. In one embodiment, the RNAi agent includes a pattern of modified nucleotides as provided below in Tables 9 and 10 where locations of 2′-C16, 2′-O-methyl, GNA, phosphorothioate and 2′-fluoro modifications, irrespective of the individual nucleotide base sequences of the displayed RNAi agents.

Another aspect of the instant disclosure provides a double stranded RNAi agent for inhibiting expression of an APOE gene, where the double stranded RNAi agent includes a sense strand complementary to an antisense strand, where the antisense strand includes a region complementary to part of an mRNA encoding APOE, where each strand is about 14 to about 30 nucleotides in length, where the double stranded RNAi agent is represented by formula (III):

(III)

sense:

5′ n_p-N_a-(X X X)_i-N_b-Y Y Y-N_b-(Z Z Z)_j-N_a-n_q 3′

antisense:

3′ n_p′-N_a′-(X′X′X′)_k-N_b′-Y′Y′Y′-N_b′-(Z′Z′Z′)_l-

N_a′-n_q′ 5′

where:

i, j, k, and l are each independently 0 or 1;

p, p′, q, and q′ are each independently 0-6;

each N_band N_b′ independently represents an oligonucleotide sequence including 0-10 nucleotides which are either modified or unmodified or combinations thereof;

each n_p, n_p′, n_q, and n_q′, each of which may or may not be present, independently represents an overhang nucleotide;

XXX, YYY, ZZZ, X′X′X′, Y′Y′Y′, and Z′Z′Z′ each independently represent one motif of three identical modifications on three consecutive nucleotides;

modifications on N_bdiffer from the modification on Y and modifications on N_b′ differ from the modification on Y′; and

where the sense strand is conjugated to at least one ligand.

In one embodiment, i is 0; j is 0; i is 1; j is 1; both i and j are 0; or both i and j are 1.

In another embodiment, k is 0; l is 0; k is 1; l is 1; both k and l are 0; or both k and l are 1.

In certain embodiments, XXX is complementary to X′X′X′, YYY is complementary to Y′Y′Y′, and ZZZ is complementary to Z′Z′Z′.

In another embodiment, the YYY motif occurs at or near the cleavage site of the sense strand.

In an additional embodiment, the Y′Y′Y′ motif occurs at the 11, 12 and 13 positions of the antisense strand from the 5′-end. Optionally, the Y′ is 2′-O-methyl.

In some embodiments, formula (III) is represented by formula (IIIa):

(IIIa)

sense:

5′ n_p-N_a-Y Y Y-N_a-n_q 3′

antisense:

3′ n_p′-N_a′-Y′Y′Y′-N_a′-n_q′ 5′.

In another embodiment, formula (III) is represented by formula (IIIb):

(IIIb)

sense:

5′ n_p-N_a-Y Y Y-N_b-Z Z Z-N_a-n_q3′

antisense:

3′ n_p′-N_a′-Y′Y′Y′-N_b′-Z′Z′Z′-N_a′-n_q′ 5′

where each N_band N_b′ independently represents an oligonucleotide sequence including 1-5 modified nucleotides.

In an additional embodiment, formula (III) is represented by formula (IIIc):

(IIIc)

sense:

5′ n_p-N_a-X X X-N_b-Y Y Y-N_a-n_q 3′

antisense:

3′ n_p′-N_a′-X′X′X′-N-Y′Y′Y′-N_a′-n_q′ 5′

where each N_band N_b′ independently represents an oligonucleotide sequence including 1-5 modified nucleotides.

In certain embodiments, formula (III) is represented by formula (IIId):

(IIId)

sense:

5′ n_p-N_a-X X X-N_b-Y Y Y-N_b-Z Z Z-N_a-n_q 3′

antisense:

3′ n_p′-N_a′-X′X′X′-N_b′-Y′Y′Y′-N_b′-Z′Z′Z′-N_a′-n_q′ 5′

where each N_band N_b′ independently represents an oligonucleotide sequence including 1-5 modified nucleotides and each N_aand N_a′ independently represents an oligonucleotide sequence including 2-10 modified nucleotides.

In another embodiment, the double stranded region is 15-30 nucleotide pairs in length. Optionally, the double stranded region is 17-23 nucleotide pairs in length.

In certain embodiments, the double stranded region is 17-25 nucleotide pairs in length. Optionally, the double stranded region is 23-27 nucleotide pairs in length.

In some embodiments, the double stranded region is 19-21 nucleotide pairs in length. Optionally, the double stranded region is 21-23 nucleotide pairs in length.

In certain embodiments, each strand has 15-30 nucleotides. Optionally, each strand has 19-30 nucleotides. Optionally, each strand has 19-23 nucleotides.

In certain embodiments, the double stranded region is 19-21 nucleotide pairs in length and each strand has 19-23 nucleotides.

In another embodiment, the modifications on the nucleotides of the RNAi agent are LNA, glycol nucleic acid (GNA), HNA, CeNA, 2′-methoxyethyl, 2′-O-alkyl, 2′-O-allyl, 2′-C-allyl, 2′-fluoro, 2′-deoxy or 2′-hydroxyl, and combinations thereof. Optionally, the modifications on nucleotides include 2′-O-methyl, 2′-fluoro or GNA, and combinations thereof. In a related embodiment, the modifications on the nucleotides are 2′-O-methyl or 2′-fluoro modifications.

In one embodiment the RNAi agent includes a ligand that is or includes one or more lipophilic, e.g., C16, moieties attached through a bivalent or trivalent branched linker.

In other embodiments, the agent further comprises a targeting ligand that targets a liver tissue, e.g., one or more GalNAc derivatives.

In yet other embodiments, the agents further comprise a lipophilic ligand, e.g., a C16 ligand, conjugated to the 3′ end of the sense strand through a monovalent or branched bivalent or trivalent linker and a targeting ligand that targets a liver tissue, e.g., one or more GalNAc derivatives conjugated to the 3′ end of the sense strand through a monovalent or branched bivalent or trivalent linker.

In certain embodiments, the ligand is attached to the 3′ end of the sense strand.

In some embodiments, the RNAi agent further includes at least one phosphorothioate or methylphosphonate internucleotide linkage. In a related embodiment, the phosphorothioate or methylphosphonate internucleotide linkage is at the 3′-terminus of one strand. Optionally, the strand is the antisense strand. In another embodiment, the strand is the sense strand. In a related embodiment, the phosphorothioate or methylphosphonate internucleotide linkage is at the 5′-terminus of one strand. Optionally, the strand is the antisense strand. In another embodiment, the strand is the sense strand.

In another embodiment, the phosphorothioate or methylphosphonate internucleotide linkage is at the both the 5′- and 3′-terminus of one strand. Optionally, the strand is the antisense strand. In another embodiment, the strand is the sense strand.

In an additional embodiment, the base pair at the 1 position of the 5′-end of the antisense strand of the RNAi agent duplex is an A:U base pair.

In certain embodiments, the Y nucleotides contain a 2′-fluoro modification.

In some embodiments, the Y′ nucleotides contain a 2′-O-methyl modification.

In certain embodiments, p′>0. Optionally, p′=2.

In some embodiments, q′=0, p=0, q=0, and p′ overhang nucleotides are complementary to the target mRNA.

In certain embodiments, q′=0, p=0, q=0, and p′ overhang nucleotides are non-complementary to the target mRNA.

In one embodiment, the sense strand of the RNAi agent has a total of 21 nucleotides and the antisense strand has a total of 23 nucleotides.

In another embodiment, at least one n_p′ is linked to a neighboring nucleotide via a phosphorothioate linkage. Optionally, all n_p′ are linked to neighboring nucleotides via phosphorothioate linkages.

In certain embodiments, the APOE RNAi agent of the instant disclosure is one of those listed in Tables 2-5 and 7-10. In certain embodiments, the APOE RNAi agent of the instant disclosure is one of those listed in Tables 7 and 8. In some embodiments, all of the nucleotides of the sense strand and all of the nucleotides of the antisense strand include a modification. In certain embodiments, the APOE RNAi agent of the instant disclosure is one of those listed in Tables 9 and 10. In some embodiments, all of the nucleotides of the sense strand and all of the nucleotides of the antisense strand include a modification.

Another aspect of the instant disclosure provides a double stranded RNAi agent for inhibiting expression of an APOE gene in a cell, where the double stranded RNAi agent includes a sense strand complementary to an antisense strand, where the antisense strand includes a region complementary to part of an mRNA encoding an APOE gene, where each strand is about 14 to about 30 nucleotides in length, where the double stranded RNAi agent is represented by formula (III):

(III)

sense:

5′ n_p-N_a-(X X X)_i-N_b-Y Y Y-N_b-(Z Z Z)_j-N_a-n_q 3′

antisense:

3′ n_p′-N_a′-(X′X′X′)_k-N_b′-Y′Y′Y′-N_b′-(Z′Z′Z′)_l-

N_a′-n_q′ 5′

where:

i, j, k. and l are each independently 0 or 1;

p, p′, q, and q′ are each independently 0-6;

each N_band N_b′ independently represents an oligonucleotide sequence including 0-10 nucleotides which are either modified or unmodified or combinations thereof;

each n_p, n_p′, n_q, and n_q′, each of which may or may not be present independently represents an overhang nucleotide;

XXX, YYY, ZZZ. X′X′X′, Y′Y′Y′, and Z′Z′Z′ each independently represent one motif of three identical modifications on three consecutive nucleotides, and where the modifications are 2′-O-methyl or 2′-fluoro modifications;

modifications on N_bdiffer from the modification on Y and modifications on N_b′ differ from the modification on Y′; and

where the sense strand is conjugated to at least one ligand, optionally where the ligand is one or more lipophilic, e.g., Cl6, ligands, and/or one or more GalNAc derivatives.

(III)

sense:

5′ n_p-N_a-(X X X)_i-N_b-Y Y Y-N_b-(Z Z Z)_j-N_a-n_q 3′

antisense:

3′ n_p′-N_a′-(X′X′X′)_k-N_b′-Y′Y′Y′-N_b′-(Z′Z′Z′)_l-

N_a′-n_q′ 5′

where:

i, j, k, and l are each independently 0 or 1;

each n_p, n_q, and n_q′, each of which may or may not be present, independently represents an overhang nucleotide;

p, q, and q′ are each independently 0-6;

n_p′>0 and at least one n_p′ is linked to a neighboring nucleotide via a phosphorothioate linkage;

each N_band N_b′ independently represents an oligonucleotide sequence including 0-10 nucleotides which are either modified or unmodified or combinations thereof;

XXX, YYY, ZZZ, X′X′X′, Y′Y′Y′, and Z′Z′Z′ each independently represent one motif of three identical modifications on three consecutive nucleotides, and where the modifications are 2′-O-methyl, glycol nucleic acid (GNA) or 2′-fluoro modifications;

modifications on N_bdiffer from the modification on Y and modifications on N_b′ differ from the modification on Y′; and

where the sense strand is conjugated to at least one ligand, optionally where the ligand is one or more lipophilic, e.g., C16, ligands, and/or one or more GalNAc derivatives.

Another aspect of the instant disclosure provides a double stranded RNAi agent for inhibiting expression of an APOE gene in a cell, where the double stranded RNAi agent includes a sense strand complementary to an antisense strand, where the antisense strand includes a region complementary to part of an mRNA encoding APOE (SEQ ID NO: 1, or a nucleotide sequence having at least 90% nucleotide sequence identity, e.g. 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity, to the entire nucleotide sequence of SEQ ID NO:1), where each strand is about 14 to about 30 nucleotides in length, where the double stranded RNAi agent is represented by formula (III):

(III)

sense:

5′ n_p-N_a-(X X X)_i-N_b-Y Y Y-N_b-(Z Z Z)_j-N_a-n_q 3′

antisense:

3′ n_p′-N_a′-(X′X′X′)_k-N_b′-Y′Y′Y′-N_b′-(Z′Z′Z′)_l-

N_a′-n_q′ 5′

where:

i, j, k, and l are each independently 0 or 1;

each n_p, n_q, and n_q′, each of which may or may not be present, independently represents an overhang nucleotide;

p, q, and q′ are each independently 0-6;

n_p′>0 and at least one n_p′ is linked to a neighboring nucleotide via a phosphorothioate linkage;

each N_band N_b′ independently represents an oligonucleotide sequence including 0-10 nucleotides which are either modified or unmodified or combinations thereof;

modifications on N_bdiffer from the modification on Y and modifications on N_b′ differ from the modification on Y′; and

where the sense strand is conjugated to at least one ligand, optionally where the ligand is one or more lipophilic, e.g., C16, ligands, and/or one or more GalNAc derivatives.

An additional aspect of the instant disclosure provides a double stranded RNAi agent for inhibiting expression of an APOE gene in a cell, where the double stranded RNAi agent includes a sense strand complementary to an antisense strand, where the antisense strand includes a region complementary to part of an mRNA encoding APOE (SEQ ID NO: 1, or a nucleotide sequence having at least 90% nucleotide sequence identity, e.g. 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity, to the entire nucleotide sequence of SEQ ID NO: 1), where each strand is about 14 to about 30 nucleotides in length, where the double stranded RNAi agent is represented by formula (III):

(III)

sense:

5′ n_p-N_a-(X X X)_i-N_b-Y Y Y-N_b-(Z Z Z)_j-N_a-n_q 3′

antisense:

3′ n_p′-N_a′-(X′X′X′)_k-N_b′-Y′Y′Y′-N_b′-(Z′Z′Z′)_l-

N_a′-n_q′ 5′

where:

i, j, k, and l are each independently 0 or 1;

each n_p, n_q, and n_q′, each of which may or may not be present, independently represents an overhang nucleotide;

p, q, and q′ are each independently 0-6;

n_p′>0 and at least one n_p′ is linked to a neighboring nucleotide via a phosphorothioate linkage;

each N_band N_b′ independently represents an oligonucleotide sequence including 0-10 nucleotides which are either modified or unmodified or combinations thereof;

modifications on N_bdiffer from the modification on Y and modifications on N_b′ differ from the modification on Y′;

where the sense strand includes at least one phosphorothioate linkage; and

where the sense strand is conjugated to at least one ligand, optionally where the ligand is one or more lipophilic, e.g., C16, ligands and/or one or more GalNAc derivatives.

Another aspect of the instant disclosure provides a double stranded RNAi agent for inhibiting expression of an APOE gene in a cell, where the double stranded RNAi agent includes a sense strand complementary to an antisense strand, where the antisense strand includes a region complementary to part of an mRNA encoding APOE (SEQ ID NO: 1, or a nucleotide sequence having at least 90% nucleotide sequence identity, e.g. 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity, to the entire nucleotide sequence of SEQ ID NO: 1), where each strand is about 14 to about 30 nucleotides in length, where the double stranded RNAi agent is represented by formula (III):

(IIIa)

sense:

5′ n_p-N_a-Y Y Y-N_a-n_q 3′

antisense:

3′ n_p′-N_a′-Y′Y′Y′-N_a′-n_q′ 5′

where:

each n_p, n_q, and n_q′, each of which may or may not be present, independently represents an overhang nucleotide;

p, q, and q′ are each independently 0-6;

n_p′>0 and at least one n_p′ is linked to a neighboring nucleotide via a phosphorothioate linkage;

each N_aand N_a′ independently represents an oligonucleotide sequence including 0-25 nucleotides which are either modified or unmodified or combinations thereof, each sequence including at least two differently modified nucleotides; YYY and Y′Y′Y′ each independently represent one motif of three identical modifications on three consecutive nucleotides, and where the modifications are 2′-O-methyl or 2′-fluoro modifications;

where the sense strand includes at least one phosphorothioate linkage; and

where the sense strand is conjugated to at least one ligand, optionally where the ligand is one or more lipophilic, e.g., C16 ligands, and/or one or more GalNAc derivatives.

An additional aspect of the instant disclosure provides a double stranded RNAi agent for inhibiting expression of an APOE gene, where the double stranded RNAi agent targeted to APOE includes a sense strand and an antisense strand forming a double stranded region, where the sense strand includes at least 15 contiguous nucleotides differing by no more than 3 nucleotides (i.e., differing by 3, 2, 1, or 0 nucleotides) from any one of the nucleotide sequences of SEQ ID NOs: 1, 3, 5, 7, and 9, or a nucleotide sequence having at least 90% nucleotide sequence identity, e.g. 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity, to the entire nucleotide sequence of any one of SEQ ID NOs: 1, 3, 5, 7, or 9, and the antisense strand includes at least 15 contiguous nucleotides differing by no more than 3 nucleotides (i.e., differing by 3, 2, 1, or 0 nucleotides) from any one of the nucleotide sequences of SEQ ID NOs: 2, 4, 6, 8, and 10, or a nucleotide sequence having at least 90% nucleotide sequence identity, e.g. 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity, to the entire nucleotide sequence of any one of SEQ ID NOs: 2, 4, 6, 8, and 10; where a substitution of a uracil for any thymine in the sequences provided in the SEQ ID NOs: 1-10 (when comparing aligned sequences) does not count as a difference that contributes to the differing by no more than 3 nucleotides from any one of the nucleotide sequences provided in SEQ ID NOs: 1-10, where substantially all of the nucleotides of the sense strand include a modification that is a 2′-O-methyl modification, a GNA or a 2′-fluoro modification, where the sense strand includes two phosphorothioate internucleotide linkages at the 5′-terminus, where substantially all of the nucleotides of the antisense strand include a modification selected from the group consisting of a 2′-O-methyl modification and a 2′-fluoro modification, where the antisense strand includes two phosphorothioate internucleotide linkages at the 5′-terminus and two phosphorothioate internucleotide linkages at the 3′-terminus, and where the sense strand is conjugated to one or more lipophilic, e.g., C16, ligands, optionally, further comprising a liver targeting ligand, e.g., a ligand comprising one or more GalNAc derivatives.

Another aspect of the instant disclosure provides a double stranded RNAi agent for inhibiting expression of an APOE gene, where the double stranded RNAi agent targeted to APOE includes a sense strand and an antisense strand forming a double stranded region, where the sense strand includes at least 15 contiguous nucleotides differing by no more than 3 nucleotides (i.e., differing by 3, 2, 1, or 0 nucleotides) from any one of the nucleotide sequences of SEQ ID NOs: 1, 3, 5, 7, and 9, or a nucleotide sequence having at least 90% nucleotide sequence identity, e.g. 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity, to the entire nucleotide sequence of any one of SEQ ID NOs: 1, 3, 5, 7, or 9, and the antisense strand includes at least 15 contiguous nucleotides differing by no more than 3 nucleotides (i.e., differing by 3, 2, 1, or 0 nucleotides) from any one of the nucleotide sequences of SEQ ID NOs: 2, 4, 6, 8, and 10, or a nucleotide sequence having at least 90% nucleotide sequence identity, e.g. 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100% identity, to the entire nucleotide sequence of any one of SEQ ID NOs: 2, 4, 6, 8, and 10, where a substitution of a uracil for any thymine in the sequences provided in the SEQ ID NOs: 1-10 (when comparing aligned sequences) does not count as a difference that contributes to the differing by no more than 3 nucleotides from any one of the nucleotide sequences provided in SEQ ID NOs:1-10; where the sense strand includes at least one 3′-terminal deoxy-thymidine nucleotide (dT), and where the antisense strand includes at least one 3′-terminal deoxy-thymidine nucleotide (dT).

In one embodiment, all of the nucleotides of the sense strand and all of the nucleotides of the antisense strand are modified nucleotides.

In another embodiment, each strand has 19-30 nucleotides.

In certain embodiments, the antisense strand of the RNAi agent includes at least one thermally destabilizing modification of the duplex within the first 9 nucleotide positions of the 5′ region or a precursor thereof. Optionally, the thermally destabilizing modification of the duplex is one or more of

embedded image

where B is nucleobase.

Another aspect of the instant disclosure provides a cell containing a double stranded RNAi agent of the instant disclosure.

An additional aspect of the instant disclosure provides a pharmaceutical composition for inhibiting expression of an APOE gene that includes a double stranded RNAi agent of the instant disclosure.

In one embodiment, the double stranded RNAi agent is administered in an unbuffered solution. Optionally, the unbuffered solution is saline or water.

In another embodiment, the double stranded RNAi agent is administered with a buffer solution. Optionally, the buffer solution includes acetate, citrate, prolamine, carbonate, or phosphate or any combination thereof. In another embodiment, the buffer solution is phosphate buffered saline (PBS).

Another aspect of the disclosure provides a pharmaceutical composition that includes a double stranded RNAi agent of the instant disclosure and a lipid formulation.

In one embodiment, the lipid formulation includes a lipid nanoparticle (LNP).

An additional aspect of the disclosure provides a method of inhibiting expression of an APOE gene in a cell, the method involving: (a) contacting the cell with a double stranded RNAi agent of the instant disclosure or a pharmaceutical composition of the instant disclosure; and (b) maintaining the cell produced in step (a) for a time sufficient to obtain degradation of the mRNA transcript of an APOE gene, thereby inhibiting expression of the APOE gene in the cell.

In one embodiment, the cell is within a subject. Optionally, the subject is a human.

In certain embodiments, the subject is a rhesus monkey, a cynomolgous monkey, a mouse, or a rat.

In certain embodiments, the human subject suffers from an APOE-associated neurodegenerative disease, e.g., an amyloid-p-mediated disease, such as Alzheimer's's disease, Down's syndrome, and cerebral amyloid angiopathy, or a tau-mediated disease, e.g., a primary tauopathy, such as Frontotemporal dementia (FTD), Progressive supranuclear palsy (PSP), Cordicobasal degeneration (CBD), Pick's disease (PiD), Globular glial tauopathies (GGTs), frontotemporal dementia with parkinsonism (FTDP, FTDP-17), Chronic traumatic encelopathy (CTE), Dementia pugilistica, Frontotemporal lobar degeneration (FTLD), Argyrophilic grain disease (AGD), and Primary age-related tauopathy (PART), or a secondary tauopathy, e.g., AD, Creuzfeld Jakob's disease, Down's Syndrome, and Familial British Dementia.

In certain embodiments, the method further involves administering an additional therapeutic agent to the subject, such as a cholinesterase inhibitors and/or memantine.

In certain embodiments, the double stranded RNAi agent is administered at a dose of about 0.01 mg/kg to about 50 mg/kg.

In some embodiments, the double stranded RNAi agent is administered to the subject intrathecally.

In one embodiment, the method reduces the expression of an APOE gene in a brain (e.g., striatum) or spine tissue. Optionally, the brain or spine tissue is striatum, cortex, cerebellum, cervical spine, lumbar spine, or thoracic spine.

In some embodiments, the double stranded RNAi agent is administered to the subject subcutaneously.

In one embodiment, the method reduces the expression of an APOE gene in the liver.

In other embodiments, the method reduces the expression of an APOE gene in the liver and the brain.

Another aspect of the instant disclosure provides a method of inhibiting the expression of APOE in a subject, the method involving: administering to the subject a therapeutically effective amount of a double stranded RNAi agent of the disclosure or a pharmaceutical composition of the disclosure, thereby inhibiting the expression of APOE in the subject.

An additional aspect of the disclosure provides a method for treating or preventing an disorder or APOE-associated neurodegenerative disease or disorder in a subject, the method involving administering to the subject a therapeutically effective amount of a double stranded RNAi agent of the disclosure or a pharmaceutical composition of the disclosure, thereby treating or preventing an APOE-associated neurodegenerative disease or disorder in the subject.

In certain embodiments, the APOE-associated neurodegenerative disease is an amyloid-β-mediated disease, such as an amyloid-β-mediated disease selected from the group consisting of Alzheimer's's disease, Down's syndrome, and cerebral amyloid angiopathy.

In certain embodiments, the APOE-associated neurodegenerative disease is a tau-mediated disease, such as a primary tauopathy or a secondary tauopathy.

In certain embodiments, the primary tauopathy is selected from the group consisting of Frontotemporal dementia (FTD), Progressive supranuclear palsy (PSP), Cordicobasal degeneration (CBD), Pick's disease (PiD), Globular glial tauopathies (GGTs), frontotemporal dementia with parkinsonism (FTDP, FTDP-17), Chronic traumatic encelopathy (CTE), Dementia pugilistica, Frontotemporal lobar degeneration (FTLD), Argyrophilic grain disease (AGD), and Primary age-related tauopathy (PART).

In certain embodiments, the secondary tauopathy is selected from the group consisting of AD, Creuzfeld Jakob's disease, Down's Syndrome, and Familial British Dementia.

Another aspect of the instant disclosure provides a kit for performing a method of the instant disclosure, the kit including: a) a double stranded RNAi agent of the instant disclosure, and b) instructions for use, and c) optionally, a device for administering the double stranded RNAi agent to the subject.

An additional aspect of the instant disclosure provides a double stranded ribonucleic acid (RNAi) agent for inhibiting expression of an APOE gene, where the RNAi agent possesses a sense strand and an antisense strand, and where the antisense strand includes a region of complementarity which includes at least 15 contiguous nucleotides differing by no more than 3 nucleotides (i.e., differing by 3, 2, 1, or 0 nucleotides), e.g., at least 15 nucleotides (i.e., differing by 3, 2, 1, or 0 nucleotides), at least 19 nucleotides (i.e., differing by 3, 2, 1, or 0 nucleotides), from any one of the antisense strand nucleobase sequences of Tables 2-5 and 7-10. In one embodiment, the RNAi agent includes one or more of the following modifications: a 2′-O-methyl modified nucleotide, a 2′-fluoro modified nucleotide, a 2′-C-alkyl-modified nucleotide, a nucleotide comprising a glycol nucleic acid (GNA), a phosphorothioate (PS) and a vinyl phosphonate (VP). Optionally, the RNAi agent includes at least one of each of the following modifications: a 2′-O-methyl modified nucleotide, a 2′-fluoro modified nucleotide, a 2′-C-alkyl-modified nucleotide, a nucleotide comprising a glycol nucleic acid (GNA), a phosphorothioate and a vinyl phosphonate (VP).

In another embodiment, the RNAi agent includes four or more PS modifications, optionally six to ten PS modifications, optionally eight PS modifications.

In an additional embodiment, each of the sense strand and the antisense strand of the RNAi agent possesses a 5′-terminus and a 3′-terminus, and the RNAi agent includes eight PS modifications positioned at each of the penultimate and ultimate internucleotide linkages from the respective 3′- and 5′-termini of each of the sense and antisense strands of the RNAi agent.

In another embodiment, each of the sense strand and the antisense strand of the RNAi agent includes a 5′-terminus and a 3′-terminus, and the RNAi agent includes only one nucleotide including a GNA. Optionally, the nucleotide including a GNA is positioned on the antisense strand at the seventh nucleobase residue from the 5′-terminus of the antisense strand.

In an additional embodiment, each of the sense strand and the antisense strand of the RNAi agent includes a 5′-terminus and a 3′-terminus, and the RNAi agent includes one to four 2′-C-alkyl-modified nucleotides. Optionally, the 2′-C-alkyl-modified nucleotide is a 2′-C16-modified nucleotide. Optionally, the RNAi agent includes a single 2′-C-alkyl, e.g., C16-modified nucleotide. Optionally, the single 2′-C-alkyl, e.g., C16-modified nucleotide is located on the sense strand at the sixth nucleobase position from the 5′-terminus of the sense strand.

In another embodiment, each of the sense strand and the antisense strand of the RNAi agent includes a 5′-terminus and a 3′-terminus, and the RNAi agent includes two or more 2′-fluoro modified nucleotides. Optionally, each of the sense strand and the antisense strand of the RNAi agent includes two or more 2′-fluoro modified nucleotides. Optionally, the 2′-fluoro modified nucleotides are located on the sense strand at nucleobase positions 7, 9, 10 and 11 from the 5′-terminus of the sense strand and on the antisense strand at nucleobase positions 2, 14 and 16 from the 5′-terminus of the antisense strand.

In an additional embodiment, each of the sense strand and the antisense strand of the RNAi agent includes a 5′-terminus and a 3′-terminus, and the RNAi agent includes one or more VP modifications. Optionally, the RNAi agent includes a single VP modification at the 5′-terminus of the antisense strand.

In another embodiment, each of the sense strand and the antisense strand of the RNAi agent includes a 5′-terminus and a 3′-terminus, and the RNAi agent includes two or more 2′-O-methyl modified nucleotides. Optionally, the RNAi agent includes 2′-O-methyl modified nucleotides at all nucleobase locations not modified by a 2′-fluoro, a 2′-C-alkyl or a glycol nucleic acid (GNA). Optionally, the two or more 2′-O-methyl modified nucleotides are located on the sense strand at positions 1, 2, 3, 4, 5, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20 and 21 from the 5′-terminus of the sense strand and on the antisense strand at positions 1, 3, 4, 5, 6, 8, 9, 10, 11, 12, 13, 15, 17, 18, 19, 20, 21, 22 and 23 from the 5′-terminus of the antisense strand.

In one aspect, the present invention provides a method of inhibiting expression of an APOE gene in an astrocyte. The method includes contacting the astrocyte with the dsRNA agent or pharmaceutical composition of the invention; and maintaining the astrocyte produced for a time sufficient to obtain degradation of the mRNA transcript of the APOE gene, thereby inhibiting expression of the APOE gene in the astrocyte.

In certain embodiments, the cell is within a subject, e.g., a human subject.

In some embodiment, the contacting the astrocyte is by intrathecal administration of the pharmaceutical composition.

In certain embodiments, the antisense strand of the dsRNA agent comprises at least 15 contiguous nucleotides differing by no more than three nucleotides from any one of the antisense strand nucleotide sequences of a duplex selected from the group consisting of AD-1204704, AD-1204705, AD-1204708, and AD-1204712.

BRIEF DESCRIPTIONS OF THE FIGURES

FIG. 1A is a graph depicting the percent of APOE mRNA remaining in the right hemisphere of the brain (BRH) of homozygous humanized APOE knock-in mice administered a single 300 μg dose of the indicated duplexes or artificial CSF (aCSF) control by intracerebroventricular injection (ICV) at day 14 post-dose.

FIG. 1B is a graph depicting the percent of APOE mRNA remaining in the liver of homozygous humanized APOE knock-in mice administered a single 300 μg dose of the indicated duplexes or artificial CSF (aCSF) control by intracerebroventricular injection (ICV) at day 14 post-dose.

FIG. 2 is a graph depicting the correlation of the activity of the agents AD-1204704, AD-1204705, AD-1204705, AD-1204706 AD-1204707, AD-1204708, AD-1204709, AD-1204710, AD-1204711, AD-1204712, and AD-1204713 in vitro to the activity of the agents in vivo.

DETAILED DESCRIPTION OF THE INVENTION

The present disclosure provides RNAi compositions, which effect the RNA-induced silencing complex (RISC)-mediated cleavage of RNA transcripts of an gene. The APOE gene may be within a cell, e.g., a cell within a subject, such as a human. The present disclosure also provides methods of using the RNAi compositions of the disclosure for inhibiting the expression of an APOE gene or for treating a subject having a disorder that would benefit from inhibiting or reducing the expression of an APOE gene, e.g., a pathogenic APOE allele, i.e., APOE4, e.g., an APOE-associated neurodegenerative disease, for example, an amyloid-β-mediated disease or a tau-mediated disease.

The RNAi agents of the disclosure include an RNA strand (the antisense strand) having a region which is about 30 nucleotides or less in length, e.g., 15-30, 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24, 20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 nucleotides in length, which region is substantially complementary to at least part of an mRNA transcript of an APOE gene. In certain embodiments, the RNAi agents of the disclosure include an RNA strand (the antisense strand) having a region which is about 21-23 nucleotides in length, which region is substantially complementary to at least part of an mRNA transcript of an APOE gene.

In certain embodiments, the RNAi agents of the disclosure include an RNA strand (the antisense strand) which can include longer lengths, for example up to 66 nucleotides, e.g., 36-66, 26-36, 25-36, 31-60, 22-43, 27-53 nucleotides in length with a region of at least 19 contiguous nucleotides that is substantially complementary to at least a part of an mRNA transcript of an APOE gene. These RNAi agents with the longer length antisense strands preferably include a second RNA strand (the sense strand) of 20-60 nucleotides in length wherein the sense and antisense strands form a duplex of 18-30 contiguous nucleotides.

The use of these RNAi agents enables the targeted degradation of mRNAs of an APOE gene in mammals. Thus, methods and compositions including these RNAi agents are useful for treating a subject who would benefit by a reduction in the levels or activity of an APOE protein, such as a subject having an APOE-associated neurodegenerative disease, e.g. an amyloid-β-mediated disease or a tau-mediated disease.

The following detailed description discloses how to make and use compositions containing RNAi agents to inhibit the expression of an APOE gene, as well as compositions and methods for treating subjects having diseases and disorders that would benefit from inhibition or reduction of the expression of the genes.

I. Definitions

In order that the present disclosure may be more readily understood, certain terms are first defined. In addition, it should be noted that whenever a value or range of values of a parameter are recited, it is intended that values and ranges intermediate to the recited values are also intended to be part of this disclosure.

The articles “a” and “an” are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element, e.g., a plurality of elements.

The term “including” is used herein to mean, and is used interchangeably with, the phrase “including but not limited to”. The term “or” is used herein to mean, and is used interchangeably with, the term “and/or,” unless context clearly indicates otherwise.

The term “about” is used herein to mean within the typical ranges of tolerances in the art. For example, “about” can be understood as about 2 standard deviations from the mean. In certain embodiments, about means±10%. In certain embodiments, about means±5%. When about is present before a series of numbers or a range, it is understood that “about” can modify each of the numbers in the series or range.

The term “at least”, “no less than”, or “or more” prior to a number or series of numbers is understood to include the number adjacent to the term “at least”, and all subsequent numbers or integers that could logically be included, as clear from context. For example, the number of nucleotides in a nucleic acid molecule must be an integer. For example, “at least 18 nucleotides of a 21 nucleotide nucleic acid molecule” means that 18, 19, 20, or 21 nucleotides have the indicated property. When at least is present before a series of numbers or a range, it is understood that “at least” can modify each of the numbers in the series or range.

As used herein, “no more than” or “less than” is understood as the value adjacent to the phrase and logical lower values or integers, as logical from context, to zero. For example, a duplex with an overhang of “no more than 2 nucleotides” has a 2, 1, or 0 nucleotide overhang. When “no more than” is present before a series of numbers or a range, it is understood that “no more than” can modify each of the numbers in the series or range.

As used herein, methods of detection can include determination that the amount of analyte present is below the level of detection of the method.

In the event of a conflict between an indicated target site and the nucleotide sequence for a sense or antisense strand, the indicated sequence takes precedence.

In the event of a conflict between a chemical structure and a chemical name, the chemical structure takes precedence.

The terms “APOE” or “APOE”, also known as “Apolipoprotein E,” “Alzheimer's Disease 2,” “LPG” and “LDLCQ5,” refer to the well-known gene that encodes the protein, APOE. APOE is synthesized throughout the body, primarily in the liver and functions as a lipid transport protein and is a major ligand for low density lipoprotein (LDL) receptors. APOE has been shown to play a role in cholesterol metabolism and cardiovascular disease and, more recently, has emerged as a major risk factor for Alzheimer's disease and is associated with the pathology of other neurodegenerative diseases.

Nucleotide and amino acid sequences of APOE can be found, for example, at GenBank Accession No. NM_000041.4 (Homo sapiens APOE, SEQ ID NO: 1, reverse complement, SEQ ID NO: 2); GenBank Accession No. NM_001270681.1 (Rattus norvegicus APOE, SEQ ID NO: 3; reverse complement, SEQ ID NO: 4); GenBank Accession No. NM_001305843.1 (Mus musculus APOE, SEQ ID NO: 5, reverse complement, SEQ ID NO: 6); GenBank Accession No. XM_028839202.1 (Macaca mulatta APOE, SEQ ID NO: 7, reverse complement, SEQ ID NO: 8); and GenBank Accession No. XM_005589554.2 (Macaca fascicularis APOE, SEQ ID NO: 9; reverse complement, SEQ ID NO: 10).

Additional examples of APOE sequences can be found in publically available databases, for example, GenBank, OMIM, and UniProt. Additional information on APOE can be found, for example, at www.ncbi.nlm.nih.gov/gene/348.

The term APOE as used herein also refers to variations of the APOE gene including variants of human APOE provided in the SNP database, for example, at ncbi.nlm.nih.gov/clinvar/?term=APOE [gene].

The human APOE gene contains two single-nucleotide polymorphisms that result in the three most common variants, APOE2 (also referred to as APOE*ε2 or ε2; Cys112, Cys158), APOE3 (also referred to as APOE*ε3 or ε3; Cys112, Arg 158), and APOE4 (also referred to as APOE*ε4 or ε4 (Arg112, Arg158). GenBank Accession No. NM_000041.4 (Homo sapiens APOE, SEQ ID NO: 1, reverse complement, SEQ ID NO: 2) is the nucleotide sequence of the APOE*ε3 (APOE3) variant; the APOE*ε2 (APOE2) variant has a single nucleotide change at nucleotide 595C>T of SEQ ID NO:1, and the APOE*ε4 (APOE4) variant has a single nucleotide change at nucleotide 457T>C of SEQ ID NO:1.

It is to be understood that, unless specified herein, the term “APOE,” “ApoE,” or the like, refers to any one or more of the three APOE variants or alleles. For example, as used herein, the term “an APOE gene” refers to an APOE2 allele, an APOE3 allele, and/or an APOE4 allele” while the term “APOE4 allele,” or the like, only refers to an APOE4 allele.

As used herein, “target sequence” refers to a contiguous portion of the nucleotide sequence of an mRNA molecule formed during the transcription of an APOE gene, including mRNA that is a product of RNA processing of a primary transcription product. In one embodiment, the target portion of the sequence will be at least long enough to serve as a substrate for RNAi-directed cleavage at or near that portion of the nucleotide sequence of an mRNA molecule formed during the transcription of an APOE gene.

The target sequence is about 15-30 nucleotides in length. For example, the target sequence can be from about 15-30 nucleotides, 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24, 20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 nucleotides in length. In certain embodiments, the target sequence is 19-23 nucleotides in length, optionally 21-23 nucleotides in length. Ranges and lengths intermediate to the above recited ranges and lengths are also contemplated to be part of the disclosure.

As used herein, the term “strand comprising a sequence” refers to an oligonucleotide comprising a chain of nucleotides that is described by the sequence referred to using the standard nucleotide nomenclature.

“G,” “C,” “A,” “T”, and “U” each generally stand for a nucleotide that contains guanine, cytosine, adenine, thymidine, and uracil as a base, respectively in the context of a modified or unmodified nucleotide. However, it will be understood that the term “ribonucleotide” or “nucleotide” can also refer to a modified nucleotide, as further detailed below, or a surrogate replacement moiety (see, e.g., Table 1). The skilled person is well aware that guanine, cytosine, adenine, thymidine, and uracil can be replaced by other moieties without substantially altering the base pairing properties of an oligonucleotide comprising a nucleotide bearing such replacement moiety. For example, without limitation, a nucleotide comprising inosine as its base can base pair with nucleotides containing adenine, cytosine, or uracil. Hence, nucleotides containing uracil, guanine, or adenine can be replaced in the nucleotide sequences of dsRNA featured in the disclosure by a nucleotide containing, for example, inosine. In another example, adenine and cytosine anywhere in the oligonucleotide can be replaced with guanine and uracil, respectively to form G-U Wobble base pairing with the target mRNA. Sequences containing such replacement moieties are suitable for the compositions and methods featured in the disclosure.

The terms “iRNA”, “RNAi agent,” “iRNA agent,” “RNA interference agent” as used interchangeably herein, refer to an agent that contains RNA as that term is defined herein, and which mediates the targeted cleavage of an RNA transcript via an RNA-induced silencing complex (RISC) pathway. RNA interference (RNAi) is a process that directs the sequence-specific degradation of mRNA. RNAi modulates, e.g., inhibits, the expression of APOE in a cell, e.g., a cell within a subject, such as a mammalian subject.

In one embodiment, an RNAi agent of the disclosure includes a single stranded RNAi that interacts with a target RNA sequence, e.g., an APOE target mRNA sequence, to direct the cleavage of the target RNA. Without wishing to be bound by theory it is believed that long double stranded RNA introduced into cells is broken down into double-stranded short interfering RNAs (siRNAs) comprising a sense strand and an antisense strand by a Type III endonuclease known as Dicer (Sharp et al. (2001) Genes Dev. 15:485). Dicer, a ribonuclease-III-like enzyme, processes these dsRNA into 19-23 base pair short interfering RNAs with characteristic two base 3′ overhangs (Bernstein, et al., (2001) Nature 409:363). These siRNAs are then incorporated into an RNA-induced silencing complex (RISC) where one or more helicases unwind the siRNA duplex, enabling the complementary antisense strand to guide target recognition (Nykanen, et al., (2001) Cell 107:309). Upon binding to the appropriate target mRNA, one or more endonucleases within the RISC cleave the target to induce silencing (Elbashir, et al., (2001) Genes Dev. 15:188). Thus, in one aspect the disclosure relates to a single stranded RNA (ssRNA) (the antisense strand of a siRNA duplex) generated within a cell and which promotes the formation of a RISC complex to effect silencing of the target gene, i.e., an APOE gene. Accordingly, the term “siRNA” is also used herein to refer to an RNAi as described above.

In another embodiment, the RNAi agent may be a single-stranded RNA that is introduced into a cell or organism to inhibit a target mRNA. Single-stranded RNAi agents bind to the RISC endonuclease, Argonaute 2, which then cleaves the target mRNA. The single-stranded siRNAs are generally 15-30 nucleotides and are chemically modified. The design and testing of single-stranded RNAs are described in U.S. Pat. No. 8,101,348 and in Lima et al., (2012) Cell 150:883-894, the entire contents of each of which are hereby incorporated herein by reference. Any of the antisense nucleotide sequences described herein may be used as a single-stranded siRNA as described herein or as chemically modified by the methods described in Lima et al., (2012) Cell 150:883-894.

In another embodiment, a “RNAi agent” for use in the compositions and methods of the disclosure is a double stranded RNA and is referred to herein as a “double stranded RNAi agent,” “double stranded RNA (dsRNA) molecule,” “dsRNA agent,” or “dsRNA”. The term “dsRNA” refers to a complex of ribonucleic acid molecules, having a duplex structure comprising two anti-parallel and substantially complementary nucleic acid strands, referred to as having “sense” and “antisense” orientations with respect to a target RNA, i.e., an APOE gene. In some embodiments of the disclosure, a double stranded RNA (dsRNA) triggers the degradation of a target RNA, e.g., an mRNA, through a post-transcriptional gene-silencing mechanism referred to herein as RNA interference or RNAi.

In general, a dsRNA molecule can include ribonucleotides, but as described in detail herein, each or both strands can also include one or more non-ribonucleotides, e.g., a deoxyribonucleotide, a modified nucleotide. In addition, as used in this specification, an “RNAi agent” may include ribonucleotides with chemical modifications; an RNAi agent may include substantial modifications at multiple nucleotides. As used herein, the term “modified nucleotide” refers to a nucleotide having, independently, a modified sugar moiety, a modified internucleotide linkage, or a modified nucleobase. Thus, the term modified nucleotide encompasses substitutions, additions or removal of, e.g., a functional group or atom, to internucleoside linkages, sugar moieties, or nucleobases. The modifications suitable for use in the agents of the disclosure include all types of modifications disclosed herein or known in the art. Any such modifications, as used in a siRNA type molecule, are encompassed by “RNAi agent” for the purposes of this specification and claims.

In certain embodiments of the instant disclosure, inclusion of a deoxy-nucleotide—which is acknowledged as a naturally occurring form of nucleotide—if present within a RNAi agent can be considered to constitute a modified nucleotide.

The duplex region may be of any length that permits specific degradation of a desired target RNA through a RISC pathway, and may range from about 15-36 base pairs in length, for example, about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, or 36 base pairs in length, such as about 15-30, 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24, 20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 base pairs in length. In certain embodiments, the duplex region is 19-21 base pairs in length, e.g., 21 base pairs in length. Ranges and lengths intermediate to the above recited ranges and lengths are also contemplated to be part of the disclosure.

The two strands forming the duplex structure may be different portions of one larger RNA molecule, or they may be separate RNA molecules. Where the two strands are part of one larger molecule, and therefore are connected by an uninterrupted chain of nucleotides between the 3′-end of one strand and the 5′-end of the respective other strand forming the duplex structure, the connecting RNA chain is referred to as a “hairpin loop.” A hairpin loop can comprise at least one unpaired nucleotide. In some embodiments, the hairpin loop can comprise at at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 20, at least 23 or more unpaired nucleotides or nucleotides not directed to the target site of the dsRNA. In some embodiments, the hairpin loop can be 10 or fewer nucleotides. In some embodiments, the hairpin loop can be 8 or fewer unpaired nucleotides. In some embodiments, the hairpin loop can be 4-10 unpaired nucleotides. In some embodiments, the hairpin loop can be 4-8 nucleotides.

Where the two substantially complementary strands of a dsRNA are comprised by separate RNA molecules, those molecules need not, but can be covalently connected. In certain embodiments where the two strands are connected covalently by means other than an uninterrupted chain of nucleotides between the 3′-end of one strand and the 5′-end of the respective other strand forming the duplex structure, the connecting structure is referred to as a “linker” (though it is noted that certain other structures defined elsewhere herein can also be referred to as a “linker”). The RNA strands may have the same or a different number of nucleotides. The maximum number of base pairs is the number of nucleotides in the shortest strand of the dsRNA minus any overhangs that are present in the duplex. In addition to the duplex structure, an RNAi may comprise one or more nucleotide overhangs. In one embodiment of the RNAi agent, at least one strand comprises a 3′ overhang of at least 1 nucleotide. In another embodiment, at least one strand comprises a 3′ overhang of at least 2 nucleotides, e.g., 2, 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, or 15 nucleotides. In other embodiments, at least one strand of the RNAi agent comprises a 5′ overhang of at least 1 nucleotide. In certain embodiments, at least one strand comprises a 5′ overhang of at least 2 nucleotides, e.g., 2, 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, or 15 nucleotides. In still other embodiments, both the 3′ and the 5′ end of one strand of the RNAi agent comprise an overhang of at least 1 nucleotide.

In one embodiment, an RNAi agent of the disclosure is a dsRNA, each strand of which independently comprises 19-23 nucleotides, that interacts with a target RNA sequence, e.g., an APOE target mRNA sequence, to direct the cleavage of the target RNA.

As used herein, the term “nucleotide overhang” refers to at least one unpaired nucleotide that protrudes from the duplex structure of a RNAi agent, e.g., a dsRNA. For example, when a 3′-end of one strand of a dsRNA extends beyond the 5′-end of the other strand, or vice versa, there is a nucleotide overhang. A dsRNA can comprise an overhang of at least one nucleotide; alternatively, the overhang can comprise at least two nucleotides, at least three nucleotides, at least four nucleotides, at least five nucleotides or more. A nucleotide overhang can comprise or consist of a nucleotide/nucleoside analog, including a deoxynucleotide/nucleoside. The overhang(s) can be on the sense strand, the antisense strand or any combination thereof. Furthermore, the nucleotide(s) of an overhang can be present on the 5′-end, 3′-end or both ends of either an antisense or sense strand of a dsRNA.

In one embodiment, the antisense strand of a dsRNA has a 1-10 nucleotide, e.g., a 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotide, overhang at the 3′-end or the 5′-end. In one embodiment, the sense strand of a dsRNA has a 1-10 nucleotide, e.g., a 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotide, overhang at the 3′-end or the 5′-end. In another embodiment, one or more of the nucleotides in the overhang is replaced with a nucleoside thiophosphate.

In certain embodiments, the antisense strand of a dsRNA has a 1-10 nucleotide, e.g., 0-3, 1-3, 2-4, 2-5, 4-10, 5-10, e.g., a 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotide, overhang at the 3′-end or the 5′-end. In one embodiment, the sense strand of a dsRNA has a 1-10 nucleotide, e.g., a 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotide, overhang at the 3′-end or the 5′-end. In another embodiment, one or more of the nucleotides in the overhang is replaced with a nucleoside thiophosphate.

In certain embodiments, the overhang on the sense strand or the antisense strand can include extended lengths longer than 10 nucleotides, e.g., 1-30 nucleotides, 2-30 nucleotides, 10-30 nucleotides, or 10-15 nucleotides in length. In certain embodiments, an extended overhang is on the sense strand of the duplex. In certain embodiments, an extended overhang is present on the 3′end of the sense strand of the duplex. In certain embodiments, an extended overhang is present on the 5′end of the sense strand of the duplex. In certain embodiments, an extended overhang is on the antisense strand of the duplex. In certain embodiments, an extended overhang is present on the 3′end of the antisense strand of the duplex. In certain embodiments, an extended overhang is present on the 5′end of the antisense strand of the duplex. In certain embodiments, one or more of the nucleotides in the overhang is replaced with a nucleoside thiophosphate. In certain embodiments, the overhang includes a self-complementary portion such that the overhang is capable of forming a hairpin structure that is stable under physiological conditions.

The terms “blunt” or “blunt ended” as used herein in reference to a dsRNA mean that there are no unpaired nucleotides or nucleotide analogs at a given terminal end of a dsRNA, i.e., no nucleotide overhang. One or both ends of a dsRNA can be blunt. Where both ends of a dsRNA are blunt, the dsRNA is said to be blunt ended. To be clear, a “blunt ended” dsRNA is a dsRNA that is blunt at both ends, i.e., no nucleotide overhang at either end of the molecule. Most often such a molecule will be double stranded over its entire length.

The term “antisense strand” or “guide strand” refers to the strand of a RNAi agent, e.g., a dsRNA, which includes a region that is substantially complementary to a target sequence, e.g., an APOE mRNA.

As used herein, the term “region of complementarity” refers to the region on the antisense strand that is substantially complementary to a sequence, for example a target sequence, e.g., an APOE nucleotide sequence, as defined herein. Where the region of complementarity is not fully complementary to the target sequence, the mismatches can be in the internal or terminal regions of the molecule. Generally, the most tolerated mismatches are in the terminal regions, e.g., within 5, 4, 3, or 2 nucleotides of the 5′- or 3′-terminus of the RNAi agent.

The term “sense strand” or “passenger strand” as used herein, refers to the strand of a RNAi agent that includes a region that is substantially complementary to a region of the antisense strand as that term is defined herein.

As used herein, the term “cleavage region” refers to a region that is located immediately adjacent to the cleavage site. The cleavage site is the site on the target at which cleavage occurs. In some embodiments, the cleavage region comprises three bases on either end of, and immediately adjacent to, the cleavage site. In some embodiments, the cleavage region comprises two bases on either end of, and immediately adjacent to, the cleavage site. In some embodiments, the cleavage site specifically occurs at the site bound by nucleotides 10 and 11 of the antisense strand, and the cleavage region comprises nucleotides 11, 12 and 13.

As used herein, and unless otherwise indicated, the term “complementary,” when used to describe a first nucleotide sequence in relation to a second nucleotide sequence, refers to the ability of an oligonucleotide or polynucleotide comprising the first nucleotide sequence to hybridize and form a duplex structure under certain conditions with an oligonucleotide or polynucleotide comprising the second nucleotide sequence, as will be understood by the skilled person.

Complementary sequences within a RNAi agent, e.g., within a dsRNA as described herein, include base-pairing of the oligonucleotide or polynucleotide comprising a first nucleotide sequence to an oligonucleotide or polynucleotide comprising a second nucleotide sequence over the entire length of one or both nucleotide sequences. Such sequences can be referred to as “fully complementary” with respect to each other herein. However, where a first sequence is referred to as “substantially complementary” with respect to a second sequence herein, the two sequences can be fully complementary, or they can form one or more, but generally not more than 5, 4, 3 or 2 mismatched base pairs upon hybridization for a duplex up to 30 base pairs, while retaining the ability to hybridize under the conditions most relevant to their ultimate application, e.g., inhibition of gene expression via a RISC pathway. However, where two oligonucleotides are designed to form, upon hybridization, one or more single stranded overhangs, such overhangs shall not be regarded as mismatches with regard to the determination of complementarity. For example, a dsRNA comprising one oligonucleotide 21 nucleotides in length and another oligonucleotide 23 nucleotides in length, wherein the longer oligonucleotide comprises a sequence of 21 nucleotides that is fully complementary to the shorter oligonucleotide, can yet be referred to as “fully complementary” for the purposes described herein.

“Complementary” sequences, as used herein, can also include, or be formed entirely from, non-Watson-Crick base pairs or base pairs formed from non-natural and modified nucleotides, in so far as the above requirements with respect to their ability to hybridize are fulfilled. Such non-Watson-Crick base pairs include, but are not limited to, G:U Wobble or Hoogsteen base pairing.

The terms “complementary,” “fully complementary” and “substantially complementary” herein can be used with respect to the base matching between two oligonucleotides or polynucleotides, such as the sense strand and the antisense strand of a dsRNA, or between the antisense strand of a RNAi agent and a target sequence, as will be understood from the context of their use.

As used herein, a polynucleotide that is “substantially complementary to at least part of” a messenger RNA (mRNA) refers to a polynucleotide that is substantially complementary to a contiguous portion of the mRNA of interest (e.g., an mRNA encoding APOE). For example, a polynucleotide is complementary to at least a part of an APOE mRNA if the sequence is substantially complementary to a non-interrupted portion of an mRNA encoding APOE.

Accordingly, in some embodiments, the antisense strand polynucleotides disclosed herein are fully complementary to the target APOE sequence. In other embodiments, the antisense strand polynucleotides disclosed herein are substantially complementary to the target APOE sequence and comprise a contiguous nucleotide sequence which is at least about 80% complementary over its entire length to the equivalent region of the nucleotide sequence of SEQ ID NOs: 1, 3, 5, 7, or 9 for APOE, or a fragment of SEQ ID NOs: 1, 3, 5, 7, or 9 for APOE, such as about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% complementary.

In other embodiments, the antisense polynucleotides disclosed herein are substantially complementary to the target APOE sequence and comprise a contiguous nucleotide sequence which is at least about 80% complementary over its entire length to any one of the sense strand nucleotide sequences in any one of Tables 2-5 and 7-10 for APOE, or a fragment of any one of the sense strand nucleotide sequences in any one of Tables 2-5 and 7-10 for APOE, such as about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% complementary.

In one embodiment, an RNAi agent of the disclosure includes a sense strand that is substantially complementary to an antisense polynucleotide which, in turn, is the same as a target APOE sequence, and wherein the sense strand polynucleotide comprises a contiguous nucleotide sequence which is at least about 80% complementary over its entire length to the equivalent region of the nucleotide sequence of SEQ ID NOs: 2, 4, 6, 8, or 10, or a fragment of any one of SEQ ID NOs: 2, 4, 6, 8, or 10, such as about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99% complementary.

In one embodiment, at least partial suppression of the expression of an APOE gene, is assessed by a reduction of the amount of APOE mRNA which can be isolated from or detected in a first cell or group of cells in which an APOE gene is transcribed and which has or have been treated such that the expression of an APOE gene is inhibited, as compared to a second cell or group of cells substantially identical to the first cell or group of cells but which has or have not been so treated (control cells). The degree of inhibition may be expressed in terms of:

$\frac{(mRNA in control cells) - (mRNA in treated cells)}{(mRNA in control cells)} • 100 %$

The phrase “contacting a cell with an RNAi agent,” such as a dsRNA, as used herein, includes contacting a cell by any possible means. Contacting a cell with an RNAi agent includes contacting a cell in vitro with the RNAi agent or contacting a cell in vivo with the RNAi agent. The contacting may be done directly or indirectly. Thus, for example, the RNAi agent may be put into physical contact with the cell by the individual performing the method, or alternatively, the RNAi agent may be put into a situation that will permit or cause it to subsequently come into contact with the cell.

Contacting a cell in vitro may be done, for example, by incubating the cell with the RNAi agent. Contacting a cell in vivo may be done, for example, by injecting the RNAi agent into or near the tissue where the cell is located, or by injecting the RNAi agent into another area, e.g., the central nervous system (CNS), optionally via intrathecal, intravitreal or other injection, or to the bloodstream or the subcutaneous space, such that the agent will subsequently reach the tissue where the cell to be contacted is located. For example, the RNAi agent may contain or be coupled to a ligand, e.g., a lipophilic moiety or moieties as described below and further detailed, e.g., in PCT/US2019/031170, which is incorporated herein by reference, that directs or otherwise stabilizes the RNAi agent at a site of interest, e.g., the CNS. In some embodiments, the RNAi agent may contain or be coupled to a ligand, e.g., one or more GalNAc derivatives as described below, that directs or otherwise stabilizes the RNAi agent at a site of interest, e.g., the liver. In other embodiments, the RNAi agent may contain or be coupled to a lipophilic moiety or moieties and one or more GalNAc derivatives. Combinations of in vitro and in vivo methods of contacting are also possible. For example, a cell may also be contacted in vitro with an RNAi agent and subsequently transplanted into a subject.

In one embodiment, contacting a cell with an RNAi agent includes “introducing” or “delivering the RNAi agent into the cell” by facilitating or effecting uptake or absorption into the cell. Absorption or uptake of a RNAi agent can occur through unaided diffusive or active cellular processes, or by auxiliary agents or devices. Introducing a RNAi agent into a cell may be in vitro or in vivo. For example, for in vivo introduction, a RNAi agent can be injected into a tissue site or administered systemically. In vitro introduction into a cell includes methods known in the art such as electroporation and lipofection. Further approaches are described herein below or are known in the art.

The term “lipophile” or “lipophilic moiety” broadly refers to any compound or chemical moiety having an affinity for lipids. One way to characterize the lipophilicity of the lipophilic moiety is by the octanol-water partition coefficient, log K_ow, where K_owis the ratio of a chemical's concentration in the octanol-phase to its concentration in the aqueous phase of a two-phase system at equilibrium. The octanol-water partition coefficient is a laboratory-measured property of a substance. However, it may also be predicted by using coefficients attributed to the structural components of a chemical which are calculated using first-principle or empirical methods (see, for example, Tetko et al., J. Chem. Inf Comput. Sci. 41:1407-21 (2001), which is incorporated herein by reference in its entirety). It provides a thermodynamic measure of the tendency of the substance to prefer a non-aqueous or oily milieu rather than water (i.e. its hydrophilic/lipophilic balance). In principle, a chemical substance is lipophilic in character when its log K_owexceeds 0. Typically, the lipophilic moiety possesses a log K_owexceeding 1, exceeding 1.5, exceeding 2, exceeding 3, exceeding 4, exceeding 5, or exceeding 10. For instance, the log K_owof 6-amino hexanol, for instance, is predicted to be approximately 0.7. Using the same method, the log K_owof cholesteryl N-(hexan-6-ol) carbamate is predicted to be 10.7.

The lipophilicity of a molecule can change with respect to the functional group it carries. For instance, adding a hydroxyl group or amine group to the end of a lipophilic moiety can increase or decrease the partition coefficient (e.g., log K_ow) value of the lipophilic moiety.

Alternatively, the hydrophobicity of the double-stranded RNAi agent, conjugated to one or more lipophilic moieties, can be measured by its protein binding characteristics. For instance, in certain embodiments, the unbound fraction in the plasma protein binding assay of the double-stranded RNAi agent could be determined to positively correlate to the relative hydrophobicity of the double-stranded RNAi agent, which could then positively correlate to the silencing activity of the double-stranded RNAi agent.

In one embodiment, the plasma protein binding assay determined is an electrophoretic mobility shift assay (EMSA) using human serum albumin protein. An exemplary protocol of this binding assay is illustrated in detail in, e.g., PCT/US2019/031170. The hydrophobicity of the double-stranded RNAi agent, measured by fraction of unbound dsRNA in the binding assay, exceeds 0.15, exceeds 0.2, exceeds 0.25, exceeds 0.3, exceeds 0.35, exceeds 0.4, exceeds 0.45, or exceeds 0.5 for an enhanced in vivo delivery of dsRNA.

Accordingly, conjugating the lipophilic moieties to the internal position(s) of the double-stranded RNAi agent provides optimal hydrophobicity for the enhanced in vivo delivery of siRNA.

The term “lipid nanoparticle” or “LNP” is a vesicle comprising a lipid layer encapsulating a pharmaceutically active molecule, such as a nucleic acid molecule, e.g., a rNAi agent or a plasmid from which a RNAi agent is transcribed. LNPs are described in, for example, U.S. Pat. Nos. 6,858,225, 6,815,432, 8,158,601, and 8,058,069, the entire contents of which are hereby incorporated herein by reference.

As used herein, a “subject” is an animal, such as a mammal, including a primate (such as a human, a non-human primate, e.g., a monkey, and a chimpanzee), or a non-primate (such as a a rat, or a mouse). In a preferred embodiment, the subject is a human, such as a human being treated or assessed for a disease, disorder, or condition that would benefit from reduction in APOE expression; a human at risk for a disease, disorder, or condition that would benefit from reduction in APOE expression; a human having a disease, disorder, or condition that would benefit from reduction in APOE expression; or human being treated for a disease, disorder, or condition that would benefit from reduction in APOE expression as described herein.

As used herein, the terms “treating” or “treatment” refer to a beneficial or desired result including, but not limited to, alleviation or amelioration of one or more signs or symptoms associated with APOE gene expression or APOE protein production, e.g., APOE-associated neurodegenerative disease, such as an amyloid-β-mediated disease, e.g. Alzheimer's disease, Down's syndrome, and cerebral amyloid angiopathy, or a tau-mediated disease, e.g. a primary tauopathy, such as frontotemporal dementia, Progressive supranuclear palsy (PSP), Cordicobasal degeneration (CBD), Pick's disease (PiD), Chronic traumatic encelopathy (CTE), Frontotemporal dementia (FTD, FTDP-17), Frontotemporal lobar degeneration (FTLD), Argyrophilic grain disease (AGD), Primary age-related tauopathy (PART), and Globular glial tauopathies (GGTs), or a secondary tauopathy, e.g., AD, Creuzfeld Jakob's disease, Down's Syndrome, Familial British Dementia, and Dementia pugilistica. Treatment” can also mean prolonging survival as compared to expected survival in the absence of treatment.

The term “lower” in the context of the level of APOE in a subject or a disease marker or symptom refers to a statistically significant decrease in such level. The decrease can be, for example, at least 10%, 15%, 20%, 25%, 30%, %, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more. In certain embodiments, a decrease is at least 20%. In certain embodiments, the decrease is at least 50% in a disease marker, e.g., protein or gene expression level. “Lower” in the context of the level of APOE in a subject is preferably down to a level accepted as within the range of normal for an individual without such disorder. In certain embodiments, “lower” is the decrease in the difference between the level of a marker or symptom for a subject suffering from a disease and a level accepted within the range of normal for an individual, e.g., the level of decrease in bodyweight between an obese individual and an individual having a weight accepted within the range of normal. As used herein, lowering can refer to lowering or predominantly lowering the level of mRNA of an APOE gene having a nucleotide repeat expansion.

As used herein, “prevention” or “preventing,” when used in reference to a disease, disorder, or condition thereof, that would benefit from a reduction in expression of an APOE gene or production of an APOE protein, refers to a reduction in the likelihood that a subject will develop a symptom associated with such a disease, disorder, or condition, e.g., a symptom of an APOE-associated neurodegenerative disease. The failure to develop a disease, disorder, or condition, or the reduction in the development of a symptom associated with such a disease, disorder, or condition (e.g., by at least about 10% on a clinically accepted scale for that disease or disorder), or the exhibition of delayed symptoms delayed (e.g., by days, weeks, months or years) is considered effective prevention.

As used herein, the term “APOE-associated neurodegenerative disease” or “APOE-associated neurodegenerative disorder” is understood as any disease or disorder that would benefit from reduction in the expression and/or activity of APOE. Exemplary APOE-associated neurodegenerative diseases include amyloid-β-mediated diseases, such as, Alzheimer's's disease, Down's syndrome, and cerebral amyloid angiopathy, and tau-mediated diseases, e.g. primary tauopathies, such as Frontotemporal dementia (FTD), Progressive supranuclear palsy (PSP), Cordicobasal degeneration (CBD), Pick's disease (PiD), Globular glial tauopathies (GGTs), frontotemporal dementia with parkinsonism (FTDP, FTDP-17), Chronic traumatic encelopathy (CTE), Dementia pugilistica, Frontotemporal lobar degeneration (FTLD), Argyrophilic grain disease (AGD), and Primary age-related tauopathy (PART), and secondary tauopathies, e.g., AD, Creuzfeld Jakob's disease, Down's Syndrome, and Familial British Dementia.

As used herein, the term “amyloid-β-mediated disease” is a disorder resulting from extracellular accumulation of amyloid-β, which leads to formation of amyloid plaques in brain tissue. Exemplary amyloid-β-mediated diseases include Alzheimer's disease, Down's syndrome, and cerebral amyloid angiopathy (CAA).

As used herein, the term “tau-mediated disease” is a disorder resulting from the aggregation of tau protein into neurofibrillary tangles. Tangles are formed by hyperphosphorylation of tau, causing the protein to dissociate from microtubules and from aggregates. Tauopathies can be divided into “primary tauopathies”, in which the pathology is driven primarily by tau aggregation, and “secondary tauopathies”, in which another factor drives the disease (for example, amyloid-β plaques in Alzheimer's disease) and the presence of tauopathies worsens disease progression. Examples of primary tauopathies include Frontotemporal dementia (FTD) Progressive supranuclear palsy (PSP), Cordicobasal degeneration (CBD), Pick's disease (PiD), Globular glial tauopathies (GGTs), Frontotemporal dementia with parkinsonism (FTDP, FTDP-17), Chronic traumatic encelopathy (CTE), Dementia pugilistica Argyrophilic grain disease (AGD), and Primary age-related tauopathy (PART). Examples of secondary tauopathies include AD, Creuzfeld Jakob's disease, Down's Syndrome and Familial British Dementia.

APOE polymorphism has been associated with multiple tauopathies. The APOE4 allele was found to accelerate neurodegeneration and lower age at onset in frontotemporal dementia (FTD) in patients with MAPT mutations (Koriath, C. et al. (2019) Alzheimers Dement 11:277-280). In addition, the presence of APOE4 correlated with more advanced chronic traumatic encephalopathy (CTE) in autopsy brains of football players with low exposure of repetitive head impacts (Verscaj, C. et al. (2017) Neurology 88 (16) Supplement S9.001) and in brains of boxers (Jordan, B. D. et al. (1997) JAMA 278(2): 136-140). The presence f the APOE4 allele is also associated with increased risk of Creutzfeldt-Jakob disease (CJD) while the presence of the APOE3 allele is associated with protection against susceptibility to Creutzfeldt-Jakob disease (CJD) (Wei, Y. et al. (2013) J Clinical Neuroscience 21(3): 390-394).

Furthermore, Shi et al. described that in the P301S mouse model of FTD, when APOE4 was present there was a marked increase in tau levels, brain atrophy and neuroinflammation as compared the when APOE2, APOE3 or an APOE knockout were present (Shi et al., (2017) Nature 549: 523-527). In another studying using a mouse model that expresses human tau with the P301L mutation found in FTD with parkinsonism, hyperphosphorylated tau, tau aggregation, behavioral abnormalities were worsened on an APOE2 background (Zhao, N. et al., (2018) Nat Commun 9:4388). Zhao et al. further identified an association between the APOE ε2/ε2 genotype with risk of tauopathies in confirmed cases of progressive supranuclear palsy (PSP) and corticobasal degeneration, suggesting that APOE2 might be protective in when amyloid pathology is present, APOE2 is related to increased severity of tau pathology in the absence of amyloid pathology.

“Alzheimer's disease” (“AD”) is a chronic neurodegenerative disease that usually starts slowly and gradually worsens over time. The most common early symptom is difficulty in remembering recent events. As the disease advances, symptoms can include problems with language, disorientation (including easily getting lost), mood swings, loss of motivation, not managing self-care, and behavioral issues. As a person's condition declines, they often withdraw from family and society. Gradually, bodily functions are lost, ultimately leading to death.

Neuropathologically, AD is characterised by loss of neurons and synapses in the cerebral cortex and certain subcortical regions. This loss results in gross atrophy of the affected regions, including degeneration in the temporal lobe and parietal lobe, and parts of the frontal cortex and cingulate gyrus. Degeneration is also present in brainstem nuclei like the locus coeruleus. Studies using MRI and PET have documented reductions in the size of specific brain regions in people with AD as they progressed from mild cognitive impairment to Alzheimer's disease, and in comparison with similar images from healthy older adults.

Both amyloid plaques and neurofibrillary tangles are clearly visible by microscopy in brains of those afflicted by AD. Plaques are dense, mostly insoluble deposits of beta-amyloid peptide and cellular material outside and around neurons. Tangles (neurofibrillary tangles) are aggregates of the microtubule-associated protein tau which has become hyperphosphorylated and accumulate inside the cells themselves. Although many older individuals develop some plaques and tangles as a consequence of ageing, the brains of people with AD have a greater number of them in specific brain regions such as the temporal lobe. Lewy bodies are not rare in the brains of people with AD.

The National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and the Alzheimer's Disease and Related Disorders Association (ADRDA, now known as the Alzheimer's Association) established the most commonly used NINCDS-ADRDA Alzheimer's Criteria for diagnosis in 1984, extensively updated in 2007. These criteria require that the presence of cognitive impairment, and a suspected dementia syndrome, be confirmed by neuropsychological testing for a clinical diagnosis of possible or probable AD. A histopathologic confirmation including a microscopic examination of brain tissue is required for a definitive diagnosis. Good statistical reliability and validity have been shown between the diagnostic criteria and definitive histopathological confirmation. Eight intellectual domains are most commonly impaired in AD-memory, language, perceptual skills, attention, motor skills, orientation, problem solving and executive functional abilities. These domains are equivalent to the NINCDS-ADRDA Alzheimer's Criteria as listed in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) published by the American Psychiatric Association.

At present, drugs available to treat AD patients include cholinesterase inhibitors and memantine. These drugs can improve quality of life of patients by treating symptoms related to, for example, memory, thinking, and language, however, they do not change the progression of the disease or the rate of decline.

The cause of AD is poorly understood but, as discussed above, the presence of APOE4 has shown to be a major risk determinant of late-onset Alzheimer's disease (AD), the symptoms of which develop after age 65, and numerous studies in non-human animal models of amyloid-β-mediated disease (AD) and tau-mediated disease have demonstrated that inhibiting APOE, e.g., APOE4, has a beneficial effect on the formation of amyloid plaques and cognitive abilities.

“Down's syndrome” (“DS”), also known as trisomy 21, is a genetic order caused by the presence of all or part of a third copy of chromosome 21. DS is a life-long condition associated with intellectual disability, a characteristic facial appearance, weak muscle tone in infancy, and people with DS often experience a gradual decline in cognitive ability. The third chromosome 21 carries an extra amyloid precursor protein (APP) gene, and excess amyloid production leading to buildup of amyloid-β plaques and consequently increased risk of early-onset Alzheimer's disease (AD) to more than 50%. Another gene that is triplicated in DS is DYRK1A, which affects alternative splicing of tau, priming tau for abnormal hyperphosphorylation and promote neurofibrillary degeneration (Hartley D. et al. (2016) Alzheimers Dement 11(6): 700-709). DS individuals with AD have neuropathological changes similar to general AD patients, including amyloid plaques, tau neurofibrillary tangles, oxidative damage, and neuron loss. Elevated levels of both amyloid and tau are found in cerebrospinal fluid of DS individuals (Lee, N.C. et al. (2017) Neurology and Therapy 6: 69-81).

“Cerebral amyloid angiopathy” (“CAA”) is a form of angiopathy in which amyloid plaques are deposited in the walls of small to medium blood vessels and certain areas of the brain. The amyloid plaques damage brain cells and impair various parts of the brain. In addition, the amyloid deposits in blood vessels replace the muscle and elastic fibers that give the blood vessels flexibility, causing them to become prone to breakage. CAA may lead to dementia, intracranial hemorrhage and transient neurologic events. CAA has been recognized as one of the morphologic hallmarks of Alzheimer's disease. Mutations in the amyloid-β precursor protein (APP) gene are the most common cause of hereditary CAA (Desimone C. V. et al. (2017) J Am Coll Cardiol 70(9): 1173-1182).

“Frontotemporal dementia” (“FTD”), which encompasses diseases such as Pick's disease, Progressive supranuclear palsy (PSP), and Cordicobasal denegearion (CBD). FTD is a common type of dementia in patients younger than 65 years of age and encompasses a group of neurodegenerative diseases characterized by progressive decline in behavior, executive function, or language. In FTD, nerve cells in the frontal and temporal lobes of the brain are lost, and therefore FTD is also called Frontotemporal lobar degeneration (FTLD). Mutations in the microtubule-associated protein tau (MAPT) gene and accumulation of tau are found in several subtypes of FTD, including Pick's disease, Progressive supranuclear palsy (PSP), and Cordicobasal denegearion (CBD).

“Pick's disease” is characterized by striking knife-edge atrophy of frontal, temporal, and cingulate gyri where the parietal lobe is better preserved.

“Corticobasal degeneration” (“CBD”) is characterized by predominant loss of cells in the dorsal prefrontal cortex, supplemental motor area, peri-Rolandic cortex, and subcortical nuclei.

“Progressive supranuclear palsy” (“PSP”) is associated with atrophy of the frontal convexity; subcortical atrophy is severe at the level of globus pallidus, subthalamic nucleus, and brainstem nuclei (Olney, N. T. et al. (2017) Neurol Clin 35(2): 339-374).

“Globular glial tauopathies” (“GGTs”) are a type of rare frontotemporal lobar degeneration (FLD) that have widespread, globular inclusions in astrocytes and oligodendrocytes containing the 4-repeat tau isoform. These cases are associated with a range of clinical presentations that correlate with the severity and distribution of underlying tau pathology and neurodegeneration (Ahmed, Z. et al. (2013) Acta Neuropathol 126(4): 537-544).

“Frontotemporal dementia with parkinsonism” (“FTDP”) is a less common type of FTD that also affects movement. Chromosome 17 was found be linked to FTDP (FTDP-17) and mutations on the microtubule-associated protein tau (MAPT) on chromosome 17 were found in many kindreds with familial FTDP-17. FTDP-17 due to mutations in MAPT starts between 25-65 years of age, and penetrance is close to 100%. Symptoms involve executive dysfunction and altered personality and behavior with aphasia and parkinsonism evolving in many individuals (Boeve, B. F. et al. (2008) Arch Neurol 65(4): 460-464).

“Chronic traumatic encephalopathy” (“CTE”) is a debilitating neurodegenerative disease resulting from repetitive mild traumatic brain injuries found in many athletes, especially football players. The neuropathological signature of CTE includes accumulation of phosphorylated tau in sulci and peri-vascular regions, microgliosis, and astrocytosis; from some tau deposits at early stage, the disease can progress to global brain atrophy at late stage. CTE can progress through many years from mild symptoms such as short-term memory deficits and mild aggression to advanced language deficits and psychotic symptoms including paranoia and parkinsonism (Fesharaki-Zadeh, A. (2019) Front Neurol 10:713).

“Dementia pugilistica” is a form of CTE that involves gross impairment of cognitive and motor functions due to repetitive blows to the head from boxing (Castellani. R. J et al. (2017) J Alzheimers Dis 60(4): 1209-1221).

“Argyrophilic grain disease” (“AGD”) is a highly frequent sporadic tauopathy and the second-most-common neurodegenerative disease after Alzheimer's disease in several studies. AGD is a late-onset neurodegenerative disease characterized by small spindle- or comma-shaped, silver stain positive lesions in neuronal processes referred to as argyrophilic grains (AG). Phosphorylated-tau is a major component of AG. The most common AGD manifestation is slowly progressive, amnestic and mild cognitive impairment, accompanied by a high prevalence of neuropsychiatric symptoms. Due to the lack of prominent clinical features, AGD is often only diagnosed postmortem based on three pathologic features: AG, oligodendrocytic coiled bodies and neuronal tangles (Rodriguez, R. D. et al. (2015) Dement Neuropsychol 9(1): 2-8).

“Primary age-related tauopathy” (“PART”) is a pathology commonly observed postmortem in the brains of aged individuals whose cognitive functions are normal or only mildly impaired. PART brains have tau neurofibrillary tangles indistinguishable from that of Alzheimer's disease but do not have amyloid-β plaques (Crary, J. F. et al. (2014) Acta Neuropathol 128(6): 755-66).

“Creuzfeld Jakob's disease” (“CJD”) belongs to a family of human and animal diseases known as the transmissible spongiform encephalopathies (TSEs) or prion diseases. A prion-derived from “protein” and “infectious”—causes CJD in people and TSEs in animals. Spongiform refers to the characteristic appearance of infected brains, which become filled with holes until they resemble sponges when examined under a microscope. CJD is a rare, degenerative and fatal brain disorder, usually appears in later life and runs a rapid course. Typical onset of symptoms occurs at about age 60, and about 70 percent of individuals die within one year. In the early stages of the disease, people may have failing memory, behavioral changes, lack of coordination, and visual disturbances. As the illness progresses, mental deterioration becomes pronounced and involuntary movements, blindness, weakness of extremities, and coma may occur. In addition to prion plaques, tau pathology is also observed in several brain regions of CJD patients, and the cerebrospinal fluid of patients with widespread taupathology also has elevated total tau protein (Kovacs, G. G et al. (2017) Brain Pathol 3: 332-344).

“Familial British dementia” (“FBD”) is a type of cerebral amyloid angiopathy that was first documented in affected members of a large British pedigree with clinical presentations including dementia, spastic tetreparesis and cerebellar ataxia. FBD is caused by a mutation in the BRI2 gene. Amyloid plaques in FBD are made up of amyloid-Bri, and tau positive neurofibrillary tangles are found in areas affected by amyloid-Bri lesions. Immunoblotting of tau in FBD is similar to the patterns of tau in Alzheimer's disease (Holton J. L. et al. (2001) Am J Patho 2: 515-526).

“Therapeutically effective amount,” as used herein, is intended to include the amount of an RNAi agent that, when administered to a subject having an APOE-associated neurodegenerative disease, is sufficient to effect treatment of the disease (e.g., by diminishing, ameliorating, or maintaining the existing disease or one or more symptoms of disease). The “therapeutically effective amount” may vary depending on the RNAi agent, how the agent is administered, the disease and its severity and the history, age, weight, family history, genetic makeup, the types of preceding or concomitant treatments, if any, and other individual characteristics of the subject to be treated.

“Prophylactically effective amount,” as used herein, is intended to include the amount of a RNAi agent that, when administered to a subject having an APOE-associated neurodegenerative disorder, is sufficient to prevent or ameliorate the disease or one or more symptoms of the disease. Ameliorating the disease includes slowing the course of the disease or reducing the severity of later-developing disease. The “prophylactically effective amount” may vary depending on the RNAi agent, how the agent is administered, the degree of risk of disease, and the history, age, weight, family history, genetic makeup, the types of preceding or concomitant treatments, if any, and other individual characteristics of the patient to be treated.

A “therapeutically-effective amount” or “prophylactically effective amount” also includes an amount of a RNAi agent that produces some desired local or systemic effect at a reasonable benefit/risk ratio applicable to any treatment. A RNAi agent employed in the methods of the present disclosure may be administered in a sufficient amount to produce a reasonable benefit/risk ratio applicable to such treatment.

The phrase “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human subjects and animal subjects without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

The phrase “pharmaceutically-acceptable carrier” as used herein means a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, manufacturing aid (e.g., lubricant, talc magnesium, calcium or zinc stearate, or steric acid), or solvent encapsulating material, involved in carrying or transporting the subject compound from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the subject being treated. Some examples of materials which can serve as pharmaceutically-acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) lubricating agents, such as magnesium state, sodium lauryl sulfate and talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) pH buffered solutions; (21) polyesters, polycarbonates or polyanhydrides; (22) bulking agents, such as polypeptides and amino acids (23) serum component, such as serum albumin, HDL and LDL; and (22) other non-toxic compatible substances employed in pharmaceutical formulations.

The term “sample,” as used herein, includes a collection of similar fluids, cells, or tissues isolated from a subject, as well as fluids, cells, or tissues present within a subject. Examples of biological fluids include blood, serum and serosal fluids, plasma, cerebrospinal fluid, ocular fluids, lymph, urine, saliva, and the like. Tissue samples may include samples from tissues, organs or localized regions. For example, samples may be derived from particular organs, parts of organs, or fluids or cells within those organs. In certain embodiments, samples may be derived from the brain (e.g., whole brain or certain segments of brain, e.g., striatum, or certain types of cells in the brain, such as, e.g., neurons and glial cells (astrocytes, oligodendrocytes, microglial cells)). In other embodiments, a “sample derived from a subject” refers to liver tissue (or subcomponents thereof) derived from the subject. In some embodiments, a “sample derived from a subject” refers to blood drawn from the subject or plasma or serum derived therefrom. In further embodiments, a “sample derived from a subject” refers to brain tissue (or subcomponents thereof) or retinal tissue (or subcomponents thereof) derived from the subject.

II. RNAi Agents of the Disclosure

Described herein are RNAi agents which inhibit the expression of an APOE gene. In some embodiments, the RNAi agents provided herein inhibit the expression of an APOE2 allele, an APOE3 allele, and an APOE4 allele. In other embodiments, the RNAi agent provided herein inhibit the expression of an APOE4 allele, e.g., the RNAi agents do not substantially inhibit the expression of an APOE2 allele or an APOE3 allele, e.g., the inhibition of APOE2 and/or APOE3 expression is no more than about 10%. In one embodiment, the RNAi agent includes double stranded ribonucleic acid (dsRNA) molecules for inhibiting the expression of an APOE gene in a cell, such as a cell within a subject, e.g., a mammal, such as a human having an APOE-associated neurodegenerative disease e.g., an amyloid-β-mediated disease, such as, Alzheimer's's disease, Down's syndrome, and cerebral amyloid angiopathy, and tau-mediated diseases, e.g. a primary tauopathy, such as Frontotemporal dementia (FTD), Progressive supranuclear palsy (PSP), Cordicobasal degeneration (CBD), Pick's disease (PiD), Globular glial tauopathies (GGTs), frontotemporal dementia with parkinsonism (FTDP, FTDP-17), Chronic traumatic encelopathy (CTE), Dementia pugilistica, Frontotemporal lobar degeneration (FTLD), Argyrophilic grain disease (AGD), and Primary age-related tauopathy (PART), or a secondary tauopathy, e.g., AD, Creuzfeld Jakob's disease, Down's Syndrome, and Familial British Dementia. The dsRNA includes an antisense strand having a region of complementarity which is complementary to at least a part of an mRNA formed in the expression of an APOE gene, The region of complementarity is about 15-30 nucleotides or less in length. Upon contact with a cell expressing the APOE gene, the RNAi agent inhibits the expression of the APOE gene (e.g., a human gene, a primate gene, a non-primate gene) by at least 50% as assayed by, for example, a PCR or branched DNA (bDNA)-based method, or by a protein-based method, such as by immunofluorescence analysis, using, for example, western blotting or flowcytometric techniques. In one embodiment, the level of knockdown is assayed at a 10 nM concentration of siRNA in human neuroblastoma BE(2)-C cells using a Dual-Luciferase assay method provided in Example 1 below.

A dsRNA includes two RNA strands that are complementary and hybridize to form a duplex structure under conditions in which the dsRNA will be used. One strand of a dsRNA (the antisense strand) includes a region of complementarity that is substantially complementary, and generally fully complementary, to a target sequence. The target sequence can be derived from the sequence of an mRNA formed during the expression of an APOE gene. The other strand (the sense strand) includes a region that is complementary to the antisense strand, such that the two strands hybridize and form a duplex structure when combined under suitable conditions. As described elsewhere herein and as known in the art, the complementary sequences of a dsRNA can also be contained as self-complementary regions of a single nucleic acid molecule, as opposed to being on separate oligonucleotides.

Generally, the duplex structure is 15 to 30 base pairs in length, e.g., 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24, 20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 base pairs in length. In certain preferred embodiments, the duplex structure is 18 to 25 base pairs in length, e.g., 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-25, 20-24, 20-23, 20-22, 20-21, 21-25, 21-24, 21-23, 21-22, 22-25, 22-24, 22-23, 23-25, 23-24 or 24-25 base pairs in length, for example, 19-21 basepairs in length. Ranges and lengths intermediate to the above recited ranges and lengths are also contemplated to be part of the disclosure.

Similarly, the region of complementarity to the target sequence is 15 to 30 nucleotides in length, e.g., 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24,20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 nucleotides in length, for example 19-23 nucleotides in length or 21-23 nucleotides in length. Ranges and lengths intermediate to the above recited ranges and lengths are also contemplated to be part of the disclosure.

In some embodiments, the dsRNA is 15 to 23 nucleotides in length, or 25 to 30 nucleotides in length. In general, the dsRNA is long enough to serve as a substrate for the Dicer enzyme. For example, it is well known in the art that dsRNAs longer than about 21-23 nucleotides can serve as substrates for Dicer. As the ordinarily skilled person will also recognize, the region of an RNA targeted for cleavage will most often be part of a larger RNA molecule, often an mRNA molecule. Where relevant, a “part” of an mRNA target is a contiguous sequence of an mRNA target of sufficient length to allow it to be a substrate for RNAi-directed cleavage (i.e., cleavage through a RISC pathway).

One of skill in the art will also recognize that the duplex region is a primary functional portion of a dsRNA, e.g., a duplex region of about 15 to 36 base pairs, e.g., 15-36, 15-35, 15-34, 15-33, 15-32, 15-31, 15-30, 15-29, 15-28, 15-27, 15-26, 15-25, 15-24, 15-23, 15-22, 15-21, 15-20, 15-19, 15-18, 15-17, 18-30, 18-29, 18-28, 18-27, 18-26, 18-25, 18-24, 18-23, 18-22, 18-21, 18-20, 19-30, 19-29, 19-28, 19-27, 19-26, 19-25, 19-24, 19-23, 19-22, 19-21, 19-20, 20-30, 20-29, 20-28, 20-27, 20-26, 20-25, 20-24, 20-23, 20-22, 20-21, 21-30, 21-29, 21-28, 21-27, 21-26, 21-25, 21-24, 21-23, or 21-22 base pairs, for example, 19-21 base pairs. Thus, in one embodiment, to the extent that it becomes processed to a functional duplex, of e.g., 15-30 base pairs, that targets a desired RNA for cleavage, an RNA molecule or complex of RNA molecules having a duplex region greater than 30 base pairs is a dsRNA. Thus, an ordinarily skilled artisan will recognize that in one embodiment, a miRNA is a dsRNA. In another embodiment, a dsRNA is not a naturally occurring miRNA. In another embodiment, a RNAi agent useful to target APOE expression is not generated in the target cell by cleavage of a larger dsRNA.

A dsRNA as described herein can further include one or more single-stranded nucleotide overhangs e.g., 1, 2, 3, or 4 nucleotides. A nucleotide overhang can comprise or consist of a nucleotide/nucleoside analog, including a deoxynucleotide/nucleoside. The overhang(s) can be on the sense strand, the antisense strand or any combination thereof. Furthermore, the nucleotide(s) of an overhang can be present on the 5′-end, 3′-end or both ends of either an antisense or sense strand of a dsRNA.

A dsRNA can be synthesized by standard methods known in the art.

In one aspect, a dsRNA of the disclosure includes at least two nucleotide sequences, a sense sequence and an antisense sequence. The sense strand sequence for APOE may be selected from the group of sequences provided in any one of Tables 2-5 and 7-10, and the corresponding nucleotide sequence of the antisense strand of the sense strand may be selected from the group of sequences of any one of Tables 2-5 and 7-10. In this aspect, one of the two sequences is complementary to the other of the two sequences, with one of the sequences being substantially complementary to a sequence of an mRNA generated in the expression of an APOE gene. As such, in this aspect, a dsRNA will include two oligonucleotides, where one oligonucleotide is described as the sense strand (passenger strand) in any one of Tables 2-5 and 7-10, and the second oligonucleotide is described as the corresponding antisense strand (guide strand) of the sense strand in any one of Tables 2-5 and 7-10 for APOE.

In one embodiment, the substantially complementary sequences of the dsRNA are contained on separate oligonucleotides. In another embodiment, the substantially complementary sequences of the dsRNA are contained on a single oligonucleotide.

It will be understood that, although the sequences in Tables 3, 5, 8, and 10 are described as modified or conjugated sequences and the sequences in Tables 2, 4, 7, and 9 are described as unmodified, the RNA of the RNAi agent of the disclosure e.g., a dsRNA of the disclosure, may comprise any one of the sequences set forth in any one of Tables 2-5 and 7-10 that is un-modified, un-conjugated, or modified or conjugated differently than described therein. One or more lipophilic ligands and/or one or more GalNAc ligands can be included in any of the positions of the RNAi agents provided in the instant application.

The skilled person is well aware that dsRNAs having a duplex structure of about 20 to 23 base pairs, e.g., 21, base pairs have been hailed as particularly effective in inducing RNA interference (Elbashir et al., (2001) EMBO J., 20:6877-6888). However, others have found that shorter or longer RNA duplex structures can also be effective (Chu and Rana (2007) RNA 14:1714-1719; Kim et al. (2005) Nat Biotech 23:222-226). In the embodiments described above, by virtue of the nature of the oligonucleotide sequences provided herein, dsRNAs described herein can include at least one strand of a length of minimally 21 nucleotides. It can be reasonably expected that shorter duplexes minus only a few nucleotides on one or both ends can be similarly effective as compared to the dsRNAs described above. Hence, dsRNAs having a sequence of at least 15, 16, 17, 18, 19, 20, or more contiguous nucleotides derived from one of the sequences provided herein, and differing in their ability to inhibit the expression of an APOE gene by not more than 10, 15, 20, 25, or 30% inhibition from a dsRNA comprising the full sequence using the in vitro assay with Cos 7 and a 10 nM concentration of the RNA agent and the PCR assay as provided in the examples herein, are contemplated to be within the scope of the present disclosure.

In addition, the RNAs described herein identify a site(s) in an APOE transcript that is susceptible to RISC-mediated cleavage. As such, the present disclosure further features RNAi agents that target within this site(s). As used herein, a RNAi agent is said to target within a particular site of an RNA transcript if the RNAi agent promotes cleavage of the transcript anywhere within that particular site. Such a RNAi agent will generally include at least about 15 contiguous nucleotides, preferably at least 19 nucleotides, from one of the sequences provided herein coupled to additional nucleotide sequences taken from the region contiguous to the selected sequence in an APOE gene.

An RNAi agent as described herein can contain one or more mismatches to the target sequence. In one embodiment, an RNAi agent as described herein contains no more than 3 mismatches (i.e., 3, 2, 1, or 0 mismatches). In one embodiment, an RNAi agent as described herein contains no more than 2 mismatches. In one embodiment, an RNAi agent as described herein contains no more than 1 mismatch. In one embodiment, an RNAi agent as described herein contains 0 mismatches. In certain embodiments, if the antisense strand of the RNAi agent contains mismatches to the target sequence, the mismatch can optionally be restricted to be within the last 5 nucleotides from either the 5′- or 3′-end of the region of complementarity. For example, in such embodiments, for a 23 nucleotide RNAi agent, the strand which is complementary to a region of an APOE gene generally does not contain any mismatch within the central 13 nucleotides. The methods described herein or methods known in the art can be used to determine whether an RNAi agent containing a mismatch to a target sequence is effective in inhibiting the expression of an APOE gene. Consideration of the efficacy of RNAi agents with mismatches in inhibiting expression of an APOE gene is important, especially if the particular region of complementarity in an APOE gene is known to have polymorphic sequence variation within the population.

III. Modified RNAi Agents of the Disclosure

In one embodiment, the RNA of the RNAi agent of the disclosure e.g., a dsRNA, is un-modified, and does not comprise, e.g., chemical modifications or conjugations known in the art and described herein. In preferred embodiments, the RNA of an RNAi agent of the disclosure, e.g., a dsRNA, is chemically modified to enhance stability or other beneficial characteristics. In certain embodiments of the disclosure, substantially all of the nucleotides of an RNAi agent of the disclosure are modified. In other embodiments of the disclosure, all of the nucleotides of an RNAi agent of the disclosure are modified. RNAi agents of the disclosure in which “substantially all of the nucleotides are modified” are largely but not wholly modified and can include not more than 5, 4, 3, 2, or 1 unmodified nucleotides. In still other embodiments of the disclosure, RNAi agents of the disclosure can include not more than 5, 4, 3, 2 or 1 modified nucleotides.

The nucleic acids featured in the disclosure can be synthesized or modified by methods well established in the art, such as those described in “Current protocols in nucleic acid chemistry,” Beaucage, S. L. et al. (Edrs.), John Wiley & Sons, Inc., New York, N.Y., USA, which is hereby incorporated herein by reference. Modifications include, for example, end modifications, e.g., 5′-end modifications (phosphorylation, conjugation, inverted linkages) or 3′-end modifications (conjugation, DNA nucleotides, inverted linkages, etc.); base modifications, e.g., replacement with stabilizing bases, destabilizing bases, or bases that base pair with an expanded repertoire of partners, removal of bases (abasic nucleotides), or conjugated bases; sugar modifications (e.g., at the 2′-position or 4′-position) or replacement of the sugar; or backbone modifications, including modification or replacement of the phosphodiester linkages. Specific examples of RNAi agents useful in the embodiments described herein include, but are not limited to, RNAs containing modified backbones or no natural internucleoside linkages. RNAs having modified backbones include, among others, those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art, modified RNAs that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides. In some embodiments, a modified RNAi agent will have a phosphorus atom in its internucleoside backbone.

Modified RNA backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3′-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3′-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3′-5′ linkages, 2′-5′-linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3′-5′ to 5′-3′ or 2′-5′ to 5′-2′. Various salts, e.g., sodium salts, mixed salts and free acid forms are also included.

Representative U.S. patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U.S. Pat. Nos. 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,195; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,316; 5,550,111; 5,563,253; 5,571,799; 5,587,361; 5,625,050; 6,028,188; 6,124,445; 6,160,109; 6,169,170; 6,172,209; 6,239,265; 6,277,603; 6,326,199; 6,346,614; 6,444,423; 6,531,590; 6,534,639; 6,608,035; 6,683,167; 6,858,715; 6,867,294; 6,878,805; 7,015,315; 7,041,816; 7,273,933; 7,321,029; and RE39,464, the entire contents of each of which are hereby incorporated herein by reference.

Modified RNA backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatoms and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH₂component parts.

Representative U.S. patents that teach the preparation of the above oligonucleosides include, but are not limited to, U.S. Pat. Nos. 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,64,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; and, 5,677,439, the entire contents of each of which are hereby incorporated herein by reference.

In other embodiments, suitable RNA mimetics are contemplated for use in RNAi agents, in which both the sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an RNA mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar backbone of an RNA is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative U.S. patents that teach the preparation of PNA compounds include, but are not limited to, U.S. Pat. Nos. 5,539,082; 5,714,331; and 5,719,262, the entire contents of each of which are hereby incorporated herein by reference. Additional PNA compounds suitable for use in the RNAi agents of the disclosure are described in, for example, in Nielsen et al., Science, 1991, 254, 1497-1500.

Some embodiments featured in the disclosure include RNAs with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular —CH₂—NH—CH₂—, —CH₂—N(CH₃)—O—CH₂— [known as a methylene (methylimino) or MMI backbone], —CH₂—O—N(CH₃)—CH₂—, —CH₂—N(CH₃)—N(CH₃)—CH₂— and —N(CH₃)—CH₂—CH₂— the above-referenced U.S. Pat. No. 5,489,677, and the amide backbones of the above-referenced U.S. Pat. No. 5,602,240. In some embodiments, the RNAs featured herein have morpholino backbone structures of the above-referenced U.S. Pat. No. 5,034,506. The native phosphodiester backbone can be represented as O—P(O)(OH)—OCH₂—.

Modified RNAs can also contain one or more substituted sugar moieties. The RNAi agents, e.g., dsRNAs, featured herein can include one of the following at the 2′-position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl can be substituted or unsubstituted C₁to C₁₀alkyl or C₂to C₁₀alkenyl and alkynyl. Exemplary suitable modifications include O[(CH₂)_nO]_mCH₃, O(CH₂)_-nOCH₃, O(CH₂)_nNH₂, O(CH₂)_nCH₃, O(CH₂)_nONH₂, and O(CH₂)_nON[(CH₂)·CH₃)]₂, where n and m are from 1 to about 10. In other embodiments, dsRNAs include one of the following at the 2′ position: C₁to C₁₀lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH₃, OCN, Cl, Br, CN, CF₃, OCF₃, SOCH₃, SO₂CH₃, ONO₂, NO₂, N₃, NH₂, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of a RNAi agent, or a group for improving the pharmacodynamic properties of a RNAi agent, and other substituents having similar properties. In some embodiments, the modification includes a 2′-methoxyethoxy (2′-O—CH₂CH₂OCH₃, also known as 2′-O-(2-methoxyethyl) or 2′-MOE) (Martin et al., Helv. Chim. Acta, 1995, 78:486-504) i.e., an alkoxy-alkoxy group. Another exemplary modification is 2′-dimethylaminooxyethoxy, i.e., a O(CH₂)₂ON(CH₃)₂group, also known as 2′-DMAOE, as described in examples herein below, and 2′-dimethylaminoethoxyethoxy (also known in the art as 2′-O-dimethylaminoethoxyethyl or 2′-DMAEOE), i.e., 2′-O—CH₂—O—CH₂—N(CH₂)₂. Further exemplary modifications include: 5′-Me-2′-F nucleotides, 5′-Me-2′-OMe nucleotides, 5′-Me-2′-deoxynucleotides, (both R and S isomers in these three families); 2′-alkoxyalkyl; and 2′-NMA (N-methylacetamide).

Other modifications include 2′-methoxy (2′-OCH₃), 2′-aminopropoxy (2′-OCH₂CH₂CH₂NH₂), 2′-O-hexadecyl, and 2′-fluoro (2′-F). Similar modifications can also be made at other positions on the RNA of a RNAi agent, particularly the 3′ position of the sugar on the 3′ terminal nucleotide or in 2′-5′ linked dsRNAs and the 5′ position of 5′ terminal nucleotide. RNAi agents can also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative U.S. patents that teach the preparation of such modified sugar structures include, but are not limited to, U.S. Pat. Nos. 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; and 5,700,920, certain of which are commonly owned with the instant application. The entire contents of each of the foregoing are hereby incorporated herein by reference.

An RNAi agent of the disclosure can also include nucleobase (often referred to in the art simply as “base”) modifications or substitutions. As used herein, “unmodified” or “natural” nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases include other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl anal other 8-substituted adenines and guanines, 5-halo, particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-daazaadenine and 3-deazaguanine and 3-deazaadenine. Further nucleobases include those disclosed in U.S. Pat. No. 3,687,808, those disclosed in Modified Nucleosides in Biochemistry, Biotechnology and Medicine, Herdewijn, P. ed. Wiley-VCH, 2008; those disclosed in The Concise Encyclopedia Of Polymer Science And Engineering, pages 858-859, Kroschwitz, J. L, ed. John Wiley & Sons, 1990, these disclosed by Englisch et al., (1991) Angewandte Chemie, International Edition, 30:613, and those disclosed by Sanghvi, Y S., Chapter 15, dsRNA Research and Applications, pages 289-302, Crooke, S. T. and Lebleu, B., Ed., CRC Press, 1993. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds featured in the disclosure. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and 0-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2° C. (Sanghvi, Y. S., Crooke, S. T. and Lebleu, B., Eds., dsRNA Research and Applications, CRC Press, Boca Raton, 1993, pp. 276-278) and are exemplary base substitutions, even more particularly when combined with 2′-O-methoxyethyl sugar modifications.

Representative U.S. patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include, but are not limited to, the above noted U.S. Pat. Nos. 3,687,808, 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617; 5,681,941; 5,750,692; 6,015,886; 6,147,200; 6,166,197; 6,222,025; 6,235,887; 6,380,368; 6,528,640; 6,639,062; 6,617,438; 7,045,610; 7,427,672; and 7,495,088, the entire contents of each of which are hereby incorporated herein by reference.

In some embodiments, an RNAi agent of the disclosure can also be modified to include one or more bicyclic sugar moieties. A “bicyclic sugar” is a furanosyl ring modified by a ring formed by the bridging of two carbons, whether adjacent or non-adjacent. A “bicyclic nucleoside” (“BNA”) is a nucleoside having a sugar moiety comprising a ring formed by bridging two carbons, whether adjacent or non-adjacent, of the sugar ring, thereby forming a bicyclic ring system. In certain embodiments, the bridge connects the 4′-carbon and the 2′-carbon of the sugar ring, optionally, via the 2′-acyclic oxygen atom. Thus, in some embodiments an agent of the invention may include one or more locked nucleic acids (LNA). A locked nucleic acid is a nucleotide having a modified ribose moiety in which the ribose moiety comprises an extra bridge connecting the 2′ and 4′ carbons. In other words, an LNA is a nucleotide comprising a bicyclic sugar moiety comprising a 4′-CH₂—O-2′ bridge. This structure effectively “locks” the ribose in the 3′-endo structural conformation. The addition of locked nucleic acids to siRNAs has been shown to increase siRNA stability in serum, and to reduce off-target effects (Elmen, J. et al., (2005) Nucleic Acids Research 33(1):439-447; Mook, O R. et al., (2007) Mol Canc Ther 6(3):833-843; Grunweller, A. et al., (2003) Nucleic Acids Research 31(12):3185-3193). Examples of bicyclic nucleosides for use in the polynucleotides of the invention include without limitation nucleosides comprising a bridge between the 4′ and the 2′ ribosyl ring atoms. In certain embodiments, the antisense polynucleotide agents of the invention include one or more bicyclic nucleosides comprising a 4′ to 2′ bridge.

A locked nucleoside can be represented by the structure (omitting stereochemistry),

embedded image

wherein B is a nucleobase or modified nucleobase and L is the linking group that joins the 2′-carbon to the 4′-carbon of the ribose ring. Examples of such 4′ to 2′ bridged bicyclic nucleosides, include but are not limited to 4′-(CH₂)—O-2′ (LNA); 4′-(CH₂)—S-2′; 4′-(CH₂)₂—O-2′ (ENA); 4′-CH(CH₃)—O-2′ (also referred to as “constrained ethyl” or “cEt”) and 4′-CH(CH₂OCH₃)—O-2′ (and analogs thereof; see, e.g., U.S. Pat. No. 7,399,845); 4′-C(CH₃)(CH₃)—O-2′ (and analogs thereof; see e.g., U.S. Pat. No. 8,278,283); 4′-CH₂—N(OCH₃)-2′ (and analogs thereof; see e.g., U.S. Pat. No. 8,278,425); 4′-CH₂—O—N(CH₃)-2′ (see, e.g., U.S. Patent Publication No. 2004/0171570); 4′-CH₂—N(R)—O-2′, wherein R is H, C1-C12 alkyl, or a nitrogen protecting group (see, e.g., U.S. Pat. No. 7,427,672); 4′-CH₂—C(H)(CH₃)-2′ (see, e.g., Chattopadhyaya et al., J. Org. Chem., 2009, 74, 118-134); and 4′-CH₂—C(═CH₂)-2′ (and analogs thereof; see, e.g., U.S. Pat. No. 8,278,426). The entire contents of each of the foregoing are hereby incorporated herein by reference.

Additional representative US patents and US patent Publications that teach the preparation of locked nucleic acid nucleotides include, but are not limited to, the following: U.S. Pat. Nos. 6,268,490; 6,525,191; 6,670,461; 6,770,748; 6,794,499; 6,998,484; 7,053,207; 7,034,133; 7,084,125; 7,399,845; 7,427,672; 7,569,686; 7,741,457; 8,022,193; 8,030,467; 8,278,425; 8,278,426; 8,278,283; US 2008/0039618; and US 2009/0012281, the entire contents of each of which are hereby incorporated herein by reference.

Any of the foregoing bicyclic nucleosides can be prepared having one or more stereochemical sugar configurations including for example α-L-ribofuranose and β-D-ribofuranose (see WO 99/14226).

An RNAi agent of the disclosure can also be modified to include one or more constrained ethyl nucleotides. As used herein, a “constrained ethyl nucleotide” or “cEt” is a locked nucleic acid comprising a bicyclic sugar moiety comprising a 4′-CH(CH3)-0-2′ bridge. In one embodiment, a constrained ethyl nucleotide is in the S conformation referred to herein as “S-cEt.”

An RNAi agent of the disclosure may also include one or more “conformationally restricted nucleotides” (“CRN”). CRN are nucleotide analogs with a linker connecting the C2′ and C4′ carbons of ribose or the C3 and —C5′ carbons of ribose. CRN lock the ribose ring into a stable conformation and increase the hybridization affinity to mRNA. The linker is of sufficient length to place the oxygen in an optimal position for stability and affinity resulting in less ribose ring puckering.

Representative publications that teach the preparation of certain of the above noted CRN include, but are not limited to, US 2013/0190383; and WO 2013/036868, the entire contents of each of which are hereby incorporated herein by reference.

In some embodiments, a RNAi agent of the disclosure comprises one or more monomers that are UNA (unlocked nucleic acid) nucleotides. UNA is unlocked acyclic nucleic acid, wherein any of the bonds of the sugar has been removed, forming an unlocked “sugar” residue. In one example, UNA also encompasses monomer with bonds between C1′-C4′ have been removed (i.e. the covalent carbon-oxygen-carbon bond between the C1′ and C4′ carbons). In another example, the C2′-C3′ bond (i.e. the covalent carbon-carbon bond between the C2′ and C3′ carbons) of the sugar has been removed (see Nuc. Acids Symp. Series, 52, 133-134 (2008) and Fluiter et al., Mol. Biosyst., 2009, 10, 1039 hereby incorporated by reference).

Representative U.S. publications that teach the preparation of UNA include, but are not limited to, U.S. Pat. No. 8,314,227; and US Patent Publication Nos. 2013/0096289; 2013/0011922; and 2011/0313020, the entire contents of each of which are hereby incorporated herein by reference.

Potentially stabilizing modifications to the ends of RNA molecules can include N-(acetylaminocaproyl)-4-hydroxyprolinol (Hyp-C6-NHAc), N-(caproyl-4-hydroxyprolinol (Hyp-C6), N-(acetyl-4-hydroxyprolinol (Hyp-NHAc), thymidine-2′-O-deoxythymidine (ether), N-(aminocaproyl)-4-hydroxyprolinol (Hyp-C6-amino), 2-docosanoyl-uridine-3″-phosphate, inverted base dT(idT) and others. Disclosure of this modification can be found in WO 2011/005861.

Other modifications of a RNAi agent of the disclosure include a 5′ phosphate or 5′ phosphate mimic, e.g., a 5′-terminal phosphate or phosphate mimic on the antisense strand of a RNAi agent. Suitable phosphate mimics are disclosed in, for example US 2012/0157511, the entire contents of which are incorporated herein by reference.

A. Modified RNAi Agents Comprising Motifs of the Disclosure

In certain aspects of the disclosure, the double-stranded RNAi agents of the disclosure include agents with chemical modifications as disclosed, for example, in WO 2013/075035, the entire contents of which are incorporated herein by reference. As shown herein and in WO 2013/075035, a superior result may be obtained by introducing one or more motifs of three identical modifications on three consecutive nucleotides into a sense strand or antisense strand of an RNAi agent, particularly at or near the cleavage site. In some embodiments, the sense strand and antisense strand of the RNAi agent may otherwise be completely modified. The introduction of these motifs interrupts the modification pattern, if present, of the sense or antisense strand. The RNAi agent may be optionally conjugated with a lipophilic ligand, e.g., a C16 ligand, for instance on the sense strand. The RNAi agent may be optionally modified with a (S)-glycol nucleic acid (GNA) modification, for instance on one or more residues of the antisense strand. The resulting RNAi agents present superior gene silencing activity.

Accordingly, the disclosure provides double stranded RNAi agents capable of inhibiting the expression of a target gene (i.e., an APOE gene) in vivo. The RNAi agent comprises a sense strand and an antisense strand. Each strand of the RNAi agent may be 15-30 nucleotides in length. For example, each strand may be 16-30 nucleotides in length, 17-30 nucleotides in length, 25-30 nucleotides in length, 27-30 nucleotides in length, 17-23 nucleotides in length, 17-21 nucleotides in length, 17-19 nucleotides in length, 19-25 nucleotides in length, 19-23 nucleotides in length, 19-21 nucleotides in length, 21-25 nucleotides in length, or 21-23 nucleotides in length. In certain embodiments, each strand is 19-23 nucleotides in length.

The sense strand and antisense strand typically form a duplex double stranded RNA (“dsRNA”), also referred to herein as an “RNAi agent.” The duplex region of an RNAi agent may be 15-30 nucleotide pairs in length. For example, the duplex region can be 16-30 nucleotide pairs in length, 17-30 nucleotide pairs in length, 27-30 nucleotide pairs in length, 17-23 nucleotide pairs in length, 17-21 nucleotide pairs in length, 17-19 nucleotide pairs in length, 19-25 nucleotide pairs in length, 19-23 nucleotide pairs in length, 19-21 nucleotide pairs in length, 21-25 nucleotide pairs in length, or 21-23 nucleotide pairs in length. In another example, the duplex region is selected from 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, and 27 nucleotides in length. In preferred embodiments, the duplex region is 19-21 nucleotide pairs in length.

In one embodiment, the RNAi agent may contain one or more overhang regions or capping groups at the 3′-end, 5′-end, or both ends of one or both strands. The overhang can be 1-6 nucleotides in length, for instance 2-6 nucleotides in length, 1-5 nucleotides in length, 2-5 nucleotides in length, 1-4 nucleotides in length, 2-4 nucleotides in length, 1-3 nucleotides in length, 2-3 nucleotides in length, or 1-2 nucleotides in length. In preferred embodiments, the nucleotide overhang region is 2 nucleotides in length. The overhangs can be the result of one strand being longer than the other, or the result of two strands of the same length being staggered. The overhang can form a mismatch with the target mRNA or it can be complementary to the gene sequences being targeted or can be another sequence. The first and second strands can also be joined, e.g., by additional bases to form a hairpin, or by other non-base linkers.

In one embodiment, the nucleotides in the overhang region of the RNAi agent can each independently be a modified or unmodified nucleotide including, but no limited to 2′-sugar modified, such as, 2-F, 2′-O-methyl, thymidine (T), and any combinations thereof.

For example, TT can be an overhang sequence for either end on either strand. The overhang can form a mismatch with the target mRNA or it can be complementary to the gene sequences being targeted or can be another sequence.

The 5′- or 3′-overhangs at the sense strand, antisense strand or both strands of the RNAi agent may be phosphorylated. In some embodiments, the overhang region(s) contains two nucleotides having a phosphorothioate between the two nucleotides, where the two nucleotides can be the same or different. In one embodiment, the overhang is present at the 3′-end of the sense strand, antisense strand, or both strands. In one embodiment, this 3′-overhang is present in the antisense strand. In one embodiment, this 3′-overhang is present in the sense strand.

The RNAi agent may contain only a single overhang, which can strengthen the interference activity of the RNAi, without affecting its overall stability. For example, the single-stranded overhang may be located at the 3-terminal end of the sense strand or, alternatively, at the 3-terminal end of the antisense strand. The RNAi may also have a blunt end, located at the 5′-end of the antisense strand (or the 3′-end of the sense strand) or vice versa. Generally, the antisense strand of the RNAi has a nucleotide overhang at the 3′-end, and the 5′-end is blunt. While not wishing to be bound by theory, the asymmetric blunt end at the 5′-end of the antisense strand and 3′-end overhang of the antisense strand favor the guide strand loading into RISC process.

In one embodiment, the RNAi agent is a double ended bluntmer of 19 nucleotides in length, wherein the sense strand contains at least one motif of three 2′-F modifications on three consecutive nucleotides at positions 7, 8, 9 from the 5′end. The antisense strand contains at least one motif of three 2′-O-methyl modifications on three consecutive nucleotides at positions 11, 12, 13 from the 5′end.

In another embodiment, the RNAi agent is a double ended bluntmer of 20 nucleotides in length, wherein the sense strand contains at least one motif of three 2′-F modifications on three consecutive nucleotides at positions 8, 9, 10 from the 5′end. The antisense strand contains at least one motif of three 2′-O-methyl modifications on three consecutive nucleotides at positions 11, 12, 13 from the 5′end.

In yet another embodiment, the RNAi agent is a double ended bluntmer of 21 nucleotides in length, wherein the sense strand contains at least one motif of three 2′-F modifications on three consecutive nucleotides at positions 9, 10, 11 from the 5′end. The antisense strand contains at least one motif of three 2′-O-methyl modifications on three consecutive nucleotides at positions 11, 12, 13 from the 5′end.

In one embodiment, the RNAi agent comprises a 21 nucleotide sense strand and a 23 nucleotide antisense strand, wherein the sense strand contains at least one motif of three 2′-F modifications on three consecutive nucleotides at positions 9, 10, 11 from the 5′end; the antisense strand contains at least one motif of three 2′-O-methyl modifications on three consecutive nucleotides at positions 11, 12, 13 from the 5′end, wherein one end of the RNAi agent is blunt, while the other end comprises a 2 nucleotide overhang. Preferably, the 2 nucleotide overhang is at the 3′-end of the antisense strand. When the 2 nucleotide overhang is at the 3′-end of the antisense strand, there may be two phosphorothioate internucleotide linkages between the terminal three nucleotides, wherein two of the three nucleotides are the overhang nucleotides, and the third nucleotide is a paired nucleotide next to the overhang nucleotide. In one embodiment, the RNAi agent additionally has two phosphorothioate internucleotide linkages between the terminal three nucleotides at both the 5′-end of the sense strand and at the 5′-end of the antisense strand. In one embodiment, every nucleotide in the sense strand and the antisense strand of the RNAi agent, including the nucleotides that are part of the motifs are modified nucleotides. In one embodiment each residue is independently modified with a 2′-O-methyl or 2′-fluoro, e.g., in an alternating motif. Optionally, the RNAi agent further comprises a ligand (e.g., a lipophilic ligand, optionally a C16 ligand).

In one embodiment, the RNAi agent comprises a sense and an antisense strand, wherein the sense strand is 25-30 nucleotide residues in length, wherein starting from the 5′ terminal nucleotide (position 1) positions 1 to 23 of the first strand comprise at least 8 ribonucleotides; the antisense strand is 36-66 nucleotide residues in length and, starting from the 3′ terminal nucleotide, comprises at least 8 ribonucleotides in the positions paired with positions 1-23 of sense strand to form a duplex; wherein at least the 3′ terminal nucleotide of antisense strand is unpaired with sense strand, and up to 6 consecutive 3′ terminal nucleotides are unpaired with sense strand, thereby forming a 3′ single stranded overhang of 1-6 nucleotides; wherein the 5′ terminus of antisense strand comprises from 10-30 consecutive nucleotides which are unpaired with sense strand, thereby forming a 10-30 nucleotide single stranded 5′ overhang; wherein at least the sense strand 5′ terminal and 3′ terminal nucleotides are base paired with nucleotides of antisense strand when sense and antisense strands are aligned for maximum complementarity, thereby forming a substantially duplexed region between sense and antisense strands; and antisense strand is sufficiently complementary to a target RNA along at least 19 ribonucleotides of antisense strand length to reduce target gene expression when the double stranded nucleic acid is introduced into a mammalian cell; and wherein the sense strand contains at least one motif of three 2′-F modifications on three consecutive nucleotides, where at least one of the motifs occurs at or near the cleavage site. The antisense strand contains at least one motif of three 2′-O-methyl modifications on three consecutive nucleotides at or near the cleavage site.

In one embodiment, the RNAi agent comprises sense and antisense strands, wherein the RNAi agent comprises a first strand having a length which is at least 25 and at most 29 nucleotides and a second strand having a length which is at most 30 nucleotides with at least one motif of three 2′-O-methyl modifications on three consecutive nucleotides at position 11, 12, 13 from the 5′ end; wherein the 3′ end of the first strand and the 5′ end of the second strand form a blunt end and the second strand is 1-4 nucleotides longer at its 3′ end than the first strand, wherein the duplex region region which is at least 25 nucleotides in length, and the second strand is sufficiently complementary to a target mRNA along at least 19 nucleotide of the second strand length to reduce target gene expression when the RNAi agent is introduced into a mammalian cell, and wherein dicer cleavage of the RNAi agent preferentially results in an siRNA comprising the 3′ end of the second strand, thereby reducing expression of the target gene in the mammal. Optionally, the RNAi agent further comprises a ligand.

In one embodiment, the sense strand of the RNAi agent contains at least one motif of three identical modifications on three consecutive nucleotides, where one of the motifs occurs at the cleavage site in the sense strand.

In one embodiment, the antisense strand of the RNAi agent can also contain at least one motif of three identical modifications on three consecutive nucleotides, where one of the motifs occurs at or near the cleavage site in the antisense strand.

For an RNAi agent having a duplex region of 17-23 nucleotide in length, the cleavage site of the antisense strand is typically around the 10, 11 and 12 positions from the 5′-end. Thus the motifs of three identical modifications may occur at the 9, 10, 11 positions; 10, 11, 12 positions; 11, 12, 13 positions; 12, 13, 14 positions; or 13, 14, 15 positions of the antisense strand, the count starting from the 1^stnucleotide from the 5′-end of the antisense strand, or, the count starting from the 1^stpaired nucleotide within the duplex region from the 5′-end of the antisense strand. The cleavage site in the antisense strand may also change according to the length of the duplex region of the RNAi from the 5′-end.

The sense strand of the RNAi agent may contain at least one motif of three identical modifications on three consecutive nucleotides at the cleavage site of the strand; and the antisense strand may have at least one motif of three identical modifications on three consecutive nucleotides at or near the cleavage site of the strand. When the sense strand and the antisense strand form a dsRNA duplex, the sense strand and the antisense strand can be so aligned that one motif of the three nucleotides on the sense strand and one motif of the three nucleotides on the antisense strand have at least one nucleotide overlap, i.e., at least one of the three nucleotides of the motif in the sense strand forms a base pair with at least one of the three nucleotides of the motif in the antisense strand. Alternatively, at least two nucleotides may overlap, or all three nucleotides may overlap.

In one embodiment, the sense strand of the RNAi agent may contain more than one motif of three identical modifications on three consecutive nucleotides. The first motif may occur at or near the cleavage site of the strand and the other motifs may be a wing modification. The term “wing modification” herein refers to a motif occurring at another portion of the strand that is separated from the motif at or near the cleavage site of the same strand. The wing modification is either adajacent to the first motif or is separated by at least one or more nucleotides. When the motifs are immediately adjacent to each other then the chemistry of the motifs are distinct from each other and when the motifs are separated by one or more nucleotide than the chemistries can be the same or different. Two or more wing modifications may be present. For instance, when two wing modifications are present, each wing modification may occur at one end relative to the first motif which is at or near cleavage site or on either side of the lead motif.

Like the sense strand, the antisense strand of the RNAi agent may contain more than one motif of three identical modifications on three consecutive nucleotides, with at least one of the motifs occurring at or near the cleavage site of the strand. This antisense strand may also contain one or more wing modifications in an alignment similar to the wing modifications that may be present on the sense strand.

In one embodiment, the wing modification on the sense strand or antisense strand of the RNAi agent typically does not include the first one or two terminal nucleotides at the 3′-end, 5′-end or both ends of the strand.

In another embodiment, the wing modification on the sense strand or antisense strand of the RNAi agent typically does not include the first one or two paired nucleotides within the duplex region at the 3′-end, 5′-end or both ends of the strand.

When the sense strand and the antisense strand of the RNAi agent each contain at least one wing modification, the wing modifications may fall on the same end of the duplex region, and have an overlap of one, two or three nucleotides.

When the sense strand and the antisense strand of the RNAi agent each contain at least two wing modifications, the sense strand and the antisense strand can be so aligned that two modifications each from one strand fall on one end of the duplex region, having an overlap of one, two or three nucleotides; two modifications each from one strand fall on the other end of the duplex region, having an overlap of one, two or three nucleotides; two modifications one strand fall on each side of the lead motif, having an overlap of one, two, or three nucleotides in the duplex region.

In one embodiment, the RNAi agent comprises mismatch(es) with the target, within the duplex, or combinations thereof. The mistmatch may occur in the overhang region or the duplex region. The base pair may be ranked on the basis of their propensity to promote dissociation or melting (e.g., on the free energy of association or dissociation of a particular pairing, the simplest approach is to examine the pairs on an individual pair basis, though next neighbor or similar analysis can also be used). In terms of promoting dissociation: A:U is preferred over G:C; G:U is preferred over G:C; and I:C is preferred over G:C (I=inosine). Mismatches, e.g., non-canonical or other than canonical pairings (as described elsewhere herein) are preferred over canonical (A:T, A:U, G:C) pairings; and pairings which include a universal base are preferred over canonical pairings.

In one embodiment, the RNAi agent comprises at least one of the first 1, 2, 3, 4, or 5 base pairs within the duplex regions from the 5′-end of the antisense strand independently selected from the group of: A:U, G:U, I:C, and mismatched pairs, e.g., non-canonical or other than canonical pairings or pairings which include a universal base, to promote the dissociation of the antisense strand at the 5′-end of the duplex.

In one embodiment, the nucleotide at the 1 position within the duplex region from the 5′-end in the antisense strand is selected from the group consisting of A, dA, dU, U, and dT. Alternatively, at least one of the first 1, 2 or 3 base pair within the duplex region from the 5′-end of the antisense strand is an AU base pair. For example, the first base pair within the duplex region from the 5′-end of the antisense strand is an AU base pair.

In another embodiment, the nucleotide at the 3′-end of the sense strand is deoxy-thymidine (dT). In another embodiment, the nucleotide at the 3′-end of the antisense strand is deoxy-thymidine (dT). In one embodiment, there is a short sequence of deoxy-thymidine nucleotides, for example, two dT nucleotides on the 3′-end of the sense or antisense strand.

In one embodiment, the sense strand sequence may be represented by formula (I):

5′ n_p-N_a-(X X X )_i-N_b-Y Y Y -N_b-(Z Z Z )_j-N_a-N_q 3′

(I)

wherein:

i and j are each independently 0 or 1;

p and q are each independently 0-6;

each N_aindependently represents an oligonucleotide sequence comprising 0-25 modified nucleotides, each sequence comprising at least two differently modified nucleotides; each N_bindependently represents an oligonucleotide sequence comprising 0-10 modified nucleotides;

each n_pand n_qindependently represent an overhang nucleotide;

wherein Nb and Y do not have the same modification; and

XXX, YYY and ZZZ each independently represent one motif of three identical modifications on three consecutive nucleotides. Preferably YYY is all 2′-F modified nucleotides.

In one embodiment, the N_aor N_bcomprise modifications of alternating pattern.

In one embodiment, the YYY motif occurs at or near the cleavage site of the sense strand. For example, when the RNAi agent has a duplex region of 17-23 nucleotides in length, the YYY motif can occur at or the vicinity of the cleavage site (e.g.: can occur at positions 6, 7, 8, 7, 8, 9, 8, 9, 10, 9, 10, 11, 10, 11, 12 or 11, 12, 13) of—the sense strand, the count starting from the 1⁴nucleotide, from the 5′-end; or optionally, the count starting at the 1^stpaired nucleotide within the duplex region, from the 5′-end.

In one embodiment, i is 1 and j is 0, or i is 0 and j is 1, or both i and j are 1. The sense strand can therefore be represented by the following formulas:

5′ n_p-N_a-YYY-N_b-ZZZ-N_a-n_q 3′ (Ib);

5′ n_p-N_a-XXX-N_b-YYY-N_a-n_q 3′ (Ic);

or

5′ n_p-N_a-XXX-N_b-YYY-N_b-ZZZ-N_a-n_q 3′ (Id)

When the sense strand is represented by formula (Ib), N_brepresents an oligonucleotide sequence comprising 0-10, 0-7, 0-5, 0-4, 0-2 or 0 modified nucleotides.

Each N_aindependently can represent an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.

When the sense strand is represented as formula (Ic), N_brepresents an oligonucleotide sequence comprising 0-10, 0-7, 0-10, 0-7, 0-5, 0-4, 0-2 or 0 modified nucleotides. Each N_acan independently represent an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.

When the sense strand is represented as formula (Id), each N_bindependently represents an oligonucleotide sequence comprising 0-10, 0-7, 0-5, 0-4, 0-2 or 0 modified nucleotides. Preferably, N_bis 0, 1, 2, 3, 4, 5 or 6. Each N_acan independently represent an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.

Each of X, Y and Z may be the same or different from each other.

In other embodiments, i is 0 and j is 0, and the sense strand may be represented by the formula:

5′ np -Na-YYY- Na-nq 3′(Ia).

When the sense strand is represented by formula (Ia), each N_aindependently can represent an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.

In one embodiment, the antisense strand sequence of the RNAi may be represented by formula (II):

5′ n_q′-N_a′-(Z′Z′Z′)_k-N_b′-Y′Y′Y′-N_b′-(X′X′X′)_i-N′_a-

n_p′ 3′ (II)

wherein:

k and l are each independently 0 or 1;

p′ and q′ are each independently 0-6;

each N_a′ independently represents an oligonucleotide sequence comprising 0-25 modified nucleotides, each sequence comprising at least two differently modified nucleotides;

each N_b′ independently represents an oligonucleotide sequence comprising 0-10 modified nucleotides;

each n_p′ and n_q′ independently represent an overhang nucleotide;

wherein N_b′ and Y′ do not have the same modification;

and

X′X′X′, Y′Y′Y′ and Z′Z′Z′ each independently represent one motif of three identical modifications on three consecutive nucleotides.

In one embodiment, the N_a′ or N_b′ comprise modifications of alternating pattern.

The Y′Y′Y′ motif occurs at or near the cleavage site of the antisense strand. For example, when the RNAi agent has a duplex region of 17-23 nucleotide in length, the Y′Y′Y′ motif can occur at positions 9, 10, 11; 10, 11, 12; 11, 12, 13; 12, 13, 14; or 13, 14, 15 of the antisense strand, with the count starting from the 1^stnucleotide, from the 5′-end; or optionally, the count starting at the 1^stpaired nucleotide within the duplex region, from the 5′-end. Preferably, the Y′Y′Y′ motif occurs at positions 11, 12, 13.

In one embodiment, Y′Y′Y′ motif is all 2′-OMe modified nucleotides.

In one embodiment, k is 1 and 1 is 0, or k is 0 and 1 is 1, or both k and l are 1.

The antisense strand can therefore be represented by the following formulas:

5′ n_q′-N_a′-Z′Z′Z′-N_b′-Y′Y′Y′-N_a′-n_p′ 3′ (IIb);

5′ n_q′-N_a′-Y′Y′Y′-N_b′-X′X′X′-n_p′ 3′ (IIc);

or

5′ n_q′-N_a′- Z′Z′Z′-N_b′-Y′Y′Y′-N_b′- X′X′X′-N_a′-n_p′

3′ (IId).

When the antisense strand is represented by formula (IIb), N_b′ represents an oligonucleotide sequence comprising 0-10, 0-7, 0-10, 0-7, 0-5, 0-4, 0-2 or 0 modified nucleotides. Each N_a′ independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.

When the antisense strand is represented as formula (IIc), N_b′ represents an oligonucleotide sequence comprising 0-10, 0-7, 0-10, 0-7, 0-5, 0-4, 0-2 or 0 modified nucleotides. Each N_a′ independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.

When the antisense strand is represented as formula (IId), each N_b′ independently represents an oligonucleotide sequence comprising 0-10, 0-7, 0-10, 0-7, 0-5, 0-4, 0-2 or 0 modified nucleotides. Each N_a′ independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides. Preferably, N_bis 0, 1, 2, 3, 4, 5 or 6.

In other embodiments, k is 0 and 1 is 0 and the antisense strand may be represented by the formula:

5′ n_p′-N_a′-Y′Y′Y′- N_a′-n_q′ 3′ (Ia).

When the antisense strand is represented as formula (IIa), each N_a′ independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.

Each of X′, Y′ and Z′ may be the same or different from each other.

Each nucleotide of the sense strand and antisense strand may be independently modified with LNA, HNA, CeNA, 2′-methoxyethyl, 2′-O-methyl, 2′-O-allyl, 2′-C-allyl, 2′-hydroxyl, or 2′-fluoro. For example, each nucleotide of the sense strand and antisense strand is independently modified with 2′-O-methyl or 2′-fluoro. Each X, Y, Z, X′, Y′ and Z′, in particular, may represent a 2′-O-methyl modification or a 2′-fluoro modification.

In one embodiment, the sense strand of the RNAi agent may contain YYY motif occurring at 9, 10 and 11 positions of the strand when the duplex region is 21 nt, the count starting from the 1^stnucleotide from the 5′-end, or optionally, the count starting at the 1^stpaired nucleotide within the duplex region, from the 5′-end; and Y represents 2′-F modification. The sense strand may additionally contain XXX motif or ZZZ motifs as wing modifications at the opposite end of the duplex region; and XXX and ZZZ each independently represents a 2′-OMe modification or 2′-F modification.

In one embodiment the antisense strand may contain Y′Y′Y′ motif occurring at positions 11, 12, 13 of the strand, the count starting from the 1^stnucleotide from the 5′-end, or optionally, the count starting at the 1^stpaired nucleotide within the duplex region, from the 5′-end; and Y′ represents 2′-O-methyl modification. The antisense strand may additionally contain X′X′X′ motif or Z′Z′Z′ motifs as wing modifications at the opposite end of the duplex region; and X′X′X′ and Z′Z′Z′ each independently represents a 2′-OMe modification or 2′-F modification.

The sense strand represented by any one of the above formulas (Ia), (Ib), (Ic), and (Id) forms a duplex with a antisense strand being represented by any one of formulas (IIa), (IIb), (IIc), and (IId), respectively.

Accordingly, the RNAi agents for use in the methods of the disclosure may comprise a sense strand and an antisense strand, each strand having 14 to 30 nucleotides, the RNAi duplex represented by formula (III):

sense:

5′ n_p -N_a-(X X X)_i -N_b- Y Y Y -N_b -(Z Z Z)_j-N_a-n_q

3′

antisense:

3′ n_p′-N_a′ -(X′X′X′)_k-N_b′-Y′Y′Y′-N_b′-(Z′Z′Z′)_i-

N_a′-n_q′ 5′ (III)

wherein:

i, j, k, and l are each independently 0 or 1;

p, p′, q, and q′ are each independently 0-6;

each N_aand N_a′ independently represents an oligonucleotide sequence comprising 0-25 modified nucleotides, each sequence comprising at least two differently modified nucleotides;

each N_band N_b′ independently represents an oligonucleotide sequence comprising 0-10 modified nucleotides;

wherein

each n_p′, n_p, n_q′, and n_q, each of which may or may not be present, independently represents an overhang nucleotide; and

XXX, YYY, ZZZ, X′X′X′, Y′Y′Y′, and Z′Z′Z′ each independently represent one motif of three identical modifications on three consecutive nucleotides.

In one embodiment, i is 0 and j is 0; or i is 1 and j is 0; or i is 0 and j is 1; or both i and j are 0; or both i and j are 1. In another embodiment, k is 0 and 1 is 0; or k is 1 and 1 is 0; k is 0 and 1 is 1; or both k and l are 0; or both k and l are 1.

Exemplary combinations of the sense strand and antisense strand forming a RNAi duplex include the formulas below:

5′n_p-N_a-Y YY-N_a-n_q3′

3′ n_p′-Na′-Y′Y′Y′ -N_a′n_q′ 5′

(IIIa)

5′ n_p -N_a-Y Y Y -N_b-Z Z Z -N_a-n_q 3′

3′ n_p′-N_a′-Y′Y′Y′-N_b′-Z′Z′Z′-N_a′-n_q′ 5′

(IIIb)

5′ n_p-N_a-X X X -N_b-Y Y Y -N_a-n_q 3′

3′ n_p′-N_a′-X′X′X′-N_b′-Y′Y′Y′-N_a′-n_q′ 5′

(IIIc)

5′ n_p -N_a -XXX -N_b-Y Y Y -N- Z Z Z -N_a-n_q 3′

3′ n_p′-N_a′-X′X′X′-N_b′-Y′Y′Y′-N_b′-Z′Z′Z′-N_a-n_q′ 5′

(IIId)

When the RNAi agent is represented by formula (IIIa), each N_aindependently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.

When the RNAi agent is represented by formula (IIIb), each N_bindependently represents an oligonucleotide sequence comprising 1-10, 1-7, 1-5 or 1-4 modified nucleotides. Each N_aindependently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.

When the RNAi agent is represented as formula (IIIc), each N_b, N_b′ independently represents an oligonucleotide sequence comprising 0-10, 0-7, 0-10, 0-7, 0-5, 0-4, 0-2 or 0 modified nucleotides. Each N_aindependently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides.

When the RNAi agent is represented as formula (IIId), each N_b, N_b′ independently represents an oligonucleotide sequence comprising 0-10, 0-7, 0-10, 0-7, 0-5, 0-4, 0-2 or 0 modified nucleotides. Each N_a, N_a′ independently represents an oligonucleotide sequence comprising 2-20, 2-15, or 2-10 modified nucleotides. Each of N_a, N_a′, N_band N_b′ independently comprises modifications of alternating pattern.

In one embodiment, when the RNAi agent is represented by formula (IIId), the N_amodifications are 2′-O-methyl or 2′-fluoro modifications. In another embodiment, when the RNAi agent is represented by formula (IIId), the N_amodifications are 2′-O-methyl or 2′-fluoro modifications and n_p′>0 and at least one n_p′ is linked to a neighboring nucleotide a via phosphorothioate linkage. In yet another embodiment, when the RNAi agent is represented by formula (IIId), the N_amodifications are 2′-O-methyl or 2′-fluoro modifications, n_p′>0 and at least one n_p′ is linked to a neighboring nucleotide via phosphorothioate linkage, and the sense strand is conjugated to one or more C16 (or related) moieties attached through a bivalent or trivalent branched linker (described below). In another embodiment, when the RNAi agent is represented by formula (IIId), the N_amodifications are 2′-O-methyl or 2′-fluoro modifications, n_p′>0 and at least one n_p′ is linked to a neighboring nucleotide via phosphorothioate linkage, the sense strand comprises at least one phosphorothioate linkage, and the sense strand is conjugated to one or more lipophilic, e.g., C16 (or related) moieties, optionally attached through a bivalent or trivalent branched linker.

In one embodiment, when the RNAi agent is represented by formula (IIIa), the N_amodifications are 2′-O-methyl or 2′-fluoro modifications, n_p′>0 and at least one n_p′ is linked to a neighboring nucleotide via phosphorothioate linkage, the sense strand comprises at least one phosphorothioate linkage, and the sense strand is conjugated to one or more lipophilic, e.g., C16 (or related) moieties attached through a bivalent or trivalent branched linker.

In one embodiment, the RNAi agent is a multimer containing at least two duplexes represented by formula (III), (IIIa), (IIIb), (IIIc), and (IIId), wherein the duplexes are connected by a linker. The linker can be cleavable or non-cleavable. Optionally, the multimer further comprises a ligand. Each of the duplexes can target the same gene or two different genes; or each of the duplexes can target same gene at two different target sites.

In one embodiment, the RNAi agent is a multimer containing three, four, five, six or more duplexes represented by formula (III), (IIIa), (IIIb), (IIIc), and (IIId), wherein the duplexes are connected by a linker. The linker can be cleavable or non-cleavable. Optionally, the multimer further comprises a ligand. Each of the duplexes can target the same gene or two different genes; or each of the duplexes can target same gene at two different target sites.

In one embodiment, two RNAi agents represented by formula (III), (IIIa), (IIIb), (IIIc), and (IIId) are linked to each other at the 5′ end, and one or both of the 3′ ends and are optionally conjugated to a ligand. Each of the agents can target the same gene or two different genes; or each of the agents can target same gene at two different target sites.

Various publications describe multimeric RNAi agents that can be used in the methods of the disclosure. Such publications include WO2007/091269, WO2010/141511, WO2007/117686, WO2009/014887, and WO2011/031520; and U.S. Pat. No. 7,858,769, the entire contents of each of which are hereby incorporated herein by reference.

In certain embodiments, the compositions and methods of the disclosure include a vinyl phosphonate (VP) modification of an RNAi agent as described herein. In exemplary embodiments, a 5′ vinyl phosphonate modified nucleotide of the disclosure has the structure:

embedded image

wherein X is O or S;

R is hydrogen, hydroxy, fluoro, or C_1-20alkoxy (e.g., methoxy or n-hexadecyloxy);

R^5′ is ═C(H)—P(O)(OH)₂and the double bond between the C5′ carbon and R^5′ is in the E or Z orientation (e.g., E orientation); and

B is a nucleobase or a modified nucleobase, optionally where B is adenine, guanine, cytosine, thymine, or uracil.

A vinyl phosphonate of the instant disclosure may be attached to either the antisense or the sense strand of a dsRNA of the disclosure. In certain embodiments, a vinyl phosphonate of the instant disclosure is attached to the antisense strand of a dsRNA, optionally at the 5′ end of the antisense strand of the dsRNA.

Vinyl phosphate modifications are also contemplated for the compositions and methods of the instant disclosure. An exemplary vinyl phosphate structure includes the preceding structure, where R^5′ is ═C(H)—OP(O)(OH)₂and the double bond between the C5′ carbon and R^5′ is in the E or Z orientation (e.g., E orientation).

E. Thermally Destabilizing Modifications

In certain embodiments, a dsRNA molecule can be optimized for RNA interference by incorporating thermally destabilizing modifications in the seed region of the antisense strand (i.e., at positions 2-9 of the 5′-end of the antisense strand) to reduce or inhibit off-target gene silencing. It has been discovered that dsRNAs with an antisense strand comprising at least one thermally destabilizing modification of the duplex within the first 9 nucleotide positions, counting from the 5′ end, of the antisense strand have reduced off-target gene silencing activity. Accordingly, in some embodiments, the antisense strand comprises at least one (e.g., one, two, three, four, five or more) thermally destabilizing modification of the duplex within the first 9 nucleotide positions of the 5′ region of the antisense strand. In some embodiments, one or more thermally destabilizing modification(s) of the duplex is/are located in positions 2-9, or preferably positions 4-8, from the 5′-end of the antisense strand. In some further embodiments, the thermally destabilizing modification(s) of the duplex is/are located at position 6, 7 or 8 from the 5′-end of the antisense strand. In still some further embodiments, the thermally destabilizing modification of the duplex is located at position 7 from the 5′-end of the antisense strand. The term “thermally destabilizing modification(s)” includes modification(s) that would result with a dsRNA with a lower overall melting temperature (Tm) (preferably a Tm with one, two, three or four degrees lower than the Tm of the dsRNA without having such modification(s). In some embodiments, the thermally destabilizing modification of the duplex is located at position 2, 3, 4, 5 or 9 from the 5′-end of the antisense strand.

The thermally destabilizing modifications can include, but are not limited to, abasic modification; mismatch with the opposing nucleotide in the opposing strand; and sugar modification such as 2′-deoxy modification or acyclic nucleotide, e.g., unlocked nucleic acids (UNA) or glycol nucleic acid (GNA).

Exemplified abasic modifications include, but are not limited to the following:

embedded image

Wherein R═H, Me, Et or OMe; R′═H, Me, Et or OMe; R″═H, Me, Et or OMe

embedded image

wherein B is a modified or unmodified nucleobase.

Exemplified sugar modifications include, but are not limited to the following:

embedded image

wherein B is a modified or unmodified nucleobase.

In some embodiments the thermally destabilizing modification of the duplex is selected from the group consisting of:

embedded image

wherein B is a modified or unmodified nucleobase and the asterisk on each structure represents either R, S or racemic.

The term “acyclic nucleotide” refers to any nucleotide having an acyclic ribose sugar, for example, where any of bonds between the ribose carbons (e.g., C1′-C2′, C2′-C3′, C3′-C4′, C4′-04′, or C1′-04′) is absent or at least one of ribose carbons or oxygen (e.g., C1′, C2′, C3′, C4′ or 04′) are independently or in combination absent from the nucleotide. In some embodiments, acyclic nucleotide is

embedded image

wherein B is a modified or unmodified nucleobase, R¹and R²independently are H, halogen, OR₃, or alkyl; and R₃is H, alkyl, cycloalkyl, aryl, aralkyl, heteroaryl or sugar). The term “UNA” refers to unlocked acyclic nucleic acid, wherein any of the bonds of the sugar has been removed, forming an unlocked “sugar” residue. In one example, UNA also encompasses monomers with bonds between C1′-C4′ being removed (i.e. the covalent carbon-oxygen-carbon bond between the C1′ and C4′ carbons). In another example, the C2′-C3′ bond (i.e. the covalent carbon-carbon bond between the C2′ and C3′ carbons) of the sugar is removed (see Mikhailov et. al., Tetrahedron Letters, 26 (17): 2059 (1985); and Fluiter et al., Mol. Biosyst., 10: 1039 (2009), which are hereby incorporated by reference in their entirety). The acyclic derivative provides greater backbone flexibility without affecting the Watson-Crick pairings. The acyclic nucleotide can be linked via 2′-5′ or 3′-5′ linkage.

The term ‘GNA’ refers to glycol nucleic acid which is a polymer similar to DNA or RNA but differing in the composition of its “backbone” in that is composed of repeating glycerol units linked by phosphodiester bonds:

embedded image

The thermally destabilizing modification of the duplex can be mismatches (i.e., noncomplementary base pairs) between the thermally destabilizing nucleotide and the opposing nucleotide in the opposite strand within the dsRNA duplex. Exemplary mismatch base pairs include G:G, G:A, G:U, G:T, A:A, A:C, C:C, C:U, C:T, U:U, T:T, U:T, or a combination thereof. Other mismatch base pairings known in the art are also amenable to the present invention. A mismatch can occur between nucleotides that are either naturally occurring nucleotides or modified nucleotides, i.e., the mismatch base pairing can occur between the nucleobases from respective nucleotides independent of the modifications on the ribose sugars of the nucleotides. In certain embodiments, the dsRNA molecule contains at least one nucleobase in the mismatch pairing that is a 2′-deoxy nucleobase; e.g., the 2′-deoxy nucleobase is in the sense strand.

In some embodiments, the thermally destabilizing modification of the duplex in the seed region of the antisense strand includes nucleotides with impaired W—C H-bonding to complementary base on the target mRNA, such as:

embedded image

More examples of abasic nucleotide, acyclic nucleotide modifications (including UNA and GNA), and mismatch modifications have been described in detail in WO 2011/133876, which is herein incorporated by reference in its entirety.

The thermally destabilizing modifications may also include universal base with reduced or abolished capability to form hydrogen bonds with the opposing bases, and phosphate modifications.

In some embodiments, the thermally destabilizing modification of the duplex includes nucleotides with non-canonical bases such as, but not limited to, nucleobase modifications with impaired or completely abolished capability to form hydrogen bonds with bases in the opposite strand. These nucleobase modifications have been evaluated for destabilization of the central region of the dsRNA duplex as described in WO 2010/0011895, which is herein incorporated by reference in its entirety. Exemplary nucleobase modifications are:

embedded image

In some embodiments, the thermally destabilizing modification of the duplex in the seed region of the antisense strand includes one or more α-nucleotide complementary to the base on the target mRNA, such as:

embedded image

wherein R is H, OH, OCH₃, F, NH₂, NHMe, NMe₂or O-alkyl.

Exemplary phosphate modifications known to decrease the thermal stability of dsRNA duplexes compared to natural phosphodiester linkages are:

embedded image

The alkyl for the R group can be a C₁-C₆alkyl. Specific alkyls for the R group include, but are not limited to methyl, ethyl, propyl, isopropyl, butyl, pentyl and hexyl.

As the skilled artisan will recognize, in view of the functional role of nucleobases is defining specificity of a RNAi agent of the disclosure, while nucleobase modifications can be performed in the various manners as described herein, e.g., to introduce destabilizing modifications into a RNAi agent of the disclosure, e.g., for purpose of enhancing on-target effect relative to off-target effect, the range of modifications available and, in general, present upon RNAi agents of the disclosure tends to be much greater for non-nucleobase modifications, e.g., modifications to sugar groups or phosphate backbones of polyribonucleotides. Such modifications are described in greater detail in other sections of the instant disclosure and are expressly contemplated for RNAi agents of the disclosure, either possessing native nucleobases or modified nucleobases as described above or elsewhere herein.

In addition to the antisense strand comprising a thermally destabilizing modification, the dsRNA can also comprise one or more stabilizing modifications. For example, the dsRNA can comprise at least two (e.g., two, three, four, five, six, seven, eight, nine, ten or more) stabilizing modifications. Without limitations, the stabilizing modifications all can be present in one strand. In some embodiments, both the sense and the antisense strands comprise at least two stabilizing modifications. The stabilizing modification can occur on any nucleotide of the sense strand or antisense strand. For instance, the stabilizing modification can occur on every nucleotide on the sense strand or antisense strand; each stabilizing modification can occur in an alternating pattern on the sense strand or antisense strand; or the sense strand or antisense strand comprises both stabilizing modification in an alternating pattern. The alternating pattern of the stabilizing modifications on the sense strand may be the same or different from the antisense strand, and the alternating pattern of the stabilizing modifications on the sense strand can have a shift relative to the alternating pattern of the stabilizing modifications on the antisense strand.

In some embodiments, the antisense strand comprises at least two (e.g., two, three, four, five, six, seven, eight, nine, ten or more) stabilizing modifications. Without limitations, a stabilizing modification in the antisense strand can be present at any positions. In some embodiments, the antisense comprises stabilizing modifications at positions 2, 6, 8, 9, 14, and 16 from the 5′-end. In some other embodiments, the antisense comprises stabilizing modifications at positions 2, 6, 14, and 16 from the 5′-end. In still some other embodiments, the antisense comprises stabilizing modifications at positions 2, 14, and 16 from the 5′-end.

In some embodiments, the antisense strand comprises at least one stabilizing modification adjacent to the destabilizing modification. For example, the stabilizing modification can be the nucleotide at the 5′-end or the 3′-end of the destabilizing modification, i.e., at position −1 or +1 from the position of the destabilizing modification. In some embodiments, the antisense strand comprises a stabilizing modification at each of the 5′-end and the 3′-end of the destabilizing modification, i.e., positions −1 and +1 from the position of the destabilizing modification.

In some embodiments, the antisense strand comprises at least two stabilizing modifications at the 3′-end of the destabilizing modification, i.e., at positions +1 and +2 from the position of the destabilizing modification.

In some embodiments, the sense strand comprises at least two (e.g., two, three, four, five, six, seven, eight, nine, ten or more) stabilizing modifications. Without limitations, a stabilizing modification in the sense strand can be present at any positions. In some embodiments, the sense strand comprises stabilizing modifications at positions 7, 10, and 11 from the 5′-end. In some other embodiments, the sense strand comprises stabilizing modifications at positions 7, 9, 10, and 11 from the 5′-end. In some embodiments, the sense strand comprises stabilizing modifications at positions opposite or complimentary to positions 11, 12, and 15 of the antisense strand, counting from the 5′-end of the antisense strand. In some other embodiments, the sense strand comprises stabilizing modifications at positions opposite or complimentary to positions 11, 12, 13, and 15 of the antisense strand, counting from the 5′-end of the antisense strand. In some embodiments, the sense strand comprises a block of two, three, or four stabilizing modifications.

In some embodiments, the sense strand does not comprise a stabilizing modification in position opposite or complimentary to the thermally destabilizing modification of the duplex in the antisense strand.

Exemplary thermally stabilizing modifications include, but are not limited to, 2′-fluoro modifications. Other thermally stabilizing modifications include, but are not limited to, LNA.

In some embodiments, the dsRNA of the disclosure comprises at least four (e.g., four, five, six, seven, eight, nine, ten, or more) 2′-fluoro nucleotides. Without limitations, the 2′-fluoro nucleotides all can be present in one strand. In some embodiments, both the sense and the antisense strands comprise at least two 2′-fluoro nucleotides. The 2′-fluoro modification can occur on any nucleotide of the sense strand or antisense strand. For instance, the 2′-fluoro modification can occur on every nucleotide on the sense strand or antisense strand; each 2′-fluoro modification can occur in an alternating pattern on the sense strand or antisense strand; or the sense strand or antisense strand comprises both 2′-fluoro modifications in an alternating pattern. The alternating pattern of the 2′-fluoro modifications on the sense strand may be the same or different from the antisense strand, and the alternating pattern of the 2′-fluoro modifications on the sense strand can have a shift relative to the alternating pattern of the 2′-fluoro modifications on the antisense strand.

In some embodiments, the antisense strand comprises at least two (e.g., two, three, four, five, six, seven, eight, nine, ten, or more) 2′-fluoro nucleotides. Without limitations, a 2′-fluoro modification in the antisense strand can be present at any positions. In some embodiments, the antisense comprises 2′-fluoro nucleotides at positions 2, 6, 8, 9, 14, and 16 from the 5′-end. In some other embodiments, the antisense comprises 2′-fluoro nucleotides at positions 2, 6, 14, and 16 from the 5′-end. In still some other embodiments, the antisense comprises 2′-fluoro nucleotides at positions 2, 14, and 16 from the 5′-end.

In some embodiments, the antisense strand comprises at least one 2′-fluoro nucleotide adjacent to the destabilizing modification. For example, the 2′-fluoro nucleotide can be the nucleotide at the 5′-end or the 3′-end of the destabilizing modification, i.e., at position −1 or +1 from the position of the destabilizing modification. In some embodiments, the antisense strand comprises a 2′-fluoro nucleotide at each of the 5′-end and the 3′-end of the destabilizing modification, i.e., positions −1 and +1 from the position of the destabilizing modification.

In some embodiments, the antisense strand comprises at least two 2′-fluoro nucleotides at the 3′-end of the destabilizing modification, i.e., at positions +1 and +2 from the position of the destabilizing modification.

In some embodiments, the sense strand comprises at least two (e.g., two, three, four, five, six, seven, eight, nine, ten or more) 2′-fluoro nucleotides. Without limitations, a 2′-fluoro modification in the sense strand can be present at any positions. In some embodiments, the antisense comprises 2′-fluoro nucleotides at positions 7, 10, and 11 from the 5′-end. In some other embodiments, the sense strand comprises 2′-fluoro nucleotides at positions 7, 9, 10, and 11 from the 5′-end. In some embodiments, the sense strand comprises 2′-fluoro nucleotides at positions opposite or complimentary to positions 11, 12, and 15 of the antisense strand, counting from the 5′-end of the antisense strand. In some other embodiments, the sense strand comprises 2′-fluoro nucleotides at positions opposite or complimentary to positions 11, 12, 13, and 15 of the antisense strand, counting from the 5′-end of the antisense strand. In some embodiments, the sense strand comprises a block of two, three or four 2′-fluoro nucleotides.

In some embodiments, the sense strand does not comprise a 2′-fluoro nucleotide in position opposite or complimentary to the thermally destabilizing modification of the duplex in the antisense strand.

In some embodiments, the dsRNA molecule of the disclosure comprises a 21 nucleotides (nt) sense strand and a 23 nucleotides (nt) antisense, wherein the antisense strand contains at least one thermally destabilizing nucleotide, where the at least one thermally destabilizing nucleotide occurs in the seed region of the antisense strand (i.e., at position 2-9 of the 5′-end of the antisense strand), wherein one end of the dsRNA is blunt, while the other end is comprises a 2 nt overhang, and wherein the dsRNA optionally further has at least one (e.g., one, two, three, four, five, six or all seven) of the following characteristics: (i) the antisense comprises 2, 3, 4, 5 or 6 2′-fluoro modifications; (ii) the antisense comprises 1, 2, 3, 4 or 5 phosphorothioate internucleotide linkages; (iii) the sense strand is conjugated with a ligand; (iv) the sense strand comprises 2, 3, 4 or 5 2′-fluoro modifications; (v) the sense strand comprises 1, 2, 3, 4 or 5 phosphorothioate internucleotide linkages; (vi) the dsRNA comprises at least four 2′-fluoro modifications; and (vii) the dsRNA comprises a blunt end at 5′-end of the antisense strand. Preferably, the 2 nt overhang is at the 3′-end of the antisense.

In some embodiments, the dsRNA molecule of the disclosure comprising a sense and antisense strands, wherein: the sense strand is 25-30 nucleotide residues in length, wherein starting from the 5′ terminal nucleotide (position 1), positions 1 to 23 of said sense strand comprise at least 8 ribonucleotides; antisense strand is 36-66 nucleotide residues in length and, starting from the 3′ terminal nucleotide, at least 8 ribonucleotides in the positions paired with positions 1-23 of sense strand to form a duplex; wherein at least the 3′ terminal nucleotide of antisense strand is unpaired with sense strand, and up to 6 consecutive 3′ terminal nucleotides are unpaired with sense strand, thereby forming a 3′ single stranded overhang of 1-6 nucleotides; wherein the 5′ terminus of antisense strand comprises from 10-30 consecutive nucleotides which are unpaired with sense strand, thereby forming a 10-30 nucleotide single stranded 5′ overhang; wherein at least the sense strand 5′ terminal and 3′ terminal nucleotides are base paired with nucleotides of antisense strand when sense and antisense strands are aligned for maximum complementarity, thereby forming a substantially duplexed region between sense and antisense strands; and antisense strand is sufficiently complementary to a target RNA along at least 19 ribonucleotides of antisense strand length to reduce target gene expression when said double stranded nucleic acid is introduced into a mammalian cell; and wherein the antisense strand contains at least one thermally destabilizing nucleotide, where at least one thermally destabilizing nucleotide is in the seed region of the antisense strand (i.e. at position 2-9 of the 5′-end of the antisense strand). For example, the thermally destabilizing nucleotide occurs between positions opposite or complimentary to positions 14-17 of the 5′-end of the sense strand, and wherein the dsRNA optionally further has at least one (e.g., one, two, three, four, five, six or all seven) of the following characteristics: (i) the antisense comprises 2, 3, 4, 5, or 6 2′-fluoro modifications; (ii) the antisense comprises 1, 2, 3, 4, or 5 phosphorothioate internucleotide linkages; (iii) the sense strand is conjugated with a ligand; (iv) the sense strand comprises 2, 3, 4, or 5 2′-fluoro modifications; (v) the sense strand comprises 1, 2, 3, 4, or 5 phosphorothioate internucleotide linkages; and (vi) the dsRNA comprises at least four 2′-fluoro modifications; and (vii) the dsRNA comprises a duplex region of 12-30 nucleotide pairs in length.

In some embodiments, the dsRNA molecule of the disclosure comprises a sense and antisense strands, wherein said dsRNA molecule comprises a sense strand having a length which is at least 25 and at most 29 nucleotides and an antisense strand having a length which is at most 30 nucleotides with the sense strand comprises a modified nucleotide that is susceptible to enzymatic degradation at position 11 from the 5′end, wherein the 3′ end of said sense strand and the 5′ end of said antisense strand form a blunt end and said antisense strand is 1-4 nucleotides longer at its 3′ end than the sense strand, wherein the duplex region which is at least 25 nucleotides in length, and said antisense strand is sufficiently complementary to a target mRNA along at least 19 nt of said antisense strand length to reduce target gene expression when said dsRNA molecule is introduced into a mammalian cell, and wherein dicer cleavage of said dsRNA preferentially results in an siRNA comprising said 3′ end of said antisense strand, thereby reducing expression of the target gene in the mammal, wherein the antisense strand contains at least one thermally destabilizing nucleotide, where the at least one thermally destabilizing nucleotide is in the seed region of the antisense strand (i.e. at position 2-9 of the 5′-end of the antisense strand), and wherein the dsRNA optionally further has at least one (e.g., one, two, three, four, five, six or all seven) of the following characteristics: (i) the antisense comprises 2, 3, 4, 5, or 6 2′-fluoro modifications; (ii) the antisense comprises 1, 2, 3, 4, or 5 phosphorothioate internucleotide linkages; (iii) the sense strand is conjugated with a ligand; (iv) the sense strand comprises 2, 3, 4, or 5 2′-fluoro modifications; (v) the sense strand comprises 1, 2, 3, 4, or 5 phosphorothioate internucleotide linkages; and (vi) the dsRNA comprises at least four 2′-fluoro modifications; and (vii) the dsRNA has a duplex region of 12-29 nucleotide pairs in length.

In some embodiments, every nucleotide in the sense strand and antisense strand of the dsRNA molecule may be modified. Each nucleotide may be modified with the same or different modification which can include one or more alteration of one or both of the non-linking phosphate oxygens or of one or more of the linking phosphate oxygens; alteration of a constituent of the ribose sugar, e.g., of the 2′ hydroxyl on the ribose sugar; wholesale replacement of the phosphate moiety with “dephospho” linkers; modification or replacement of a naturally occurring base; and replacement or modification of the ribose-phosphate backbone.

As nucleic acids are polymers of subunits, many of the modifications occur at a position which is repeated within a nucleic acid, e.g., a modification of a base, or a phosphate moiety, or a non-linking O of a phosphate moiety. In some cases, the modification will occur at all of the subject positions in the nucleic acid but in many cases it will not. By way of example, a modification may only occur at a 3′ or 5′ terminal position, may only occur in a terminal region, e.g., at a position on a terminal nucleotide or in the last 2, 3, 4, 5, or 10 nucleotides of a strand. A modification may occur in a double strand region, a single strand region, or in both. A modification may occur only in the double strand region of an RNA or may only occur in a single strand region of an RNA. E.g., a phosphorothioate modification at a non-linking O position may only occur at one or both termini, may only occur in a terminal region, e.g., at a position on a terminal nucleotide or in the last 2, 3, 4, 5, or 10 nucleotides of a strand, or may occur in double strand and single strand regions, particularly at termini. The 5′ end or ends can be phosphorylated.

It may be possible, e.g., to enhance stability, to include particular bases in overhangs, or to include modified nucleotides or nucleotide surrogates, in single strand overhangs, e.g., in a 5′ or 3′ overhang, or in both. E.g., it can be desirable to include purine nucleotides in overhangs. In some embodiments all or some of the bases in a 3′ or 5′ overhang may be modified, e.g., with a modification described herein. Modifications can include, e.g., the use of modifications at the 2′ position of the ribose sugar with modifications that are known in the art, e.g., the use of deoxyribonucleotides, 2′-deoxy-2′-fluoro (2′-F) or 2′-O-methyl modified instead of the ribosugar of the nucleobase, and modifications in the phosphate group, e.g., phosphorothioate modifications. Overhangs need not be homologous with the target sequence.

In some embodiments, each residue of the sense strand and antisense strand is independently modified with LNA, HNA, CeNA, 2′-methoxyethyl, 2′-O-methyl, 2′-O-allyl, 2′-C-allyl, 2′-deoxy, or 2′-fluoro. The strands can contain more than one modification. In some embodiments, each residue of the sense strand and antisense strand is independently modified with 2′-O-methyl or 2′-fluoro. It is to be understood that these modifications are in addition to the at least one thermally destabilizing modification of the duplex present in the antisense strand.

At least two different modifications are typically present on the sense strand and antisense strand. Those two modifications may be the 2′-deoxy, 2′-O-methyl or 2′-fluoro modifications, acyclic nucleotides or others. In some embodiments, the sense strand and antisense strand each comprises two differently modified nucleotides selected from 2′-O-methyl or 2′-deoxy. In some embodiments, each residue of the sense strand and antisense strand is independently modified with 2′-O-methyl nucleotide, 2′-deoxy nucleotide, 2′-deoxy-2′-fluoro nucleotide, 2′-O—N-methylacetamido (2′-O-NMA) nucleotide, a 2′-O-dimethylaminoethoxyethyl (2′-O-DMAEOE) nucleotide, 2′-O-aminopropyl (2′-O-AP) nucleotide, or 2′-ara-F nucleotide. Again, it is to be understood that these modifications are in addition to the at least one thermally destabilizing modification of the duplex present in the antisense strand.

In some embodiments, the dsRNA molecule of the disclosure comprises modifications of an alternating pattern, particular in the B1, B2, B3, B1′, B2′, B3′, B4′ regions. The term “alternating motif” or “alternative pattern” as used herein refers to a motif having one or more modifications, each modification occurring on alternating nucleotides of one strand. The alternating nucleotide may refer to one per every other nucleotide or one per every three nucleotides, or a similar pattern. For example, if A, B and C each represent one type of modification to the nucleotide, the alternating motif can be “ABABABABABAB . . . ,” “AABBAABBAABB . . . ,” “AABAABAABAAB . . . ,” “AAABAAABAAAB . . . ,” “AAABBBAAABBB . . . ,” or “ABCABCABCABC . . . ,” etc.

The type of modifications contained in the alternating motif may be the same or different. For example, if A, B, C, D each represent one type of modification on the nucleotide, the alternating pattern, i.e., modifications on every other nucleotide, may be the same, but each of the sense strand or antisense strand can be selected from several possibilities of modifications within the alternating motif such as “ABABAB . . . ”, “ACACAC . . . ” “BDBDBD . . . ” or “CDCDCD . . . ,” etc.

In some embodiments, the dsRNA molecule of the disclosure comprises the modification pattern for the alternating motif on the sense strand relative to the modification pattern for the alternating motif on the antisense strand is shifted. The shift may be such that the modified group of nucleotides of the sense strand corresponds to a differently modified group of nucleotides of the antisense strand and vice versa. For example, the sense strand when paired with the antisense strand in the dsRNA duplex, the alternating motif in the sense strand may start with “ABABAB” from 5′-3′ of the strand and the alternating motif in the antisense strand may start with “BABABA” from 3′-5′ of the strand within the duplex region. As another example, the alternating motif in the sense strand may start with “AABBAABB” from 5′-3′ of the strand and the alternating motif in the antisense strand may start with “BBAABBAA” from 3′-5′ of the strand within the duplex region, so that there is a complete or partial shift of the modification patterns between the sense strand and the antisense strand.

The dsRNA molecule of the disclosure may further comprise at least one phosphorothioate or methylphosphonate internucleotide linkage. The phosphorothioate or methylphosphonate internucleotide linkage modification may occur on any nucleotide of the sense strand or antisense strand or both in any position of the strand. For instance, the internucleotide linkage modification may occur on every nucleotide on the sense strand or antisense strand; each internucleotide linkage modification may occur in an alternating pattern on the sense strand or antisense strand; or the sense strand or antisense strand comprises both internucleotide linkage modifications in an alternating pattern. The alternating pattern of the internucleotide linkage modification on the sense strand may be the same or different from the antisense strand, and the alternating pattern of the internucleotide linkage modification on the sense strand may have a shift relative to the alternating pattern of the internucleotide linkage modification on the antisense strand.

In some embodiments, the dsRNA molecule comprises the phosphorothioate or methylphosphonate internucleotide linkage modification in the overhang region. For example, the overhang region comprises two nucleotides having a phosphorothioate or methylphosphonate internucleotide linkage between the two nucleotides. Internucleotide linkage modifications also may be made to link the overhang nucleotides with the terminal paired nucleotides within duplex region. For example, at least 2, 3, 4, or all the overhang nucleotides may be linked through phosphorothioate or methylphosphonate internucleotide linkage, and optionally, there may be additional phosphorothioate or methylphosphonate internucleotide linkages linking the overhang nucleotide with a paired nucleotide that is next to the overhang nucleotide. For instance, there may be at least two phosphorothioate internucleotide linkages between the terminal three nucleotides, in which two of the three nucleotides are overhang nucleotides, and the third is a paired nucleotide next to the overhang nucleotide. Preferably, these terminal three nucleotides may be at the 3′-end of the antisense strand.

In some embodiments, the sense strand of the dsRNA molecule comprises 1-10 blocks of two to ten phosphorothioate or methylphosphonate internucleotide linkages separated by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 phosphate internucleotide linkages, wherein one of the phosphorothioate or methylphosphonate internucleotide linkages is placed at any position in the oligonucleotide sequence and the said sense strand is paired with an antisense strand comprising any combination of phosphorothioate, methylphosphonate and phosphate internucleotide linkages or an antisense strand comprising either phosphorothioate or methylphosphonate or phosphate linkage.

In some embodiments, the antisense strand of the dsRNA molecule comprises two blocks of two phosphorothioate or methylphosphonate internucleotide linkages separated by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 phosphate internucleotide linkages, wherein one of the phosphorothioate or methylphosphonate internucleotide linkages is placed at any position in the oligonucleotide sequence and the said antisense strand is paired with a sense strand comprising any combination of phosphorothioate, methylphosphonate and phosphate internucleotide linkages or an antisense strand comprising either phosphorothioate or methylphosphonate or phosphate linkage.

In some embodiments, the antisense strand of the dsRNA molecule comprises two blocks of three phosphorothioate or methylphosphonate internucleotide linkages separated by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 phosphate internucleotide linkages, wherein one of the phosphorothioate or methylphosphonate internucleotide linkages is placed at any position in the oligonucleotide sequence and the said antisense strand is paired with a sense strand comprising any combination of phosphorothioate, methylphosphonate and phosphate internucleotide linkages or an antisense strand comprising either phosphorothioate or methylphosphonate or phosphate linkage.

In some embodiments, the antisense strand of the dsRNA molecule comprises two blocks of four phosphorothioate or methylphosphonate internucleotide linkages separated by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 phosphate internucleotide linkages, wherein one of the phosphorothioate or methylphosphonate internucleotide linkages is placed at any position in the oligonucleotide sequence and the said antisense strand is paired with a sense strand comprising any combination of phosphorothioate, methylphosphonate and phosphate internucleotide linkages or an antisense strand comprising either phosphorothioate or methylphosphonate or phosphate linkage.

In some embodiments, the antisense strand of the dsRNA molecule comprises two blocks of five phosphorothioate or methylphosphonate internucleotide linkages separated by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 phosphate internucleotide linkages, wherein one of the phosphorothioate or methylphosphonate internucleotide linkages is placed at any position in the oligonucleotide sequence and the said antisense strand is paired with a sense strand comprising any combination of phosphorothioate, methylphosphonate and phosphate internucleotide linkages or an antisense strand comprising either phosphorothioate or methylphosphonate or phosphate linkage.

In some embodiments, the antisense strand of the dsRNA molecule comprises two blocks of six phosphorothioate or methylphosphonate internucleotide linkages separated by 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 phosphate internucleotide linkages, wherein one of the phosphorothioate or methylphosphonate internucleotide linkages is placed at any position in the oligonucleotide sequence and the said antisense strand is paired with a sense strand comprising any combination of phosphorothioate, methylphosphonate and phosphate internucleotide linkages or an antisense strand comprising either phosphorothioate or methylphosphonate or phosphate linkage.

In some embodiments, the antisense strand of the dsRNA molecule comprises two blocks of seven phosphorothioate or methylphosphonate internucleotide linkages separated by 1, 2, 3, 4, 5, 6, 7, or 8 phosphate internucleotide linkages, wherein one of the phosphorothioate or methylphosphonate internucleotide linkages is placed at any position in the oligonucleotide sequence and the said antisense strand is paired with a sense strand comprising any combination of phosphorothioate, methylphosphonate and phosphate internucleotide linkages or an antisense strand comprising either phosphorothioate or methylphosphonate or phosphate linkage.

In some embodiments, the antisense strand of the dsRNA molecule comprises two blocks of eight phosphorothioate or methylphosphonate internucleotide linkages separated by 1, 2, 3, 4, 5, or 6 phosphate internucleotide linkages, wherein one of the phosphorothioate or methylphosphonate internucleotide linkages is placed at any position in the oligonucleotide sequence and the said antisense strand is paired with a sense strand comprising any combination of phosphorothioate, methylphosphonate and phosphate internucleotide linkages or an antisense strand comprising either phosphorothioate or methylphosphonate or phosphate linkage.

In some embodiments, the antisense strand of the dsRNA molecule comprises two blocks of nine phosphorothioate or methylphosphonate internucleotide linkages separated by 1, 2, 3, or 4 phosphate internucleotide linkages, wherein one of the phosphorothioate or methylphosphonate internucleotide linkages is placed at any position in the oligonucleotide sequence and the said antisense strand is paired with a sense strand comprising any combination of phosphorothioate, methylphosphonate and phosphate internucleotide linkages or an antisense strand comprising either phosphorothioate or methylphosphonate or phosphate linkage.

In some embodiments, the dsRNA molecule of the disclosure further comprises one or more phosphorothioate or methylphosphonate internucleotide linkage modification within 1-10 of the internal region of the duplex of each of the sense or antisense strand. For example, at least 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides may be linked through phosphorothioate methylphosphonate internucleotide linkage at position 8-16 of the duplex region counting from the 5′-end of the sense strand; the dsRNA molecule can optionally further comprise one or more phosphorothioate or methylphosphonate internucleotide linkage modification within 1-10 of the termini position(s).

In some embodiments, the dsRNA molecule of the disclosure further comprises one to five phosphorothioate or methylphosphonate internucleotide linkage modification(s) within position 1-5 and one to five phosphorothioate or methylphosphonate internucleotide linkage modification(s) within position 18-23 of the sense strand (counting from the 5′-end), and one to five phosphorothioate or methylphosphonate internucleotide linkage modification at positions 1 and 2 and one to five within positions 18-23 of the antisense strand (counting from the 5′-end).

In some embodiments, the dsRNA molecule of the disclosure further comprises one phosphorothioate internucleotide linkage modification within position 1-5 and one phosphorothioate or methylphosphonate internucleotide linkage modification within position 18-23 of the sense strand (counting from the 5′-end), and one phosphorothioate internucleotide linkage modification at positions 1 and 2 and two phosphorothioate or methylphosphonate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end).

In some embodiments, the dsRNA molecule of the disclosure further comprises two phosphorothioate internucleotide linkage modifications within position 1-5 and one phosphorothioate internucleotide linkage modification within position 18-23 of the sense strand (counting from the 5′-end), and one phosphorothioate internucleotide linkage modification at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end).

In some embodiments, the dsRNA molecule of the disclosure further comprises two phosphorothioate internucleotide linkage modifications within position 1-5 and two phosphorothioate internucleotide linkage modifications within position 18-23 of the sense strand (counting from the 5′-end), and one phosphorothioate internucleotide linkage modification at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end).

In some embodiments, the dsRNA molecule of the disclosure further comprises two phosphorothioate internucleotide linkage modifications within position 1-5 and two phosphorothioate internucleotide linkage modifications within position 18-23 of the sense strand (counting from the 5′-end), and one phosphorothioate internucleotide linkage modification at positions 1 and 2 and one phosphorothioate internucleotide linkage modification within positions 18-23 of the antisense strand (counting from the 5′-end).

In some embodiments, the dsRNA molecule of the disclosure further comprises one phosphorothioate internucleotide linkage modification within position 1-5 and one phosphorothioate internucleotide linkage modification within position 18-23 of the sense strand (counting from the 5′-end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end).

In some embodiments, the dsRNA molecule of the disclosure further comprises one phosphorothioate internucleotide linkage modification within position 1-5 and one within position 18-23 of the sense strand (counting from the 5′-end), and two phosphorothioate internucleotide linkage modification at positions 1 and 2 and one phosphorothioate internucleotide linkage modification within positions 18-23 of the antisense strand (counting from the 5′-end).

In some embodiments, the dsRNA molecule of the disclosure further comprises one phosphorothioate internucleotide linkage modification within position 1-5 (counting from the 5′-end) of the sense strand, and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and one phosphorothioate internucleotide linkage modification within positions 18-23 of the antisense strand (counting from the 5′-end).

In some embodiments, the dsRNA molecule of the disclosure further comprises two phosphorothioate internucleotide linkage modifications within position 1-5 (counting from the 5′-end) of the sense strand, and one phosphorothioate internucleotide linkage modification at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end).

In some embodiments, the dsRNA molecule of the disclosure further comprises two phosphorothioate internucleotide linkage modifications within position 1-5 and one within position 18-23 of the sense strand (counting from the 5′-end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and one phosphorothioate internucleotide linkage modification within positions 18-23 of the antisense strand (counting from the 5′-end).

In some embodiments, the dsRNA molecule of the disclosure further comprises two phosphorothioate internucleotide linkage modifications within position 1-5 and one phosphorothioate internucleotide linkage modification within position 18-23 of the sense strand (counting from the 5′-end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications within positions 18-23 of the antisense strand (counting from the 5′-end).

In some embodiments, the dsRNA molecule of the disclosure further comprises two phosphorothioate internucleotide linkage modifications at position 1 and 2, and two phosphorothioate internucleotide linkage modifications at position 20 and 21 of the sense strand (counting from the 5′-end), and one phosphorothioate internucleotide linkage modification at positions 1 and one at position 21 of the antisense strand (counting from the 5′-end).

In some embodiments, the dsRNA molecule of the disclosure further comprises one phosphorothioate internucleotide linkage modification at position 1, and one phosphorothioate internucleotide linkage modification at position 21 of the sense strand (counting from the 5′-end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications at positions 20 and 21 the antisense strand (counting from the 5′-end).

In some embodiments, the dsRNA molecule of the disclosure further comprises two phosphorothioate internucleotide linkage modifications at position 1 and 2, and two phosphorothioate internucleotide linkage modifications at position 21 and 22 of the sense strand (counting from the 5′-end), and one phosphorothioate internucleotide linkage modification at positions 1 and one phosphorothioate internucleotide linkage modification at position 21 of the antisense strand (counting from the 5′-end).

In some embodiments, the dsRNA molecule of the disclosure further comprises one phosphorothioate internucleotide linkage modification at position 1, and one phosphorothioate internucleotide linkage modification at position 21 of the sense strand (counting from the 5′-end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications at positions 21 and 22 the antisense strand (counting from the 5′-end).

In some embodiments, the dsRNA molecule of the disclosure further comprises two phosphorothioate internucleotide linkage modifications at position 1 and 2, and two phosphorothioate internucleotide linkage modifications at position 22 and 23 of the sense strand (counting from the 5′-end), and one phosphorothioate internucleotide linkage modification at positions 1 and one phosphorothioate internucleotide linkage modification at position 21 of the antisense strand (counting from the 5′-end).

In some embodiments, the dsRNA molecule of the disclosure further comprises one phosphorothioate internucleotide linkage modification at position 1, and one phosphorothioate internucleotide linkage modification at position 21 of the sense strand (counting from the 5′-end), and two phosphorothioate internucleotide linkage modifications at positions 1 and 2 and two phosphorothioate internucleotide linkage modifications at positions 23 and 23 the antisense strand (counting from the 5′-end).

In some embodiments, compound of the disclosure comprises a pattern of backbone chiral centers. In some embodiments, a common pattern of backbone chiral centers comprises at least 5 internucleotidic linkages in the Sp configuration. In some embodiments, a common pattern of backbone chiral centers comprises at least 6 internucleotidic linkages in the Sp configuration. In some embodiments, a common pattern of backbone chiral centers comprises at least 7 internucleotidic linkages in the Sp configuration. In some embodiments, a common pattern of backbone chiral centers comprises at least 8 internucleotidic linkages in the Sp configuration. In some embodiments, a common pattern of backbone chiral centers comprises at least 9 internucleotidic linkages in the Sp configuration. In some embodiments, a common pattern of backbone chiral centers comprises at least 10 internucleotidic linkages in the Sp configuration. In some embodiments, a common pattern of backbone chiral centers comprises at least 11 internucleotidic linkages in the Sp configuration. In some embodiments, a common pattern of backbone chiral centers comprises at least 12 internucleotidic linkages in the Sp configuration. In some embodiments, a common pattern of backbone chiral centers comprises at least 13 internucleotidic linkages in the Sp configuration. In some embodiments, a common pattern of backbone chiral centers comprises at least 14 internucleotidic linkages in the Sp configuration. In some embodiments, a common pattern of backbone chiral centers comprises at least 15 internucleotidic linkages in the Sp configuration. In some embodiments, a common pattern of backbone chiral centers comprises at least 16 internucleotidic linkages in the Sp configuration. In some embodiments, a common pattern of backbone chiral centers comprises at least 17 internucleotidic linkages in the Sp configuration. In some embodiments, a common pattern of backbone chiral centers comprises at least 18 internucleotidic linkages in the Sp configuration. In some embodiments, a common pattern of backbone chiral centers comprises at least 19 internucleotidic linkages in the Sp configuration. In some embodiments, a common pattern of backbone chiral centers comprises no more than 8 internucleotidic linkages in the Rp configuration. In some embodiments, a common pattern of backbone chiral centers comprises no more than 7 internucleotidic linkages in the Rp configuration. In some embodiments, a common pattern of backbone chiral centers comprises no more than 6 internucleotidic linkages in the Rp configuration. In some embodiments, a common pattern of backbone chiral centers comprises no more than 5 internucleotidic linkages in the Rp configuration. In some embodiments, a common pattern of backbone chiral centers comprises no more than 4 internucleotidic linkages in the Rp configuration. In some embodiments, a common pattern of backbone chiral centers comprises no more than 3 internucleotidic linkages in the Rp configuration. In some embodiments, a common pattern of backbone chiral centers comprises no more than 2 internucleotidic linkages in the Rp configuration. In some embodiments, a common pattern of backbone chiral centers comprises no more than 1 internucleotidic linkages in the Rp configuration. In some embodiments, a common pattern of backbone chiral centers comprises no more than 8 internucleotidic linkages which are not chiral (as a non-limiting example, a phosphodiester). In some embodiments, a common pattern of backbone chiral centers comprises no more than 7 internucleotidic linkages which are not chiral. In some embodiments, a common pattern of backbone chiral centers comprises no more than 6 internucleotidic linkages which are not chiral. In some embodiments, a common pattern of backbone chiral centers comprises no more than 5 internucleotidic linkages which are not chiral. In some embodiments, a common pattern of backbone chiral centers comprises no more than 4 internucleotidic linkages which are not chiral. In some embodiments, a common pattern of backbone chiral centers comprises no more than 3 internucleotidic linkages which are not chiral. In some embodiments, a common pattern of backbone chiral centers comprises no more than 2 internucleotidic linkages which are not chiral. In some embodiments, a common pattern of backbone chiral centers comprises no more than 1 internucleotidic linkages which are not chiral. In some embodiments, a common pattern of backbone chiral centers comprises at least 10 internucleotidic linkages in the Sp configuration, and no more than 8 internucleotidic linkages which are not chiral. In some embodiments, a common pattern of backbone chiral centers comprises at least 11 internucleotidic linkages in the Sp configuration, and no more than 7 internucleotidic linkages which are not chiral. In some embodiments, a common pattern of backbone chiral centers comprises at least 12 internucleotidic linkages in the Sp configuration, and no more than 6 internucleotidic linkages which are not chiral. In some embodiments, a common pattern of backbone chiral centers comprises at least 13 internucleotidic linkages in the Sp configuration, and no more than 6 internucleotidic linkages which are not chiral. In some embodiments, a common pattern of backbone chiral centers comprises at least 14 internucleotidic linkages in the Sp configuration, and no more than 5 internucleotidic linkages which are not chiral. In some embodiments, a common pattern of backbone chiral centers comprises at least 15 internucleotidic linkages in the Sp configuration, and no more than 4 internucleotidic linkages which are not chiral. In some embodiments, the internucleotidic linkages in the Sp configuration are optionally contiguous or not contiguous. In some embodiments, the internucleotidic linkages in the Rp configuration are optionally contiguous or not contiguous. In some embodiments, the internucleotidic linkages which are not chiral are optionally contiguous or not contiguous.

In some embodiments, compound of the disclosure comprises a block is a stereochemistry block. In some embodiments, a block is an Rp block in that each internucleotidic linkage of the block is Rp. In some embodiments, a 5′-block is an Rp block. In some embodiments, a 3′-block is an Rp block. In some embodiments, a block is an Sp block in that each internucleotidic linkage of the block is Sp. In some embodiments, a 5′-block is an Sp block. In some embodiments, a 3′-block is an Sp block. In some embodiments, provided oligonucleotides comprise both Rp and Sp blocks. In some embodiments, provided oligonucleotides comprise one or more Rp but no Sp blocks. In some embodiments, provided oligonucleotides comprise one or more Sp but no Rp blocks. In some embodiments, provided oligonucleotides comprise one or more PO blocks wherein each internucleotidic linkage in a natural phosphate linkage.

In some embodiments, compound of the disclosure comprises a 5′-block is an Sp block wherein each sugar moiety comprises a 2′-F modification. In some embodiments, a 5′-block is an Sp block wherein each of internucleotidic linkage is a modified internucleotidic linkage and each sugar moiety comprises a 2′-F modification. In some embodiments, a 5′-block is an Sp block wherein each of internucleotidic linkage is a phosphorothioate linkage and each sugar moiety comprises a 2′-F modification. In some embodiments, a 5′-block comprises 4 or more nucleoside units. In some embodiments, a 5′-block comprises 5 or more nucleoside units. In some embodiments, a 5′-block comprises 6 or more nucleoside units. In some embodiments, a 5′-block comprises 7 or more nucleoside units. In some embodiments, a 3′-block is an Sp block wherein each sugar moiety comprises a 2′-F modification. In some embodiments, a 3′-block is an Sp block wherein each of internucleotidic linkage is a modified internucleotidic linkage and each sugar moiety comprises a 2′-F modification. In some embodiments, a 3′-block is an Sp block wherein each of internucleotidic linkage is a phosphorothioate linkage and each sugar moiety comprises a 2′-F modification. In some embodiments, a 3′-block comprises 4 or more nucleoside units. In some embodiments, a 3′-block comprises 5 or more nucleoside units. In some embodiments, a 3′-block comprises 6 or more nucleoside units. In some embodiments, a 3′-block comprises 7 or more nucleoside units.

In some embodiments, compound of the disclosure comprises a type of nucleoside in a region or an oligonucleotide is followed by a specific type of internucleotidic linkage, e.g., natural phosphate linkage, modified internucleotidic linkage, Rp chiral internucleotidic linkage, Sp chiral internucleotidic linkage, etc. In some embodiments, A is followed by Sp. In some embodiments, A is followed by Rp. In some embodiments, A is followed by natural phosphate linkage (PO). In some embodiments, U is followed by Sp. In some embodiments, U is followed by Rp. In some embodiments, U is followed by natural phosphate linkage (PO). In some embodiments, C is followed by Sp. In some embodiments, C is followed by Rp. In some embodiments, C is followed by natural phosphate linkage (PO). In some embodiments, G is followed by Sp. In some embodiments, G is followed by Rp. In some embodiments, G is followed by natural phosphate linkage (PO). In some embodiments, C and U are followed by Sp. In some embodiments, C and U are followed by Rp. In some embodiments, C and U are followed by natural phosphate linkage (PO). In some embodiments, A and G are followed by Sp. In some embodiments, A and G are followed by Rp.

In some embodiments, the antisense strand comprises phosphorothioate internucleotide linkages between nucleotide positions 21 and 22, and between nucleotide positions 22 and 23, wherein the antisense strand contains at least one thermally destabilizing modification of the duplex located in the seed region of the antisense strand (i.e., at position 2-9 of the 5′-end of the antisense strand), and wherein the dsRNA optionally further has at least one (e.g., one, two, three, four, five, six, seven or all eight) of the following characteristics: (i) the antisense comprises 2, 3, 4, 5 or 6 2′-fluoro modifications; (ii) the antisense comprises 3, 4 or 5 phosphorothioate internucleotide linkages; (iii) the sense strand is conjugated with a ligand; (iv) the sense strand comprises 2, 3, 4 or 5 2′-fluoro modifications; (v) the sense strand comprises 1, 2, 3, 4 or 5 phosphorothioate internucleotide linkages; (vi) the dsRNA comprises at least four 2′-fluoro modifications; (vii) the dsRNA comprises a duplex region of 12-40 nucleotide pairs in length; and (viii) the dsRNA has a blunt end at 5′-end of the antisense strand.

In some embodiments, the antisense strand comprises phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 21 and 22, and between nucleotide positions 22 and 23, wherein the antisense strand contains at least one thermally destabilizing modification of the duplex located in the seed region of the antisense strand (i.e., at position 2-9 of the 5′-end of the antisense strand), and wherein the dsRNA optionally further has at least one (e.g., one, two, three, four, five, six, seven or all eight) of the following characteristics: (i) the antisense comprises 2, 3, 4, 5 or 6 2′-fluoro modifications; (ii) the sense strand is conjugated with a ligand; (iii) the sense strand comprises 2, 3, 4 or 5 2′-fluoro modifications; (iv) the sense strand comprises 1, 2, 3, 4 or 5 phosphorothioate internucleotide linkages; (v) the dsRNA comprises at least four 2′-fluoro modifications; (vi) the dsRNA comprises a duplex region of 12-40 nucleotide pairs in length; (vii) the dsRNA comprises a duplex region of 12-40 nucleotide pairs in length; and (viii) the dsRNA has a blunt end at 5′-end of the antisense strand.

In some embodiments, the sense strand comprises phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, and between nucleotide positions 2 and 3, wherein the antisense strand contains at least one thermally destabilizing modification of the duplex located in the seed region of the antisense strand (i.e., at position 2-9 of the 5′-end of the antisense strand), and wherein the dsRNA optionally further has at least one (e.g., one, two, three, four, five, six, seven or all eight) of the following characteristics: (i) the antisense comprises 2, 3, 4, 5 or 6 2′-fluoro modifications; (ii) the antisense comprises 1, 2, 3, 4 or 5 phosphorothioate internucleotide linkages; (iii) the sense strand is conjugated with a ligand; (iv) the sense strand comprises 2, 3, 4 or 5 2′-fluoro modifications; (v) the sense strand comprises 3, 4 or 5 phosphorothioate internucleotide linkages; (vi) the dsRNA comprises at least four 2′-fluoro modifications; (vii) the dsRNA comprises a duplex region of 12-40 nucleotide pairs in length; and (viii) the dsRNA has a blunt end at 5′-end of the antisense strand.

In some embodiments, the sense strand comprises phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, and between nucleotide positions 2 and 3, the antisense strand comprises phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 21 and 22, and between nucleotide positions 22 and 23, wherein the antisense strand contains at least one thermally destabilizing modification of the duplex located in the seed region of the antisense strand (i.e., at position 2-9 of the 5′-end of the antisense strand), and wherein the dsRNA optionally further has at least one (e.g., one, two, three, four, five, six or all seven) of the following characteristics: (i) the antisense comprises 2, 3, 4, 5 or 6 2′-fluoro modifications; (ii) the sense strand is conjugated with a ligand; (iii) the sense strand comprises 2, 3, 4 or 5 2′-fluoro modifications; (iv) the sense strand comprises 3, 4 or 5 phosphorothioate internucleotide linkages; (v) the dsRNA comprises at least four 2′-fluoro modifications; (vi) the dsRNA comprises a duplex region of 12-40 nucleotide pairs in length; and (vii) the dsRNA has a blunt end at 5′-end of the antisense strand.

In some embodiments, the dsRNA molecule of the disclosure comprises mismatch(es) with the target, within the duplex, or combinations thereof. The mismatch can occur in the overhang region or the duplex region. The base pair can be ranked on the basis of their propensity to promote dissociation or melting (e.g., on the free energy of association or dissociation of a particular pairing, the simplest approach is to examine the pairs on an individual pair basis, though next neighbor or similar analysis can also be used). In terms of promoting dissociation: A:U is preferred over G:C; G:U is preferred over G:C; and I:C is preferred over G:C (I=inosine). Mismatches, e.g., non-canonical or other than canonical pairings (as described elsewhere herein) are preferred over canonical (A:T, A:U, G:C) pairings; and pairings which include a universal base are preferred over canonical pairings.

In some embodiments, the dsRNA molecule of the disclosure comprises at least one of the first 1, 2, 3, 4, or 5 base pairs within the duplex regions from the 5′-end of the antisense strand can be chosen independently from the group of: A:U, G:U, I:C, and mismatched pairs, e.g., non-canonical or other than canonical pairings or pairings which include a universal base, to promote the dissociation of the antisense strand at the 5′-end of the duplex.

In some embodiments, the nucleotide at the 1 position within the duplex region from the 5′-end in the antisense strand is selected from the group consisting of A, dA, dU, U, and dT.

Alternatively, at least one of the first 1, 2 or 3 base pair within the duplex region from the 5′-end of the antisense strand is an AU base pair. For example, the first base pair within the duplex region from the 5′-end of the antisense strand is an AU base pair.

It was found that introducing 4′-modified or 5′-modified nucleotide to the 3′-end of a phosphodiester (PO), phosphorothioate (PS), or phosphorodithioate (PS2) linkage of a dinucleotide at any position of single stranded or double stranded oligonucleotide can exert steric effect to the internucleotide linkage and, hence, protecting or stabilizing it against nucleases.

In some embodiments, 5′-modified nucleoside is introduced at the 3′-end of a dinucleotide at any position of single stranded or double stranded siRNA. For instance, a 5′-alkylated nucleoside may be introduced at the 3′-end of a dinucleotide at any position of single stranded or double stranded siRNA. The alkyl group at the 5′ position of the ribose sugar can be racemic or chirally pure R or S isomer. An exemplary 5′-alkylated nucleoside is 5′-methyl nucleoside. The 5′-methyl can be either racemic or chirally pure R or S isomer.

In some embodiments, 4′-modified nucleoside is introduced at the 3′-end of a dinucleotide at any position of single stranded or double stranded siRNA. For instance, a 4′-alkylated nucleoside may be introduced at the 3′-end of a dinucleotide at any position of single stranded or double stranded siRNA. The alkyl group at the 4′ position of the ribose sugar can be racemic or chirally pure R or S isomer. An exemplary 4′-alkylated nucleoside is 4′-methyl nucleoside. The 4′-methyl can be either racemic or chirally pure R or S isomer. Alternatively, a 4′-O-alkylated nucleoside may be introduced at the 3′-end of a dinucleotide at any position of single stranded or double stranded siRNA. The 4′-O-alkyl of the ribose sugar can be racemic or chirally pure R or S isomer. An exemplary 4′-O-alkylated nucleoside is 4′-O-methyl nucleoside. The 4′-O-methyl can be either racemic or chirally pure R or S isomer.

In some embodiments, 5′-alkylated nucleoside is introduced at any position on the sense strand or antisense strand of a dsRNA, and such modification maintains or improves potency of the dsRNA. The 5′-alkyl can be either racemic or chirally pure R or S isomer. An exemplary 5′-alkylated nucleoside is 5′-methyl nucleoside. The 5′-methyl can be either racemic or chirally pure R or S isomer.

In some embodiments, 4′-alkylated nucleoside is introduced at any position on the sense strand or antisense strand of a dsRNA, and such modification maintains or improves potency of the dsRNA. The 4′-alkyl can be either racemic or chirally pure R or S isomer. An exemplary 4′-alkylated nucleoside is 4′-methyl nucleoside. The 4′-methyl can be either racemic or chirally pure R or S isomer.

In some embodiments, 4′-O-alkylated nucleoside is introduced at any position on the sense strand or antisense strand of a dsRNA, and such modification maintains or improves potency of the dsRNA. The 5′-alkyl can be either racemic or chirally pure R or S isomer. An exemplary 4′-O-alkylated nucleoside is 4′-O-methyl nucleoside. The 4′-O-methyl can be either racemic or chirally pure R or S isomer.

In some embodiments, the dsRNA molecule of the disclosure can comprise 2′-5′ linkages (with 2′-H, 2′-OH and 2′-OMe and with P═O or P═S). For example, the 2′-5′ linkages modifications can be used to promote nuclease resistance or to inhibit binding of the sense to the antisense strand, or can be used at the 5′ end of the sense strand to avoid sense strand activation by RISC.

In another embodiment, the dsRNA molecule of the disclosure can comprise L sugars (e.g., L ribose, L-arabinose with 2′-H, 2′-OH and 2′-OMe). For example, these L sugars modifications can be used to promote nuclease resistance or to inhibit binding of the sense to the antisense strand, or can be used at the 5′ end of the sense strand to avoid sense strand activation by RISC.

Various publications describe multimeric siRNA which can all be used with the dsRNA of the disclosure. Such publications include WO2007/091269, U.S. Pat. No. 7,858,769, WO2010/141511, WO2007/117686, WO2009/014887, and WO2011/031520 which are hereby incorporated by their entirely.

As described in more detail below, the RNAi agent that contains conjugations of one or more carbohydrate moieties to an RNAi agent can optimize one or more properties of the RNAi agent. In many cases, the carbohydrate moiety will be attached to a modified subunit of the RNAi agent. For example, the ribose sugar of one or more ribonucleotide subunits of a dsRNA agent can be replaced with another moiety, e.g., a non-carbohydrate (preferably cyclic) carrier to which is attached a carbohydrate ligand. A ribonucleotide subunit in which the ribose sugar of the subunit has been so replaced is referred to herein as a ribose replacement modification subunit (RRMS). A cyclic carrier may be a carbocyclic ring system, i.e., all ring atoms are carbon atoms, or a heterocyclic ring system, i.e., one or more ring atoms may be a heteroatom, e.g., nitrogen, oxygen, sulfur. The cyclic carrier may be a monocyclic ring system, or may contain two or more rings, e.g. fused rings. The cyclic carrier may be a fully saturated ring system, or it may contain one or more double bonds.

The ligand may be attached to the polynucleotide via a carrier. The carriers include (i) at least one “backbone attachment point,” preferably two “backbone attachment points” and (ii) at least one “tethering attachment point.” A “backbone attachment point” as used herein refers to a functional group, e.g. a hydroxyl group, or generally, a bond available for, and that is suitable for incorporation of the carrier into the backbone, e.g., the phosphate, or modified phosphate, e.g., sulfur containing, backbone, of a ribonucleic acid. A “tethering attachment point” (TAP) in some embodiments refers to a constituent ring atom of the cyclic carrier, e.g., a carbon atom or a heteroatom (distinct from an atom which provides a backbone attachment point), that connects a selected moiety. The moiety can be, e.g., a carbohydrate, e.g. monosaccharide, disaccharide, trisaccharide, tetrasaccharide, oligosaccharide and polysaccharide. Optionally, the selected moiety is connected by an intervening tether to the cyclic carrier. Thus, the cyclic carrier will often include a functional group, e.g., an amino group, or generally, provide a bond, that is suitable for incorporation or tethering of another chemical entity, e.g., a ligand to the constituent ring.

The RNAi agents may be conjugated to a ligand via a carrier, wherein the carrier can be cyclic group or acyclic group; preferably, the cyclic group is selected from pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, [1,3]dioxolane, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, quinoxalinyl, pyridazinonyl, tetrahydrofuryl and decalin; preferably, the acyclic group is selected from serinol backbone or diethanolamine backbone.

In certain specific embodiments, the RNAi agent for use in the methods of the disclosure is an agent selected from the group of agents listed in any one of Tables 2-5 and 7-10. These agents may further comprise a ligand, such as one or more lipophilic moieties, one or more GalNAc derivatives, or both of one of more lipophilic moieties and one or more GalNAc derivatives.

IV. iRNAs Conjugated to Ligands

Another modification of the RNA of an iRNA of the invention involves chemically linking to the iRNA one or more ligands, moieties or conjugates that enhance the activity, cellular distribution or cellular uptake of the iRNA, e.g., into a cell. Such moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al., Proc. Natl. Acid. Sci. USA, 1989, 86: 6553-6556), cholic acid (Manoharan et al., Biorg. Med. Chem. Let., 1994, 4:1053-1060), a thioether, e.g., beryl-S-tritylthiol (Manoharan et al., Ann. N. Y. Acad. Sci., 1992, 660:306-309; Manoharan et al., Biorg. Med. Chem. Let., 1993, 3:2765-2770), a thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992, 20:533-538), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., EMBO J, 1991, 10:1111-1118; Kabanov et al., FEBS Lett., 1990, 259:327-330; Svinarchuk et al., Biochimie, 1993, 75:49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethyl-ammonium 1,2-di-O-hexadecyl-rac-glycero-3-phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36:3651-3654; Shea et al., Nucl. Acids Res., 1990, 18:3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al., Nucleosides & Nucleotides, 1995, 14:969-973), or adamantane acetic acid (Manoharan et al., Tetrahedron Lett., 1995, 36:3651-3654), a palmityl moiety (Mishra et al., Biochim. Biophys. Acta, 1995, 1264:229-237), or an octadecylamine or hexylamino-carbonyloxycholesterol moiety (Crooke et al., J. Pharmacol. Exp. Ther., 1996, 277:923-937).

In certain embodiments, a ligand alters the distribution, targeting or lifetime of an iRNA agent into which it is incorporated. In some embodiments, a ligand provides an enhanced affinity for a selected target, e.g., molecule, cell or cell type, compartment, e.g., a cellular or organ compartment, tissue, organ or region of the body, as, e.g., compared to a species absent such a ligand. Typical ligands will not take part in duplex pairing in a duplexed nucleic acid.

Ligands can include a naturally occurring substance, such as a protein (e.g., human serum albumin (HSA), low-density lipoprotein (LDL), or globulin); carbohydrate (e.g., a dextran, pullulan, chitin, chitosan, inulin, cyclodextrin or hyaluronic acid); or a lipid. The ligand may also be a recombinant or synthetic molecule, such as a synthetic polymer, e.g., a synthetic polyamino acid. Examples of polyamino acids include polyamino acid is a polylysine (PLL), poly L-aspartic acid, poly L-glutamic acid, styrene-maleic acid anhydride copolymer, poly(L-lactide-co-glycolied) copolymer, divinyl ether-maleic anhydride copolymer, N-(2-hydroxypropyl)methacrylamide copolymer (HMPA), polyethylene glycol (PEG), polyvinyl alcohol (PVA), polyurethane, poly(2-ethylacryllic acid), N-isopropylacrylamide polymers, or polyphosphazine. Example of polyamines include: polyethylenimine, polylysine (PLL), spermine, spermidine, polyamine, pseudopeptide-polyamine, peptidomimetic polyamine, dendrimer polyamine, arginine, amidine, protamine, cationic lipid, cationic porphyrin, quaternary salt of a polyamine, or an α helical peptide.

Ligands can also include targeting groups, e.g., a cell or tissue targeting agent, e.g., a lectin, glycoprotein, lipid or protein, e.g., an antibody, that binds to a specified cell type such as a glial cell. A targeting group can be a thyrotropin, melanotropin, lectin, glycoprotein, surfactant protein A, Mucin carbohydrate, multivalent lactose, multivalent galactose, N-acetyl-galactosamine, N-acetyl-glucosamine multivalent mannose, multivalent fucose, glycosylated polyaminoacids, multivalent galactose, transferrin, bisphosphonate, polyglutamate, polyaspartate, a lipid, cholesterol, a steroid, bile acid, folate, vitamin B12, biotin, or an RGD peptide or RGD peptide mimetic. In certain embodiments, the ligand is a multivalent galactose, e.g., an N-acetyl-galactosamine.

Other examples of ligands include dyes, intercalating agents (e.g. acridines), cross-linkers (e.g. psoralene, mitomycin C), porphyrins (TPPC4, texaphyrin, Sapphyrin), polycyclic aromatic hydrocarbons (e.g., phenazine, dihydrophenazine), artificial endonucleases (e.g. EDTA), lipophilic molecules, e.g., cholesterol, cholic acid, adamantane acetic acid, 1-pyrene butyric acid, dihydrotestosterone, 1,3-Bis-O(hexadecyl)glycerol, geranyloxyhexyl group, hexadecylglycerol, borneol, menthol, 1,3-propanediol, heptadecyl group, palmitic acid, myristic acid,O3-(oleoyl)lithocholic acid, O3-(oleoyl)cholenic acid, dimethoxytrityl, or phenoxazine) and peptide conjugates (e.g., antennapedia peptide, Tat peptide), alkylating agents, phosphate, amino, mercapto, PEG (e.g., PEG-40K), MPEG, [MPEG]₂, polyamino, alkyl, substituted alkyl, radiolabeled markers, enzymes, haptens (e.g. biotin), transport/absorption facilitators (e.g., aspirin, vitamin E, folic acid), synthetic ribonucleases (e.g., imidazole, bisimidazole, histamine, imidazole clusters, acridine-imidazole conjugates, Eu3+ complexes of tetraazamacrocycles), dinitrophenyl, HRP, or AP.

Ligands can be proteins, e.g., glycoproteins, or peptides, e.g., molecules having a specific affinity for a co-ligand, or antibodies e.g., an antibody, that binds to a specified cell type such as a brain cell or a glial cell. Ligands may also include hormones and hormone receptors. They can also include non-peptidic species, such as lipids, lectins, carbohydrates, vitamins, cofactors, multivalent lactose, multivalent galactose, N-acetyl-galactosamine, N-acetyl-glucosamine multivalent mannose, or multivalent fucose. The ligand can be, for example, a lipopolysaccharide, an activator of p38 MAP kinase, or an activator of NF-κB.

The ligand can be a substance, e.g., a drug, which can increase the uptake of the iRNA agent into the cell, for example, by disrupting the cell's cytoskeleton, e.g., by disrupting the cell's microtubules, microfilaments, or intermediate filaments. The drug can be, for example, taxon, vincristine, vinblastine, cytochalasin, nocodazole, japlakinolide, latrunculin A, phalloidin, swinholide A, indanocine, or myoservin.

In some embodiments, a ligand attached to an iRNA as described herein acts as a pharmacokinetic modulator (PK modulator). PK modulators include lipophiles, bile acids, steroids, phospholipid analogues, peptides, protein binding agents, PEG, vitamins etc. Exemplary PK modulators include, but are not limited to, cholesterol, fatty acids, cholic acid, lithocholic acid, dialkylglycerides, diacylglyceride, phospholipids, sphingolipids, naproxen, ibuprofen, vitamin E, biotin etc. Oligonucleotides that comprise a number of phosphorothioate linkages are also known to bind to serum protein, thus short oligonucleotides, e.g., oligonucleotides of about 5 bases, 10 bases, 15 bases or 20 bases, comprising multiple of phosphorothioate linkages in the backbone are also amenable to the present invention as ligands (e.g. as PK modulating ligands). In addition, aptamers that bind serum components (e.g. serum proteins) are also suitable for use as PK modulating ligands in the embodiments described herein.

Ligand-conjugated iRNAs of the invention may be synthesized by the use of an oligonucleotide that bears a pendant reactive functionality, such as that derived from the attachment of a linking molecule onto the oligonucleotide (described below). This reactive oligonucleotide may be reacted directly with commercially-available ligands, ligands that are synthesized bearing any of a variety of protecting groups, or ligands that have a linking moiety attached thereto.

The oligonucleotides used in the conjugates of the present invention may be conveniently and routinely made through the well-known technique of solid-phase synthesis. Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems® (Foster City, Calif.). Any other means for such synthesis known in the art may additionally or alternatively be employed. It is also known to use similar techniques to prepare other oligonucleotides, such as the phosphorothioates and alkylated derivatives.

In the ligand-conjugated oligonucleotides and ligand-molecule bearing sequence-specific linked nucleosides of the present invention, the oligonucleotides and oligonucleosides may be assembled on a suitable DNA synthesizer utilizing standard nucleotide or nucleoside precursors, or nucleotide or nucleoside conjugate precursors that already bear the linking moiety, ligand-nucleotide or nucleoside-conjugate precursors that already bear the ligand molecule, or non-nucleoside ligand-bearing building blocks.

When using nucleotide-conjugate precursors that already bear a linking moiety, the synthesis of the sequence-specific linked nucleosides is typically completed, and the ligand molecule is then reacted with the linking moiety to form the ligand-conjugated oligonucleotide. In some embodiments, the oligonucleotides or linked nucleosides of the present invention are synthesized by an automated synthesizer using phosphoramidites derived from ligand-nucleoside conjugates in addition to the standard phosphoramidites and non-standard phosphoramidites that are commercially available and routinely used in oligonucleotide synthesis.

A. Lipid Conjugates

In certain embodiments, the ligand or conjugate is a lipid or lipid-based molecule. Such a lipid or lipid-based molecule can typically bind a serum protein, such as human serum albumin (HSA). An HSA binding ligand allows for distribution of the conjugate to a target tissue, e.g., a non-kidney target tissue of the body. For example, the target tissue can be the liver, including parenchymal cells of the liver. Other molecules that can bind HSA can also be used as ligands. For example, naproxen or aspirin can be used. A lipid or lipid-based ligand can (a) increase resistance to degradation of the conjugate, (b) increase targeting or transport into a target cell or cell membrane, or (c) can be used to adjust binding to a serum protein, e.g., HSA.

A lipid-based ligand can be used to modulate, e.g., control (e.g., inhibit) the binding of the conjugate to a target tissue. For example, a lipid or lipid-based ligand that binds to HSA more strongly will be less likely to be targeted to the kidney and therefore less likely to be cleared from the body. A lipid or lipid-based ligand that binds to HSA less strongly can be used to target the conjugate to the kidney.

In certain embodiments, the lipid-based ligand binds HSA. For example, the ligand can bind HSA with a sufficient affinity such that distribution of the conjugate to a non-kidney tissue is enhanced. However, the affinity is typically not so strong that the HSA-ligand binding cannot be reversed.

In certain embodiments, the lipid-based ligand binds HSA weakly or not at all, such that distribution of the conjugate to the kidney is enhanced. Other moieties that target to kidney cells can also be used in place of or in addition to the lipid-based ligand.

In another aspect, the ligand is a moiety, e.g., a vitamin, which is taken up by a target cell, e.g., a proliferating cell. These are particularly useful for treating disorders characterized by unwanted cell proliferation, e.g., of the malignant or non-malignant type, e.g., cancer cells.

Exemplary vitamins include vitamin A, E, and K. Other exemplary vitamins include are B vitamin, e.g., folic acid, B12, riboflavin, biotin, pyridoxal or other vitamins or nutrients taken up by cancer cells. Also included are HSA and low density lipoprotein (LDL).

B. Cell Permeation Agents

In another aspect, the ligand is a cell-permeation agent, such as a helical cell-permeation agent. In certain embodiments, the agent is amphipathic. An exemplary agent is a peptide such as tat or antennopedia. If the agent is a peptide, it can be modified, including a peptidylmimetic, invertomers, non-peptide or pseudo-peptide linkages, and use of D-amino acids. The helical agent is typically an α-helical agent and can have a lipophilic and a lipophobic phase.

The ligand can be a peptide or peptidomimetic. A peptidomimetic (also referred to herein as an oligopeptidomimetic) is a molecule capable of folding into a defined three-dimensional structure similar to a natural peptide. The attachment of peptide and peptidomimetics to iRNA agents can affect pharmacokinetic distribution of the iRNA, such as by enhancing cellular recognition and absorption. The peptide or peptidomimetic moiety can be about 5-50 amino acids long, e.g., about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 amino acids long.

A peptide or peptidomimetic can be, for example, a cell permeation peptide, cationic peptide, amphipathic peptide, or hydrophobic peptide (e.g., consisting primarily of Tyr, Trp, or Phe). The peptide moiety can be a dendrimer peptide, constrained peptide or crosslinked peptide. In another alternative, the peptide moiety can include a hydrophobic membrane translocation sequence (MTS). An exemplary hydrophobic MTS-containing peptide is RFGF having the amino acid sequence AAVALLPAVLLALLAP (SEQ ID NO:11). An RFGF analogue (e.g., amino acid sequence AALLPVLLAAP (SEQ ID NO:12)) containing a hydrophobic MTS can also be a targeting moiety. The peptide moiety can be a “delivery” peptide, which can carry large polar molecules including peptides, oligonucleotides, and protein across cell membranes. For example, sequences from the HIV Tat protein (GRKKRRQRRRPPQ (SEQ ID NO:13)) and the Drosophila Antennapedia protein (RQIKIWFQNRRMKWKK (SEQ ID NO:14)) have been found to be capable of functioning as delivery peptides. A peptide or peptidomimetic can be encoded by a random sequence of DNA, such as a peptide identified from a phage-display library, or one-bead-one-compound (OBOC) combinatorial library (Lam et al., Nature, 354:82-84, 1991). Typically, the peptide or peptidomimetic tethered to a dsRNA agent via an incorporated monomer unit is a cell targeting peptide such as an arginine-glycine-aspartic acid (RGD)-peptide, or RGD mimic. A peptide moiety can range in length from about 5 amino acids to about 40 amino acids. The peptide moieties can have a structural modification, such as to increase stability or direct conformational properties. Any of the structural modifications described below can be utilized.

An RGD peptide for use in the compositions and methods of the invention may be linear or cyclic, and may be modified, e.g., glycosylated or methylated, to facilitate targeting to a specific tissue(s). RGD-containing peptides and peptidiomimemtics may include D-amino acids, as well as synthetic RGD mimics. In addition to RGD, one can use other moieties that target the integrin ligand. Preferred conjugates of this ligand target PECAM-1 or VEGF.

An RGD peptide moiety can be used to target a particular cell type, e.g., a tumor cell, such as an endothelial tumor cell or a breast cancer tumor cell (Zitzmann et al., Cancer Res., 62:5139-43, 2002). An RGD peptide can facilitate targeting of an dsRNA agent to tumors of a variety of other tissues, including the lung, kidney, spleen, or liver (Aoki et al., Cancer Gene Therapy 8:783-787, 2001). Typically, the RGD peptide will facilitate targeting of an iRNA agent to the kidney. The RGD peptide can be linear or cyclic, and can be modified, e.g., glycosylated or methylated to facilitate targeting to specific tissues. For example, a glycosylated RGD peptide can deliver an iRNA agent to a tumor cell expressing αvβ₃(Haubner et al., Jour. Nucl. Med., 42:326-336, 2001).

A “cell permeation peptide” is capable of permeating a cell, e.g., a microbial cell, such as a bacterial or fungal cell, or a mammalian cell, such as a human cell. A microbial cell-permeating peptide can be, for example, an α-helical linear peptide (e.g., LL-37 or Ceropin P1), a disulfide bond-containing peptide (e.g., α-defensin, β-defensin or bactenecin), or a peptide containing only one or two dominating amino acids (e.g., PR-39 or indolicidin). A cell permeation peptide can also include a nuclear localization signal (NLS). For example, a cell permeation peptide can be a bipartite amphipathic peptide, such as MPG, which is derived from the fusion peptide domain of HIV-1 gp41 and the NLS of SV40 large T antigen (Simeoni et al., Nucl. Acids Res. 31:2717-2724, 2003).

C. Carbohydrate Conjugates

In some embodiments of the compositions and methods of the invention, an iRNA further comprises a carbohydrate. The carbohydrate conjugated iRNA are advantageous for the in vivo delivery of nucleic acids, as well as compositions suitable for in vivo therapeutic use, as described herein. As used herein, “carbohydrate” refers to a compound which is either a carbohydrate per se made up of one or more monosaccharide units having at least 6 carbon atoms (which can be linear, branched or cyclic) with an oxygen, nitrogen or sulfur atom bonded to each carbon atom; or a compound having as a part thereof a carbohydrate moiety made up of one or more monosaccharide units each having at least six carbon atoms (which can be linear, branched or cyclic), with an oxygen, nitrogen or sulfur atom bonded to each carbon atom. Representative carbohydrates include the sugars (mono-, di-, tri- and oligosaccharides containing from about 4, 5, 6, 7, 8, or 9 monosaccharide units), and polysaccharides such as starches, glycogen, cellulose and polysaccharide gums. Specific monosaccharides include C5 and above (e.g., C5, C6, C7, or C8) sugars; di- and tri-saccharides include sugars having two or three monosaccharide units (e.g., C5, C6, C7, or C8).

In certain embodiments, a carbohydrate conjugate comprises a monosaccharide.

In certain embodiments, the monosaccharide is an N-acetylgalactosamine (GalNAc). GalNAc conjugates, which comprise one or more N-acetylgalactosamine (GalNAc) derivatives, are described, for example, in U.S. Pat. No. 8,106,022, the entire content of which is hereby incorporated herein by reference. In some embodiments, the GalNAc conjugate serves as a ligand that targets the iRNA to particular cells. In some embodiments, the GalNAc conjugate targets the iRNA to liver cells, e.g., by serving as a ligand for the asialoglycoprotein receptor of liver cells (e.g., hepatocytes).

In some embodiments, the carbohydrate conjugate comprises one or more GalNAc derivatives. The GalNAc derivatives may be attached via a linker, e.g., a bivalent or trivalent branched linker. In some embodiments the GalNAc conjugate is conjugated to the 3′ end of the sense strand. In some embodiments, the GalNAc conjugate is conjugated to the iRNA agent (e.g., to the 3′ end of the sense strand) via a linker, e.g., a linker as described herein. In some embodiments the GalNAc conjugate is conjugated to the 5′ end of the sense strand. In some embodiments, the GalNAc conjugate is conjugated to the iRNA agent (e.g., to the 5′ end of the sense strand) via a linker, e.g., a linker as described herein.

In certain embodiments of the invention, the GalNAc or GalNAc derivative is attached to an iRNA agent of the invention via a monovalent linker. In some embodiments, the GalNAc or GalNAc derivative is attached to an iRNA agent of the invention via a bivalent linker. In yet other embodiments of the invention, the GalNAc or GalNAc derivative is attached to an iRNA agent of the invention via a trivalent linker. In other embodiments of the invention, the GalNAc or GalNAc derivative is attached to an iRNA agent of the invention via a tetravalent linker.

In certain embodiments, the double stranded RNAi agents of the invention comprise one GalNAc or GalNAc derivative attached to the iRNA agent. In certain embodiments, the double stranded RNAi agents of the invention comprise a plurality (e.g., 2, 3, 4, 5, or 6) GalNAc or GalNAc derivatives, each independently attached to a plurality of nucleotides of the double stranded RNAi agent through a plurality of monovalent linkers.

In some embodiments, for example, when the two strands of an iRNA agent of the invention are part of one larger molecule connected by an uninterrupted chain of nucleotides between the 3′-end of one strand and the 5′-end of the respective other strand forming a hairpin loop comprising, a plurality of unpaired nucleotides, each unpaired nucleotide within the hairpin loop may independently comprise a GalNAc or GalNAc derivative attached via a monovalent linker. The hairpin loop may also be formed by an extended overhang in one strand of the duplex.

In some embodiments, the GalNAc conjugate is

embedded image

In some embodiments, the RNAi agent is attached to the carbohydrate conjugate via a linker as shown in the following schematic, wherein X is O or S

embedded image

In some embodiments, the RNAi agent is conjugated to L96 as defined in Table 1 and shown below:

embedded image

In certain embodiments, a carbohydrate conjugate for use in the compositions and methods of the invention is selected from the group consisting of:

embedded image

In certain embodiments, a carbohydrate conjugate for use in the compositions and methods of the invention is a monosaccharide. In certain embodiments, the monosaccharide is an N-acetylgalactosamine, such as

embedded image

Another representative carbohydrate conjugate for use in the embodiments described herein includes, but is not limited to,

embedded image

when one of X or Y is an oligonucleotide, the other is a hydrogen.

In some embodiments, a suitable ligand is a ligand disclosed in WO 2019/055633, the entire contents of which are incorporated herein by reference. In one embodiment the ligand comprises the structure below:

embedded image

In certain embodiments, the RNAi agents of the disclosure may include GalNAc ligands, even if such GalNAc ligands are currently projected to be of limited value for the preferred intrathecal/CNS delivery route(s) of the instant disclosure.

In certain embodiments, the double stranded RNAi agents of the invention comprise one GalNAc or GalNAc derivative attached to the iRNA agent, e.g., the 5′end of the sense strand of a dsRNA agent, or the 5′ end of one or both sense strands of a dual targeting RNAi agent as described herein. In certain embodiments, the double stranded RNAi agents of the invention comprise a plurality (e.g., 2, 3, 4, 5, or 6) GalNAc or GalNAc derivatives, each independently attached to a plurality of nucleotides of the double stranded RNAi agent through a plurality of monovalent linkers.

In some embodiments, the carbohydrate conjugate further comprises one or more additional ligands as described above, such as, but not limited to, a PK modulator or a cell permeation peptide.

Additional carbohydrate conjugates and linkers suitable for use in the present invention include those described in WO 2014/179620 and WO 2014/179627, the entire contents of each of which are incorporated herein by reference.

D. Linkers

In some embodiments, the conjugate or ligand described herein can be attached to an iRNA oligonucleotide with various linkers that can be cleavable or non-cleavable.

The term “linker” or “linking group” means an organic moiety that connects two parts of a compound, e.g., covalently attaches two parts of a compound. Linkers typically comprise a direct bond or an atom such as oxygen or sulfur, a unit such as NR8, C(O), C(O)NH, SO, SO₂, SO₂NH or a chain of atoms, such as, but not limited to, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocyclylalkyl, heterocyclylalkenyl, heterocyclylalkynyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, cycloalkenyl, alkylarylalkyl, alkylarylalkenyl, alkylarylalkynyl, alkenylarylalkyl, alkenylarylalkenyl, alkenylarylalkynyl, alkynylarylalkyl, alkynylarylalkenyl, alkynylarylalkynyl, alkylheteroarylalkyl, alkylheteroarylalkenyl, alkylheteroarylalkynyl, alkenylheteroarylalkyl, alkenylheteroarylalkenyl, alkenylheteroarylalkynyl, alkynylheteroarylalkyl, alkynylheteroarylalkenyl, alkynylheteroarylalkynyl, alkylheterocyclylalkyl, alkylheterocyclylalkenyl, alkylhererocyclylalkynyl, alkenylheterocyclylalkyl, alkenylheterocyclylalkenyl, alkenylheterocyclylalkynyl, alkynylheterocyclylalkyl, alkynylheterocyclylalkenyl, alkynylheterocyclylalkynyl, alkylaryl, alkenylaryl, alkynylaryl, alkylheteroaryl, alkenylheteroaryl, alkynylhereroaryl, which one or more methylenes can be interrupted or terminated by O, S, S(O), SO₂, N(R8), C(O), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic; where R8 is hydrogen, acyl, aliphatic or substituted aliphatic. In certain embodiments, the linker is between about 1-24 atoms, 2-24, 3-24, 4-24, 5-24, 6-24, 6-18, 7-18, 8-18 atoms, 7-17, 8-17, 6-16, 7-16, or 8-16 atoms.

A cleavable linking group is one which is sufficiently stable outside the cell, but which upon entry into a target cell is cleaved to release the two parts the linker is holding together. In a preferred embodiment, the cleavable linking group is cleaved at least about 10 times, 20, times, 30 times, 40 times, 50 times, 60 times, 70 times, 80 times, 90 times or more, or at least about 100 times faster in a target cell or under a first reference condition (which can, e.g., be selected to mimic or represent intracellular conditions) than in the blood of a subject, or under a second reference condition (which can, e.g., be selected to mimic or represent conditions found in the blood or serum).

Cleavable linking groups are susceptible to cleavage agents, e.g., pH, redox potential or the presence of degradative molecules. Generally, cleavage agents are more prevalent or found at higher levels or activities inside cells than in serum or blood. Examples of such degradative agents include: redox agents which are selected for particular substrates or which have no substrate specificity, including, e.g., oxidative or reductive enzymes or reductive agents such as mercaptans, present in cells, that can degrade a redox cleavable linking group by reduction; esterases; endosomes or agents that can create an acidic environment, e.g., those that result in a pH of five or lower; enzymes that can hydrolyze or degrade an acid cleavable linking group by acting as a general acid, peptidases (which can be substrate specific), and phosphatases.

A cleavable linkage group, such as a disulfide bond can be susceptible to pH. The pH of human serum is 7.4, while the average intracellular pH is slightly lower, ranging from about 7.1-7.3. Endosomes have a more acidic pH, in the range of 5.5-6.0, and lysosomes have an even more acidic pH at around 5.0. Some linkers will have a cleavable linking group that is cleaved at a preferred pH, thereby releasing a cationic lipid from the ligand inside the cell, or into the desired compartment of the cell.

A linker can include a cleavable linking group that is cleavable by a particular enzyme. The type of cleavable linking group incorporated into a linker can depend on the cell to be targeted. For example, a liver-targeting ligand can be linked to a cationic lipid through a linker that includes an ester group. Liver cells are rich in esterases, and therefore the linker will be cleaved more efficiently in liver cells than in cell types that are not esterase-rich. Other cell-types rich in esterases include cells of the lung, renal cortex, and testis.

Linkers that contain peptide bonds can be used when targeting cell types rich in peptidases, such as liver cells and synoviocytes.

In general, the suitability of a candidate cleavable linking group can be evaluated by testing the ability of a degradative agent (or condition) to cleave the candidate linking group. It will also be desirable to also test the candidate cleavable linking group for the ability to resist cleavage in the blood or when in contact with other non-target tissue. Thus, one can determine the relative susceptibility to cleavage between a first and a second condition, where the first is selected to be indicative of cleavage in a target cell and the second is selected to be indicative of cleavage in other tissues or biological fluids, e.g., blood or serum. The evaluations can be carried out in cell free systems, in cells, in cell culture, in organ or tissue culture, or in whole animals. It can be useful to make initial evaluations in cell-free or culture conditions and to confirm by further evaluations in whole animals. In preferred embodiments, useful candidate compounds are cleaved at least about 2, 4, 10, 20, 30, 40, 50, 60, 70, 80, 90, or about 100 times faster in the cell (or under in vitro conditions selected to mimic intracellular conditions) as compared to blood or serum (or under in vitro conditions selected to mimic extracellular conditions).

i. Redox Cleavable Linking Groups

In certain embodiments, a cleavable linking group is a redox cleavable linking group that is cleaved upon reduction or oxidation. An example of reductively cleavable linking group is a disulphide linking group (—S—S—). To determine if a candidate cleavable linking group is a suitable “reductively cleavable linking group,” or for example is suitable for use with a particular iRNA moiety and particular targeting agent one can look to methods described herein. For example, a candidate can be evaluated by incubation with dithiothreitol (DTT), or other reducing agent using reagents know in the art, which mimic the rate of cleavage which would be observed in a cell, e.g., a target cell. The candidates can also be evaluated under conditions which are selected to mimic blood or serum conditions. In one, candidate compounds are cleaved by at most about 10% in the blood. In other embodiments, useful candidate compounds are degraded at least about 2, 4, 10, 20, 30, 40, 50, 60, 70, 80, 90, or about 100 times faster in the cell (or under in vitro conditions selected to mimic intracellular conditions) as compared to blood (or under in vitro conditions selected to mimic extracellular conditions). The rate of cleavage of candidate compounds can be determined using standard enzyme kinetics assays under conditions chosen to mimic intracellular media and compared to conditions chosen to mimic extracellular media.

ii. Phosphate-Based Cleavable Linking Groups

In certain embodiments, a cleavable linker comprises a phosphate-based cleavable linking group. A phosphate-based cleavable linking group is cleaved by agents that degrade or hydrolyze the phosphate group. An example of an agent that cleaves phosphate groups in cells are enzymes such as phosphatases in cells. Examples of phosphate-based linking groups are —O—P(O)(ORk)-O—, —O—P(S)(ORk)-O—, —O—P(S)(SRk)-O—, —S—P(O)(ORk)-O—, —O—P(O)(ORk)-S—, —S—P(O)(ORk)-S—, —O—P(S)(ORk)-S—, —S—P(S)(ORk)-O—, —O—P(O)(Rk)-O—, —O—P(S)(Rk)-O—, —S—P(O)(Rk)-O—, —S—P(S)(Rk)-O—, —S—P(O)(Rk)-S—, —O—P(S)(Rk)-S. Exemplary embodiments are —O—P(O)(OH)—O—, —O—P(S)(OH)—O—, —O—P(S)(SH)—O—, —S—P(O)(OH)—O—, —O—P(O)(OH)—S—, —S—P(O)(OH)—S—, —O—P(S)(OH)—S—, —S—P(S)(OH)—O—, —O—P(O)(H)—O—, —O—P(S)(H)—O—, —S—P(O)(H)—O, —S—P(S)(H)—O—, —S—P(O)(H)—S—, —O—P(S)(H)—S—, wherein Rk at each occurrence can be, independently, C1-C20 alkyl, C1-C20 haloalkyl, C6-C10 aryl, or C7-C12 aralkyl. In certain preferred embodiments a phosphate-based linking group is —O—P(O)(OH)—O—. These candidates can be evaluated using methods analogous to those described above.

iii. Acid Cleavable Linking Groups

In certain embodiments, a cleavable linker comprises an acid cleavable linking group. An acid cleavable linking group is a linking group that is cleaved under acidic conditions. In preferred embodiments acid cleavable linking groups are cleaved in an acidic environment with a pH of about 6.5 or lower (e.g., about 6.0, 5.75, 5.5, 5.25, 5.0, or lower), or by agents such as enzymes that can act as a general acid. In a cell, specific low pH organelles, such as endosomes and lysosomes can provide a cleaving environment for acid cleavable linking groups. Examples of acid cleavable linking groups include but are not limited to hydrazones, esters, and esters of amino acids. Acid cleavable groups can have the general formula —C═NN—, C(O)O, or —OC(O). A preferred embodiment is when the carbon attached to the oxygen of the ester (the alkoxy group) is an aryl group, substituted alkyl group, or tertiary alkyl group such as dimethyl pentyl or t-butyl. These candidates can be evaluated using methods analogous to those described above.

iv. Ester-Based Cleavable Linking Groups

In certain embodiments, a cleavable linker comprises an ester-based cleavable linking group. An ester-based cleavable linking group is cleaved by enzymes such as esterases and amidases in cells. Examples of ester-based cleavable linking groups include but are not limited to esters of alkylene, alkenylene and alkynylene groups. Ester cleavable linking groups have the general formula —C(O)O—, or —OC(O)—. These candidates can be evaluated using methods analogous to those described above.

v. Peptide-Based Cleavable Linking Groups

In yet another embodiment, a cleavable linker comprises a peptide-based cleavable linking group. A peptide-based cleavable linking group is cleaved by enzymes such as peptidases and proteases in cells. Peptide-based cleavable linking groups are peptide bonds formed between amino acids to yield oligopeptides (e.g., dipeptides, tripeptides etc.) and polypeptides. Peptide-based cleavable groups do not include the amide group (—C(O)NH—). The amide group can be formed between any alkylene, alkenylene or alkynelene. A peptide bond is a special type of amide bond formed between amino acids to yield peptides and proteins. The peptide based cleavage group is generally limited to the peptide bond (i.e., the amide bond) formed between amino acids yielding peptides and proteins and does not include the entire amide functional group. Peptide-based cleavable linking groups have the general formula—NHCHRAC(O)NHCHRBC(O)—, where RA and RB are the R groups of the two adjacent amino acids. These candidates can be evaluated using methods analogous to those described above.

In some embodiments, an iRNA of the invention is conjugated to a carbohydrate through a linker. Non-limiting examples of iRNA carbohydrate conjugates with linkers of the compositions and methods of the invention include, but are not limited to,

embedded image

when one of X or Y is an oligonucleotide, the other is a hydrogen.

In certain embodiments of the compositions and methods of the invention, a ligand is one or more “GalNAc” (N-acetylgalactosamine) derivatives attached through a bivalent or trivalent branched linker.

In certain embodiments, a dsRNA of the invention is conjugated to a bivalent or trivalent branched linker selected from the group of structures shown in any of formula (XLV)-(XLVI):

embedded image

wherein:

q2A, q2B, q3A, q3B, q4A, q4B, q5A, q5B and q5C represent independently for each occurrence 0-20 and wherein the repeating unit can be the same or different;

P^2A, P^2B, P^3A, P^3B, P^4A, P^4B, P^5A, P^5B, P^5C, T^2A, T^2B, T^3A, T^3B, T^4A, T^4B, T^4A, T^5B, T^5C, are each independently for each occurrence absent, CO, NH, O, S, OC(O), NHC(O), CH₂, CH₂NH or CH₂O;

Q^2A, Q^2B, Q^3A, Q^3B, Q^4A, Q^4B, Q^5A, Q^5B, Q^5C, are independently for each occurrence absent, alkylene, substituted alkylene wherein one or more methylenes can be interrupted or terminated by one or more of O, S, S(O), SO₂, N(R^N), C(R′)═C(R″), C≡C or C(O);

R^2A, R^2B, R^3A, R^3B, R^4A, R^4B, R^5A, R^5B, R^5Care each independently for each occurrence absent, NH, O, S, CH₂, C(O)O, C(O)NH, NHCH(R^a)C(O), —C(O)—CH(R^a)—NH—, CO, CH═N—O,

embedded image

or heterocyclyl;

L^2A, L^2B, L^3A, L^3B, L^4A, L^4B, L^5A, L^5Band L^5Crepresent the ligand; i.e. each independently for each occurrence a monosaccharide (such as GalNAc), disaccharide, trisaccharide, tetrasaccharide, oligosaccharide, or polysaccharide; and R^ais H or amino acid side chain. Trivalent conjugating GalNAc derivatives are particularly useful for use with RNAi agents for inhibiting the expression of a target gene, such as those of formula (XLIX):

embedded image

wherein L^5AL^5Band L^5Crepresent a monosaccharide, such as GalNAc derivative.

Examples of suitable bivalent and trivalent branched linker groups conjugating GalNAc derivatives include, but are not limited to, the structures recited above as formulas II, VII, XI, X, and XIII.

Representative U.S. patents that teach the preparation of RNA conjugates include, but are not limited to, U.S. Pat. Nos. 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717, 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241, 5,391,723; 5,416,203, 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928; 5,688,941; 6,294,664; 6,320,017; 6,576,752; 6,783,931; 6,900,297; 7,037,646; and 8,106,022, the entire contents of each of which are hereby incorporated herein by reference.

It is not necessary for all positions in a given compound to be uniformly modified, and in fact more than one of the aforementioned modifications can be incorporated in a single compound or even at a single nucleoside within an iRNA. The present invention also includes iRNA compounds that are chimeric compounds.

“Chimeric” iRNA compounds or “chimeras,” in the context of this invention, are iRNA compounds, preferably dsRNA agents, that contain two or more chemically distinct regions, each made up of at least one monomer unit, i.e., a nucleotide in the case of a dsRNA compound. These iRNAs typically contain at least one region wherein the RNA is modified so as to confer upon the iRNA increased resistance to nuclease degradation, increased cellular uptake, or increased binding affinity for the target nucleic acid. An additional region of the iRNA can serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of iRNA inhibition of gene expression. Consequently, comparable results can often be obtained with shorter iRNAs when chimeric dsRNAs are used, compared to phosphorothioate deoxy dsRNAs hybridizing to the same target region. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.

In certain instances, the RNA of an iRNA can be modified by a non-ligand group. A number of non-ligand molecules have been conjugated to iRNAs in order to enhance the activity, cellular distribution or cellular uptake of the iRNA, and procedures for performing such conjugations are available in the scientific literature. Such non-ligand moieties have included lipid moieties, such as cholesterol (Kubo, T. et al., Biochem. Biophys. Res. Comm., 2007, 365(1):54-61; Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989, 86:6553), cholic acid (Manoharan et al., Bioorg. Med. Chem. Lett., 1994, 4:1053), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., Ann. N.Y. Acad. Sci., 1992, 660:306; Manoharan et al., Bioorg. Med. Chem. Let., 1993, 3:2765), a thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992, 20:533), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., EMBO J., 1991, 10:111; Kabanov et al., FEBS Lett., 1990, 259:327; Svinarchuk et al., Biochimie, 1993, 75:49), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36:3651; Shea et al., Nucl. Acids Res., 1990, 18:3777), a polyamine or a polyethylene glycol chain (Manoharan et al., Nucleosides & Nucleotides, 1995, 14:969), or adamantane acetic acid (Manoharan et al., Tetrahedron Lett., 1995, 36:3651), a palmityl moiety (Mishra et al., Biochim. Biophys. Acta, 1995, 1264:229), or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., J. Pharmacol. Exp. Ther., 1996, 277:923). Representative United States patents that teach the preparation of such RNA conjugates have been listed above. Typical conjugation protocols involve the synthesis of RNAs bearing an aminolinker at one or more positions of the sequence. The amino group is then reacted with the molecule being conjugated using appropriate coupling or activating reagents. The conjugation reaction can be performed either with the RNA still bound to the solid support or following cleavage of the RNA, in solution phase. Purification of the RNA conjugate by HPLC typically affords the pure conjugate.

V. In Vivo Testing of APOE Knockdown

Human APOE knock-in mouse models, including transgenic mice expressing one or more human APOE isoforms (APOE2, APOE3, and APOE4) have been generated (see, e.g., Trommer, et al. (2005) Neuroreport 15:2655-2658) and can be used to demonstrate the in vivo efficacy of the RNAi agents provided herein.

Mouse models of APOE-associated neurodegenerative disease (e.g., Alzheimer's disease) have also been generated and can further be used to demonstrate the in vivo efficacy of the RNAi agents provided herein. Such models may combine transgenic expression of one or more isoforms of human APOE with constitutive or inducible expression, e.g., overexpression, of, for example, human amyloid precursor protein (APP), in some instances comprising a pathogenic mutation (e.g., a Swedish mutation (KM670/671NL)), constitutive or inducible expression, e.g., overexpression, of, human presenilin 1 (PS1), in some instances comprising a pathogenic mutation (e.g., L166P) mutation (see, e.g., Huynh, et al. (2017) Neuron 96: 1013-1023), and/or constitutive or inducible expression, e.g., overexpression, of 1N4R human tau protein, in some instances comprising a pathogenic mutation (e.g., a P301S mutation) (Shi, et al. (2017) Nature 549: 523-527).

VI. Delivery of an RNAi Agent of the Disclosure

The delivery of a RNAi agent of the disclosure to a cell e.g., a cell within a subject, such as a human subject (e.g., a subject in need thereof, such as a subject having an APOE-associated neurodegenerative disorder, e.g., an amyloid-β-mediated disease, such as, Alzheimer's's disease, Down's syndrome, and cerebral amyloid angiopathy, or a tau-mediated disease, e.g. a primary tauopathy, such as Frontotemporal dementia (FTD), Progressive supranuclear palsy (PSP), Cordicobasal degeneration (CBD), Pick's disease (PiD), Globular glial tauopathies (GGTs), frontotemporal dementia with parkinsonism (FTDP, FTDP-17), Chronic traumatic encelopathy (CTE), Dementia pugilistica, Frontotemporal lobar degeneration (FTLD), Argyrophilic grain disease (AGD), and Primary age-related tauopathy (PART), or a secondary tauopathy, e.g., AD, Creuzfeld Jakob's disease, Down's Syndrome, and Familial British Dementia can be achieved in a number of different ways. For example, delivery may be performed by contacting a cell with an RNAi agent of the disclosure either in vitro or in vivo. In vivo delivery may also be performed directly by administering a composition comprising an RNAi agent, e.g., a dsRNA, to a subject. Alternatively, in vivo delivery may be performed indirectly by administering one or more vectors that encode and direct the expression of the RNAi agent. These alternatives are discussed further below.

In general, any method of delivering a nucleic acid molecule (in vitro or in vivo) can be adapted for use with a RNAi agent of the disclosure (see e.g., Akhtar S. and Julian R L., (1992) Trends Cell. Biol. 2(5):139-144 and WO94/02595, which are incorporated herein by reference in their entireties). For in vivo delivery, factors to consider in order to deliver an RNAi agent include, for example, biological stability of the delivered agent, prevention of non-specific effects, and accumulation of the delivered agent in the target tissue. The non-specific effects of an RNAi agent can be minimized by local administration, for example, by direct injection or implantation into a tissue or topically administering the preparation. Local administration to a treatment site maximizes local concentration of the agent, limits the exposure of the agent to systemic tissues that can otherwise be harmed by the agent or that can degrade the agent, and permits a lower total dose of the RNAi agent to be administered. Several studies have shown successful knockdown of gene products when an RNAi agent is administered locally. For example, intraocular delivery of a VEGF dsRNA by intravitreal injection in cynomolgus monkeys (Tolentino, M J. et al., (2004) Retina 24:132-138) and subretinal injections in mice (Reich, S J. et al. (2003) Mol. Vis. 9:210-216) were both shown to prevent neovascularization in an experimental model of age-related macular degeneration. In addition, direct intratumoral injection of a dsRNA in mice reduces tumor volume (Pille, J. et al. (2005) Mol. Ther. 11:267-274) and can prolong survival of tumor-bearing mice (Kim, W J. et al., (2006) Mol. Ther. 14:343-350; Li, S. et al., (2007) Mol. Ther. 15:515-523). RNA interference has also shown success with local delivery to the CNS by direct injection (Dorn, G. et al., (2004) Nucleic Acids 32:e49; Tan, P H. et al. (2005) Gene Ther. 12:59-66; Makimura, H. et a.l (2002) BMC Neurosci. 3:18; Shishkina, G T., et al. (2004) Neuroscience 129:521-528; Thakker, E R., et al. (2004) Proc. Nat. Acad. Sci. U.S.A. 101:17270-17275; Akaneya, Y., et al. (2005) J. Neurophysiol. 93:594-602) and to the lungs by intranasal administration (Howard, K A. et al., (2006) Mol. Ther. 14:476-484; Zhang, X. et al., (2004) J. Biol. Chem. 279:10677-10684; Bitko, V. et al., (2005) Nat. Med. 11:50-55). For administering a RNAi agent systemically for the treatment of a disease, the RNA can be modified or alternatively delivered using a drug delivery system; both methods act to prevent the rapid degradation of the dsRNA by endo- and exo-nucleases in vivo. Modification of the RNA or the pharmaceutical carrier can also permit targeting of the RNAi agent to the target tissue and avoid undesirable off-target effects (e.g., without wishing to be bound by theory, use of GNAs as described herein has been identified to destabilize the seed region of a dsRNA, resulting in enhanced preference of such dsRNAs for on-target effectiveness, relative to off-target effects, as such off-target effects are significantly weakened by such seed region destabilization). RNAi agents can be modified by chemical conjugation to lipophilic groups such as cholesterol to enhance cellular uptake and prevent degradation. For example, a RNAi agent directed against ApoB conjugated to a lipophilic cholesterol moiety was injected systemically into mice and resulted in knockdown of apoB mRNA in both the liver and jejunum (Soutschek, J. et al., (2004) Nature 432:173-178). Conjugation of an RNAi agent to an aptamer has been shown to inhibit tumor growth and mediate tumor regression in a mouse model of prostate cancer (McNamara, J O. et al., (2006) Nat. Biotechnol. 24:1005-1015). In an alternative embodiment, the RNAi agent can be delivered using drug delivery systems such as a nanoparticle, a dendrimer, a polymer, liposomes, or a cationic delivery system. Positively charged cationic delivery systems facilitate binding of molecule RNAi agent (negatively charged) and also enhance interactions at the negatively charged cell membrane to permit efficient uptake of an RNAi agent by the cell. Cationic lipids, dendrimers, or polymers can either be bound to an RNAi agent, or induced to form a vesicle or micelle (see e.g., Kim S H. et al., (2008) Journal of Controlled Release 129(2):107-116) that encases an RNAi agent. The formation of vesicles or micelles further prevents degradation of the RNAi agent when administered systemically. Methods for making and administering cationic-RNAi agent complexes are well within the abilities of one skilled in the art (see e.g., Sorensen, D R., et al. (2003) J. Mol. Biol 327:761-766; Verma, U N. et al., (2003) Clin. Cancer Res. 9:1291-1300; Arnold, A S et al. (2007) J. Hypertens. 25:197-205, which are incorporated herein by reference in their entirety). Some non-limiting examples of drug delivery systems useful for systemic delivery of RNAi agents include DOTAP (Sorensen, D R., et al (2003), supra; Verma, U N. et al., (2003), supra), Oligofectamine, “solid nucleic acid lipid particles” (Zimmermann, T S. et al., (2006) Nature 441:111-114), cardiolipin (Chien, P Y. et al., (2005) Cancer Gene Ther. 12:321-328; Pal, A. et al., (2005) Int J. Oncol. 26:1087-1091), polyethyleneimine (Bonnet M E. et al., (2008) Pharm. Res. August 16 Epub ahead of print; Aigner, A. (2006) J. Biomed. Biotechnol. 71659), Arg-Gly-Asp (RGD) peptides (Liu, S. (2006) Mol. Pharm. 3:472-487), and polyamidoamines (Tomalia, D A. et al., (2007) Biochem. Soc. Trans. 35:61-67; Yoo, H. et al., (1999) Pharm. Res. 16:1799-1804). In some embodiments, a RNAi agent forms a complex with cyclodextrin for systemic administration. Methods for administration and pharmaceutical compositions of RNAi agents and cyclodextrins can be found in U.S. Pat. No. 7,427,605, which is herein incorporated by reference in its entirety.

Certain aspects of the instant disclosure relate to a method of reducing the expression of an APOE target gene in a cell, comprising contacting said cell with the double-stranded RNAi agent of the disclosure. In one embodiment, the cell is a hepatic cell, optionally a hepatocyte. In one embodiment, the cell is an extrahepatic cell, optionally a CNS cell.

Another aspect of the disclosure relates to a method of reducing the expression of an APOE target gene in a subject, comprising administering to the subject the double-stranded RNAi agent of the disclosure.

Another aspect of the disclosure relates to a method of treating a subject having an APOE-associated neurodegenerative disorder, comprising administering to the subject a therapeutically effective amount of the double-stranded RNAi agent of the disclosure, thereby treating the subject. Exemplary CNS disorders that can be treated by the method of the disclosure include amyloid-β-mediated diseases, such as, Alzheimer's's disease, Down's syndrome, and cerebral amyloid angiopathy, and tau-mediated diseases, e.g. primary tauopathies, such as Frontotemporal dementia (FTD), Progressive supranuclear palsy (PSP), Cordicobasal degeneration (CBD), Pick's disease (PiD), Globular glial tauopathies (GGTs), frontotemporal dementia with parkinsonism (FTDP, FTDP-17), Chronic traumatic encelopathy (CTE), Dementia pugilistica, Frontotemporal lobar degeneration (FTLD), Argyrophilic grain disease (AGD), and Primary age-related tauopathy (PART), and secondary tauopathies, e.g., AD, Creuzfeld Jakob's disease, Down's Syndrome, and Familial British Dementia. In one embodiment, the double-stranded RNAi agent is administered subcutaneously.

In one embodiment, the double-stranded RNAi agent is administered intrathecally. By intrathecal administration of the double-stranded RNAi agent, the method can reduce the expression of an APOE target gene in a brain (e.g., striatum) or spine tissue, for instance, cortex, cerebellum, cervical spine, lumbar spine, and thoracic spine.

For ease of exposition the formulations, compositions and methods in this section are discussed largely with regard to modified siRNA compounds. It may be understood, however, that these formulations, compositions and methods can be practiced with other siRNA compounds, e.g., unmodified siRNA compounds, and such practice is within the disclosure. A composition that includes a RNAi agent can be delivered to a subject by a variety of routes. Exemplary routes include: intrathecal, intravenous, topical, rectal, anal, vaginal, nasal, pulmonary, and ocular.

The RNAi agents of the disclosure can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically include one or more species of RNAi agent and a pharmaceutically acceptable carrier. As used herein the language “pharmaceutically acceptable carrier” is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

The pharmaceutical compositions of the present disclosure may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic, vaginal, rectal, intranasal, transdermal), oral, or parenteral. Parenteral administration includes intravenous drip, subcutaneous, intraperitoneal or intramuscular injection, or intrathecal or intraventricular administration.

The route and site of administration may be chosen to enhance targeting. For example, to target muscle cells, intramuscular injection into the muscles of interest would be a logical choice. Lung cells might be targeted by administering the RNAi agent in aerosol form. The vascular endothelial cells could be targeted by coating a balloon catheter with the RNAi agent and mechanically introducing the RNA.

Formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids, and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. Coated condoms, gloves and the like may also be useful.

Compositions for oral administration include powders or granules, suspensions or solutions in water, syrups, elixirs or non-aqueous media, tablets, capsules, lozenges, or troches. In the case of tablets, carriers that can be used include lactose, sodium citrate and salts of phosphoric acid. Various disintegrants such as starch, and lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc, are commonly used in tablets. For oral administration in capsule form, useful diluents are lactose and high molecular weight polyethylene glycols. When aqueous suspensions are required for oral use, the nucleic acid compositions can be combined with emulsifying and suspending agents. If desired, certain sweetening or flavoring agents can be added.

Compositions for intrathecal or intraventricular administration may include sterile aqueous solutions which may also contain buffers, diluents, and other suitable additives.

Formulations for parenteral administration may include sterile aqueous solutions which may also contain buffers, diluents, and other suitable additives. Intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir. For intravenous use, the total concentration of solutes may be controlled to render the preparation isotonic.

In one embodiment, the administration of the siRNA compound, e.g., a double-stranded siRNA compound, or ssiRNA compound, composition is parenteral, e.g., intravenous (e.g., as a bolus or as a diffusible infusion), intradermal, intraperitoneal, intramuscular, intrathecal, intraventricular, intracranial, subcutaneous, transmucosal, buccal, sublingual, endoscopic, rectal, oral, vaginal, topical, pulmonary, intranasal, urethral, or ocular. Administration can be provided by the subject or by another person, e.g., a health care provider. The medication can be provided in measured doses or in a dispenser which delivers a metered dose. Selected modes of delivery are discussed in more detail below.

Intrathecal Administration.

In one embodiment, the double-stranded RNAi agent is delivered by intrathecal injection (i.e., injection into the spinal fluid which bathes the brain and spinal cord tissue). Intrathecal injection of RNAi agents into the spinal fluid can be performed as a bolus injection or via minipumps which can be implanted beneath the skin, providing a regular and constant delivery of siRNA into the spinal fluid. The circulation of the spinal fluid from the choroid plexus, where it is produced, down around the spinal chord and dorsal root ganglia and subsequently up past the cerebellum and over the cortex to the arachnoid granulations, where the fluid can exit the CNS, that, depending upon size, stability, and solubility of the compounds injected, molecules delivered intrathecally could hit targets throughout the entire CNS.

In some embodiments, the intrathecal administration is via a pump. The pump may be a surgically implanted osmotic pump. In one embodiment, the osmotic pump is implanted into the subarachnoid space of the spinal canal to facilitate intrathecal administration.

In some embodiments, the intrathecal administration is via an intrathecal delivery system for a pharmaceutical including a reservoir containing a volume of the pharmaceutical agent, and a pump configured to deliver a portion of the pharmaceutical agent contained in the reservoir. More details about this intrathecal delivery system may be found in WO 2015/116658, which is incorporated by reference in its entirety.

The amount of intrathecally injected RNAi agents may vary from one target gene to another target gene and the appropriate amount that has to be applied may have to be determined individually for each target gene. Typically, this amount ranges from 10 μg to 2 mg, preferably 50 μg to 1500 μg, more preferably 100 μg to 1000 μg.

Vector Encoded RNAi Agents of the Disclosure

RNAi agents targeting the APOE gene can be expressed from transcription units inserted into DNA or RNA vectors (see, e.g., Couture, A, et al., TIG. (1996), 12:5-10; WO 00/22113, WO 00/22114, and U.S. Pat. No. 6,054,299). Expression is preferablysustained (months or longer), depending upon the specific construct used and the target tissue or cell type. These transgenes can be introduced as a linear construct, a circular plasmid, or a viral vector, which can be an integrating or non-integrating vector. The transgene can also be constructed to permit it to be inherited as an extrachromosomal plasmid (Gassmann, et al., (1995) Proc. Natl. Acad. Sci. USA 92:1292).

The individual strand or strands of a RNAi agent can be transcribed from a promoter on an expression vector. Where two separate strands are to be expressed to generate, for example, a dsRNA, two separate expression vectors can be co-introduced (e.g., by transfection or infection) into a target cell. Alternatively, each individual strand of a dsRNA can be transcribed by promoters both of which are located on the same expression plasmid. In one embodiment, a dsRNA is expressed as inverted repeat polynucleotides joined by a linker polynucleotide sequence such that the dsRNA has a stem and loop structure.

RNAi agent expression vectors are generally DNA plasmids or viral vectors. Expression vectors compatible with eukaryotic cells, preferably those compatible with vertebrate cells, can be used to produce recombinant constructs for the expression of a RNAi agent as described herein. Delivery of RNAi agent expressing vectors can be systemic, such as by intravenous or intramuscular administration, by administration to target cells ex-planted from the patient followed by reintroduction into the patient, or by any other means that allows for introduction into a desired target cell.

Viral vector systems which can be utilized with the methods and compositions described herein include, but are not limited to, (a) adenovirus vectors; (b) retrovirus vectors, including but not limited to lentiviral vectors, moloney murine leukemia virus, etc.; (c) adeno-associated virus vectors; (d) herpes simplex virus vectors; (e) SV 40 vectors; (f) polyoma virus vectors; (g) papilloma virus vectors; (h) picornavirus vectors; (i) pox virus vectors such as an orthopox, e.g., vaccinia virus vectors or avipox, e.g. canary pox or fowl pox; and (j) a helper-dependent or gutless adenovirus. Replication-defective viruses can also be advantageous. Different vectors will or will not become incorporated into the cells' genome. The constructs can include viral sequences for transfection, if desired. Alternatively, the construct can be incorporated into vectors capable of episomal replication, e.g. EPV and EBV vectors. Constructs for the recombinant expression of a RNAi agent will generally require regulatory elements, e.g., promoters, enhancers, etc., to ensure the expression of the RNAi agent in target cells. Other aspects to consider for vectors and constructs are known in the art.

VII. Pharmaceutical Compositions of the Invention

The present disclosure also includes pharmaceutical compositions and formulations which include the RNAi agents of the disclosure. In one embodiment, provided herein are pharmaceutical compositions containing an RNAi agent, as described herein, and a pharmaceutically acceptable carrier. The pharmaceutical compositions containing the RNAi agent are useful for treating a disease or disorder associated with the expression or activity of APOE, e.g., an APOE-associated neurodegenerative disease, such as an amyloid-β-mediated disease, e.g. Alzheimer's disease, Down's syndrome, and cerebral amyloid angiopathy, a tau-mediated disease, e.g. a primary tauopathy, such as Frontotemporal dementia (FTD), Progressive supranuclear palsy (PSP), Cordicobasal degeneration (CBD), Pick's disease (PiD), Globular glial tauopathies (GGTs), frontotemporal dementia with parkinsonism (FTDP, FTDP-17), Chronic traumatic encelopathy (CTE), Dementia pugilistica, Frontotemporal lobar degeneration (FTLD), Argyrophilic grain disease (AGD), and Primary age-related tauopathy (PART), or a secondary tauopathy, e.g., AD, Creuzfeld Jakob's disease, Down's Syndrome, and Familial British Dementia.

Such pharmaceutical compositions are formulated based on the mode of delivery. One example is compositions that are formulated for systemic administration via parenteral delivery, e.g., by intravenous (IV), intramuscular (IM), or for subcutaneous (subQ) delivery. Another example is compositions that are formulated for direct delivery into the CNS, e.g., by intrathecal or intravitreal routes of injection, optionally by infusion into the brain (e.g., striatum), such as by continuous pump infusion.

In some embodiments, the pharmaceutical compositions of the invention are pyrogen free or non-pyrogenic.

The pharmaceutical compositions of the disclosure may be administered in dosages sufficient to inhibit expression of an APOE gene. In general, a suitable dose of an RNAi agent of the disclosure will be in the range of about 0.001 to about 200.0 milligrams per kilogram body weight of the recipient per day, generally in the range of about 1 to 50 mg per kilogram body weight per day.

A repeat-dose regimen may include administration of a therapeutic amount of a RNAi agent on a regular basis, such as monthly to once every six months. In certain embodiments, the RNAi agent is administered about once per quarter (i.e., about once every three months) to about twice per year.

After an initial treatment regimen (e.g., loading dose), the treatments can be administered on a less frequent basis.

In other embodiments, a single dose of the pharmaceutical compositions can be long lasting, such that subsequent doses are administered at not more than 1, 2, 3, or 4 or more month intervals. In some embodiments of the disclosure, a single dose of the pharmaceutical compositions of the disclosure is administered once per month. In other embodiments of the disclosure, a single dose of the pharmaceutical compositions of the disclosure is administered once per quarter to twice per year.

The skilled artisan will appreciate that certain factors can influence the dosage and timing required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health or age of the subject, and other diseases present. Moreover, treatment of a subject with a therapeutically effective amount of a composition can include a single treatment or a series of treatments.

Advances in mouse genetics have generated a number of mouse models for the study of various APOE-associated neurodegenerative diseases that would benefit from reduction in the expression of APOE. Such models can be used for in vivo testing of RNAi agents, as well as for determining a therapeutically effective dose. Suitable mouse models are known in the art and include, for example, the mouse models described elsewhere herein.

The pharmaceutical compositions of the present disclosure can be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration can be topical (e.g., by a transdermal patch), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal, oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; subdermal, e.g., via an implanted device; or intracranial, e.g., by intraparenchymal, intrathecal or intraventricular, administration.

The RNAi agents can be delivered in a manner to target a particular tissue, such as the liver, the CNS (e.g., neuronal, glial or vascular tissue of the brain), or both the liver and CNS.

Pharmaceutical compositions and formulations for topical administration can include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like can be necessary or desirable. Coated condoms, gloves and the like can also be useful. Suitable topical formulations include those in which the RNAi agents featured in the disclosure are in admixture with a topical delivery agent such as lipids, liposomes, fatty acids, fatty acid esters, steroids, chelating agents and surfactants. Suitable lipids and liposomes include neutral (e.g., dioleoylphosphatidyl DOPE ethanolamine, dimyristoylphosphatidyl choline DMPC, distearolyphosphatidyl choline) negative (e.g., dimyristoylphosphatidyl glycerol DMPG) and cationic (e.g., dioleoyltetramethylaminopropyl DOTAP and dioleoylphosphatidyl ethanolamine DOTMA). RNAi agents featured in the disclosure can be encapsulated within liposomes or can form complexes thereto, in particular to cationic liposomes. Alternatively, RNAi agents can be complexed to lipids, in particular to cationic lipids. Suitable fatty acids and esters include but are not limited to arachidonic acid, oleic acid, eicosanoic acid, lauric acid, caprylic acid, capric acid, myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein, dilaurin, glyceryl 1-monocaprate, 1-dodecylazacycloheptan-2-one, an acylcarnitine, an acylcholine, or a C_1-20alkyl ester (e.g., isopropylmyristate IPM), monoglyceride, diglyceride or pharmaceutically acceptable salt thereof. Topical formulations are described in detail in U.S. Pat. No. 6,747,014, which is incorporated herein by reference.

A. RNAi Agent Formulations Comprising Membranous Molecular Assemblies

A RNAi agent for use in the compositions and methods of the disclosure can be formulated for delivery in a membranous molecular assembly, e.g., a liposome or a micelle. As used herein, the term “liposome” refers to a vesicle composed of amphiphilic lipids arranged in at least one bilayer, e.g., one bilayer or a plurality of bilayers. Liposomes include unilamellar and multilamellar vesicles that have a membrane formed from a lipophilic material and an aqueous interior. The aqueous portion contains the RNAi agent composition. The lipophilic material isolates the aqueous interior from an aqueous exterior, which typically does not include the RNAi agent composition, although in some examples, it may. Liposomes are useful for the transfer and delivery of active ingredients to the site of action. Because the liposomal membrane is structurally similar to biological membranes, when liposomes are applied to a tissue, the liposomal bilayer fuses with bilayer of the cellular membranes. As the merging of the liposome and cell progresses, the internal aqueous contents that include the RNAi agent are delivered into the cell where the RNAi agent can specifically bind to a target RNA and can mediate RNAi. In some cases the liposomes are also specifically targeted, e.g., to direct the RNAi agent to particular cell types.

A liposome containing an RNAi agent can be prepared by a variety of methods. In one example, the lipid component of a liposome is dissolved in a detergent so that micelles are formed with the lipid component. For example, the lipid component can be an amphipathic cationic lipid or lipid conjugate. The detergent can have a high critical micelle concentration and may be nonionic. Exemplary detergents include cholate, CHAPS, octylglucoside, deoxycholate, and lauroyl sarcosine. The RNAi agent preparation is then added to the micelles that include the lipid component. The cationic groups on the lipid interact with the RNAi agent and condense around the RNAi agent to form a liposome. After condensation, the detergent is removed, e.g., by dialysis, to yield a liposomal preparation of RNAi agent.

If necessary a carrier compound that assists in condensation can be added during the condensation reaction, e.g., by controlled addition. For example, the carrier compound can be a polymer other than a nucleic acid (e.g., spermine or spermidine). pH can also adjusted to favor condensation.

Methods for producing stable polynucleotide delivery vehicles, which incorporate a polynucleotide/cationic lipid complex as structural components of the delivery vehicle, are further described in, e.g., WO 96/37194, the entire contents of which are incorporated herein by reference. Liposome formation can also include one or more aspects of exemplary methods described in Felgner, P. L. et al., (1987) Proc. Natl. Acad. Sci. USA 8:7413-7417; U.S. Pat. Nos. 4,897,355; 5,171,678; Bangham et al., (1965) M. Mol. Biol. 23:238; Olson et al., (1979) Biochim. Biophys. Acta 557:9; Szoka et al., (1978) Proc. Natl. Acad. Sci. 75: 4194; Mayhew et al., (1984) Biochim. Biophys. Acta 775:169; Kim et al., (1983) Biochim. Biophys. Acta 728:339; and Fukunaga et al., (1984) Endocrinol. 115:757. Commonly used techniques for preparing lipid aggregates of appropriate size for use as delivery vehicles include sonication and freeze-thaw plus extrusion (see, e.g., Mayer et al., (1986) Biochim. Biophys. Acta 858:161. Microfluidization can be used when consistently small (50 to 200 nm) and relatively uniform aggregates are desired (Mayhew et al., (1984) Biochim. Biophys. Acta 775:169. These methods are readily adapted to packaging RNAi agent preparations into liposomes.

Liposomes fall into two broad classes. Cationic liposomes are positively charged liposomes which interact with the negatively charged nucleic acid molecules to form a stable complex. The positively charged nucleic acid/liposome complex binds to the negatively charged cell surface and is internalized in an endosome. Due to the acidic pH within the endosome, the liposomes are ruptured, releasing their contents into the cell cytoplasm (Wang et al. (1987) Biochem. Biophys. Res. Commun., 147:980-985).

Liposomes, which are pH-sensitive or negatively charged, entrap nucleic acids rather than complex with them. Since both the nucleic acid and the lipid are similarly charged, repulsion rather than complex formation occurs. Nevertheless, some nucleic acid is entrapped within the aqueous interior of these liposomes. pH sensitive liposomes have been used to deliver nucleic acids encoding the thymidine kinase gene to cell monolayers in culture. Expression of the exogenous gene was detected in the target cells (Zhou et al. (1992) Journal of Controlled Release, 19:269-274).

One major type of liposomal composition includes phospholipids other than naturally-derived phosphatidylcholine. Neutral liposome compositions, for example, can be formed from dimyristoyl phosphatidylcholine (DMPC) or dipalmitoyl phosphatidylcholine (DPPC). Anionic liposome compositions generally are formed from dimyristoyl phosphatidylglycerol, while anionic fusogenic liposomes are formed primarily from dioleoyl phosphatidylethanolamine (DOPE). Another type of liposomal composition is formed from phosphatidylcholine (PC) such as, for example, soybean PC, and egg PC. Another type is formed from mixtures of phospholipid or phosphatidylcholine or cholesterol.

Examples of other methods to introduce liposomes into cells in vitro and in vivo include U.S. Pat. Nos. 5,283,185; 5,171,678; WO 94/00569; WO 93/24640; WO 91/16024; Felgner, (1994) J. Biol. Chem. 269:2550; Nabel, (1993) Proc. Natl. Acad. Sci. 90:11307; Nabel, (1992) Human Gene Ther. 3:649; Gershon, (1993) Biochem. 32:7143; and Strauss, (1992) EMBO J. 11:417.

Non-ionic liposomal systems have also been examined to determine their utility in the delivery of drugs to the skin, in particular systems comprising non-ionic surfactant and cholesterol. Non-ionic liposomal formulations comprising Novasome™ I (glyceryl dilaurate/cholesterol/polyoxyethylene-10-stearyl ether) and Novasome™ II (glyceryl distearate/cholesterol/polyoxyethylene-10-stearyl ether) were used to deliver cyclosporin-A into the dermis of mouse skin. Results indicated that such non-ionic liposomal systems were effective in facilitating the deposition of cyclosporine A into different layers of the skin (Hu et al., (1994) S.T.P. Pharma. Sci., 4(6):466).

Liposomes also include “sterically stabilized” liposomes, a term which, as used herein, refers to liposomes comprising one or more specialized lipids that, when incorporated into liposomes, result in enhanced circulation lifetimes relative to liposomes lacking such specialized lipids. Examples of sterically stabilized liposomes are those in which part of the vesicle-forming lipid portion of the liposome (A) comprises one or more glycolipids, such as monosialoganglioside G_M1, or (B) is derivatized with one or more hydrophilic polymers, such as a polyethylene glycol (PEG) moiety. While not wishing to be bound by any particular theory, it is thought in the art that, at least for sterically stabilized liposomes containing gangliosides, sphingomyelin, or PEG-derivatized lipids, the enhanced circulation half-life of these sterically stabilized liposomes derives from a reduced uptake into cells of the reticuloendothelial system (RES) (Allen et al., (1987) FEBS Letters, 223:42; Wu et al., (1993) Cancer Research, 53:3765).

Various liposomes comprising one or more glycolipids are known in the art. Papahadjopoulos et al. (Ann. N.Y. Acad. Sci., (1987), 507:64) reported the ability of monosialoganglioside G_M1, galactocerebroside sulfate and phosphatidylinositol to improve blood half-lives of liposomes. These findings were expounded upon by Gabizon et al. (Proc. Natl. Acad. Sci. U.S.A., (1988), 85,:6949). U.S. Pat. No. 4,837,028 and WO 88/04924, both to Allen et al., disclose liposomes comprising (1) sphingomyelin and (2) the ganglioside G_M1or a galactocerebroside sulfate ester. U.S. Pat. No. 5,543,152 (Webb et al.) discloses liposomes comprising sphingomyelin. Liposomes comprising 1,2-sn-dimyristoylphosphatidylcholine are disclosed in WO 97/13499 (Lim et al).

In one embodiment, cationic liposomes are used. Cationic liposomes possess the advantage of being able to fuse to the cell membrane. Non-cationic liposomes, although not able to fuse as efficiently with the plasma membrane, are taken up by macrophages in vivo and can be used to deliver RNAi agents to macrophages.

Further advantages of liposomes include: liposomes obtained from natural phospholipids are biocompatible and biodegradable; liposomes can incorporate a wide range of water and lipid soluble drugs; liposomes can protect encapsulated RNAi agents in their internal compartments from metabolism and degradation (Rosoff, in “Pharmaceutical Dosage Forms,” Lieberman, Rieger and Banker (Eds.), 1988, volume 1, p. 245). Important considerations in the preparation of liposome formulations are the lipid surface charge, vesicle size and the aqueous volume of the liposomes.

A positively charged synthetic cationic lipid, N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA) can be used to form small liposomes that interact spontaneously with nucleic acid to form lipid-nucleic acid complexes which are capable of fusing with the negatively charged lipids of the cell membranes of tissue culture cells, resulting in delivery of RNAi agent (see, e.g., Felgner, P. L. et al., (1987) Proc. Natl. Acad. Sci. USA 8:7413-7417, and U.S. Pat. No. 4,897,355 for a description of DOTMA and its use with DNA).

A DOTMA analogue, 1,2-bis(oleoyloxy)-3-(trimethylammonia)propane (DOTAP) can be used in combination with a phospholipid to form DNA-complexing vesicles. LipofectinT^MBethesda Research Laboratories, Gaithersburg, Md.) is an effective agent for the delivery of highly anionic nucleic acids into living tissue culture cells that comprise positively charged DOTMA liposomes which interact spontaneously with negatively charged polynucleotides to form complexes. When enough positively charged liposomes are used, the net charge on the resulting complexes is also positive. Positively charged complexes prepared in this way spontaneously attach to negatively charged cell surfaces, fuse with the plasma membrane, and efficiently deliver functional nucleic acids into, for example, tissue culture cells. Another commercially available cationic lipid, 1,2-bis(oleoyloxy)-3,3-(trimethylammonia)propane (“DOTAP”) (Boehringer Mannheim, Indianapolis, Ind.) differs from DOTMA in that the oleoyl moieties are linked by ester, rather than ether linkages.

Other reported cationic lipid compounds include those that have been conjugated to a variety of moieties including, for example, carboxyspermine which has been conjugated to one of two types of lipids and includes compounds such as 5-carboxyspermylglycine dioctaoleoylamide (“DOGS”) (Transfectam™, Promega, Madison, Wis.) and dipalmitoylphosphatidylethanolamine 5-carboxyspermyl-amide (“DPPES”) (see, e.g., U.S. Pat. No. 5,171,678).

Another cationic lipid conjugate includes derivatization of the lipid with cholesterol (“DC-Chol”) which has been formulated into liposomes in combination with DOPE (See, Gao, X. and Huang, L., (1991) Biochim. Biophys. Res. Commun. 179:280). Lipopolylysine, made by conjugating polylysine to DOPE, has been reported to be effective for transfection in the presence of serum (Zhou, X. et al., (1991) Biochim. Biophys. Acta 1065:8). For certain cell lines, these liposomes containing conjugated cationic lipids, are said to exhibit lower toxicity and provide more efficient transfection than the DOTMA-containing compositions. Other commercially available cationic lipid products include DMRIE and DMRIE-HP (Vical, La Jolla, Calif.) and Lipofectamine (DOSPA) (Life Technology, Inc., Gaithersburg, Md.). Other cationic lipids suitable for the delivery of oligonucleotides are described in WO 98/39359 and WO 96/37194.

Liposomal formulations are particularly suited for topical administration, liposomes present several advantages over other formulations. Such advantages include reduced side effects related to high systemic absorption of the administered drug, increased accumulation of the administered drug at the desired target, and the ability to administer RNAi agent into the skin. In some implementations, liposomes are used for delivering RNAi agent to epidermal cells and also to enhance the penetration of RNAi agent into dermal tissues, e.g., into skin. For example, the liposomes can be applied topically. Topical delivery of drugs formulated as liposomes to the skin has been documented (see, e.g., Weiner et al., (1992) Journal of Drug Targeting, vol. 2, 405-410 and du Plessis et al., (1992) Antiviral Research, 18:259-265; Mannino, R. J. and Fould-Fogerite, S., (1998) Biotechniques 6:682-690; Itani, T. et al., (1987) Gene 56:267-276; Nicolau, C. et al. (1987) Meth. Enzymol. 149:157-176; Straubinger, R. M. and Papahadjopoulos, D. (1983) Meth. Enzymol. 101:512-527; Wang, C. Y. and Huang, L., (1987) Proc. Natl. Acad. Sci. USA 84:7851-7855).

Non-ionic liposomal systems have also been examined to determine their utility in the delivery of drugs to the skin, in particular systems comprising non-ionic surfactant and cholesterol. Non-ionic liposomal formulations comprising Novasome I (glyceryl dilaurate/cholesterol/polyoxyethylene-10-stearyl ether) and Novasome II (glyceryl distearate/cholesterol/polyoxyethylene-10-stearyl ether) were used to deliver a drug into the dermis of mouse skin. Such formulations with RNAi agent are useful for treating a dermatological disorder.

Liposomes that include RNAi agents can be made highly deformable. Such deformability can enable the liposomes to penetrate through pore that are smaller than the average radius of the liposome. For example, transfersomes are a type of deformable liposomes. Transferosomes can be made by adding surface edge activators, usually surfactants, to a standard liposomal composition. Transfersomes that include RNAi agent can be delivered, for example, subcutaneously by infection in order to deliver RNAi agent to keratinocytes in the skin. In order to cross intact mammalian skin, lipid vesicles must pass through a series of fine pores, each with a diameter less than 50 nm, under the influence of a suitable transdermal gradient. In addition, due to the lipid properties, these transferosomes can be self-optimizing (adaptive to the shape of pores, e.g., in the skin), self-repairing, and can frequently reach their targets without fragmenting, and often self-loading.

Other formulations amenable to the present disclosure are described in U.S. provisional application Ser. No. 61/018,616, filed Jan. 2, 2008; 61/018,611, filed Jan. 2, 2008; 61/039,748, filed Mar. 26, 2008; 61/047,087, filed Apr. 22, 2008 and 61/051,528, filed May 8, 2008. PCT application number PCT/US2007/080331, filed Oct. 3, 2007, also describes formulations that are amenable to the present disclosure.

Transfersomes, yet another type of liposomes, are highly deformable lipid aggregates which are attractive candidates for drug delivery vehicles. Transfersomes can be described as lipid droplets which are so highly deformable that they are easily able to penetrate through pores which are smaller than the droplet. Transfersomes are adaptable to the environment in which they are used, e.g., they are self-optimizing (adaptive to the shape of pores in the skin), self-repairing, frequently reach their targets without fragmenting, and often self-loading. To make transfersomes it is possible to add surface edge-activators, usually surfactants, to a standard liposomal composition. Transfersomes have been used to deliver serum albumin to the skin. The transfersome-mediated delivery of serum albumin has been shown to be as effective as subcutaneous injection of a solution containing serum albumin.

Surfactants find wide application in formulations such as those described herein, particularly in emulsions (including microemulsions) and liposomes. The most common way of classifying and ranking the properties of the many different types of surfactants, both natural and synthetic, is by the use of the hydrophile/lipophile balance (HLB). The nature of the hydrophilic group (also known as the “head”) provides the most useful means for categorizing the different surfactants used in formulations (Rieger, in Pharmaceutical Dosage Forms, Marcel Dekker, Inc., New York, N.Y., 1988, p. 285).

If the surfactant molecule is not ionized, it is classified as a nonionic surfactant. Nonionic surfactants find wide application in pharmaceutical and cosmetic products and are usable over a wide range of pH values. In general, their HLB values range from 2 to about 18 depending on their structure. Nonionic surfactants include nonionic esters such as ethylene glycol esters, propylene glycol esters, glyceryl esters, polyglyceryl esters, sorbitan esters, sucrose esters, and ethoxylated esters. Nonionic alkanolamides and ethers such as fatty alcohol ethoxylates, propoxylated alcohols, and ethoxylated/propoxylated block polymers are also included in this class. The polyoxyethylene surfactants are the most popular members of the nonionic surfactant class.

If the surfactant molecule carries a negative charge when it is dissolved or dispersed in water, the surfactant is classified as anionic. Anionic surfactants include carboxylates such as soaps, acyl lactylates, acyl amides of amino acids, esters of sulfuric acid such as alkyl sulfates and ethoxylated alkyl sulfates, sulfonates such as alkyl benzene sulfonates, acyl isethionates, acyl taurates and sulfosuccinates, and phosphates. The most important members of the anionic surfactant class are the alkyl sulfates and the soaps.

If the surfactant molecule carries a positive charge when it is dissolved or dispersed in water, the surfactant is classified as cationic. Cationic surfactants include quaternary ammonium salts and ethoxylated amines. The quaternary ammonium salts are the most used members of this class.

If the surfactant molecule has the ability to carry either a positive or negative charge, the surfactant is classified as amphoteric. Amphoteric surfactants include acrylic acid derivatives, substituted alkylamides, N-alkylbetaines and phosphatides.

The use of surfactants in drug products, formulations and in emulsions has been reviewed (Rieger, in Pharmaceutical Dosage Forms, Marcel Dekker, Inc., New York, N.Y., 1988, p. 285).

The RNAi agent for use in the methods of the disclosure can also be provided as micellar formulations. “Micelles” are defined herein as a particular type of molecular assembly in which amphipathic molecules are arranged in a spherical structure such that all the hydrophobic portions of the molecules are directed inward, leaving the hydrophilic portions in contact with the surrounding aqueous phase. The converse arrangement exists if the environment is hydrophobic.

A mixed micellar formulation suitable for delivery through transdermal membranes may be prepared by mixing an aqueous solution of the siRNA composition, an alkali metal C₈to C₂₂alkyl sulphate, and a micelle forming compounds. Exemplary micelle forming compounds include lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linoleic acid, linolenic acid, monoolein, monooleates, monolaurates, borage oil, evening of primrose oil, menthol, trihydroxy oxo cholanyl glycine and pharmaceutically acceptable salts thereof, glycerin, polyglycerin, lysine, polylysine, triolein, polyoxyethylene ethers and analogues thereof, polidocanol alkyl ethers and analogues thereof, chenodeoxycholate, deoxycholate, and mixtures thereof. The micelle forming compounds may be added at the same time or after addition of the alkali metal alkyl sulphate. Mixed micelles will form with substantially any kind of mixing of the ingredients but vigorous mixing in order to provide smaller size micelles.

In one method a first micellar composition is prepared which contains the siRNA composition and at least the alkali metal alkyl sulphate. The first micellar composition is then mixed with at least three micelle forming compounds to form a mixed micellar composition. In another method, the micellar composition is prepared by mixing the siRNA composition, the alkali metal alkyl sulphate and at least one of the micelle forming compounds, followed by addition of the remaining micelle forming compounds, with vigorous mixing.

Phenol or m-cresol may be added to the mixed micellar composition to stabilize the formulation and protect against bacterial growth. Alternatively, phenol or m-cresol may be added with the micelle forming ingredients. An isotonic agent such as glycerin may also be added after formation of the mixed micellar composition.

For delivery of the micellar formulation as a spray, the formulation can be put into an aerosol dispenser and the dispenser is charged with a propellant. The propellant, which is under pressure, is in liquid form in the dispenser. The ratios of the ingredients are adjusted so that the aqueous and propellant phases become one, i.e., there is one phase. If there are two phases, it is necessary to shake the dispenser prior to dispensing a portion of the contents, e.g., through a metered valve. The dispensed dose of pharmaceutical agent is propelled from the metered valve in a fine spray.

Propellants may include hydrogen-containing chlorofluorocarbons, hydrogen-containing fluorocarbons, dimethyl ether and diethyl ether. In certain embodiments, HFA 134a (1,1,1,2 tetrafluoroethane) may be used.

The specific concentrations of the essential ingredients can be determined by relatively straightforward experimentation. For absorption through the oral cavities, it is often desirable to increase, e.g., at least double or triple, the dosage for through injection or administration through the gastrointestinal tract.

Lipid Particles

RNAi agents, e.g., dsRNAs of in the disclosure may be fully encapsulated in a lipid formulation, e.g., a LNP, or other nucleic acid-lipid particle.

As used herein, the term “LNP” refers to a stable nucleic acid-lipid particle. LNPs typically contain a cationic lipid, a non-cationic lipid, and a lipid that prevents aggregation of the particle (e.g., a PEG-lipid conjugate). LNPs are extremely useful for systemic applications, as they exhibit extended circulation lifetimes following intravenous (i.v.) injection and accumulate at distal sites (e.g., sites physically separated from the administration site). LNPs include “pSPLP,” which inciude an encapsulated condensing agent-nucleic acid complex as set forth in WO 00/03683. The particles of the present disclosure typically have a mean diameter of about 50 nm to about 150 nm, more typically about 60 nm to about 130 nm, more typically about 70 nm to about 110 nm, most typically about 70 nm to about 90 nm, and are substantially nontoxic. In addition, the nucleic acids when present in the nucleic acid-lipid particles of the present disclosure are resistant in aqueous solution to degradation with a nuclease. Nucleic acid-lipid particles and their method of preparation are disclosed in, e.g., U.S. Pat. Nos. 5,976,567; 5,981,501; 6,534,484; 6,586,410; 6,815,432; United States Patent publication No. 2010/0324120 and WO 96/40964.

In one embodiment, the lipid to drug ratio (mass/mass ratio) (e.g., lipid to dsRNA ratio) will be in the range of from about 1:1 to about 50:1, from about 1:1 to about 25:1, from about 3:1 to about 15:1, from about 4:1 to about 10:1, from about 5:1 to about 9:1, or about 6:1 to about 9:1. Ranges intermediate to the above recited ranges are also contemplated to be part of the disclosure.

Certain specific LNP formulations for delivery of RNAi agents have been described in the art, including, e.g., “LNP01” formulations as described in, e.g., WO 2008/042973, which is hereby incorporated by reference.

Additional exemplary lipid-dSRNA formulations are identified in the table below.

cationic lipid/non-cationic

lipid/cholesterol/PEG-lipid conjugate

Ionizable/Cationic Lipid
Lipid:siRNA ratio

SNALP-1
1,2-Dilinolenyloxy-N,N-
DLinDMA/DPPC/Cholesterol/PEG-

dimethylaminopropane (DLinDMA)
eDMA

(57.1/7.1/34.4/1.4)

lipid:siRNA ~7:1

2-XTC
2,2-Dilinoleyl-4-dimethylaminoethyl-[1,3]-
XTC/DPPC/Cholesterol/PEG-cDMA

dioxolane (XTC)
57.1/7.1/34.4/1.4

lipid:siRNA ~7:1

LNP05
2,2-Dilinoleyl-4-dimethylaminoethyl-[1,3]-
XTC/DSPC/Cholesterol/PEG-DMG

dioxolane (XTC)
57.5/7.5/31.5/3.5

lipid:siRNA ~6:1

LNP06
2,2-Dilinoleyl-4-dimethylaminoethyl-[1,3]-
XTC/DSPC/Cholesterol/PEG-DMG

dioxolane (XTC)
57.5/7.5/31.5/3.5

lipid:siRNA ~11:1

LNP07
2,2-Dilinoleyl-4-dimethylaminoethyl-[1,3]-
XTC/DSPC/Cholesterol/PEG-DMG

dioxolane (XTC)
60/7.5/31/1.5,

lipid:siRNA ~6:1

LNP08
2,2-Dilinoleyl-4-dimethylaminoethyl-[1,3]-
XTC/DSPC/Cholesterol/PEG-DMG

dioxolane (XTC)
60/7.5/31/1.5,

lipid:siRNA ~11:1

LNP09
2,2-Dilinoleyl-4-dimethylaminoethyl-[1,3]-
XTC/DSPC/Cholesterol/PEG-DMG

dioxolane (XTC)
50/10/38.5/1.5

Lipid:siRNA 10:1

LNP10
(3aR,5s,6aS)-N,N-dimethyl-2,2-
ALN100/DSPC/Cholesterol/PEG-

di((9Z,12Z)-octadeca-9,12-
DMG

dienyl)tetrahydro-3aH-
50/10/38.5/1.5

cyclopenta[d][1,3]dioxol-5-amine
Lipid:siRNA 10:1

(ALN100)

LNP11
(6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-
MC-3/DSPC/Cholesterol/PEG-DMG

tetraen-19-yl 4-(dimethylamino)butanoate
50/10/38.5/1.5

(MC3)
Lipid:siRNA 10:1

LNP12
1,1′-(2-(4-(2-((2-(bis(2-
Tech G1/DSPC/Cholesterol/PEG-

hydroxydodecyl)amino)ethyl)(2-
DMG

hydroxydodecyl)amino)ethyl)piperazin-1-
50/10/38.5/1.5

yl)ethylazanediyl)didodecan-2-ol (Tech
Lipid:siRNA 10:1

G1)

LNP13
XTC
XTC/DSPC/Chol/PEG-DMG

50/10/38.5/1.5

Lipid:siRNA: 33:1

LNP14
MC3
MC3/DSPC/Chol/PEG-DMG

40/15/40/5

Lipid:siRNA: 11:1

LNP15
MC3
MC3/DSPC/Chol/PEG-DSG/GalNAc-

PEG-DSG

50/10/35/4.5/0.5

Lipid:siRNA: 11:1

LNP16
MC3
MC3/DSPC/Chol/PEG-DMG

50/10/38.5/1.5

Lipid:siRNA: 7:1

LNP17
MC3
MC3/DSPC/Chol/PEG-DSG

50/10/38.5/1.5

Lipid:siRNA: 10:1

LNP18
MC3
MC3/DSPC/Chol/PEG-DMG

50/10/38.5/1.5

Lipid:siRNA: 12:1

LNP19
MC3
MC3/DSPC/Chol/PEG-DMG

50/10/35/5

Lipid:siRNA: 8:1

LNP20
MC3
MC3/DSPC/Chol/PEG-DPG

50/10/38.5/1.5

Lipid:siRNA: 10:1

LNP21
C12-200
C12-200/DSPC/Chol/PEG-DSG

50/10/38.5/1.5

Lipid:siRNA: 7:1

LNP22
XTC
XTC/DSPC/Chol/PEG-DSG

50/10/38.5/1.5

Lipid:siRNA: 10:1

DSPC: distearoylphosphatidylcholine

DPPC: dipalmitoylphosphatidylcholine

PEG-DMG: PEG-didimyristoyl glycerol (C14-PEG, or PEG-C14) (PEG with avg mol wt of 2000)

PEG-DSG: PEG-distyryl glycerol (C18-PEG, or PEG-C18) (PEG with avg mol wt of 2000)

PEG-cDMA: PEG-carbamoyl-1,2-dimyristyloxypropylamine (PEG with avg mol wt of 2000)

SNALP (1,2-Dilinolenyloxy-N,N-dimethylaminopropane (DLinDMA)) comprising formulations are described in WO 2009/127060, which is hereby incorporated by reference.

XTC comprising formulations are described in WO 2010/088537, the entire contents of which are hereby incorporated herein by reference.

MC3 comprising formulations are described, e.g., in United States Patent Publication No. 2010/0324120, the entire contents of which are hereby incorporated by reference.

ALNY-100 comprising formulations are described in WO 2010/054406, the entire contents of which are hereby incorporated herein by reference.

C12-200 comprising formulations are described in WO 2010/129709, the entire contents of which are hereby incorporated herein by reference.

Compositions and formulations for oral administration include powders or granules, microparticulates, nanoparticulates, suspensions or solutions in water or non-aqueous media, capsules, gel capsules, sachets, tablets or minitablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders can be desirable. In some embodiments, oral formulations are those in which dsRNAs featured in the disclosure are administered in conjunction with one or more penetration enhancer surfactants and chelators. Suitable surfactants include fatty acids or esters or salts thereof, bile acids or salts thereof. Suitable bile acids/salts include chenodeoxycholic acid (CDCA) and ursodeoxychenodeoxycholic acid (UDCA), cholic acid, dehydrocholic acid, deoxycholic acid, glucholic acid, glycholic acid, glycodeoxycholic acid, taurocholic acid, taurodeoxycholic acid, sodium tauro-24,25-dihydro-fusidate and sodium glycodihydrofusidate. Suitable fatty acids include arachidonic acid, undecanoic acid, oleic acid, lauric acid, caprylic acid, capric acid, myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein, dilaurin, glyceryl 1-monocaprate, 1-dodecylazacycloheptan-2-one, an acylcarnitine, an acylcholine, or a monoglyceride, a diglyceride or a pharmaceutically acceptable salt thereof (e.g., sodium). In some embodiments, combinations of penetration enhancers are used, for example, fatty acids/salts in combination with bile acids/salts. One exemplary combination is the sodium salt of lauric acid, capric acid and UDCA. Further penetration enhancers include polyoxyethylene-9-lauryl ether, polyoxyethylene-20-cetyl ether. DsRNAs featured in the disclosure can be delivered orally, in granular form including sprayed dried particles, or complexed to form micro or nanoparticles. DsRNA complexing agents include poly-amino acids; polyimines; polyacrylates; polyalkylacrylates, polyoxethanes, polyalkylcyanoacrylates; cationized gelatins, albumins, starches, acrylates, polyethyleneglycols (PEG) and starches; polyalkylcyanoacrylates; DEAE-derivatized polyimines, pollulans, celluloses and starches. Suitable complexing agents include chitosan, N-trimethylchitosan, poly-L-lysine, polyhistidine, polyornithine, polyspermines, protamine, polyvinylpyridine, polythiodiethylaminomethylethylene P(TDAE), polyaminostyrene (e.g., p-amino), poly(methylcyanoacrylate), poly(ethylcyanoacrylate), poly(butylcyanoacrylate), poly(isobutylcyanoacrylate), poly(isohexylcynaoacrylate), DEAE-methacrylate, DEAE-hexylacrylate, DEAE-acrylamide, DEAE-albumin and DEAE-dextran, polymethylacrylate, polyhexylacrylate, poly(D,L-lactic acid), poly(DL-lactic-co-glycolic acid (PLGA), alginate, and polyethyleneglycol (PEG). Oral formulations for dsRNAs and their preparation are described in detail in U.S. Pat. No. 6,887,906, U.S. 2003/0027780, and U.S. Pat. No. 6,747,014, each of which is incorporated herein by reference.

Compositions and formulations for parenteral, intraparenchymal (into the brain), intrathecal, intraventricular or intrahepatic administration can include sterile aqueous solutions which can also contain buffers, diluents and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.

Pharmaceutical compositions of the present disclosure include, but are not limited to, solutions, emulsions, and liposome-containing formulations. These compositions can be generated from a variety of components that include, but are not limited to, preformed liquids, self-emulsifying solids and self-emulsifying semisolids. Particularly preferred are formulations that target the brain when treating APP-associated diseases or disorders.

The pharmaceutical formulations of the present disclosure, which can conveniently be presented in unit dosage form, can be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

The compositions of the present disclosure can be formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, gel capsules, liquid syrups, soft gels, suppositories, and enemas. The compositions of the present disclosure can also be formulated as suspensions in aqueous, non-aqueous or mixed media. Aqueous suspensions can further contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol or dextran. The suspension can also contain stabilizers.

Additional Formulations

i. Emulsions

The compositions of the present disclosure can be prepared and formulated as emulsions. Emulsions are typically heterogeneous systems of one liquid dispersed in another in the form of droplets usually exceeding 0.1 μm in diameter (see e.g., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, Allen, L V., Popovich N G., and Ansel H C., 2004, Lippincott Williams & Wilkins (8th ed.), New York, N.Y.; Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199; Rosoff, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., Volume 1, p. 245; Block in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 2, p. 335; Higuchi et al., in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa., 1985, p. 301). Emulsions are often biphasic systems comprising two immiscible liquid phases intimately mixed and dispersed with each other. In general, emulsions can be of either the water-in-oil (w/o) or the oil-in-water (o/w) variety. When an aqueous phase is finely divided into and dispersed as minute droplets into a bulk oily phase, the resulting composition is called a water-in-oil (w/o) emulsion. Alternatively, when an oily phase is finely divided into and dispersed as minute droplets into a bulk aqueous phase, the resulting composition is called an oil-in-water (o/w) emulsion. Emulsions can contain additional components in addition to the dispersed phases, and the active drug which can be present as a solution in either aqueous phase, oily phase or itself as a separate phase. Pharmaceutical excipients such as emulsifiers, stabilizers, dyes, and anti-oxidants can also be present in emulsions as needed. Pharmaceutical emulsions can also be multiple emulsions that are comprised of more than two phases such as, for example, in the case of oil-in-water-in-oil (o/w/o) and water-in-oil-in-water (w/o/w) emulsions. Such complex formulations often provide certain advantages that simple binary emulsions do not. Multiple emulsions in which individual oil droplets of an o/w emulsion enclose small water droplets constitute a w/o/w emulsion. Likewise, a system of oil droplets enclosed in globules of water stabilized in an oily continuous phase provides an o/w/o emulsion.

Emulsions are characterized by little or no thermodynamic stability. Often, the dispersed or discontinuous phase of the emulsion is well dispersed into the external or continuous phase and maintained in this form through the means of emulsifiers or the viscosity of the formulation. Either of the phases of the emulsion can be a semisolid or a solid, as is the case of emulsion-style ointment bases and creams. Other means of stabilizing emulsions entail the use of emulsifiers that can be incorporated into either phase of the emulsion. Emulsifiers can broadly be classified into four categories: synthetic surfactants, naturally occurring emulsifiers, absorption bases, and finely dispersed solids (see e.g., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, Allen, L V., Popovich N G., and Ansel H C., 2004, Lippincott Williams & Wilkins (8th ed.), New York, N.Y.; Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

Synthetic surfactants, also known as surface active agents, have found wide applicability in the formulation of emulsions and have been reviewed in the literature (see e.g., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, Allen, L V., Popovich N G., and Ansel H C., 2004, Lippincott Williams & Wilkins (8th ed.), New York, N.Y.; Rieger, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285; Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), Marcel Dekker, Inc., New York, N.Y., 1988, volume 1, p. 199). Surfactants are typically amphiphilic and comprise a hydrophilic and a hydrophobic portion. The ratio of the hydrophilic to the hydrophobic nature of the surfactant has been termed the hydrophile/lipophile balance (HLB) and is a valuable tool in categorizing and selecting surfactants in the preparation of formulations. Surfactants can be classified into different classes based on the nature of the hydrophilic group: nonionic, anionic, cationic and amphoteric (see e.g., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, Allen, L V., Popovich N G., and Ansel H C., 2004, Lippincott Williams & Wilkins (8th ed.), New York, N.Y. Rieger, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285).

Naturally occurring emulsifiers used in emulsion formulations include lanolin, beeswax, phosphatides, lecithin and acacia. Absorption bases possess hydrophilic properties such that they can soak up water to form w/o emulsions yet retain their semisolid consistencies, such as anhydrous lanolin and hydrophilic petrolatum. Finely divided solids have also been used as good emulsifiers especially in combination with surfactants and in viscous preparations. These include polar inorganic solids, such as heavy metal hydroxides, nonswelling clays such as bentonite, attapulgite, hectorite, kaolin, montmorillonite, colloidal aluminum silicate and colloidal magnesium aluminum silicate, pigments and nonpolar solids such as carbon or glyceryl tristearate.

A large variety of non-emulsifying materials are also included in emulsion formulations and contribute to the properties of emulsions. These include fats, oils, waxes, fatty acids, fatty alcohols, fatty esters, humectants, hydrophilic colloids, preservatives and antioxidants (Block, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335; Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

Hydrophilic colloids or hydrocolloids include naturally occurring gums and synthetic polymers such as polysaccharides (for example, acacia, agar, alginic acid, carrageenan, guar gum, karaya gum, and tragacanth), cellulose derivatives (for example, carboxymethylcellulose and carboxypropylcellulose), and synthetic polymers (for example, carbomers, cellulose ethers, and carboxyvinyl polymers). These disperse or swell in water to form colloidal solutions that stabilize emulsions by forming strong interfacial films around the dispersed-phase droplets and by increasing the viscosity of the external phase.

Since emulsions often contain a number of ingredients such as carbohydrates, proteins, sterols and phosphatides that can readily support the growth of microbes, these formulations often incorporate preservatives. Commonly used preservatives included in emulsion formulations include methyl paraben, propyl paraben, quaternary ammonium salts, benzalkonium chloride, esters of p-hydroxybenzoic acid, and boric acid. Antioxidants are also commonly added to emulsion formulations to prevent deterioration of the formulation. Antioxidants used can be free radical scavengers such as tocopherols, alkyl gallates, butylated hydroxyanisole, butylated hydroxytoluene, or reducing agents such as ascorbic acid and sodium metabisulfite, and antioxidant synergists such as citric acid, tartaric acid, and lecithin.

The application of emulsion formulations via dermatological, oral and parenteral routes and methods for their manufacture have been reviewed in the literature (see e.g., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, Allen, L V., Popovich N G., and Ansel H C., 2004, Lippincott Williams & Wilkins (8th ed.), New York, N.Y.; Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Emulsion formulations for oral delivery have been very widely used because of ease of formulation, as well as efficacy from an absorption and bioavailability standpoint (see e.g., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, Allen, L V., Popovich N G., and Ansel H C., 2004, Lippincott Williams & Wilkins (8th ed.), New York, N.Y.; Rosoff, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Mineral-oil base laxatives, oil-soluble vitamins and high fat nutritive preparations are among the materials that have commonly been administered orally as o/w emulsions.

ii. Microemulsions

In one embodiment of the present disclosure, the compositions of RNAi agents and nucleic acids are formulated as microemulsions. A microemulsion can be defined as a system of water, oil and amphiphile which is a single optically isotropic and thermodynamically stable liquid solution (see e.g., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, Allen, L V., Popovich N G., and Ansel H C., 2004, Lippincott Williams & Wilkins (8th ed.), New York, N.Y.; Rosoff, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Typically, microemulsions are systems that are prepared by first dispersing an oil in an aqueous surfactant solution and then adding a sufficient amount of a fourth component, generally an intermediate chain-length alcohol to form a transparent system. Therefore, microemulsions have also been described as thermodynamically stable, isotropically clear dispersions of two immiscible liquids that are stabilized by interfacial films of surface-active molecules (Leung and Shah, in: Controlled Release of Drugs: Polymers and Aggregate Systems, Rosoff, M., Ed., 1989, VCH Publishers, New York, pages 185-215). Microemulsions commonly are prepared via a combination of three to five components that include oil, water, surfactant, cosurfactant and electrolyte. Whether the microemulsion is of the water-in-oil (w/o) or an oil-in-water (o/w) type is dependent on the properties of the oil and surfactant used, and on the structure and geometric packing of the polar heads and hydrocarbon tails of the surfactant molecules (Schott, in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa., 1985, p. 271).

The phenomenological approach utilizing phase diagrams has been extensively studied and has yielded a comprehensive knowledge, to one skilled in the art, of how to formulate microemulsions (see e.g., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, Allen, L V., Popovich N G., and Ansel H C., 2004, Lippincott Williams & Wilkins (8th ed.), New York, N.Y.; Rosoff, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Block, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335). Compared to conventional emulsions, microemulsions offer the advantage of solubilizing water-insoluble drugs in a formulation of thermodynamically stable droplets that are formed spontaneously.

Surfactants used in the preparation of microemulsions include, but are not limited to, ionic surfactants, non-ionic surfactants, Brij 96, polyoxyethylene oleyl ethers, polyglycerol fatty acid esters, tetraglycerol monolaurate (ML310), tetraglycerol monooleate (MO310), hexaglycerol monooleate (PO310), hexaglycerol pentaoleate (PO500), decaglycerol monocaprate (MCA750), decaglycerol monooleate (MO750), decaglycerol sesquioleate (SO750), decaglycerol decaoleate (DA0750), alone or in combination with cosurfactants. The cosurfactant, usually a short-chain alcohol such as ethanol, 1-propanol, and 1-butanol, serves to increase the interfacial fluidity by penetrating into the surfactant film and consequently creating a disordered film because of the void space generated among surfactant molecules. Microemulsions can, however, be prepared without the use of cosurfactants and alcohol-free self-emulsifying microemulsion systems are known in the art. The aqueous phase can typically be, but is not limited to, water, an aqueous solution of the drug, glycerol, PEG300, PEG400, polyglycerols, propylene glycols, and derivatives of ethylene glycol. The oil phase can include, but is not limited to, materials such as Captex 300, Captex 355, Capmul MCM, fatty acid esters, medium chain (C8-C12) mono, di, and tri-glycerides, polyoxyethylated glyceryl fatty acid esters, fatty alcohols, polyglycolized glycerides, saturated polyglycolized C8-C10 glycerides, vegetable oils and silicone oil.

Microemulsions are particularly of interest from the standpoint of drug solubilization and the enhanced absorption of drugs. Lipid based microemulsions (both o/w and w/o) have been proposed to enhance the oral bioavailability of drugs, including peptides (see e.g., U.S. Pat. Nos. 6,191,105; 7,063,860; 7,070,802; 7,157,099; Constantinides et al., Pharmaceutical Research, 1994, 11, 1385-1390; Ritschel, Meth. Find. Exp. Clin. Pharmacol., 1993, 13, 205). Microemulsions afford advantages of improved drug solubilization, protection of drug from enzymatic hydrolysis, possible enhancement of drug absorption due to surfactant-induced alterations in membrane fluidity and permeability, ease of preparation, ease of oral administration over solid dosage forms, improved clinical potency, and decreased toxicity (see e.g., U.S. Pat. Nos. 6,191,105; 7,063,860; 7,070,802; 7,157,099; Constantinides et al., Pharmaceutical Research, 1994, 11, 1385; Ho et al., J. Pharm. Sci., 1996, 85, 138-143). Often microemulsions can form spontaneously when their components are brought together at ambient temperature. This can be particularly advantageous when formulating thermolabile drugs, peptides or RNAi agents. Microemulsions have also been effective in the transdermal delivery of active components in both cosmetic and pharmaceutical applications. It is expected that the microemulsion compositions and formulations of the present disclosure will facilitate the increased systemic absorption of RNAi agents and nucleic acids from the gastrointestinal tract, as well as improve the local cellular uptake of RNAi agents and nucleic acids.

Microemulsions of the present disclosure can also contain additional components and additives such as sorbitan monostearate (Grill 3), Labrasol, and penetration enhancers to improve the properties of the formulation and to enhance the absorption of the RNAi agents and nucleic acids of the present disclosure. Penetration enhancers used in the microemulsions of the present disclosure can be classified as belonging to one of five broad categories—surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, p. 92). Each of these classes has been discussed above.

iii. Microparticles

An RNAi agent of the disclosure may be incorporated into a particle, e.g., a microparticle. Microparticles can be produced by spray-drying, but may also be produced by other methods including lyophilization, evaporation, fluid bed drying, vacuum drying, or a combination of these techniques.

iv. Penetration Enhancers

In one embodiment, the present disclosure employs various penetration enhancers to effect the efficient delivery of nucleic acids, particularly RNAi agents, to the skin of animals. Most drugs are present in solution in both ionized and nonionized forms. However, usually only lipid soluble or lipophilic drugs readily cross cell membranes. It has been discovered that even non-lipophilic drugs can cross cell membranes if the membrane to be crossed is treated with a penetration enhancer. In addition to aiding the diffusion of non-lipophilic drugs across cell membranes, penetration enhancers also enhance the permeability of lipophilic drugs.

Penetration enhancers can be classified as belonging to one of five broad categories, i.e., surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (see e.g., Malmsten, M. Surfactants and polymers in drug delivery, Informa Health Care, New York, N.Y., 2002; Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, p. 92). Each of the above mentioned classes of penetration enhancers are described below in greater detail.

Surfactants (or “surface-active agents”) are chemical entities which, when dissolved in an aqueous solution, reduce the surface tension of the solution or the interfacial tension between the aqueous solution and another liquid, with the result that absorption of RNAi agents through the mucosa is enhanced. In addition to bile salts and fatty acids, these penetration enhancers include, for example, sodium lauryl sulfate, polyoxyethylene-9-lauryl ether and polyoxyethylene-20-cetyl ether) (see e.g., Malmsten, M. Surfactants and polymers in drug delivery, Informa Health Care, New York, N.Y., 2002; Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, p. 92); and perfluorochemical emulsions, such as FC-43. Takahashi et al., J. Pharm. Pharmacol., 1988, 40, 252).

Various fatty acids and their derivatives which act as penetration enhancers include, for example, oleic acid, lauric acid, capric acid (n-decanoic acid), myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein (1-monooleoyl-rac-glycerol), dilaurin, caprylic acid, arachidonic acid, glycerol 1-monocaprate, 1-dodecylazacycloheptan-2-one, acylcarnitines, acylcholines, C_1-20alkyl esters thereof (e.g., methyl, isopropyl and t-butyl), and mono- and di-glycerides thereof (i.e., oleate, laurate, caprate, myristate, palmitate, stearate, linoleate, etc.) (see e.g., Touitou, E., et al. Enhancement in Drug Delivery, CRC Press, Danvers, Mass., 2006; Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, p. 92; Muranishi, Critical Reviews in Therapeutic Drug Carrier Systems, 1990, 7, 1-33; El Hariri et al., J. Pharm. Pharmacol., 1992, 44, 651-654).

The physiological role of bile includes the facilitation of dispersion and absorption of lipids and fat-soluble vitamins (see e.g., Malmsten, M. Surfactants and polymers in drug delivery, Informa Health Care, New York, N.Y., 2002; Brunton, Chapter 38 in: Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed., Hardman et al. Eds., McGraw-Hill, New York, 1996, pp. 934-935). Various natural bile salts, and their synthetic derivatives, act as penetration enhancers. Thus the term “bile salts” includes any of the naturally occurring components of bile as well as any of their synthetic derivatives. Suitable bile salts include, for example, cholic acid (or its pharmaceutically acceptable sodium salt, sodium cholate), dehydrocholic acid (sodium dehydrocholate), deoxycholic acid (sodium deoxycholate), glucholic acid (sodium glucholate), glycholic acid (sodium glycocholate), glycodeoxycholic acid (sodium glycodeoxycholate), taurocholic acid (sodium taurocholate), taurodeoxycholic acid (sodium taurodeoxycholate), chenodeoxycholic acid (sodium chenodeoxycholate), ursodeoxycholic acid (UDCA), sodium tauro-24,25-dihydro-fusidate (STDHF), sodium glycodihydrofusidate and polyoxyethylene-9-lauryl ether (POE) (see e.g., Malmsten, M. Surfactants and polymers in drug delivery, Informa Health Care, New York, N.Y., 2002; Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, page 92; Swinyard, Chapter 39 In: Remington's Pharmaceutical Sciences, 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, Pa., 1990, pages 782-783; Muranishi, Critical Reviews in Therapeutic Drug Carrier Systems, 1990, 7, 1-33; Yamamoto et al., J. Pharm. Exp. Ther., 1992, 263, 25; Yamashita et al., J. Pharm. Sci., 1990, 79, 579-583).

Chelating agents, as used in connection with the present disclosure, can be defined as compounds that remove metallic ions from solution by forming complexes therewith, with the result that absorption of RNAi agents through the mucosa is enhanced. With regards to their use as penetration enhancers in the present disclosure, chelating agents have the added advantage of also serving as DNase inhibitors, as most characterized DNA nucleases require a divalent metal ion for catalysis and are thus inhibited by chelating agents (Jarrett, J. Chromatogr., 1993, 618, 315-339). Suitable chelating agents include but are not limited to disodium ethylenediaminetetraacetate (EDTA), citric acid, salicylates (e.g., sodium salicylate, 5-methoxysalicylate and homovanilate), N-acyl derivatives of collagen, laureth-9 and N-amino acyl derivatives of beta-diketones (enamines)(see e.g., Katdare, A. et al., Excipient development for pharmaceutical, biotechnology, and drug delivery, CRC Press, Danvers, Mass., 2006; Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, page 92; Muranishi, Critical Reviews in Therapeutic Drug Carrier Systems, 1990, 7, 1-33; Buur et al., J. Control Rel., 1990, 14, 43-51).

As used herein, non-chelating non-surfactant penetration enhancing compounds can be defined as compounds that demonstrate insignificant activity as chelating agents or as surfactants but that nonetheless enhance absorption of RNAi agents through the alimentary mucosa (see e.g., Muranishi, Critical Reviews in Therapeutic Drug Carrier Systems, 1990, 7, 1-33). This class of penetration enhancers includes, for example, unsaturated cyclic ureas, 1-alkyl- and 1-alkenylazacyclo-alkanone derivatives (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, page 92); and non-steroidal anti-inflammatory agents such as diclofenac sodium, indomethacin and phenylbutazone (Yamashita et al., J. Pharm. Pharmacol., 1987, 39, 621-626).

Agents that enhance uptake of RNAi agents at the cellular level can also be added to the pharmaceutical and other compositions of the present disclosure. For example, cationic lipids, such as lipofectin (Junichi et al, U.S. Pat. No. 5,705,188), cationic glycerol derivatives, and polycationic molecules, such as polylysine (WO 97/30731), are also known to enhance the cellular uptake of dsRNAs.

Other agents can be utilized to enhance the penetration of the administered nucleic acids, including glycols such as ethylene glycol and propylene glycol, pyrrols such as 2-pyrrol, azones, and terpenes such as limonene and menthone.

vi. Excipients

In contrast to a carrier compound, a “pharmaceutical carrier” or “excipient” is a pharmaceutically acceptable solvent, suspending agent or any other pharmacologically inert vehicle for delivering one or more nucleic acids to an animal. The excipient can be liquid or solid and is selected, with the planned manner of administration in mind, so as to provide for the desired bulk, consistency, etc., when combined with a nucleic acid and the other components of a given pharmaceutical composition. Typical pharmaceutical carriers include, but are not limited to, binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose, etc.); fillers (e.g., lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates or calcium hydrogen phosphate, etc.); lubricants (e.g., magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, corn starch, polyethylene glycols, sodium benzoate, sodium acetate, etc.); disintegrants (e.g., starch, sodium starch glycolate, etc.); and wetting agents (e.g., sodium lauryl sulphate, etc).

Pharmaceutically acceptable organic or inorganic excipients suitable for non-parenteral administration which do not deleteriously react with nucleic acids can also be used to formulate the compositions of the present disclosure. Suitable pharmaceutically acceptable carriers include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

Formulations for topical administration of nucleic acids can include sterile and non-sterile aqueous solutions, non-aqueous solutions in common solvents such as alcohols, or solutions of the nucleic acids in liquid or solid oil bases. The solutions can also contain buffers, diluents and other suitable additives. Pharmaceutically acceptable organic or inorganic excipients suitable for non-parenteral administration which do not deleteriously react with nucleic acids can be used.

Suitable pharmaceutically acceptable excipients include, but are not limited to, water, salt solutions, alcohol, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

vii. Other Components

The compositions of the present disclosure can additionally contain other adjunct components conventionally found in pharmaceutical compositions, at their art-established usage levels. Thus, for example, the compositions can contain additional, compatible, pharmaceutically-active materials such as, for example, antipruritics, astringents, local anesthetics or anti-inflammatory agents, or can contain additional materials useful in physically formulating various dosage forms of the compositions of the present disclosure, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. However, such materials, when added, should not unduly interfere with the biological activities of the components of the compositions of the present disclosure. The formulations can be sterilized and, if desired, mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings or aromatic substances and the like which do not deleteriously interact with the nucleic acid(s) of the formulation.

Aqueous suspensions can contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol or dextran. The suspension can also contain stabilizers.

In some embodiments, pharmaceutical compositions featured in the disclosure include (a) one or more RNAi agents and (b) one or more agents which function by a non-RNAi mechanism and which are useful in treating an APOE-associated neurodegenerative disorder. Examples of such agents include, but are not limited to SSRIs, venlafaxine, bupropion, and atypical antipsychotics.

Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD₅₀(the dose lethal to 50% of the population) and the ED₅₀(the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD₅₀/ED₅₀. Compounds that exhibit high therapeutic indices are preferred.

The data obtained from cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of compositions featured herein in the disclosure lies generally within a range of circulating concentrations that include the ED₅₀with little or no toxicity. The dosage can vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the methods featured in the disclosure, the therapeutically effective dose can be estimated initially from cell culture assays. A dose can be formulated in animal models to achieve a circulating plasma concentration range of the compound or, when appropriate, of the polypeptide product of a target sequence (e.g., achieving a decreased concentration of the polypeptide) that includes the IC₅₀(i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma can be measured, for example, by high performance liquid chromatography.

In addition to their administration, as discussed above, the RNAi agents featured in the disclosure can be administered in combination with other known agents effective in treatment of pathological processes mediated by nucleotide repeat expression. In any event, the administering physician can adjust the amount and timing of RNAi agent administration on the basis of results observed using standard measures of efficacy known in the art or described herein.

VIII. Kits

In certain aspects, the instant disclosure provides kits that include a suitable container containing a pharmaceutical formulation of a siRNA compound, e.g., a double-stranded siRNA compound, or siRNA compound, (e.g., a precursor, e.g., a larger siRNA compound which can be processed into a siRNA compound, or a DNA which encodes an siRNA compound, e.g., a double-stranded siRNA compound, or siRNA compound, or precursor thereof). In certain embodiments the individual components of the pharmaceutical formulation may be provided in one container. Alternatively, it may be desirable to provide the components of the pharmaceutical formulation separately in two or more containers, e.g., one container for a siRNA compound preparation, and at least another for a carrier compound. The kit may be packaged in a number of different configurations such as one or more containers in a single box. The different components can be combined, e.g., according to instructions provided with the kit. The components can be combined according to a method described herein, e.g., to prepare and administer a pharmaceutical composition. The kit can also include a delivery device.

IX. Methods for Inhibiting APOE Expression

The present disclosure also provides methods of inhibiting expression of an APOE gene in a cell. The methods include contacting a cell with an RNAi agent, e.g., double stranded RNAi agent, in an amount effective to inhibit expression of APOE in the cell, thereby inhibiting expression of APOE in the cell. In certain embodiments of the disclosure, APOE is inhibited preferentially in CNS (e.g., brain) cells. In other embodiments of the disclosure, APOE is inhibited preferentially in the liver (e.g., hepatocytes). In certain embodiments of the disclosure, APOE is inhibited in CNS (e.g., brain) cells and in liver (e.g., hepatocytes) cells.

In some embodiments, the expression of APOE2 is inhibited. In some embodiments, the expression of APOE3 is inhibited. In some embodiments, the expression of APOE4 is inhibited. In some embodiments, the expression of APOE2 and APOE3 is inhibited. In some embodiments, the expression of APOE2, APOE3, and APOE4 is inhibited. In some embodiments, the expression of APOE4 is inhibited and the expression of APOE2 and APOE3 is substantially not inhibited, e.g., expression of APOE2 and APOE3 is inhibited by no more than 10%.

Contacting of a cell with a RNAi agent, e.g., a double stranded RNAi agent, may be done in vitro or in vivo. Contacting a cell in vivo with the RNAi agent includes contacting a cell or group of cells within a subject, e.g., a human subject, with the RNAi agent. Combinations of in vitro and in vivo methods of contacting a cell are also possible.

Contacting a cell may be direct or indirect, as discussed above. Furthermore, contacting a cell may be accomplished via a targeting ligand, including any ligand described herein or known in the art. In some embodiments, the targeting ligand is a carbohydrate moiety, e.g., a GalNAc ligand, or any other ligand that directs the RNAi agent to a site of interest.

The term “inhibiting,” as used herein, is used interchangeably with “reducing,” “silencing,” “downregulating,” “suppressing” and other similar terms, and includes any level of inhibition. In certain embodiments, a level of inhibition, e.g., for an RNAi agent of the instant disclosure, can be assessed in cell culture conditions, e.g., wherein cells in cell culture are transfected via Lipofectamine™-mediated transfection at a concentration in the vicinity of a cell of 10 nM or less, 1 nM or less, etc. Knockdown of a given RNAi agent can be determined via comparison of pre-treated levels in cell culture versus post-treated levels in cell culture, optionally also comparing against cells treated in parallel with a scrambled or other form of control RNAi agent. Knockdown in cell culture of, e.g., preferably 50% or more, can thereby be identified as indicative of “inhibiting” or “reducing”, “downregulating” or “suppressing”, etc. having occurred. It is expressly contemplated that assessment of targeted mRNA or encoded protein levels (and therefore an extent of “inhibiting”, etc. caused by a RNAi agent of the disclosure) can also be assessed in in vivo systems for the RNAi agents of the instant disclosure, under properly controlled conditions as described in the art.

The phrase “inhibiting expression of an APOE gene” or “inhibiting expression of APOE,” as used herein, includes inhibition of expression of any APOE gene (such as, e.g., a mouse APOE gene, a rat APOE gene, a monkey APOE gene, or a human APOE gene) as well as variants or mutants of an APOE gene that encode an APOE protein. Thus, the APOE gene may be a wild-type APOE gene, a mutant APOE gene, or a transgenic APOE gene in the context of a genetically manipulated cell, group of cells, or organism.

“Inhibiting expression of an APOE gene” includes any level of inhibition of an APOE gene, e.g., at least partial suppression of the expression of an APOE gene, such as an inhibition by at least 20%. In certain embodiments, inhibition is by at least 30%, at least 40%, preferably at least 50%, at least about 60%, at least 70%, at least about 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%; or to below the level of detection of the assay method.

The expression of an APOE gene may be assessed based on the level of any variable associated with APOE gene expression, e.g., APOE mRNA level or APOE protein level, or, for example, the level of amyloid or tau deposition.

Inhibition may be assessed by a decrease in an absolute or relative level of one or more of these variables compared with a control level. The control level may be any type of control level that is utilized in the art, e.g., a pre-dose baseline level, or a level determined from a similar subject, cell, or sample that is untreated or treated with a control (such as, e.g., buffer only control or inactive agent control).

In some embodiments of the methods of the disclosure, expression of an APOE gene is inhibited by at least 20%, 30%, 40%, preferably at least 50%, 60%, 70%, 80%, 85%, 90%, or 95%, or to below the level of detection of the assay. In certain embodiments, the methods include a clinically relevant inhibition of expression of APOE, e.g. as demonstrated by a clinically relevant outcome after treatment of a subject with an agent to reduce the expression of APOE.

Inhibition of the expression of an APOE gene may be manifested by a reduction of the amount of mRNA expressed by a first cell or group of cells (such cells may be present, for example, in a sample derived from a subject) in which an APOE gene is transcribed and which has or have been treated (e.g., by contacting the cell or cells with a RNAi agent of the disclosure, or by administering a RNAi agent of the disclosure to a subject in which the cells are or were present) such that the expression of an APOE gene is inhibited, as compared to a second cell or group of cells substantially identical to the first cell or group of cells but which has not or have not been so treated (control cell(s) not treated with a RNAi agent or not treated with a RNAi agent targeted to the gene of interest). The degree of inhibition may be expressed in terms of:

$\frac{(mRNA in control cells) - (mRNA in treated cells)}{(mRNA in control cells)} • 100 %$

In other embodiments, inhibition of the expression of an APOE gene may be assessed in terms of a reduction of a parameter that is functionally linked to an APOE gene expression, e.g., APOE protein expression. APOE gene silencing may be determined in any cell expressing APOE, either endogenous or heterologous from an expression construct, and by any assay known in the art.

Inhibition of the expression of an APOE protein may be manifested by a reduction in the level of the APOE protein that is expressed by a cell or group of cells (e.g., the level of protein expressed in a sample derived from a subject). As explained above, for the assessment of mRNA suppression, the inhibition of protein expression levels in a treated cell or group of cells may similarly be expressed as a percentage of the level of protein in a control cell or group of cells.

A control cell or group of cells that may be used to assess the inhibition of the expression of an APOE gene includes a cell or group of cells that has not yet been contacted with an RNAi agent of the disclosure. For example, the control cell or group of cells may be derived from an individual subject (e.g., a human or animal subject) prior to treatment of the subject with an RNAi agent.

The level of APOE mRNA that is expressed by a cell or group of cells may be determined using any method known in the art for assessing mRNA expression. In one embodiment, the level of expression of APOE in a sample is determined by detecting a transcribed polynucleotide, or portion thereof, e.g., mRNA of the APOE gene. RNA may be extracted from cells using RNA extraction techniques including, for example, using acid phenol/guanidine isothiocyanate extraction (RNAzol B; Biogenesis), RNeasy™ RNA preparation kits (Qiagen®) or PAXgene (PreAnalytix, Switzerland). Typical assay formats utilizing ribonucleic acid hybridization include nuclear run-on assays, RT-PCR, RNase protection assays, northern blotting, in situ hybridization, and microarray analysis. Circulating APOE mRNA may be detected using methods the described in WO2012/177906, the entire contents of which are hereby incorporated herein by reference.

In some embodiments, the level of expression of APOE is determined using a nucleic acid probe. The term “probe”, as used herein, refers to any molecule that is capable of selectively binding to a specific APOE nucleic acid or protein, or fragment thereof. Probes can be synthesized by one of skill in the art, or derived from appropriate biological preparations. Probes may be specifically designed to be labeled. Examples of molecules that can be utilized as probes include, but are not limited to, RNA, DNA, proteins, antibodies, and organic molecules.

Isolated mRNA can be used in hybridization or amplification assays that include, but are not limited to, Southern or northern analyses, polymerase chain reaction (PCR) analyses and probe arrays. One method for the determination of mRNA levels involves contacting the isolated mRNA with a nucleic acid molecule (probe) that can hybridize to APOE mRNA. In one embodiment, the mRNA is immobilized on a solid surface and contacted with a probe, for example by running the isolated mRNA on an agarose gel and transferring the mRNA from the gel to a membrane, such as nitrocellulose. In an alternative embodiment, the probe(s) are immobilized on a solid surface and the mRNA is contacted with the probe(s), for example, in an Affymetrix® gene chip array. A skilled artisan can readily adapt known mRNA detection methods for use in determining the level of APOE mRNA.

An alternative method for determining the level of expression of APOE in a sample involves the process of nucleic acid amplification or reverse transcriptase (to prepare cDNA) of for example mRNA in the sample, e.g., by RT-PCR (the experimental embodiment set forth in Mullis, 1987, U.S. Pat. No. 4,683,202), ligase chain reaction (Barany (1991) Proc. Natl. Acad. Sci. USA 88:189-193), self sustained sequence replication (Guatelli et al. (1990) Proc. Natl. Acad. Sci. USA 87:1874-1878), transcriptional amplification system (Kwoh et al. (1989) Proc. Natl. Acad. Sci. USA 86:1173-1177), Q-Beta Replicase (Lizardi et al. (1988) Bio/Technology 6:1197), rolling circle replication (Lizardi et al., U.S. Pat. No. 5,854,033) or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers. In particular aspects of the disclosure, the level of expression of APOE is determined by quantitative fluorogenic RT-PCR (i.e., the TaqMan™ System), by a Dual-Glo® Luciferase assay, or by other art-recognized method for measurement of APOE expression or mRNA level.

The expression level of APOE mRNA may be monitored using a membrane blot (such as used in hybridization analysis such as northern, Southern, dot, and the like), or microwells, sample tubes, gels, beads or fibers (or any solid support comprising bound nucleic acids). See U.S. Pat. Nos. 5,770,722, 5,874,219, 5,744,305, 5,677,195 and 5,445,934, which are incorporated herein by reference. The determination of APOE expression level may also comprise using nucleic acid probes in solution.

In some embodiments, the level of mRNA expression is assessed using branched DNA (bDNA) assays or real time PCR (qPCR). The use of this PCR method is described and exemplified in the Examples presented herein. Such methods can also be used for the detection of APOE nucleic acids.

The level of APOE protein expression may be determined using any method known in the art for the measurement of protein levels. Such methods include, for example, electrophoresis, capillary electrophoresis, high performance liquid chromatography (HPLC), thin layer chromatography (TLC), hyperdiffusion chromatography, fluid or gel precipitin reactions, absorption spectroscopy, a colorimetric assays, spectrophotometric assays, flow cytometry, immunodiffusion (single or double), immunoelectrophoresis, western blotting, radioimmunoassay (RIA), enzyme-linked immunosorbent assays (ELISAs), immunofluorescent assays, electrochemiluminescence assays, and the like. Such assays can also be used for the detection of proteins indicative of the presence or replication of APOE proteins.

In some embodiments, the efficacy of the methods of the disclosure in the treatment of an APOE-related disease is assessed by a decrease in APOE mRNA level (e.g, by assessment of a CSF sample for APOE level, by brain biopsy, or otherwise).

In some embodiments, the efficacy of the methods of the disclosure in the treatment of an APOE-related disease is assessed by a decrease in APOE mRNA level (e.g, by assessment of a liver sample for APOE level, by biopsy, or otherwise).

In some embodiments of the methods of the disclosure, the RNAi agent is administered to a subject such that the RNAi agent is delivered to a specific site within the subject. The inhibition of expression of APOE may be assessed using measurements of the level or change in the level of APOE mRNA or APOE protein in a sample derived from a specific site within the subject, e.g., CNS cells. In certain embodiments, the methods include a clinically relevant inhibition of expression of APOE, e.g. as demonstrated by a clinically relevant outcome after treatment of a subject with an agent to reduce the expression of APOE.

As used herein, the terms detecting or determining a level of an analyte are understood to mean performing the steps to determine if a material, e.g., protein, RNA, is present. As used herein, methods of detecting or determining include detection or determination of an analyte level that is below the level of detection for the method used.

X. Methods of Treating or Preventing APOE-Associated Neurodegenerative Diseases

The present disclosure also provides methods of using a RNAi agent of the disclosure or a composition containing a RNAi agent of the disclosure to reduce or inhibit APOE expression in a cell. The methods include contacting the cell with a dsRNA of the disclosure and maintaining the cell for a time sufficient to obtain degradation of the mRNA transcript of an APOE gene, thereby inhibiting expression of the APOE gene in the cell. Reduction in gene expression can be assessed by any methods known in the art. For example, a reduction in the expression of APOE may be determined by determining the mRNA expression level of APOE using methods routine to one of ordinary skill in the art, e.g., northern blotting, qRT-PCR; by determining the protein level of APOE using methods routine to one of ordinary skill in the art, such as western blotting, immunological techniques.

In the methods of the disclosure the cell may be contacted in vitro or in vivo, i.e., the cell may be within a subject.

A cell suitable for treatment using the methods of the disclosure may be any cell that expresses an APOE gene. A cell suitable for use in the methods of the disclosure may be a mammalian cell, e.g., a primate cell (such as a human cell or a non-human primate cell, e.g., a monkey cell or a chimpanzee cell), a non-primate cell (such as a a rat cell, or a mouse cell. In one embodiment, the cell is a human cell, e.g., a human CNS cell. In one embodiment, the cell is a human cell, e.g., a human liver cell. In one embodiment, the cell is a human cell, e.g., a human CNS cell and a human liver cell.

APOE expression is inhibited in the cell by at least about 30, 40, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, 99, or about 100%, i.e., to below the level of detection. In preferred embodiments, APOE expression is inhibited by at least 50%.

The in vivo methods of the disclosure may include administering to a subject a composition containing a RNAi agent, where the RNAi agent includes a nucleotide sequence that is complementary to at least a part of an RNA transcript of the APOE gene of the mammal to be treated. When the organism to be treated is a mammal such as a human, the composition can be administered by any means known in the art including, but not limited to oral, intraperitoneal, or parenteral routes, including intracranial (e.g., intraventricular, intraparenchymal, and intrathecal), intravenous, intramuscular, intravitreal, subcutaneous, transdermal, airway (aerosol), nasal, rectal, and topical (including buccal and sublingual) administration. In certain embodiments, the compositions are administered by intravenous infusion or injection. In certain embodiments, the compositions are administered by subcutaneous injection. In certain embodiments, the compositions are administered by intrathecal injection.

In some embodiments, the administration is via a depot injection. A depot injection may release the RNAi agent in a consistent way over a prolonged time period. Thus, a depot injection may reduce the frequency of dosing needed to obtain a desired effect, e.g., a desired inhibition of APOE, or a therapeutic or prophylactic effect. A depot injection may also provide more consistent serum concentrations. Depot injections may include subcutaneous injections or intramuscular injections. In preferred embodiments, the depot injection is a subcutaneous injection.

In some embodiments, the administration is via a pump. The pump may be an external pump or a surgically implanted pump. In certain embodiments, the pump is a subcutaneously implanted osmotic pump. In other embodiments, the pump is an infusion pump. An infusion pump may be used for intracranial, intravenous, subcutaneous, arterial, or epidural infusions. In preferred embodiments, the infusion pump is a subcutaneous infusion pump. In other embodiments, the pump is a surgically implanted pump that delivers the RNAi agent to the CNS.

The mode of administration may be chosen based upon whether local or systemic treatment is desired and based upon the area to be treated. The route and site of administration may be chosen to enhance targeting.

In one aspect, the present disclosure also provides methods for inhibiting the expression of an APOE gene in a mammal. The methods include administering to the mammal a composition comprising a dsRNA that targets an APOE gene in a cell of the mammal and maintaining the mammal for a time sufficient to obtain degradation of the mRNA transcript of the APOE gene, thereby inhibiting expression of the APOE gene in the cell. Reduction in gene expression can be assessed by any methods known it the art and by methods, e.g. qRT-PCR, described herein. Reduction in protein production can be assessed by any methods known it the art and by methods, e.g. ELISA, described herein. In one embodiment, a CNS biopsy sample or a cerebrospinal fluid (CSF) sample serves as the tissue material for monitoring the reduction in APOE gene or protein expression (or of a proxy therefore).

The present disclosure further provides methods of treatment of a subject in need thereof. The treatment methods of the disclosure include administering an RNAi agent of the disclosure to a subject, e.g., a subject that would benefit from inhibition of APOE expression, in a therapeutically effective amount of a RNAi agent targeting an APOE gene or a pharmaceutical composition comprising a RNAi agent targeting a APOE gene.

In addition, the present disclosure provides methods of preventing, treating or inhibiting the progression of an APOE-associated neurodegenerative disease or disorder, such as an amyloid-β-mediated disease, e.g., Alzheimer's's disease, Down's syndrome, and cerebral amyloid angiopathy, or a tau-mediated disease, e.g. a primary tauopathy, such as Frontotemporal dementia (FTD), Progressive supranuclear palsy (PSP), Cordicobasal degeneration (CBD), Pick's disease (PiD), Globular glial tauopathies (GGTs), frontotemporal dementia with parkinsonism (FTDP, FTDP-17), Chronic traumatic encelopathy (CTE), Dementia pugilistica, Frontotemporal lobar degeneration (FTLD), Argyrophilic grain disease (AGD), and Primary age-related tauopathy (PART), or a secondary tauopathy, e.g., AD, Creuzfeld Jakob's disease, Down's Syndrome, and Familial British Dementia.

The methods include administering to the subject a therapeutically effective amount of any of the RNAi agent, e.g., dsRNA agents, or the pharmaceutical composition provided herein, thereby preventing, treating or inhibiting the progression of the APOE-associated neurodegenerative disease or disorder in the subject.

An RNAi agent of the disclosure may be administered as a “free RNAi agent.” A free RNAi agent is administered in the absence of a pharmaceutical composition. The naked RNAi agent may be in a suitable buffer solution. The buffer solution may comprise acetate, citrate, prolamine, carbonate, or phosphate, or any combination thereof. In one embodiment, the buffer solution is phosphate buffered saline (PBS). The pH and osmolarity of the buffer solution containing the RNAi agent can be adjusted such that it is suitable for administering to a subject.

Alternatively, an RNAi agent of the disclosure may be administered as a pharmaceutical composition, such as a dsRNA liposomal formulation.

Subjects that would benefit from a reduction or inhibition of APOE gene expression are those having an APOE-associated neurodegenerative disease.

The disclosure further provides methods for the use of a RNAi agent or a pharmaceutical composition thereof, e.g., for treating a subject that would benefit from reduction or inhibition of APOE expression, e.g., a subject having an APOE-associated neurodegenerative disorder, in combination with other pharmaceuticals or other therapeutic methods, e.g., with known pharmaceuticals or known therapeutic methods, such as, for example, those which are currently employed for treating these disorders. For example, in certain embodiments, an RNAi agent targeting APOE is administered in combination with, e.g., an agent useful in treating an APOE-associated neurodegenerative disorder as described elsewhere herein or as otherwise known in the art. For example, additional agents suitable for treating a subject that would benefit from reduction in APOE expression, e.g., a subject having an APOE-associated neurodegenerative disorder, may include agents currently used to treat symptoms of APOE. The RNAi agent and additional therapeutic agents may be administered at the same time or in the same combination, e.g., intrathecally, or the additional therapeutic agent can be administered as part of a separate composition or at separate times or by another method known in the art or described herein.

In one embodiment, the method includes administering a composition featured herein such that expression of the target APOE gene is decreased, for at least one month. In preferred embodiments, expression is decreased for at least 2 months, 3 months, or 6 months.

Preferably, the RNAi agents useful for the methods and compositions featured herein specifically target RNAs (primary or processed) of the target APOE gene. Compositions and methods for inhibiting the expression of these genes using RNAi agents can be prepared and performed as described herein.

Administration of the dsRNA according to the methods of the disclosure may result in a reduction of the severity, signs, symptoms, or markers of such diseases or disorders in a patient with an APOE-associated neurodegenerative disorder. By “reduction” in this context is meant a statistically significant or clinically significant decrease in such level. The reduction can be, for example, at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or about 100%.

Efficacy of treatment or prevention of disease can be assessed, for example by measuring disease progression, disease remission, symptom severity, reduction in pain, quality of life, dose of a medication required to sustain a treatment effect, level of a disease marker or any other measurable parameter appropriate for a given disease being treated or targeted for prevention. It is well within the ability of one skilled in the art to monitor efficacy of treatment or prevention by measuring any one of such parameters, or any combination of parameters. For example, efficacy of treatment of an APOE-associated neurodegenerative disorder may be assessed, for example, by periodic monitoring of a subject's cognition, learning, and/or memory. Comparisons of the later readings with the initial readings provide a physician an indication of whether the treatment is effective. It is well within the ability of one skilled in the art to monitor efficacy of treatment or prevention by measuring any one of such parameters, or any combination of parameters. In connection with the administration of a RNAi agent targeting APOE or pharmaceutical composition thereof, “effective against” an APOE-associated neurodegenerative disorder indicates that administration in a clinically appropriate manner results in a beneficial effect for at least a statistically significant fraction of patients, such as an improvement of symptoms, a cure, a reduction in disease, extension of life, improvement in quality of life, or other effect generally recognized as positive by medical doctors familiar with treating APOE-associated neurodegenerative disorders and the related causes.

A treatment or preventive effect is evident when there is a statistically significant improvement in one or more parameters of disease status, or by a failure to worsen or to develop symptoms where they would otherwise be anticipated. As an example, a favorable change of at least 10% in a measurable parameter of disease, and preferably at least 20%, 30%, 40%, 50% or more can be indicative of effective treatment. Efficacy for a given RNAi agent drug or formulation of that drug can also be judged using an experimental animal model for the given disease as known in the art. When using an experimental animal model, efficacy of treatment is evidenced when a statistically significant reduction in a marker or symptom is observed.

Alternatively, the efficacy can be measured by a reduction in the severity of disease as determined by one skilled in the art of diagnosis based on a clinically accepted disease severity grading scale. Any positive change resulting in e.g., lessening of severity of disease measured using the appropriate scale, represents adequate treatment using a RNAi agent or RNAi agent formulation as described herein.

Subjects can be administered a therapeutic amount of dsRNA, such as about 0.01 mg/kg to about 200 mg/kg.

The RNAi agent can be administered intrathecally, via intravitreal injection, or by intravenous infusion over a period of time, on a regular basis. In certain embodiments, after an initial treatment regimen, the treatments can be administered on a less frequent basis. Administration of the RNAi agent can reduce APOE levels, e.g., in a cell, tissue, blood, CSF sample or other compartment of the patient by at least 20%, 30%, 40%, 50%, 55%, 60%, 65%, 70,% 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or at least about 99% or more. In a preferred embodiment, administration of the RNAi agent can reduce APOE levels, e.g., in a cell, tissue, blood, CSF sample or other compartment of the patient by at least 50%.

Before administration of a full dose of the RNAi agent, patients can be administered a smaller dose, such as a 5% infusion reaction, and monitored for adverse effects, such as an allergic reaction. In another example, the patient can be monitored for unwanted immunostimulatory effects, such as increased cytokine (e.g., TNF-alpha or INF-alpha) levels.

Alternatively, the RNAi agent can be administered subcutaneously, i.e., by subcutaneous injection. One or more injections may be used to deliver the desired, e.g., monthly dose of RNAi agent to a subject. The injections may be repeated over a period of time. The administration may be repeated on a regular basis. In certain embodiments, after an initial treatment regimen, the treatments can be administered on a less frequent basis. A repeat-dose regime may include administration of a therapeutic amount of RNAi agent on a regular basis, such as monthly or extending to once a quarter, twice per year, once per year. In certain embodiments, the RNAi agent is administered about once per month to about once per quarter (i.e., about once every three months).

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the RNAi agents and methods featured in the invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

An informal Sequence Listing is filed herewith and forms part of the specification as filed.

EXAMPLES
Example 1. RNAi Agent Design, Synthesis, Selection, and In Vitro Evaluation

This Example describes methods for the design, synthesis, selection, and in vitro evaluation of APOE RNAi agents.

Source of Reagents

Where the source of a reagent is not specifically given herein, such reagent can be obtained from any supplier of reagents for molecular biology at a quality/purity standard for application in molecular biology.

Bioinformatics

A set of siRNAs targeting the human apolipoprotein E (APOE; human NCBI refseqID NM_000041.4; NCBI GeneID: 348) was designed using custom R and Python scripts. The human NM_000041 REFSEQ mRNA, version 4, has a length of 1166 nucleotides.

APOE single strands and duplexes were made using routine methods known in the art. A detailed list of the unmodified APOE sense and antisense strand sequences is shown in Tables 2 and 4 and a detailed list of the modified APOE sense and antisense strand sequences is shown in Tables 3 and 5.

Table 7 provides a detailed list of the unmodified APOE sense and antisense strand sequences of those agents in Table 2 that target the pathogenic APOE4 allele and Table 8 provides a detailed list of the modified APOE sense and antisense strand sequences of those agents in Table 3 that target the pathogenic APOE4 allele.

siRNA Synthesis

siRNAs were synthesized and annealed using routine methods known in the art. Briefly, siRNA sequences were synthesized on a 1 μmol scale using a Mermade 192 synthesizer (BioAutomation) with phosphoramidite chemistry on solid supports. The solid support was controlled pore glass (500-1000 Å) loaded with a custom GalNAc ligand (3′-GalNAc conjugates), universal solid support (AM Chemicals), or the first nucleotide of interest. Ancillary synthesis reagents and standard 2-cyanoethyl phosphoramidite monomers (2′-deoxy-2′-fluoro, 2′-O-methyl, RNA, DNA) were obtained from Thermo-Fisher (Milwaukee, Wis.), Hongene (China), or Chemgenes (Wilmington, Mass., USA). Additional phosphoramidite monomers were procured from commercial suppliers, prepared in-house, or procured using custom synthesis from various CMOs. Phosphoramidites were prepared at a concentration of 100 mM in either acetonitrile or 9:1 acetonitrile:DMF and were coupled using 5-Ethylthio-1H-tetrazole (ETT, 0.25 M in acetonitrile) with a reaction time of 400 s. Phosphorothioate linkages were generated using a 100 mM solution of 3-((Dimethylamino-methylidene) amino)-3H-1,2,4-dithiazole-3-thione (DDTT, obtained from Chemgenes (Wilmington, Mass., USA)) in anhydrous acetonitrile/pyridine (9:1 v/v). Oxidation time was 5 minutes. All sequences were synthesized with final removal of the DMT group (“DMT-Off”).

Upon completion of the solid phase synthesis, solid-supported oligoribonucleotides were treated with 300 μL of Methylamine (40% aqueous) at room temperature in 96 well plates for approximately 2 hours to afford cleavage from the solid support and subsequent removal of all additional base-labile protecting groups. For sequences containing any natural ribonucleotide linkages (2′-OH) protected with a tert-butyl dimethyl silyl (TBDMS) group, a second deprotection step was performed using TEA·3HF (triethylamine trihydrofluoride). To each oligonucleotide solution in aqueous methylamine was added 200 μL of dimethyl sulfoxide (DMSO) and 300 μL TEA·3HF and the solution was incubated for approximately 30 mins at 60° C. After incubation, the plate was allowed to come to room temperature and crude oligonucleotides were precipitated by the addition of 1 mL of 9:1 acetontrile:ethanol or 1:1 ethanol:isopropanol. The plates were then centrifuged at 4° C. for 45 mins and the supernatant carefully decanted with the aid of a multichannel pipette. The oligonucleotide pellet was resuspended in 20 mM NaOAc and subsequently desalted using a HiTrap size exclusion column (5 mL, GE Healthcare) on an Agilent LC system equipped with an autosampler, UV detector, conductivity meter, and fraction collector. Desalted samples were collected in 96 well plates and then analyzed by LC-MS and UV spectrometry to confirm identity and quantify the amount of material, respectively.

Duplexing of single strands was performed on a Tecan liquid handling robot. Sense and antisense single strands were combined in an equimolar ratio to a final concentration of 10 μM in 1×PBS in 96 well plates, the plate sealed, incubated at 100° C. for 10 minutes, and subsequently allowed to return slowly to room temperature over a period of 2-3 hours. The concentration and identity of each duplex was confirmed and then subsequently utilized for in vitro screening assays.

Cell Culture and Transfections

Cells were transfected by adding 4.9 μL of Opti-MEM plus 0.1 μL of RNAiMAX per well (Invitrogen, Carlsbad Calif. cat #13778-150) to 5 μL of siRNA duplexes per well, with 4 replicates of each siRNA duplex, into a 96-well plate, and incubated at room temperature for 15 minutes. Forty μL of MEDIA containing ˜1.5×10⁴cells were then added to the siRNA mixture. Cells were incubated for 24 hours prior to RNA purification. Experiments were performed at 10 nM. Transfection experiments are performed in human hepatoma Hep3B cells (ATCC HB-8064) with EMEM (ATCC catalog no. 30-2003).

Total RNA Isolation Using DYNABEADS mRNA Isolation Kit

RNA was isolated using an automated protocol on a BioTek-EL406 platform using DYNABEADs (Invitrogen, cat #61012). Briefly, 70 μL of Lysis/Binding Buffer and 10 μL of lysis buffer containing 3 μL of magnetic beads were added to the plate with cells. Plates were incubated on an electromagnetic shaker for 10 minutes at room temperature and then magnetic beads were captured and the supernatant was removed. Bead-bound RNA were then washed 2 times with 150 μL Wash Buffer A and once with Wash Buffer B. Beads were then washed with 150 μL Elution Buffer, re-captured and supernatant removed.

cDNA Synthesis Using ABI High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, Calif., Cat #4368813)

Ten μL of a master mix containing 1 μL 10× Buffer, 0.4 μL 25× dNTPs, 1 μL 10× Random primers, 0.5 μL Reverse Transcriptase, 0.5 μL RNase inhibitor and 6.6 μL of H₂O per reaction was added to RNA isolated above. Plates were sealed, mixed, and incubated on an electromagnetic shaker for 10 minutes at room temperature, followed by 2 hour incubation at 37° C.

Real Time PCR

Two μL of cDNA were added to a master mix containing 0.5 μL of human or mouse GAPDH TaqMan Probe (ThermoFisher cat 4352934E or 4351309) and 0.5 μL of appropriate APOE probe (commercially available, e.g., from Thermo Fisher) and 5 μL Lightcycler 480 probe master mix (Roche Cat #04887301001) per well in a 384 well plates (Roche cat #04887301001). Real time PCR was done in a LightCycler480 Real Time PCR system (Roche). Each duplex was tested with N=4 and data were normalized to cells transfected with a non-targeting control siRNA. To calculate relative fold change, real time data were analyzed using the ΔΔCt method and normalized to assays performed with cells transfected with a non-targeting control siRNA.

The results of a single dose screen in Hep3B cells with the agents in Table 5 are provided in Table 6.

TABLE 1

Abbreviations of nucleotide monomers used in nucleic acid sequence representation. It will

be understood that these monomers, when present in an oligonucleotide, are mutually linked by 5′-3′-

phosphodiester bonds; and it is understood that when the nucleotide contains a 2′-fluoro modification,

then the fluoro replaces the hydroxy at that position in the parent nucleotide (i.e., it is a 2′-deoxy-2′-

fluoronucleotide).

Abbreviation
Nucleotide(s)

A
Adenosine-3′-phosphate

Ab
beta-L-adenosine-3′-phosphate

Abs
beta-L-adenosine-3'-phosphorothioate

Af
2′-fluoroadenosine-3′-phosphate

Afs
2′-fluoroadenosine-3′-phosphorothioate

As
adenosine-3′-phosphorothioate

C
cytidine-3′-phosphate

Cb
beta-L-cytidine-3′-phosphate

Cbs
beta-L-cytidine-3′-phosphorothioate

Cf
2′-fluorocytidine-3′-phosphate

Cfs
2′-fluorocytidine-3′-phosphorothioate

Cs
cytidine-3′-phosphorothioate

G
guanosine-3′-phosphate

Gb
beta-L-guanosine-3′-phosphate

Gbs
beta-L-guanosine-3′-phosphorothioate

Gf
2′-fluoroguanosine-3′-phosphate

Gfs
2′-fluoroguanosine-3′-phosphorothioate

Gs
guanosine-3′-phosphorothioate

T
5′-methyluridine-3′-phosphate

Tf
2′-fluoro-5-methyluridine-3′-phosphate

Tfs
2′-fluoro-5-methyluridine-3′-phosphorothioate

Ts
5-methyluridine-3′-phosphorothioate

U
Uridine-3′-phosphate

Uf
2′-fluorouridine-3′-phosphate

Ufs
2′-fluorouridine-3′-phosphorothioate

Us
uridine-3′-phosphorothioate

N
any nucleotide, modified or unmodified

a
2′-O-methyladenosine-3′-phosphate

as
2′-O-methyladenosine-3′-phosphorothioate

c
2′-O-methylcytidine-3′-phosphate

cs
2′-O-methylcytidine-3′-phosphorothioate

g
2′-O-methylguanosine-3′-phosphate

gs
2′-O-methylguanosine-3′-phosphorothioate

t
2′-O-methyl-5-methyluridine-3′-phosphate

ts
2′-O-methyl-5-methyluridine-3′-phosphorothioate

u
2′-O-methyluridine-3′-phosphate

us
2′-O-methyluridine-3′-phosphorothioate

s
phosphorothioate linkage

L96
N-[tris(GalNAc-alkyl)-amidodecanoyl)]-4-hydroxyprolinol

Hyp-(GalNAc-alkyl)3

embedded image

Y34
2-hydroxymethyl-tetrahydrofurane-4-methoxy-3-phosphate (abasic 2′-OMe

furanose)

Y44
inverted abasic DNA (2-hydroxymethyl-tetrahydrofurane-5-phosphate)

(Agn)
Adenosine-glycol nucleic acid (GNA)

(Cgn)
Cytidine-glycol nucleic acid (GNA)

(Ggn)
Guanosine-glycol nucleic acid (GNA)

(Tgn)
Thymidine-glycol nucleic acid (GNA) S-Isomer

P
Phosphate

VP
Vinyl-phosphonate

(Aam)
2′-O-(N-methylacetamide)adenosine-3′-phosphate

(Aams)
2′-O-(N-methylacetamide)adenosine-3′-phosphorothioate

(Gam)
2′-O-(N-methylacetamide)guanosine-3′-phosphate

(Gams)
2′-O-(N-methylacetamide)guanosine-3′-phosphorothioate

(Tam)
2′-O-(N-methylacetamide)thymidine-3′-phosphate

(Tams)
2′-O-(N-methylacetamide)thymidine-3′-phosphorothioate

dA
2′-deoxyadenosine-3′-phosphate

dAs
2′-deoxyadenosine-3′-phosphorothioate

dC
2′-deoxycytidine-3′-phosphate

dCs
2′-deoxycytidine-3′-phosphorothioate

dG
2′-deoxyguanosine-3′-phosphate

dGs
2′-deoxyguanosine-3′-phosphorothioate

dT
2′-deoxythymidine-3′-phosphate

dTs
2′-deoxythymidine-3′-phosphorothioate

dU
2′-deoxyuridine

dUs
2′-deoxyuridine-3′-phosphorothioate

(Aeo)
2′-O-methoxyethyladenosine-3′-phosphate

(Aeos)
2′-O-methoxyethyladenosine-3′-phosphorothioate

(Geo)
2′-O-methoxyethylguanosine-3′-phosphate

(Geos)
2′-O-methoxyethylguanosine-3′-phosphorothioate

(Teo)
2′-O-methoxyethyl-5-methyluridine-3′-phosphate

(Teos)
2′-O-methoxyethyl-5-methyluridine-3′-phosphorothioate

(m5Ceo)
2′-O-methoxyethyl-5-methylcytidine-3′-phosphate

(m5Ceos)
2′-O-methoxyethyl-5-methylcytidine-3′-phosphorothioate

(A3m)
3′-O-methyladenosine-2′-phosphate

(A3mx)
3′-O-methyl-xylofuranosyladenosine-2′-phosphate

(G3m)
3′-O-methylguanosine-2′-phosphate

(G3mx)
3′-O-methyl-xylofuranosylguanosine-2′-phosphate

(C3m)
3′-O-methylcytidine-2′-phosphate

(C3mx)
3′-O-methyl-xylofuranosylcytidine-2′-phosphate

(U3m)
3′-O-methyluridine-2′-phosphate

U3mx)
3′-O-methyl-xylofuranosyluridine-2′-phosphate

(m5Cam)
2′-O-(N-methylacetamide)-5-methylcytidine-3′-phosphate

(m5Cams)
2′-O-(N-methylacetamide)-5-methylcytidine-3′-phosphorothioate

(Chd)
2′-O-hexadecyl-cytidine-3′-phosphate

(Chds)
2′-O-hexadecyl-cytidine-3′-phosphorothioate

(Uhd)
2′-O-hexadecyl-uridine-3′-phosphate

(Uhds)
2′-O-hexadecyl-uridine-3′-phosphorothioate

(pshe)
Hydroxyethylphosphorothioate

TABLE 2

APOE Unmodified Sense and Antisense Strand Sequences

SEQ

SEQ
Sense Strand
Antisense Strand

Sense Sequence
ID
Antisense Sequence
ID
Target Site in
Target Site in

5′ to 3′
NO:
5′ to 3′
NO:
NM_000041.4
NM_000041.4

GGCCAAUCACAGGCAGGAAGU
15
ACUUCCUGCCUGUGAUUGGCCAG
150
NM_000041.4_50-
NM_000041.4_48-

70_A21U_s
70_U1A_as

CAGGCAGGAAGAUGAAGGUUU
16
AAACCUUCAUCUUCCUGCCUGUG
151
NM_000041.4_59-
NM_000041.4_57-

79_C21U_s
79_G1A_as

AGGAAGAUGAAGGUUCUGUGU
17
ACACAGAACCUUCAUCUUCCUGC
152
NM_000041.4_64-
NM_000041.4_62-

84_G21U_s
84_C1A_as

AUGAAGGUUCUGUGGGCUGCU
18
AGCAGCCCACAGAACCUUCAUCU
153
NM_000041.4_70-
NM_000041.4_68-

90_G21U_s
90_C1A_as

UUCUGUGGGCUGCGUUGCUGU
19
ACAGCAACGCAGCCCACAGAACC
154
NM_000041.4_77-
NM_000041.4_75-

97_G21U_s
97_C1A_as

UGGGCUGCGUUGCUGGUCACU
20
AGUGACCAGCAACGCAGCCCACA
155
NM_000041.4_82-
NM_000041.4_80-

102_A21U_s
102_U1A_as

GCGUUGCUGGUCACAUUCCUU
21
AAGGAAUGUGACCAGCAACGCAG
156
NM_000041.4_88-
NM_000041.4_86-

108_G21U_s
108_C1A_as

GCUGGUCACAUUCCUGGCAGU
22
ACUGCCAGGAAUGUGACCAGCAA
157
NM_000041.4_93-
NM_000041.4_91-

113_G21U_s
113_C1A_as

UCACAUUCCUGGCAGGAUGCU
23
AGCAUCCUGCCAGGAAUGUGACC
158
NM_000041.4_98-
NM_000041.4_96-

118_C21U_s
118_G1A_as

UGGCAGGAUGCCAGGCCAAGU
24
ACUUGGCCUGGCAUCCUGCCAGG
159
NM_000041.4_107-
NM_000041.4_105-

127_G21U_s
127_C1A_as

CAGGCCAAGGUGGAGCAAGCU
25
AGCUUGCUCCACCUUGGCCUGGC
160
NM_000041.4_118-
NM_000041.4_116-

138_G21U_s
138_C1A_as

AAGGUGGAGCAAGCGGUGGAU
26
AUCCACCGCUUGCUCCACCUUGG
161
NM_000041.4_124-
NM_000041.4_122-

144_G21U_s
144_C1A_as

CAAGCGGUGGAGACAGAGCCU
27
AGGCUCUGUCUCCACCGCUUGCU
162
NM_000041.4_133-
NM_000041.4_131-

153_G21U_s
153_C1A_as

GGUGGAGACAGAGCCGGAGCU
28
AGCUCCGGCUCUGUCUCCACCGC
163
NM_000041.4_138-
NM_000041.4_136-

158_C21U_s
158_G1A_as

CCCGAGCUGCGCCAGCAGACU
29
AGUCUGCUGGCGCAGCUCGGGCU
164
NM_000041.4_157-
NM_000041.4_155-

177_C21U_s
177_G1A_as

GCUGCGCCAGCAGACCGAGUU
30
AACUCGGUCUGCUGGCGCAGCUC
165
NM_000041.4_162-
NM_000041.4_160-

182_G21U_s
182_C1A_as

CCAGCAGACCGAGUGGCAGAU
31
AUCUGCCACUCGGUCUGCUGGCG
166
NM_000041.4_168-
NM_000041.4_166-

188_G21U_s
188_C1A_as

CAGCGCUGGGAACUGGCACUU
32
AAGUGCCAGUUCCCAGCGCUGGC
167
NM_000041.4_193-
NM_000041.4_191-

213_G21U_s
213_C1A_as

CUGGGAACUGGCACUGGGUCU
33
AGACCCAGUGCCAGUUCCCAGCG
168
NM_000041.4_198-
NM_000041.4_196-

218_G21U_s
218_C1A_as

AACUGGCACUGGGUCGCUUUU
34
AAAAGCGACCCAGUGCCAGUUCC
169
NM_000041.4_203-
NM_000041.4_201-

223_s
223_as

CACUGGGUCGCUUUUGGGAUU
35
AAUCCCAAAAGCGACCCAGUGCC
170
NM_000041.4_209-
NM_000041.4_207-

229_s
229_as

GUCGCUUUUGGGAUUACCUGU
36
ACAGGUAAUCCCAAAAGCGACCC
171
NM_000041.4_215-
NM_000041.4_213-

235_C21U_s
235_G1A_as

UUUUGGGAUUACCUGCGCUGU
37
ACAGCGCAGGUAAUCCCAAAAGC
172
NM_000041.4_220-
NM_000041.4_218-

240_G21U_s
240_C1A_as

CUGCGCUGGGUGCAGACACUU
38
AAGUGUCUGCACCCAGCGCAGGU
173
NM_000041.4_232-
NM_000041.4_230-

252_G21U_s
252_C1A_as

UGGGUGCAGACACUGUCUGAU
39
AUCAGACAGUGUCUGCACCCAGC
174
NM_000041.4_238-
NM_000041.4_236-

258_G21U_s
258_C1A_as

CAGACACUGUCUGAGCAGGUU
40
AACCUGCUCAGACAGUGUCUGCA
175
NM_000041.4_244-
NM_000041.4_242-

264_G21U_s
264_C1A_as

CAGGAGGAGCUGCUCAGCUCU
41
AGAGCUGAGCAGCUCCUCCUGCA
176
NM_000041.4_265-
NM_000041.4_263-

285_C21U_s
285_G1A_as

CUGCUCAGCUCCCAGGUCACU
42
AGUGACCUGGGAGCUGAGCAGCU
177
NM_000041.4_274-
NM_000041.4_272-

294_C21U_s
294_G1A_as

UCCCAGGUCACCCAGGAACUU
43
AAGUUCCUGGGUGACCUGGGAGC
178
NM_000041.4_283-
NM_000041.4_281-

303_G21U_s
303_C1A_as

ACCCAGGAACUGAGGGCGCUU
44
AAGCGCCCUCAGUUCCUGGGUGA
179
NM_000041.4_292-
NM_000041.4_290-

312_G21U_s
312_C1A_as

UGAGGGCGCUGAUGGACGAGU
45
ACUCGUCCAUCAGCGCCCUCAGU
180
NM_000041.4_302-
NM_000041.4_300-

322_A21U_s
322_U1A_as

GCGCUGAUGGACGAGACCAUU
46
AAUGGUCUCGUCCAUCAGCGCCC
181
NM_000041.4_307-
NM_000041.4_305-

327_G21U_s
327_C1A_as

GACGAGACCAUGAAGGAGUUU
47
AAACUCCUUCAUGGUCUCGUCCA
182
NM_000041.4_316-
NM_000041.4_314-

336_G21U_s
336_C1A_as

ACCAUGAAGGAGUUGAAGGCU
48
AGCCUUCAACUCCUUCAUGGUCU
183
NM_000041.4_322-
NM_000041.4_320-

342_C21U_s
342_G1A_as

GGAGUUGAAGGCCUACAAAUU
49
AAUUUGUAGGCCUUCAACUCCUU
184
NM_000041.4_330-
NM_000041.4_328-

350_C21U_s
350_G1A_as

AAGGCCUACAAAUCGGAACUU
50
AAGUUCCGAUUUGUAGGCCUUCA
185
NM_000041.4_337-
NM_000041.4_335-

357_G21U_s
357_C1A_as

ACAAAUCGGAACUGGAGGAAU
51
AUUCCUCCAGUUCCGAUUUGUAG
186
NM_000041.4_344-
NM_000041.4_342-

364_C21U_s
364_G1A_as

UCGGAACUGGAGGAACAACUU
52
AAGUUGUUCCUCCAGUUCCGAUU
187
NM_000041.4_349-
NM_000041.4_347-

369_G21U_s
369_C1A_as

GAGGAACAACUGACCCCGGUU
53
AACCGGGGUCAGUUGUUCCUCCA
188
NM_000041.4_358-
NM_000041.4_356-

378_G21U_s
378_C1A_as

CGCGGGCACGGCUGUCCAAGU
54
ACUUGGACAGCCGUGCCCGCGUC
189
NM_000041.4_389-
NM_000041.4_387-

409_G21U_s
409_C1A_as

GCACGGCUGUCCAAGGAGCUU
55
AAGCUCCUUGGACAGCCGUGCCC
190
NM_000041.4_394-
NM_000041.4_392-

414_G21U_s
414_C1A_as

GCUGUCCAAGGAGCUGCAGGU
56
ACCUGCAGCUCCUUGGACAGCCG
191
NM_000041.4_399-
NM_000041.4_397-

419_C21U_s
419_G1A_as

GCCCGGCUGGGCGCGGACAUU
57
AAUGUCCGCGCCCAGCCGGGCCU
192
NM_000041.4_427-
NM_000041.4_425-

447_G21U_s
447_C1A_as

CUGGGCGCGGACAUGGAGGAU
58
AUCCUCCAUGUCCGCGCCCAGCC
193
NM_000041.4_433-
NM_000041.4_431-

453_C21U_s
453_G1A_as

CGCGGACAUGGAGGACGUGCU
59
AGCACGUCCUCCAUGUCCGCGCC
194
NM_000041.4_438-
NM_000041.4_436-

458_U20C_G21U_s
458_C1A_A2G_as

GCGGACAUGGAGGACGUGUGU
60
ACACACGUCCUCCAUGUCCGCGC
195
NM_000041.4_439-
NM_000041.4_437-

459_C21U_s
459_G1A_as

GCGGACAUGGAGGACGUGCGU
61
ACGCACGUCCUCCAUGUCCGCGC
196
NM_000041.4_439-
NM_000041.4_437-

459_U19C_C21U_s
459_G1A_A3G_as

CGGACAUGGAGGACGUGCGCU
62
AGCGCACGUCCUCCAUGUCCGCG
197
NM_000041.4_440-
NM_000041.4_438-

460_U18C_G21U_s
460_C1A_A4G_as

GGACAUGGAGGACGUGCGCGU
63
ACGCGCACGUCCUCCAUGUCCGC
198
NM_000041.4_441-
NM_000041.4_439-

461_U17C_G21U_s
461_C1A_A5G_as

GACAUGGAGGACGUGCGCGGU
64
ACCGCGCACGUCCUCCAUGUCCG
199
NM_000041.4_442-
NM_000041.4_440-

462_U16C_C21U_s
462_G1A_A6G_as

ACAUGGAGGACGUGCGCGGCU
65
AGCCGCGCACGUCCUCCAUGUCC
200
NM_000041.4_443-
NM_000041.4_441-

463_U15C_C21U_s
463_G1A_A7G_as

CAUGGAGGACGUGCGCGGCCU
66
AGGCCGCGCACGUCCUCCAUGUC
201
NM_000041.4_444-
NM_000041.4_442-

464_U14C_G21U_s
464_C1A_A8G_as

AUGGAGGACGUGCGCGGCCGU
67
ACGGCCGCGCACGUCCUCCAUGU
202
NM_000041.4_445-
NM_000041.4_443-

465_U13C_C21U_s
465_G1A_A9G_as

UGGAGGACGUGCGCGGCCGCU
68
AGCGGCCGCGCACGUCCUCCAUG
203
NM_000041.4_446-
NM_000041.4_444-

466_U12C_C21U_s
466_G1A_A10G_as

GGAGGACGUGCGCGGCCGCCU
69
AGGCGGCCGCGCACGUCCUCCAU
204
NM_000041.4_447-
NM_000041.4_445-

467_UHC_s
467_A11G_as

GAGGACGUGCGCGGCCGCCUU
70
AAGGCGGCCGCGCACGUCCUCCA
205
NM_000041.4_448-
NM_000041.4_446-

468_U10C_G21U_s
468_C1A_A12G_as

AGGACGUGCGCGGCCGCCUGU
71
ACAGGCGGCCGCGCACGUCCUCC
206
NM_000041.4_449-
NM_000041.4_447-

469_U9C_G21U_s
469_C1A_A13G_as

GGACGUGCGCGGCCGCCUGGU
72
ACCAGGCGGCCGCGCACGUCCUC
207
NM_000041.4_450-
NM_000041.4_448-

470_U8C_s
470_A14G_as

GACGUGCGCGGCCGCCUGGUU
73
AACCAGGCGGCCGCGCACGUCCU
208
NM_000041.4_451-
NM_000041.4_449-

471_U7C_G21U_s
471_C1A_A15G_as

ACGUGCGCGGCCGCCUGGUGU
74
ACACCAGGCGGCCGCGCACGUCC
209
NM_000041.4_452-
NM_000041.4_450-

472_U6C_C21U_s
472_G1A_A16G_as

CGUGCGCGGCCGCCUGGUGCU
75
AGCACCAGGCGGCCGCGCACGUC
210
NM_000041.4_453-
NM_000041.4_451-

473_U5C_A21U_s
473_U1A_A17G_as

GUGCGCGGCCGCCUGGUGCAU
76
AUGCACCAGGCGGCCGCGCACGU
211
NM_000041.4_454-
NM_000041.4_452-

474_U4C_G21U_s
474_C1A_A18G_as

GCGGCCGCCUGGUGCAGUACU
77
AGUACUGCACCAGGCGGCCGCAC
212
NM_000041.4_458-
NM_000041.4_456-

478_C21U_s
478_G1A_as

CGCCUGGUGCAGUACCGCGGU
78
ACCGCGGUACUGCACCAGGCGGC
213
NM_000041.4_463-
NM_000041.4_461-

483_C21U_s
483_G1A_as

GAGGUGCAGGCCAUGCUCGGU
79
ACCGAGCAUGGCCUGCACCUCGC
214
NM_000041.4_484-
NM_000041.4_482-

504_C21U_s
504_G1A_as

GCCAUGCUCGGCCAGAGCACU
80
AGUGCUCUGGCCGAGCAUGGCCU
215
NM_000041.4_493-
NM_000041.4_491-

513_C21U_s
513_G1A_as

GGCCAGAGCACCGAGGAGCUU
81
AAGCUCCUCGGUGCUCUGGCCGA
216
NM_000041.4_502-
NM_000041.4_500-

522_G21U_s
522_C1A_as

GCUGCGGGUGCGCCUCGCCUU
82
AAGGCGAGGCGCACCCGCAGCUC
217
NM_000041.4_519-
NM_000041.4_517-

539_C21U_s
539_G1A_as

GUGCGCCUCGCCUCCCACCUU
83
AAGGUGGGAGGCGAGGCGCACCC
218
NM_000041.4_526-
NM_000041.4_524-

546_G21U_s
546_C1A_as

CGCCUCCCACCUGCGCAAGCU
84
AGCUUGCGCAGGUGGGAGGCGAG
219
NM_000041.4_534-
NM_000041.4_532-

554_s
554_as

CCCACCUGCGCAAGCUGCGUU
85
AACGCAGCUUGCGCAGGUGGGAG
220
NM_000041.4_539-
NM_000041.4_537-

559_A21U_s
559_U1A_as

CUGCGCAAGCUGCGUAAGCGU
86
ACGCUUACGCAGCUUGCGCAGGU
221
NM_000041.4_544-
NM_000041.4_542-

564_G21U_s
564_C1A_as

AAGCUGCGUAAGCGGCUCCUU
87
AAGGAGCCGCUUACGCAGCUUGC
222
NM_000041.4_550-
NM_000041.4_548-

570_C21U_s
570_G1A_as

GUAAGCGGCUCCUCCGCGAUU
88
AAUCGCGGAGGAGCCGCUUACGC
223
NM_000041.4_557-
NM_000041.4_555-

577_G21U_s
577_C1A_as

GGCUCCUCCGCGAUGCCGAUU
89
AAUCGGCAUCGCGGAGGAGCCGC
224
NM_000041.4_563-
NM_000041.4_561-

583_G21U_s
583_C1A_as

CUCCGCGAUGCCGAUGACCUU
90
AAGGUCAUCGGCAUCGCGGAGGA
225
NM_000041.4_568-
NM_000041.4_566-

588_G21U_s
588_C1A_as

GAUGCCGAUGACCUGCAGAAU
91
AUUCUGCAGGUCAUCGGCAUCGC
226
NM_000041.4_574-
NM_000041.4_572-

594_G21U_s
594_C1A_as

GAUGACCUGCAGAAGCGCCUU
92
AAGGCGCUUCUGCAGGUCAUCGG
227
NM_000041.4_580-
NM_000041.4_578-

600_G21U_s
600_C1A_as

CUGCAGAAGCGCCUGGCAGUU
93
AACUGCCAGGCGCUUCUGCAGGU
228
NM_000041.4_586-
NM_000041.4_584-

606_G21U_s
606_C1A_as

AAGCGCCUGGCAGUGUACCAU
94
AUGGUACACUGCCAGGCGCUUCU
229
NM_000041.4_592-
NM_000041.4_590-

612_G21U_s
612_C1A_as

CUGGCAGUGUACCAGGCCGGU
95
ACCGGCCUGGUACACUGCCAGGC
230
NM_000041.4_598-
NM_000041.4_596-

618_G21U_s
618_C1A_as

GAGCGCGGCCUCAGCGCCAUU
96
AAUGGCGCUGAGGCCGCGCUCGG
231
NM_000041.4_634-
NM_000041.4_632-

654_C21U_s
654_G1A_as

CGGCCUCAGCGCCAUCCGCGU
97
ACGCGGAUGGCGCUGAGGCCGCG
232
NM_000041.4_639-
NM_000041.4_637-

659_A21U_s
659_U1A_as

AGCGCCAUCCGCGAGCGCCUU
98
AAGGCGCUCGCGGAUGGCGCUGA
233
NM_000041.4_646-
NM_000041.4_644-

666_G21U_s
666_C1A_as

UGGGGCCCCUGGUGGAACAGU
99
ACUGUUCCACCAGGGGCCCCAGG
234
NM_000041.4_665-
NM_000041.4_663-

685_G21U_s
685_C1A_as

CCCCUGGUGGAACAGGGCCGU
100
ACGGCCCUGUUCCACCAGGGGCC
235
NM_000041.4_670-
NM_000041.4_668-

690_C21U_s
690_G1A_as

CGCGUGCGGGCCGCCACUGUU
101
AACAGUGGCGGCCCGCACGCGGC
236
NM_000041.4_688-
NM_000041.4_686-

708_G21U_s
708_C1A_as

GCCGCCACUGUGGGCUCCCUU
102
AAGGGAGCCCACAGUGGCGGCCC
237
NM_000041.4_697-
NM_000041.4_695-

717_G21U_s
717_C1A_as

CCUGGCCGGCCAGCCGCUACU
103
AGUAGCGGCUGGCCGGCCAGGGA
238
NM_000041.4_714-
NM_000041.4_712-

734_A21U_s
734_U1A_as

GGCCAGCCGCUACAGGAGCGU
104
ACGCUCCUGUAGCGGCUGGCCGG
239
NM_000041.4_721-
NM_000041.4_719-

741_G21U_s
741_C1A_as

GCCGCUACAGGAGCGGGCCCU
105
AGGGCCCGCUCCUGUAGCGGCUG
240
NM_000041.4_726-
NM_000041.4_724-

746_A21U_s
746_U1A_as

GCGCGGAUGGAGGAGAUGGGU
106
ACCCAUCUCCUCCAUCCGCGCGC
241
NM_000041.4_769-
NM_000041.4_767-

789_C21U_s
789_G1A_as

CGCGACCGCCUGGACGAGGUU
107
AACCUCGUCCAGGCGGUCGCGGG
242
NM_000041.4_799-
NM_000041.4_797-

819_G21U_s
819_C1A_as

GCCUGGACGAGGUGAAGGAGU
108
ACUCCUUCACCUCGUCCAGGCGG
243
NM_000041.4_806-
NM_000041.4_804-

826_C21U_s
826_G1A_as

GACGAGGUGAAGGAGCAGGUU
109
AACCUGCUCCUUCACCUCGUCCA
244
NM_000041.4_811-
NM_000041.4_809-

831_G21U_s
831_C1A_as

GGAGGUGCGCGCCAAGCUGGU
110
ACCAGCUUGGCGCGCACCUCCGC
245
NM_000041.4_834-
NM_000041.4_832-

854_A21U_s
854_U1A_as

CGCGCCAAGCUGGAGGAGCAU
111
AUGCUCCUCCAGCUUGGCGCGCA
246
NM_000041.4_841-
NM_000041.4_839-

861_G21U_s
861_C1A_as

CAGGCCCAGCAGAUACGCCUU
112
AAGGCGUAUCUGCUGGGCCUGCU
247
NM_000041.4_859-
NM_000041.4_857-

879_G21U_s
879_C1A_as

CCAGCAGAUACGCCUGCAGGU
113
ACCUGCAGGCGUAUCUGCUGGGC
248
NM_000041.4_864-
NM_000041.4_862-

884_C21U_s
884_G1A_as

CGCCUGCAGGCCGAGGCCUUU
114
AAAGGCCUCGGCCUGCAGGCGUA
249
NM_000041.4_874-
NM_000041.4_872-

894_C21U_s
894_G1A_as

GCAGGCCGAGGCCUUCCAGGU
115
ACCUGGAAGGCCUCGGCCUGCAG
250
NM_000041.4_879-
NM_000041.4_877-

899_C21U_s
899_G1A_as

CCGAGGCCUUCCAGGCCCGCU
116
AGCGGGCCUGGAAGGCCUCGGCC
251
NM_000041.4_884-
NM_000041.4_882-

904_C21U_s
904_G1A_as

GCCUUCCAGGCCCGCCUCAAU
117
AUUGAGGCGGGCCUGGAAGGCCU
252
NM_000041.4_889-
NM_000041.4_887-

909_G21U_s
909_C1A_as

CCAGGCCCGCCUCAAGAGCUU
118
AAGCUCUUGAGGCGGGCCUGGAA
253
NM_000041.4_894-
NM_000041.4_892-

914_G21U_s
914_C1A_as

CCGCCUCAAGAGCUGGUUCGU
119
ACGAACCAGCUCUUGAGGCGGGC
254
NM_000041.4_900-
NM_000041.4_898-

920_A21U_s
920_U1A_as

CAAGAGCUGGUUCGAGCCCCU
120
AGGGGCUCGAACCAGCUCUUGAG
255
NM_000041.4_906-
NM_000041.4_904-

926_s
926_as

AGCCCCUGGUGGAAGACAUGU
121
ACAUGUCUUCCACCAGGGGCUCG
256
NM_000041.4_920-
NM_000041.4_918-

940_C21U_s
940_G1A_as

CUGGUGGAAGACAUGCAGCGU
122
ACGCUGCAUGUCUUCCACCAGGG
257
NM_000041.4_925-
NM_000041.4_923-

945_C21U_s
945_G1A_as

GGAAGACAUGCAGCGCCAGUU
123
AACUGGCGCUGCAUGUCUUCCAC
258
NM_000041.4_930-
NM_000041.4_928-

950_G21U_s
950_C1A_as

GCCGGGCUGGUGGAGAAGGUU
124
AACCUUCUCCACCAGCCCGGCCC
259
NM_000041.4_952-
NM_000041.4_950-

972_G21U_s
972_C1A_as

GCUGGUGGAGAAGGUGCAGGU
125
ACCUGCACCUUCUCCACCAGCCC
260
NM_000041.4_957-
NM_000041.4_955-

977_C21U_s
977_G1A_as

ACCAGCGCCGCCCCUGUGCCU
126
AGGCACAGGGGCGGCGCUGGUGC
261
NM_000041.4_988-
NM_000041.4_986-

1008_C21U_s
1008_G1A_as

GCCCCUGUGCCCAGCGACAAU
127
AUUGUCGCUGGGCACAGGGGCGG
262
NM_000041.4_997-
NM_000041.4_995-

1017_s
1017_as

UGUGCCCAGCGACAAUCACUU
128
AAGUGAUUGUCGCUGGGCACAGG
263
NM_000041.4_1002-
NM_000041.4_1000-

1022_G21U_s
1022_C1A_as

CAGCGACAAUCACUGAACGCU
129
AGCGUUCAGUGAUUGUCGCUGGG
264
NM_000041.4_1008-
NM_000041.4_1006-

1028_C21U_s
1028_G1A_as

CAAUCACUGAACGCCGAAGCU
130
AGCUUCGGCGUUCAGUGAUUGUC
265
NM_000041.4_1014-
NM_000041.4_1012-

1034_C21U_s
1034_G1A_as

ACUGAACGCCGAAGCCUGCAU
131
AUGCAGGCUUCGGCGUUCAGUGA
266
NM_000041.4_1019-
NM_000041.4_1017-

1039_G21U_s
1039_C1A_as

ACGCCGAAGCCUGCAGCCAUU
132
AAUGGCUGCAGGCUUCGGCGUUC
267
NM_000041.4_1024-
NM_000041.4_1022-

1044_G21U_s
1044_C1A_as

GAAGCCUGCAGCCAUGCGACU
133
AGUCGCAUGGCUGCAGGCUUCGG
268
NM_000041.4_1029-
NM_000041.4_1027-

1049_C21U_s
1049_G1A_as

UGCAGCCAUGCGACCCCACGU
134
ACGUGGGGUCGCAUGGCUGCAGG
269
NM_000041.4_1035-
NM_000041.4_1033-

1055_C21U_s
1055_G1A_as

GCGACCCCACGCCACCCCGUU
135
AACGGGGUGGCGUGGGGUCGCAU
270
NM_000041.4_1044-
NM_000041.4_1042-

1064_G21U_s
1064_C1A_as

CCCACGCCACCCCGUGCCUCU
136
AGAGGCACGGGGUGGCGUGGGGU
271
NM_000041.4_1049-
NM_000041.4_1047-

1069_C21U_s
1069_G1A_as

CCACCCCGUGCCUCCUGCCUU
137
AAGGCAGGAGGCACGGGGUGGCG
272
NM_000041.4_1055-
NM_000041.4_1053-

1075_C21U_s
1075_G1A_as

CGUGCCUCCUGCCUCCGCGCU
138
AGCGCGGAGGCAGGAGGCACGGG
273
NM_000041.4_1061-
NM_000041.4_1059-

1081_A21U_s
1081_U1A_as

CUCCUGCCUCCGCGCAGCCUU
139
AAGGCUGCGCGGAGGCAGGAGGC
274
NM_000041.4_1066-
NM_000041.4_1064-

1086_G21U_s
1086_C1A_as

GCCUCCGCGCAGCCUGCAGCU
140
AGCUGCAGGCUGCGCGGAGGCAG
275
NM_000041.4_1071-
NM_000041.4_1069-

1091_G21U_s
1091_C1A_as

CCUGUCCCCGCCCCAGCCGUU
141
AACGGCUGGGGCGGGGACAGGGU
276
NM_000041.4_1098-
NM_000041.4_1096-

1118_C21U_s
1118_G1A_as

CCCGCCCCAGCCGUCCUCCUU
142
AAGGAGGACGGCUGGGGCGGGGA
277
NM_000041.4_1104-
NM_000041.4_1102-

1124_G21U_s
1124_C1A_as

CCCAGCCGUCCUCCUGGGGUU
143
AACCCCAGGAGGACGGCUGGGGC
278
NM_000041.4_1109-
NM_000041.4_1107-

1129_G21U_s
1129_C1A_as

UCCUGGGGUGGACCCUAGUUU
144
AAACUAGGGUCCACCCCAGGAGG
279
NM_000041.4_1120-
NM_000041.4_1118-

1140_s
1140_as

GGGUGGACCCUAGUUUAAUAU
145
AUAUUAAACUAGGGUCCACCCCA
280
NM_000041.4_1125-
NM_000041.4_1123-

1145_A21U_s
1145_U1A_as

GACCCUAGUUUAAUAAAGAUU
146
AAUCUUUAUUAAACUAGGGUCCA
281
NM_000041.4_1130-
NM_000041.4_1128-

1150_s
1150_as

UAGUUUAAUAAAGAUUCACCU
147
AGGUGAAUCUUUAUUAAACUAGG
282
NM_000041.4_1135-
NM_000041.4_1133-

1155_A21U_s
1155_U1A_as

UAAUAAAGAUUCACCAAGUUU
148
AAACUUGGUGAAUCUUUAUUAAA
283
NM_000041.4_1140-
NM_000041.4_1138-

1160_s
1160_as

AGAUUCACCAAGUUUCACGCU
149
AGCGUGAAACUUGGUGAAUCUUU
284
NM_000041.4_1146-
NM_000041.4_1144-

1166_A21U_s
1166_U1A_as

TABLE 3

APOE Modified Sense and Antisense Strand Sequences

SEQ

SEQ

SEQ

Sense Sequence
ID
Antisense Sequence
ID
mRNA Target Sequence
ID

5′ to 3′
NO:
5′to 3′
NO:
5′ to 3′
NO:

gsgsccaaUfcAfCfAfggcaggaaguL96
285
asCfsuucCfuGfCfcuguGfaUfuggccsasg
420
CTGGCCAATCACAGGCAGGAAGA
555

csasggcaGfgAfAfGfaugaagguuuL96
286
asAfsaccUfuCfAfucuuCfcUfgccugsusg
421
CACAGGCAGGAAGATGAAGGTTC
556

asgsgaagAfuGfAfAfgguucuguguL96
287
asCfsacaGfaAfCfcuucAfuCfuuccusgsc
422
GCAGGAAGATGAAGGTTCTGTGG
557

asusgaagGfuUfCfUfgugggcugcuL96
288
asGfscagCfcCfAfcagaAfcCfuucauscsu
423
AGATGAAGGTTCTGTGGGCTGCG
558

ususcuguGfgGfCfUfgcguugcuguL96
289
asCfsagcAfaCfGfcagcCfcAfcagaascsc
424
GGTTCTGTGGGCTGCGTTGCTGG
559

usgsggcuGfcGfUfUfgcuggucacuL96
290
asGfsugaCfcAfGfcaacGfcAfgcccascsa
425
TGTGGGCTGCGTTGCTGGTCACA
560

gscsguugCfuGfGfUfcacauuccuuL96
291
asAfsggaAfuGfUfgaccAfgCfaacgcsasg
426
CTGCGTTGCTGGTCACATTCCTG
561

gscsugguCfaCfAfUfuccuggcaguL96
292
asCfsugcCfaGfGfaaugUfgAfccagcsasa
427
TTGCTGGTCACATTCCTGGCAGG
562

uscsacauUfcCfUfGfgcaggaugcuL96
293
asGfscauCfcUfGfccagGfaAfugugascsc
428
GGTCACATTCCTGGCAGGATGCC
563

usgsgcagGfaUfGfCfcaggccaaguL96
294
asCfsuugGfcCfUfggcaUfcCfugccasgsg
429
CCTGGCAGGATGCCAGGCCAAGG
564

csasggccAfaGfGfUfggagcaagcuL96
295
asGfscuuGfcUfCfcaccUfuGfgccugsgsc
430
GCCAGGCCAAGGTGGAGCAAGCG
565

asasggugGfaGfCfAfagcgguggauL96
296
asUfsccaCfcGfCfuugcUfcCfaccuusgsg
431
CCAAGGTGGAGCAAGCGGTGGAG
566

csasagcgGfuGfGfAfgacagagccuL96
297
asGfsgcuCfuGfUfcuccAfcCfgcuugscsu
432
AGCAAGCGGTGGAGACAGAGCCG
567

gsgsuggaGfaCfAfGfagccggagcuL96
298
asGfscucCfgGfCfucugUfcUfccaccsgsc
433
GCGGTGGAGACAGAGCCGGAGCC
568

cscscgagCfuGfCfGfccagcagacuL96
299
asGfsucuGfcUfGfgcgcAfgCfucgggscsu
434
AGCCCGAGCTGCGCCAGCAGACC
569

gscsugcgCfcAfGfCfagaccgaguuL96
300
asAfscucGfgUfCfugcuGfgCfgcagcsusc
435
GAGCTGCGCCAGCAGACCGAGTG
570

cscsagcaGfaCfCfGfaguggcagauL96
301
asUfscugCfcAfCfucggUfcUfgcuggscsg
436
CGCCAGCAGACCGAGTGGCAGAG
571

csasgcgcUfgGfGfAfacuggcacuuL96
302
asAfsgugCfcAfGfuuccCfaGfcgcugsgsc
437
GCCAGCGCTGGGAACTGGCACTG
572

csusgggaAfcUfGfGfcacugggucuL96
303
asGfsaccCfaGfUfgccaGfuUfcccagscsg
438
CGCTGGGAACTGGCACTGGGTCG
573

asascuggCfaCfUfGfggucgcuuuuL96
304
asAfsaagCfgAfCfccagUfgCfcaguuscsc
439
GGAACTGGCACTGGGTCGCTTTT
574

csascuggGfuCfGfCfuuuugggauuL96
305
asAfsuccCfaAfAfagcgAfcCfcagugscsc
440
GGCACTGGGTCGCTTTTGGGATT
575

gsuscgcuUfuUfGfGfgauuaccuguL96
306
asCfsaggUfaAfUfcccaAfaAfgcgacscsc
441
GGGTCGCTTTTGGGATTACCTGC
576

ususuuggGfaUfUfAfccugcgcuguL96
307
asCfsagcGfcAfGfguaaUfcCfcaaaasgsc
442
GCTTTTGGGATTACCTGCGCTGG
577

csusgcgcUfgGfGfUfgcagacacuuL96
308
asAfsgugUfcUfGfcaccCfaGfcgcagsgsu
443
ACCTGCGCTGGGTGCAGACACTG
578

usgsggugCfaGfAfCfacugucugauL96
309
asUfscagAfcAfGfugucUfgCfacccasgsc
444
GCTGGGTGCAGACACTGTCTGAG
579

csasgacaCfuGfUfCfugagcagguuL96
310
asAfsccuGfcUfCfagacAfgUfgucugscsa
445
TGCAGACACTGTCTGAGCAGGTG
580

csasggagGfaGfCfUfgcucagcucuL96
311
asGfsagcUfgAfGfcagcUfcCfuccugscsa
446
TGCAGGAGGAGCTGCTCAGCTCC
581

csusgcucAfgCfUfCfccaggucacuL96
312
asGfsugaCfcUfGfggagCfuGfagcagscsu
447
AGCTGCTCAGCTCCCAGGTCACC
582

uscsccagGfuCfAfCfccaggaacuuL96
313
asAfsguuCfcUfGfggugAfcCfugggasgsc
448
GCTCCCAGGTCACCCAGGAACTG
583

ascsccagGfaAfCfUfgagggcgcuuL96
314
asAfsgcgCfcCfUfcaguUfcCfugggusgsa
449
TCACCCAGGAACTGAGGGCGCTG
584

usgsagggCfgCfUfGfauggacgaguL96
315
asCfsucgUfcCfAfucagCfgCfccucasgsu
450
ACTGAGGGCGCTGATGGACGAGA
585

gscsgcugAfuGfGfAfcgagaccauuL96
316
asAfsuggUfcUfCfguccAfuCfagcgcscsc
451
GGGCGCTGATGGACGAGACCATG
586

gsascgagAfcCfAfUfgaaggaguuuL96
317
asAfsacuCfcUfUfcaugGfuCfucgucscsa
452
TGGACGAGACCATGAAGGAGTTG
587

ascscaugAfaGfGfAfguugaaggcuL96
318
asGfsccuUfcAfAfcuccUfuCfaugguscsu
453
AGACCATGAAGGAGTTGAAGGCC
588

gsgsaguuGfaAfGfGfccuacaaauuL96
319
asAfsuuuGfuAfGfgccuUfcAfacuccsusu
454
AAGGAGTTGAAGGCCTACAAATC
589

asasggccUfaCfAfAfaucggaacuuL96
320
asAfsguuCfcGfAfuuugUfaGfgccuuscsa
455
TGAAGGCCTACAAATCGGAACTG
590

ascsaaauCfgGfAfAfcuggaggaauL96
321
asUfsuccUfcCfAfguucCfgAfuuugusasg
456
CTACAAATCGGAACTGGAGGAAC
591

uscsggaaCfuGfGfAfggaacaacuuL96
322
asAfsguuGfuUfCfcuccAfgUfuccgasusu
457
AATCGGAACTGGAGGAACAACTG
592

gsasggaaCfaAfCfUfgaccccgguuL96
323
asAfsccgGfgGfUfcaguUfgUfuccucscsa
458
TGGAGGAACAACTGACCCCGGTG
593

csgscgggCfaCfGfGfcuguccaaguL96
324
asCfsuugGfaCfAfgccgUfgCfccgcgsusc
459
GACGCGGGCACGGCTGTCCAAGG
594

gscsacggCfuGfUfCfcaaggagcuuL96
325
asAfsgcuCfcUfUfggacAfgCfcgugcscsc
460
GGGCACGGCTGTCCAAGGAGCTG
595

gscsugucCfaAfGfGfagcugcagguL96
326
asCfscugCfaGfCfuccuUfgGfacagcscsg
461
CGGCTGTCCAAGGAGCTGCAGGC
596

gscsccggCfuGfGfGfcgcggacauuL96
327
asAfsuguCfcGfCfgcccAfgCfcgggcscsu
462
AGGCCCGGCTGGGCGCGGACATG
597

csusgggcGfcGfGfAfcauggaggauL96
328
asUfsccuCfcAfUfguccGfcGfcccagscsc
463
GGCTGGGCGCGGACATGGAGGAC
598

csgscggaCfaUfGfGfaggacgugcuL96
329
asGfscacGfuCfCfuccaUfgUfccgcgscsc
464
GGCGCGGACATGGAGGACGTGCG
599

gscsggacAfuGfGfAfggacguguguL96
330
asCfsacaCfgUfCfcuccAfuGfuccgcsgsc
465
GCGCGGACATGGAGGACGTGTGC
600

gscsggacAfuGfGfAfggacgugcguL96
331
asCfsgcaCfgUfCfcuccAfuGfuccgcsgsc
466
GCGCGGACATGGAGGACGTGCGC
601

csgsgacaUfgGfAfGfgacgugcgcuL96
332
asGfscgcAfcGfUfccucCfaUfguccgscsg
467
CGCGGACATGGAGGACGTGCGCG
602

gsgsacauGfgAfGfGfacgugcgcguL96
333
asCfsgcgCfaCfGfuccuCfcAfuguccsgsc
468
GCGGACATGGAGGACGTGCGCGG
603

gsascaugGfaGfGfAfcgugcgcgguL96
334
asCfscgcGfcAfCfguccUfcCfaugucscsg
469
CGGACATGGAGGACGTGCGCGGC
604

ascsauggAfgGfAfCfgugcgcggcuL96
335
asGfsccgCfgCfAfcgucCfuCfcauguscsc
470
GGACATGGAGGACGTGCGCGGCC
605

csasuggaGfgAfCfGfugcgcggccuL96
336
asGfsgccGfcGfCfacguCfcUfccaugsusc
471
GACATGGAGGACGTGCGCGGCCG
606

asusggagGfaCfGfUfgcgcggccguL96
337
asCfsggcCfgCfGfcacgUfcCfuccausgsu
472
ACATGGAGGACGTGCGCGGCCGC
607

usgsgaggAfcGfUfGfcgcggccgcuL96
338
asGfscggCfcGfCfgcacGfuCfcuccasusg
473
CATGGAGGACGTGCGCGGCCGCC
608

gsgsaggaCfgUfGfCfgcggccgccuL96
339
asGfsgcgGfcCfGfcgcaCfgUfccuccsasu
474
ATGGAGGACGTGCGCGGCCGCCT
609

gsasggacGfuGfCfGfcggccgccuuL96
340
asAfsggcGfgCfCfgcgcAfcGfuccucscsa
475
TGGAGGACGTGCGCGGCCGCCTG
610

asgsgacgUfgCfGfCfggccgccuguL96
341
asCfsaggCfgGfCfcgcgCfaCfguccuscsc
476
GGAGGACGTGCGCGGCCGCCTGG
611

gsgsacguGfcGfCfGfgccgccugguL96
342
asCfscagGfcGfGfccgcGfcAfcguccsusc
477
GAGGACGTGCGCGGCCGCCTGGT
612

gsascgugCfgCfGfGfccgccugguuL96
343
asAfsccaGfgCfGfgccgCfgCfacgucscsu
478
AGGACGTGCGCGGCCGCCTGGTG
613

ascsgugcGfcGfGfCfcgccugguguL96
344
asCfsaccAfgGfCfggccGfcGfcacguscsc
479
GGACGTGCGCGGCCGCCTGGTGC
614

csgsugcgCfgGfCfCfgccuggugcuL96
345
asGfscacCfaGfGfcggcCfgCfgcacgsusc
480
GACGTGCGCGGCCGCCTGGTGCA
615

gsusgcgcGfgCfCfGfccuggugcauL96
346
asUfsgcaCfcAfGfgcggCfcGfcgcacsgsu
481
ACGTGCGCGGCCGCCTGGTGCAG
616

gscsggccGfcCfUfGfgugcaguacuL96
347
asGfsuacUfgCfAfccagGfcGfgccgcsasc
482
GTGCGGCCGCCTGGTGCAGTACC
617

csgsccugGfuGfCfAfguaccgcgguL96
348
asCfscgcGfgUfAfcugcAfcCfaggcgsgsc
483
GCCGCCTGGTGCAGTACCGCGGC
618

gsasggugCfaGfGfCfcaugcucgguL96
349
asCfscgaGfcAfUfggccUfgCfaccucsgsc
484
GCGAGGTGCAGGCCATGCTCGGC
619

gscscaugCfuCfGfGfccagagcacuL96
350
asGfsugcUfcUfGfgccgAfgCfauggcscsu
485
AGGCCATGCTCGGCCAGAGCACC
620

gsgsccagAfgCfAfCfcgaggagcuuL96
351
asAfsgcuCfcUfCfggugCfuCfuggccsgsa
486
TCGGCCAGAGCACCGAGGAGCTG
621

gscsugcgGfgUfGfCfgccucgccuuL96
352
asAfsggcGfaGfGfcgcaCfcCfgcagcsusc
487
GAGCTGCGGGTGCGCCTCGCCTC
622

gsusgcgcCfuCfGfCfcucccaccuuL96
353
asAfsgguGfgGfAfggcgAfgGfcgcacscsc
488
GGGTGCGCCTCGCCTCCCACCTG
623

csgsccucCfcAfCfCfugcgcaagcuL96
354
asGfscuuGfcGfCfagguGfgGfaggcgsasg
489
CTCGCCTCCCACCTGCGCAAGCT
624

cscscaccUfgCfGfCfaagcugcguuL96
355
asAfscgcAfgCfUfugcgCfaGfgugggsasg
490
CTCCCACCTGCGCAAGCTGCGTA
625

csusgcgcAfaGfCfUfgcguaagcguL96
356
asCfsgcuUfaCfGfcagcUfuGfcgcagsgsu
491
ACCTGCGCAAGCTGCGTAAGCGG
626

asasgcugCfgUfAfAfgcggcuccuuL96
357
asAfsggaGfcCfGfcuuaCfgCfagcuusgsc
492
GCAAGCTGCGTAAGCGGCTCCTC
627

gsusaagcGfgCfUfCfcuccgcgauuL96
358
asAfsucgCfgGfAfggagCfcGfcuuacsgsc
493
GCGTAAGCGGCTCCTCCGCGATG
628

gsgscuccUfcCfGfCfgaugccgauuL96
359
asAfsucgGfcAfUfcgcgGfaGfgagccsgsc
494
GCGGCTCCTCCGCGATGCCGATG
629

csusccgcGfaUfGfCfcgaugaccuuL96
360
asAfsgguCfaUfCfggcaUfcGfcggagsgsa
495
TCCTCCGCGATGCCGATGACCTG
630

gsasugccGfaUfGfAfccugcagaauL96
361
asUfsucuGfcAfGfgucaUfcGfgcaucsgsc
496
GCGATGCCGATGACCTGCAGAAG
631

gsasugacCfuGfCfAfgaagcgccuuL96
362
asAfsggcGfcUfUfcugcAfgGfucaucsgsg
497
CCGATGACCTGCAGAAGCGCCTG
632

csusgcagAfaGfCfGfccuggcaguuL96
363
asAfscugCfcAfGfgcgcUfuCfugcagsgsu
498
ACCTGCAGAAGCGCCTGGCAGTG
633

asasgcgcCfuGfGfCfaguguaccauL96
364
asUfsgguAfcAfCfugccAfgGfcgcuuscsu
499
AGAAGCGCCTGGCAGTGTACCAG
634

csusggcaGfuGfUfAfccaggccgguL96
365
asCfscggCfcUfGfguacAfcUfgccagsgsc
500
GCCTGGCAGTGTACCAGGCCGGG
635

gsasgcgcGfgCfCfUfcagcgccauuL96
366
asAfsuggCfgCfUfgaggCfcGfcgcucsgsg
501
CCGAGCGCGGCCTCAGCGCCATC
636

csgsgccuCfaGfCfGfccauccgcguL96
367
asCfsgcgGfaUfGfgcgcUfgAfggccgscsg
502
CGCGGCCTCAGCGCCATCCGCGA
637

asgscgccAfuCfCfGfcgagcgccuuL96
368
asAfsggcGfcUfCfgcggAfuGfgcgcusgsa
503
TCAGCGCCATCCGCGAGCGCCTG
638

usgsgggcCfcCfUfGfguggaacaguL96
369
asCfsuguUfcCfAfccagGfgGfccccasgsg
504
CCTGGGGCCCCTGGTGGAACAGG
639

cscsccugGfuGfGfAfacagggccguL96
370
asCfsggcCfcUfGfuuccAfcCfaggggscsc
505
GGCCCCTGGTGGAACAGGGCCGC
640

csgscgugCfgGfGfCfcgccacuguuL96
371
asAfscagUfgGfCfggccCfgCfacgcgsgsc
506
GCCGCGTGCGGGCCGCCACTGTG
641

gscscgccAfcUfGfUfgggcucccuuL96
372
asAfsgggAfgCfCfcacaGfuGfgcggcscsc
507
GGGCCGCCACTGTGGGCTCCCTG
642

cscsuggcCfgGfCfCfagccgcuacuL96
373
asGfsuagCfgGfCfuggcCfgGfccaggsgsa
508
TCCCTGGCCGGCCAGCCGCTACA
643

gsgsccagCfcGfCfUfacaggagcguL96
374
asCfsgcuCfcUfGfuagcGfgCfuggccsgsg
509
CCGGCCAGCCGCTACAGGAGCGG
644

gscscgcuAfcAfGfGfagcgggcccuL96
375
asGfsggcCfcGfCfuccuGfuAfgcggcsusg
510
CAGCCGCTACAGGAGCGGGCCCA
645

gscsgcggAfuGfGfAfggagauggguL96
376
asCfsccaUfcUfCfcuccAfuCfcgcgcsgsc
511
GCGCGCGGATGGAGGAGATGGGC
646

csgscgacCfgCfCfUfggacgagguuL96
377
asAfsccuCfgUfCfcaggCfgGfucgcgsgsg
512
CCCGCGACCGCCTGGACGAGGTG
647

gscscuggAfcGfAfGfgugaaggaguL96
378
asCfsuccUfuCfAfccucGfuCfcaggcsgsg
513
CCGCCTGGACGAGGTGAAGGAGC
648

gsascgagGfuGfAfAfggagcagguuL96
379
asAfsccuGfcUfCfcuucAfcCfucgucscsa
514
TGGACGAGGTGAAGGAGCAGGTG
649

gsgsagguGfcGfCfGfccaagcugguL96
380
asCfscagCfuUfGfgcgcGfcAfccuccsgsc
515
GCGGAGGTGCGCGCCAAGCTGGA
650

csgscgccAfaGfCfUfggaggagcauL96
381
asUfsgcuCfcUfCfcagcUfuGfgcgcgscsa
516
TGCGCGCCAAGCTGGAGGAGCAG
651

csasggccCfaGfCfAfgauacgccuuL96
382
asAfsggcGfuAfUfcugcUfgGfgccugscsu
517
AGCAGGCCCAGCAGATACGCCTG
652

cscsagcaGfaUfAfCfgccugcagguL96
383
asCfscugCfaGfGfcguaUfcUfgcuggsgsc
518
GCCCAGCAGATACGCCTGCAGGC
653

csgsccugCfaGfGfCfcgaggccuuuL96
384
asAfsaggCfcUfCfggccUfgCfaggcgsusa
519
TACGCCTGCAGGCCGAGGCCTTC
654

gscsaggcCfgAfGfGfccuuccagguL96
385
asCfscugGfaAfGfgccuCfgGfccugcsasg
520
CTGCAGGCCGAGGCCTTCCAGGC
655

cscsgaggCfcUfUfCfcaggcccgcuL96
386
asGfscggGfcCfUfggaaGfgCfcucggscsc
521
GGCCGAGGCCTTCCAGGCCCGCC
656

gscscuucCfaGfGfCfccgccucaauL96
387
asUfsugaGfgCfGfggccUfgGfaaggcscsu
522
AGGCCTTCCAGGCCCGCCTCAAG
657

cscsaggcCfcGfCfCfucaagagcuuL96
388
asAfsgcuCfuUfGfaggcGfgGfccuggsasa
523
TTCCAGGCCCGCCTCAAGAGCTG
658

cscsgccuCfaAfGfAfgcugguucguL96
389
asCfsgaaCfcAfGfcucuUfgAfggcggsgsc
524
GCCCGCCTCAAGAGCTGGTTCGA
659

csasagagCfuGfGfUfucgagccccuL96
390
asGfsgggCfuCfGfaaccAfgCfucuugsasg
525
CTCAAGAGCTGGTTCGAGCCCCT
660

asgsccccUfgGfUfGfgaagacauguL96
391
asCfsaugUfcUfUfccacCfaGfgggcuscsg
526
CGAGCCCCTGGTGGAAGACATGC
661

csusggugGfaAfGfAfcaugcagcguL96
392
asCfsgcuGfcAfUfgucuUfcCfaccagsgsg
527
CCCTGGTGGAAGACATGCAGCGC
662

gsgsaagaCfaUfGfCfagcgccaguuL96
393
asAfscugGfcGfCfugcaUfgUfcuuccsasc
528
GTGGAAGACATGCAGCGCCAGTG
663

gscscgggCfuGfGfUfggagaagguuL96
394
asAfsccuUfcUfCfcaccAfgCfccggcscsc
529
GGGCCGGGCTGGTGGAGAAGGTG
664

gscsugguGfgAfGfAfaggugcagguL96
395
asCfscugCfaCfCfuucuCfcAfccagcscsc
530
GGGCTGGTGGAGAAGGTGCAGGC
665

ascscagcGfcCfGfCfcccugugccuL96
396
asGfsgcaCfaGfGfggcgGfcGfcuggusgsc
531
GCACCAGCGCCGCCCCTGTGCCC
666

gscscccuGfuGfCfCfcagcgacaauL96
397
asUfsuguCfgCfUfgggcAfcAfggggcsgsg
532
CCGCCCCTGTGCCCAGCGACAAT
667

usgsugccCfaGfCfGfacaaucacuuL96
398
asAfsgugAfuUfGfucgcUfgGfgcacasgsg
533
CCTGTGCCCAGCGACAATCACTG
668

csasgcgaCfaAfUfCfacugaacgcuL96
399
asGfscguUfcAfGfugauUfgUfcgcugsgsg
534
CCCAGCGACAATCACTGAACGCC
669

csasaucaCfuGfAfAfcgccgaagcuL96
400
asGfscuuCfgGfCfguucAfgUfgauugsusc
535
GACAATCACTGAACGCCGAAGCC
670

ascsugaaCfgCfCfGfaagccugcauL96
401
asUfsgcaGfgCfUfucggCfgUfucagusgsa
536
TCACTGAACGCCGAAGCCTGCAG
671

ascsgccgAfaGfCfCfugcagccauuL96
402
asAfsuggCfuGfCfaggcUfuCfggcgususc
537
GAACGCCGAAGCCTGCAGCCATG
672

gsasagccUfgCfAfGfccaugcgacuL96
403
asGfsucgCfaUfGfgcugCfaGfgcuucsgsg
538
CCGAAGCCTGCAGCCATGCGACC
673

usgscagcCfaUfGfCfgaccccacguL96
404
asCfsgugGfgGfUfcgcaUfgGfcugcasgsg
539
CCTGCAGCCATGCGACCCCACGC
674

gscsgaccCfcAfCfGfccaccccguuL96
405
asAfscggGfgUfGfgcguGfgGfgucgcsasu
540
ATGCGACCCCACGCCACCCCGTG
675

cscscacgCfcAfCfCfccgugccucuL96
406
asGfsaggCfaCfGfggguGfgCfgugggsgsu
541
ACCCCACGCCACCCCGTGCCTCC
676

cscsacccCfgUfGfCfcuccugccuuL96
407
asAfsggcAfgGfAfggcaCfgGfgguggscsg
542
CGCCACCCCGTGCCTCCTGCCTC
677

csgsugccUfcCfUfGfccuccgcgcuL96
408
asGfscgcGfgAfGfgcagGfaGfgcacgsgsg
543
CCCGTGCCTCCTGCCTCCGCGCA
678

csusccugCfcUfCfCfgcgcagccuuL96
409
asAfsggcUfgCfGfcggaGfgCfaggagsgsc
544
GCCTCCTGCCTCCGCGCAGCCTG
679

gscscuccGfcGfCfAfgccugcagcuL96
410
asGfscugCfaGfGfcugcGfcGfgaggcsasg
545
CTGCCTCCGCGCAGCCTGCAGCG
680

cscsugucCfcCfGfCfcccagccguuL96
411
asAfscggCfuGfGfggcgGfgGfacaggsgsu
546
ACCCTGTCCCCGCCCCAGCCGTC
681

cscscgccCfcAfGfCfcguccuccuuL96
412
asAfsggaGfgAfCfggcuGfgGfgcgggsgsa
547
TCCCCGCCCCAGCCGTCCTCCTG
682

cscscagcCfgUfCfCfuccugggguuL96
413
asAfscccCfaGfGfaggaCfgGfcugggsgsc
548
GCCCCAGCCGTCCTCCTGGGGTG
683

uscscuggGfgUfGfGfacccuaguuuL96
414
asAfsacuAfgGfGfuccaCfcCfcaggasgsg
549
CCTCCTGGGGTGGACCCTAGTTT
684

gsgsguggAfcCfCfUfaguuuaauauL96
415
asUfsauuAfaAfCfuaggGfuCfcacccscsa
550
TGGGGTGGACCCTAGTTTAATAA
685

gsascccuAfgUfUfUfaauaaagauuL96
416
asAfsucuUfuAfUfuaaaCfuAfgggucscsa
551
TGGACCCTAGTTTAATAAAGATT
686

usasguuuAfaUfAfAfagauucaccuL96
417
asGfsgugAfaUfCfuuuaUfuAfaacuasgsg
552
CCTAGTTTAATAAAGATTCACCA
687

usasauaaAfgAfUfUfcaccaaguuuL96
418
asAfsacuUfgGfUfgaauCfuUfuauuasasa
553
TTTAATAAAGATTCACCAAGTTT
688

asgsauucAfcCfAfAfguuucacgcuL96
419
asGfscguGfaAfAfcuugGfuGfaaucususu
554
AAAGATTCACCAAGTTTCACGCA
689

TABLE 4

APOE Unmodified Sense and Antisense Strand Sequences

Sense Strand
SEQ ID
Antisense Strand
SEQ ID

Duplex ID
Sequence 5′ to 3′
NO:
Sequence 5′ to 3′
NO:

AD-1072375.1
GGAGUUGAAGGCCUACAAAUU
49
AAUUUGUAGGCCUUCAACUCCUU
184

AD-1072352.1
GCGCUGAUGGACGAGACCAUU
46
AAUGGUCUCGUCCAUCAGCGCCC
181

AD-1072394.1
UCGGAACUGGAGGAACAACUU
52
AAGUUGUUCCUCCAGUUCCGAUU
187

AD-1072721.1
ACGCCGAAGCCUGCAGCCAUU
132
AAUGGCUGCAGGCUUCGGCGUUC
267

AD-1072254.1
CACUGGGUCGCUUUUGGGAUU
35
AAUCCCAAAAGCGACCCAGUGCC
170

AD-1072189.1
AAGGUGGAGCAAGCGGUGGAU
26
AUCCACCGCUUGCUCCACCUUGG
161

AD-1072741.1
GACCCUAGUUUAAUAAAGAUU
146
AAUCUUUAUUAAACUAGGGUCCA
281

AD-1072382.1
AAGGCCUACAAAUCGGAACUU
50
AAGUUCCGAUUUGUAGGCCUUCA
185

AD-1072129.1
AGGAAGAUGAAGGUUCUGUGU
17
ACACAGAACCUUCAUCUUCCUGC
152

AD-1072514.1
CUCCGCGAUGCCGAUGACCUU
90
AAGGUCAUCGGCAUCGCGGAGGA
225

AD-1072124.1
CAGGCAGGAAGAUGAAGGUUU
16
AAACCUUCAUCUUCCUGCCUGUG
151

AD-1072337.1
ACCCAGGAACUGAGGGCGCUU
44
AAGCGCCCUCAGUUCCUGGGUGA
179

AD-1072135.1
AUGAAGGUUCUGUGGGCUGCU
18
AGCAGCCCACAGAACCUUCAUCU
153

AD-1072745.1
UAGUUUAAUAAAGAUUCACCU
147
AGGUGAAUCUUUAUUAAACUAGG
282

AD-1072153.1
GCGUUGCUGGUCACAUUCCUU
21
AAGGAAUGUGACCAGCAACGCAG
156

AD-1072520.1
GAUGCCGAUGACCUGCAGAAU
91
AUUCUGCAGGUCAUCGGCAUCGC
226

AD-1072389.1
ACAAAUCGGAACUGGAGGAAU
51
AUUCCUCCAGUUCCGAUUUGUAG
186

AD-1072716.1
ACUGAACGCCGAAGCCUGCAU
131
AUGCAGGCUUCGGCGUUCAGUGA
266

AD-1072222.1
CCAGCAGACCGAGUGGCAGAU
31
AUCUGCCACUCGGUCUGCUGGCG
166

AD-1072367.1
ACCAUGAAGGAGUUGAAGGCU
48
AGCCUUCAACUCCUUCAUGGUCU
183

AD-1103894.1
AGAUUCACCAAGUUUCACGCU
149
AGCGUGAAACUUGGUGAAUCUUU
284

AD-1072651.1
GCCUUCCAGGCCCGCCUCAAU
117
AUUGAGGCGGGCCUGGAAGGCCU
252

AD-1072260.1
GUCGCUUUUGGGAUUACCUGU
36
ACAGGUAAUCCCAAAAGCGACCC
171

AD-1072265.1
UUUUGGGAUUACCUGCGCUGU
37
ACAGCGCAGGUAAUCCCAAAAGC
172

AD-1072750.1
UAAUAAAGAUUCACCAAGUUU
148
AAACUUGGUGAAUCUUUAUUAAA
283

AD-1072142.1
UUCUGUGGGCUGCGUUGCUGU
19
ACAGCAACGCAGCCCACAGAACC
154

AD-1072328.1
UCCCAGGUCACCCAGGAACUU
43
AAGUUCCUGGGUGACCUGGGAGC
178

AD-1072198.1
CAAGCGGUGGAGACAGAGCCU
27
AGGCUCUGUCUCCACCGCUUGCU
162

AD-1072361.1
GACGAGACCAUGAAGGAGUUU
47
AAACUCCUUCAUGGUCUCGUCCA
182

AD-1072526.1
GAUGACCUGCAGAAGCGCCUU
92
AAGGCGCUUCUGCAGGUCAUCGG
227

AD-1072699.1
UGUGCCCAGCGACAAUCACUU
128
AAGUGAUUGUCGCUGGGCACAGG
263

AD-1072711.1
CAAUCACUGAACGCCGAAGCU
130
AGCUUCGGCGUUCAGUGAUUGUC
265

AD-1103879.1
CAAGAGCUGGUUCGAGCCCCU
120
AGGGGCUCGAACCAGCUCUUGAG
255

AD-1103849.1
GAGGAACAACUGACCCCGGUU
53
AACCGGGGUCAGUUGUUCCUCCA
188

AD-1072662.1
CCGCCUCAAGAGCUGGUUCGU
119
ACGAACCAGCUCUUGAGGCGGGC
254

AD-1103883.1
UGCAGCCAUGCGACCCCACGU
134
ACGUGGGGUCGCAUGGCUGCAGG
269

AD-1072172.1
UGGCAGGAUGCCAGGCCAAGU
24
ACUUGGCCUGGCAUCCUGCCAGG
159

AD-1072158.1
GCUGGUCACAUUCCUGGCAGU
22
ACUGCCAGGAAUGUGACCAGCAA
157

AD-1072705.1
CAGCGACAAUCACUGAACGCU
129
AGCGUUCAGUGAUUGUCGCUGGG
264

AD-1072147.1
UGGGCUGCGUUGCUGGUCACU
20
AGUGACCAGCAACGCAGCCCACA
155

AD-1072593.1
GACGAGGUGAAGGAGCAGGUU
109
AACCUGCUCCUUCACCUCGUCCA
244

AD-1072115.1
GGCCAAUCACAGGCAGGAAGU
15
ACUUCCUGCCUGUGAUUGGCCAG
150

AD-1072289.1
CAGACACUGUCUGAGCAGGUU
40
AACCUGCUCAGACAGUGUCUGCA
175

AD-1072283.1
UGGGUGCAGACACUGUCUGAU
39
AUCAGACAGUGUCUGCACCCAGC
174

AD-1103871.1
CGGCCUCAGCGCCAUCCGCGU
97
ACGCGGAUGGCGCUGAGGCCGCG
232

AD-1072183.1
CAGGCCAAGGUGGAGCAAGCU
25
AGCUUGCUCCACCUUGGCCUGGC
160

AD-1072667.1
CUGGUGGAAGACAUGCAGCGU
122
ACGCUGCAUGUCUUCCACCAGGG
257

AD-1072614.1
CGCGCCAAGCUGGAGGAGCAU
111
AUGCUCCUCCAGCUUGGCGCGCA
246

AD-1072632.1
CAGGCCCAGCAGAUACGCCUU
112
AAGGCGUAUCUGCUGGGCCUGCU
247

AD-1072211.1
CCCGAGCUGCGCCAGCAGACU
29
AGUCUGCUGGCGCAGCUCGGGCU
164

AD-1072406.1
GCACGGCUGUCCAAGGAGCUU
55
AAGCUCCUUGGACAGCCGUGCCC
190

AD-1103882.1
GCCCCUGUGCCCAGCGACAAU
127
AUUGUCGCUGGGCACAGGGGCGG
262

AD-1103855.1
GACAUGGAGGACGUGCGCGGU
64
ACCGCGCACGUCCUCCAUGUCCG
199

AD-1072726.1
GAAGCCUGCAGCCAUGCGACU
133
AGUCGCAUGGCUGCAGGCUUCGG
268

AD-1103893.1
UCCUGGGGUGGACCCUAGUUU
144
AAACUAGGGUCCACCCCAGGAGG
279

AD-1072736.1
GGGUGGACCCUAGUUUAAUAU
145
AUAUUAAACUAGGGUCCACCCCA
280

AD-1072426.1
GCGGACAUGGAGGACGUGUGU
60
ACACACGUCCUCCAUGUCCGCGC
195

AD-1072506.1
GUAAGCGGCUCCUCCGCGAUU
88
AAUCGCGGAGGAGCCGCUUACGC
223

AD-1072248.1
AACUGGCACUGGGUCGCUUUU
34
AAAAGCGACCCAGUGCCAGUUCC
169

AD-1072203.1
GGUGGAGACAGAGCCGGAGCU
28
AGCUCCGGCUCUGUCUCCACCGC
163

AD-1103888.1
CUCCUGCCUCCGCGCAGCCUU
139
AAGGCUGCGCGGAGGCAGGAGGC
274

AD-1072243.1
CUGGGAACUGGCACUGGGUCU
33
AGACCCAGUGCCAGUUCCCAGCG
168

AD-1103886.1
CCACCCCGUGCCUCCUGCCUU
137
AAGGCAGGAGGCACGGGGUGGCG
272

AD-1072347.1
UGAGGGCGCUGAUGGACGAGU
45
ACUCGUCCAUCAGCGCCCUCAGU
180

AD-1072411.1
GCUGUCCAAGGAGCUGCAGGU
56
ACCUGCAGCUCCUUGGACAGCCG
191

AD-1072319.1
CUGCUCAGCUCCCAGGUCACU
42
AGUGACCUGGGAGCUGAGCAGCU
177

AD-1103885.1
CCCACGCCACCCCGUGCCUCU
136
AGAGGCACGGGGUGGCGUGGGGU
271

AD-1072488.1
CCCACCUGCGCAAGCUGCGUU
85
AACGCAGCUUGCGCAGGUGGGAG
220

AD-1072532.1
CUGCAGAAGCGCCUGGCAGUU
93
AACUGCCAGGCGCUUCUGCAGGU
228

AD-1072493.1
CUGCGCAAGCUGCGUAAGCGU
86
ACGCUUACGCAGCUUGCGCAGGU
221

AD-1072686.1
GCUGGUGGAGAAGGUGCAGGU
125
ACCUGCACCUUCUCCACCAGCCC
260

AD-1072656.1
CCAGGCCCGCCUCAAGAGCUU
118
AAGCUCUUGAGGCGGGCCUGGAA
253

AD-1103851.1
CGCGGACAUGGAGGACGUGCU
59
AGCACGUCCUCCAUGUCCGCGCC
194

AD-1072216.1
GCUGCGCCAGCAGACCGAGUU
30
AACUCGGUCUGCUGGCGCAGCUC
165

AD-1072455.1
GAGGUGCAGGCCAUGCUCGGU
79
ACCGAGCAUGGCCUGCACCUCGC
214

AD-1072581.1
CGCGACCGCCUGGACGAGGUU
107
AACCUCGUCCAGGCGGUCGCGGG
242

AD-1072499.1
AAGCUGCGUAAGCGGCUCCUU
87
AAGGAGCCGCUUACGCAGCUUGC
222

AD-1103854.1
GGACAUGGAGGACGUGCGCGU
63
ACGCGCACGUCCUCCAUGUCCGC
198

AD-1072672.1
GGAAGACAUGCAGCGCCAGUU
123
AACUGGCGCUGCAUGUCUUCCAC
258

AD-1072644.1
CGCCUGCAGGCCGAGGCCUUU
114
AAAGGCCUCGGCCUGCAGGCGUA
249

AD-1103850.1
GCCCGGCUGGGCGCGGACAUU
57
AAUGUCCGCGCCCAGCCGGGCCU
192

AD-1103875.1
CGCGUGCGGGCCGCCACUGUU
101
AACAGUGGCGGCCCGCACGCGGC
236

AD-1072401.1
CGCGGGCACGGCUGUCCAAGU
54
ACUUGGACAGCCGUGCCCGCGUC
189

AD-1072438.1
CGCCUGGUGCAGUACCGCGGU
78
ACCGCGGUACUGCACCAGGCGGC
213

AD-1072310.1
CAGGAGGAGCUGCUCAGCUCU
41
AGAGCUGAGCAGCUCCUCCUGCA
176

AD-1072277.1
CUGCGCUGGGUGCAGACACUU
38
AAGUGUCUGCACCCAGCGCAGGU
173

AD-1103852.1
GCGGACAUGGAGGACGUGCGU
61
ACGCACGUCCUCCAUGUCCGCGC
196

AD-1072483.1
CGCCUCCCACCUGCGCAAGCU
84
AGCUUGCGCAGGUGGGAGGCGAG
219

AD-1072569.1
GCGCGGAUGGAGGAGAUGGGU
106
ACCCAUCUCCUCCAUCCGCGCGC
241

AD-1072473.1
GGCCAGAGCACCGAGGAGCUU
81
AAGCUCCUCGGUGCUCUGGCCGA
216

AD-1103868.1
GCUGCGGGUGCGCCUCGCCUU
82
AAGGCGAGGCGCACCCGCAGCUC
217

AD-1103858.1
AUGGAGGACGUGCGCGGCCGU
67
ACGGCCGCGCACGUCCUCCAUGU
202

AD-1103857.1
CAUGGAGGACGUGCGCGGCCU
66
AGGCCGCGCACGUCCUCCAUGUC
201

AD-1103861.1
GAGGACGUGCGCGGCCGCCUU
70
AAGGCGGCCGCGCACGUCCUCCA
205

AD-1103891.1
CCCGCCCCAGCCGUCCUCCUU
142
AAGGAGGACGGCUGGGGCGGGGA
277

AD-1103870.1
GAGCGCGGCCUCAGCGCCAUU
96
AAUGGCGCUGAGGCCGCGCUCGG
231

AD-1103867.1
GUGCGCGGCCGCCUGGUGCAU
76
AUGCACCAGGCGGCCGCGCACGU
211

AD-1072433.1
GCGGCCGCCUGGUGCAGUACU
77
AGUACUGCACCAGGCGGCCGCAC
212

AD-1103872.1
AGCGCCAUCCGCGAGCGCCUU
98
AAGGCGCUCGCGGAUGGCGCUGA
233

AD-1103889.1
GCCUCCGCGCAGCCUGCAGCU
140
AGCUGCAGGCUGCGCGGAGGCAG
275

AD-1103864.1
GACGUGCGCGGCCGCCUGGUU
73
AACCAGGCGGCCGCGCACGUCCU
208

AD-1072464.1
GCCAUGCUCGGCCAGAGCACU
80
AGUGCUCUGGCCGAGCAUGGCCU
215

AD-1103862.1
AGGACGUGCGCGGCCGCCUGU
71
ACAGGCGGCCGCGCACGUCCUCC
206

AD-1072637.1
CCAGCAGAUACGCCUGCAGGU
113
ACCUGCAGGCGUAUCUGCUGGGC
248

AD-1072420.1
CUGGGCGCGGACAUGGAGGAU
58
AUCCUCCAUGUCCGCGCCCAGCC
193

AD-1072238.1
CAGCGCUGGGAACUGGCACUU
32
AAGUGCCAGUUCCCAGCGCUGGC
167

AD-1103866.1
CGUGCGCGGCCGCCUGGUGCU
75
AGCACCAGGCGGCCGCGCACGUC
210

AD-1103873.1
UGGGGCCCCUGGUGGAACAGU
99
ACUGUUCCACCAGGGGCCCCAGG
234

AD-1103869.1
GUGCGCCUCGCCUCCCACCUU
83
AAGGUGGGAGGCGAGGCGCACCC
218

AD-1072588.1
GCCUGGACGAGGUGAAGGAGU
108
ACUCCUUCACCUCGUCCAGGCGG
243

AD-1072544.1
CUGGCAGUGUACCAGGCCGGU
95
ACCGGCCUGGUACACUGCCAGGC
230

AD-1103859.1
UGGAGGACGUGCGCGGCCGCU
68
AGCGGCCGCGCACGUCCUCCAUG
203

AD-1103853.1
CGGACAUGGAGGACGUGCGCU
62
AGCGCACGUCCUCCAUGUCCGCG
197

AD-1103856.1
ACAUGGAGGACGUGCGCGGCU
65
AGCCGCGCACGUCCUCCAUGUCC
200

AD-1072607.1
GGAGGUGCGCGCCAAGCUGGU
110
ACCAGCUUGGCGCGCACCUCCGC
245

AD-1103860.1
GGAGGACGUGCGCGGCCGCCU
69
AGGCGGCCGCGCACGUCCUCCAU
204

AD-1103884.1
GCGACCCCACGCCACCCCGUU
135
AACGGGGUGGCGUGGGGUCGCAU
270

AD-1072551.1
GCCGCCACUGUGGGCUCCCUU
102
AAGGGAGCCCACAGUGGCGGCCC
237

AD-1103874.1
CCCCUGGUGGAACAGGGCCGU
100
ACGGCCCUGUUCCACCAGGGGCC
235

AD-1103890.1
CCUGUCCCCGCCCCAGCCGUU
141
AACGGCUGGGGCGGGGACAGGGU
276

AD-1103881.1
ACCAGCGCCGCCCCUGUGCCU
126
AGGCACAGGGGCGGCGCUGGUGC
261

AD-1103887.1
CGUGCCUCCUGCCUCCGCGCU
138
AGCGCGGAGGCAGGAGGCACGGG
273

AD-1103863.1
GGACGUGCGCGGCCGCCUGGU
72
ACCAGGCGGCCGCGCACGUCCUC
207

AD-1072509.1
GGCUCCUCCGCGAUGCCGAUU
89
AAUCGGCAUCGCGGAGGAGCCGC
224

AD-1103892.1
CCCAGCCGUCCUCCUGGGGUU
143
AACCCCAGGAGGACGGCUGGGGC
278

AD-1103877.1
GCCGCUACAGGAGCGGGCCCU
105
AGGGCCCGCUCCUGUAGCGGCUG
240

AD-1103865.1
ACGUGCGCGGCCGCCUGGUGU
74
ACACCAGGCGGCCGCGCACGUCC
209

AD-1072649.1
GCAGGCCGAGGCCUUCCAGGU
115
ACCUGGAAGGCCUCGGCCUGCAG
250

AD-1103880.1
AGCCCCUGGUGGAAGACAUGU
121
ACAUGUCUUCCACCAGGGGCUCG
256

AD-1103878.1
CCGAGGCCUUCCAGGCCCGCU
116
AGCGGGCCUGGAAGGCCUCGGCC
251

AD-1072163.1
UCACAUUCCUGGCAGGAUGCU
23
AGCAUCCUGCCAGGAAUGUGACC
158

AD-1072681.1
GCCGGGCUGGUGGAGAAGGUU
124
AACCUUCUCCACCAGCCCGGCCC
259

AD-1072559.1
GGCCAGCCGCUACAGGAGCGU
104
ACGCUCCUGUAGCGGCUGGCCGG
239

AD-1072538.1
AAGCGCCUGGCAGUGUACCAU
94
AUGGUACACUGCCAGGCGCUUCU
229

AD-1103876.1
CCUGGCCGGCCAGCCGCUACU
103
AGUAGCGGCUGGCCGGCCAGGGA
238

TABLE 5

APOE Modified Duplex Sequences

SEQ ID

SEQ ID

Duplex ID
Sense Strand Sequence 5′ to 3′
NO:
Antisense Strand Sequence 5′ to 3′
NO:

AD-1072375.1
gsgsaguuGfaAfGfGfccuacaaauu(L96)
319
asAfsuuuGfuAfGfgccuUfcAfacuccsusu
454

AD-1072352.1
gscsgcugAfuGfGfAfcgagaccauu(L96)
316
asAfsuggUfcUfCfguccAfuCfagcgcscsc
451

AD-1072394.1
uscsggaaCfuGfGfAfggaacaacuu(L96)
322
asAfsguuGfuUfCfcuccAfgUfuccgasusu
457

AD-1072721.1
ascsgccgAfaGfCfCfugcagccauu(L96)
402
asAfsuggCfuGfCfaggcUfuCfggcgususc
537

AD-1072254.1
csascuggGfuCfGfCfuuuugggauu(L96)
305
asAfsuccCfaAfAfagcgAfcCfcagugscsc
440

AD-1072189.1
asasggugGfaGfCfAfagcgguggau(L96)
296
asUfsccaCfcGfCfuugcUfcCfaccuusgsg
431

AD-1072741.1
gsascccuAfgUfUfUfaauaaagauu(L96)
416
asAfsucuUfuAfUfuaaaCfuAfgggucscsa
551

AD-1072382.1
asasggccUfaCfAfAfaucggaacuu(L96)
320
asAfsguuCfcGfAfuuugUfaGfgccuuscsa
455

AD-1072129.1
asgsgaagAfuGfAfAfgguucugugu(L96)
287
asCfsacaGfaAfCfcuucAfuCfuuccusgsc
422

AD-1072514.1
csusccgcGfaUfGfCfcgaugaccuu(L96)
360
asAfsgguCfaUfCfggcaUfcGfcggagsgsa
495

AD-1072124.1
csasggcaGfgAfAfGfaugaagguuu(L96)
286
asAfsaccUfuCfAfucuuCfcUfgccugsusg
421

AD-1072337.1
ascsccagGfaAfCfUfgagggcgcuu(L96)
314
asAfsgcgCfcCfUfcaguUfcCfugggusgsa
449

AD-1072135.1
asusgaagGfuUfCfUfgugggcugcu(L96)
288
asGfscagCfcCfAfcagaAfcCfuucauscsu
423

AD-1072745.1
usasguuuAfaUfAfAfagauucaccu(L96)
417
asGfsgugAfaUfCfuuuaUfuAfaacuasgsg
552

AD-1072153.1
gscsguugCfuGfGfUfcacauuccuu(L96)
291
asAfsggaAfuGfUfgaccAfgCfaacgcsasg
426

AD-1072520.1
gsasugccGfaUfGfAfccugcagaau(L96)
361
asUfsucuGfcAfGfgucaUfcGfgcaucsgsc
496

AD-1072389.1
ascsaaauCfgGfAfAfcuggaggaau(L96)
321
asUfsuccUfcCfAfguucCfgAfuuugusasg
456

AD-1072716.1
ascsugaaCfgCfCfGfaagccugcau(L96)
401
asUfsgcaGfgCfUfucggCfgUfucagusgsa
536

AD-1072222.1
cscsagcaGfaCfCfGfaguggcagau(L96)
301
asUfscugCfcAfCfucggUfcUfgcuggscsg
436

AD-1072367.1
ascscaugAfaGfGfAfguugaaggcu(L96)
318
asGfsccuUfcAfAfcuccUfuCfaugguscsu
453

AD-1103894.1
asgsauucAfcCfAfAfguuucacgcu(L96)
419
asGfscguGfaAfAfcuugGfuGfaaucususu
554

AD-1072651.1
gscscuucCfaGfGfCfccgccucaau(L96)
387
asUfsugaGfgCfGfggccUfgGfaaggcscsu
522

AD-1072260.1
gsuscgcuUfuUfGfGfgauuaccugu(L96)
306
asCfsaggUfaAfUfcccaAfaAfgcgacscsc
441

AD-1072265.1
ususuuggGfaUfUfAfccugcgcugu(L96)
307
asCfsagcGfcAfGfguaaUfcCfcaaaasgsc
442

AD-1072750.1
usasauaaAfgAfUfUfcaccaaguuu(L96)
418
asAfsacuUfgGfUfgaauCfuUfuauuasasa
553

AD-1072142.1
ususcuguGfgGfCfUfgcguugcugu(L96)
289
asCfsagcAfaCfGfcagcCfcAfcagaascsc
424

AD-1072328.1
uscsccagGfuCfAfCfccaggaacuu(L96)
313
asAfsguuCfcUfGfggugAfcCfugggasgsc
448

AD-1072198.1
csasagcgGfuGfGfAfgacagagccu(L96)
297
asGfsgcuCfuGfUfcuccAfcCfgcuugscsu
432

AD-1072361.1
gsascgagAfcCfAfUfgaaggaguuu(L96)
317
asAfsacuCfcUfUfcaugGfuCfucgucscsa
452

AD-1072526.1
gsasugacCfuGfCfAfgaagcgccuu(L96)
362
asAfsggcGfcUfUfcugcAfgGfucaucsgsg
497

AD-1072699.1
usgsugccCfaGfCfGfacaaucacuu(L96)
398
asAfsgugAfuUfGfucgcUfgGfgcacasgsg
533

AD-1072711.1
csasaucaCfuGfAfAfcgccgaagcu(L96)
400
asGfscuuCfgGfCfguucAfgUfgauugsusc
535

AD-1103879.1
csasagagCfuGfGfUfucgagccccu(L96)
390
asGfsgggCfuCfGfaaccAfgCfucuugsasg
525

AD-1103849.1
gsasggaaCfaAfCfUfgaccccgguu(L96)
323
asAfsccgGfgGfUfcaguUfgUfuccucscsa
458

AD-1072662.1
cscsgccuCfaAfGfAfgcugguucgu(L96)
389
asCfsgaaCfcAfGfcucuUfgAfggcggsgsc
524

AD-1103883.1
usgscagcCfaUfGfCfgaccccacgu(L96)
404
asCfsgugGfgGfUfcgcaUfgGfcugcasgsg
539

AD-1072172.1
usgsgcagGfaUfGfCfcaggccaagu(L96)
294
asCfsuugGfcCfUfggcaUfcCfugccasgsg
429

AD-1072158.1
gscsugguCfaCfAfUfuccuggcagu(L96)
292
asCfsugcCfaGfGfaaugUfgAfccagcsasa
427

AD-1072705.1
csasgcgaCfaAfUfCfacugaacgcu(L96)
399
asGfscguUfcAfGfugauUfgUfcgcugsgsg
534

AD-1072147.1
usgsggcuGfcGfUfUfgcuggucacu(L96)
290
asGfsugaCfcAfGfcaacGfcAfgcccascsa
425

AD-1072593.1
gsascgagGfuGfAfAfggagcagguu(L96)
379
asAfsccuGfcUfCfcuucAfcCfucgucscsa
514

AD-1072115.1
gsgsccaaUfcAfCfAfggcaggaagu(L96)
285
asCfsuucCfuGfCfcuguGfaUfuggccsasg
420

AD-1072289.1
csasgacaCfuGfUfCfugagcagguu(L96)
310
asAfsccuGfcUfCfagacAfgUfgucugscsa
445

AD-1072283.1
usgsggugCfaGfAfCfacugucugau(L96)
309
asUfscagAfcAfGfugucUfgCfacccasgsc
444

AD-1103871.1
csgsgccuCfaGfCfGfccauccgcgu(L96)
367
asCfsgcgGfaUfGfgcgcUfgAfggccgscsg
502

AD-1072183.1
csasggccAfaGfGfUfggagcaagcu(L96)
295
asGfscuuGfcUfCfcaccUfuGfgccugsgsc
430

AD-1072667.1
csusggugGfaAfGfAfcaugcagcgu(L96)
392
asCfsgcuGfcAfUfgucuUfcCfaccagsgsg
527

AD-1072614.1
csgscgccAfaGfCfUfggaggagcau(L96)
381
asUfsgcuCfcUfCfcagcUfuGfgcgcgscsa
516

AD-1072632.1
csasggccCfaGfCfAfgauacgccuu(L96)
382
asAfsggcGfuAfUfcugcUfgGfgccugscsu
517

AD-1072211.1
cscscgagCfuGfCfGfccagcagacu(L96)
299
asGfsucuGfcUfGfgcgcAfgCfucgggscsu
434

AD-1072406.1
gscsacggCfuGfUfCfcaaggagcuu(L96)
325
asAfsgcuCfcUfUfggacAfgCfcgugcscsc
460

AD-1103882.1
gscscccuGfuGfCfCfcagcgacaau(L96)
397
asUfsuguCfgCfUfgggcAfcAfggggcsgsg
532

AD-1103855.1
gsascaugGfaGfGfAfcgugcgcggu(L96)
334
asCfscgcGfcAfCfguccUfcCfaugucscsg
469

AD-1072726.1
gsasagccUfgCfAfGfccaugcgacu(L96)
403
asGfsucgCfaUfGfgcugCfaGfgcuucsgsg
538

AD-1103893.1
uscscuggGfgUfGfGfacccuaguuu(L96)
414
asAfsacuAfgGfGfuccaCfcCfcaggasgsg
549

AD-1072736.1
gsgsguggAfcCfCfUfaguuuaauau(L96)
415
asUfsauuAfaAfCfuaggGfuCfcacccscsa
550

AD-1072426.1
gscsggacAfuGfGfAfggacgugugu(L96)
330
asCfsacaCfgUfCfcuccAfuGfuccgcsgsc
465

AD-1072506.1
gsusaagcGfgCfUfCfcuccgcgauu(L96)
358
asAfsucgCfgGfAfggagCfcGfcuuacsgsc
493

AD-1072248.1
asascuggCfaCfUfGfggucgcuuuu(L96)
304
asAfsaagCfgAfCfccagUfgCfcaguuscsc
439

AD-1072203.1
gsgsuggaGfaCfAfGfagccggagcu(L96)
298
asGfscucCfgGfCfucugUfcUfccaccsgsc
433

AD-1103888.1
csusccugCfcUfCfCfgcgcagccuu(L96)
409
asAfsggcUfgCfGfcggaGfgCfaggagsgsc
544

AD-1072243.1
csusgggaAfcUfGfGfcacugggucu(L96)
303
asGfsaccCfaGfUfgccaGfuUfcccagscsg
438

AD-1103886.1
cscsacccCfgUfGfCfcuccugccuu(L96)
407
asAfsggcAfgGfAfggcaCfgGfgguggscsg
542

AD-1072347.1
usgsagggCfgCfUfGfauggacgagu(L96)
315
asCfsucgUfcCfAfucagCfgCfccucasgsu
450

AD-1072411.1
gscsugucCfaAfGfGfagcugcaggu(L96)
326
asCfscugCfaGfCfuccuUfgGfacagcscsg
461

AD-1072319.1
csusgcucAfgCfUfCfccaggucacu(L96)
312
asGfsugaCfcUfGfggagCfuGfagcagscsu
447

AD-1103885.1
cscscacgCfcAfCfCfccgugccucu(L96)
406
asGfsaggCfaCfGfggguGfgCfgugggsgsu
541

AD-1072488.1
cscscaccUfgCfGfCfaagcugcguu(L96)
355
asAfscgcAfgCfUfugcgCfaGfgugggsasg
490

AD-1072532.1
csusgcagAfaGfCfGfccuggcaguu(L96)
363
asAfscugCfcAfGfgcgcUfuCfugcagsgsu
498

AD-1072493.1
csusgcgcAfaGfCfUfgcguaagcgu(L96)
356
asCfsgcuUfaCfGfcagcUfuGfcgcagsgsu
491

AD-1072686.1
gscsugguGfgAfGfAfaggugcaggu(L96)
395
asCfscugCfaCfCfuucuCfcAfccagcscsc
530

AD-1072656.1
cscsaggcCfcGfCfCfucaagagcuu(L96)
388
asAfsgcuCfuUfGfaggcGfgGfccuggsasa
523

AD-1103851.1
csgscggaCfaUfGfGfaggacgugcu(L96)
329
asGfscacGfuCfCfuccaUfgUfccgcgscsc
464

AD-1072216.1
gscsugcgCfcAfGfCfagaccgaguu(L96)
300
asAfscucGfgUfCfugcuGfgCfgcagcsusc
435

AD-1072455.1
gsasggugCfaGfGfCfcaugcucggu(L96)
349
asCfscgaGfcAfUfggccUfgCfaccucsgsc
484

AD-1072581.1
csgscgacCfgCfCfUfggacgagguu(L96)
377
asAfsccuCfgUfCfcaggCfgGfucgcgsgsg
512

AD-1072499.1
asasgcugCfgUfAfAfgcggcuccuu(L96)
357
asAfsggaGfcCfGfcuuaCfgCfagcuusgsc
492

AD-1103854.1
gsgsacauGfgAfGfGfacgugcgcgu(L96)
333
asCfsgcgCfaCfGfuccuCfcAfuguccsgsc
468

AD-1072672.1
gsgsaagaCfaUfGfCfagcgccaguu(L96)
393
asAfscugGfcGfCfugcaUfgUfcuuccsasc
528

AD-1072644.1
csgsccugCfaGfGfCfcgaggccuuu(L96)
384
asAfsaggCfcUfCfggccUfgCfaggcgsusa
519

AD-1103850.1
gscsccggCfuGfGfGfcgcggacauu(L96)
327
asAfsuguCfcGfCfgcccAfgCfcgggcscsu
462

AD-1103875.1
csgscgugCfgGfGfCfcgccacuguu(L96)
371
asAfscagUfgGfCfggccCfgCfacgcgsgsc
506

AD-1072401.1
csgscgggCfaCfGfGfcuguccaagu(L96)
324
asCfsuugGfaCfAfgccgUfgCfccgcgsusc
459

AD-1072438.1
csgsccugGfuGfCfAfguaccgcggu(L96)
348
asCfscgcGfgUfAfcugcAfcCfaggcgsgsc
483

AD-1072310.1
csasggagGfaGfCfUfgcucagcucu(L96)
311
asGfsagcUfgAfGfcagcUfcCfuccugscsa
446

AD-1072277.1
csusgcgcUfgGfGfUfgcagacacuu(L96)
308
asAfsgugUfcUfGfcaccCfaGfcgcagsgsu
443

AD-1103852.1
gscsggacAfuGfGfAfggacgugcgu(L96)
331
asCfsgcaCfgUfCfcuccAfuGfuccgcsgsc
466

AD-1072483.1
csgsccucCfcAfCfCfugcgcaagcu(L96)
354
asGfscuuGfcGfCfagguGfgGfaggcgsasg
489

AD-1072569.1
gscsgcggAfuGfGfAfggagaugggu(L96)
376
asCfsccaUfcUfCfcuccAfuCfcgcgcsgsc
511

AD-1072473.1
gsgsccagAfgCfAfCfcgaggagcuu(L96)
351
asAfsgcuCfcUfCfggugCfuCfuggccsgsa
486

AD-1103868.1
gscsugcgGfgUfGfCfgccucgccuu(L96)
352
asAfsggcGfaGfGfcgcaCfcCfgcagcsusc
487

AD-1103858.1
asusggagGfaCfGfUfgcgcggccgu(L96)
337
asCfsggcCfgCfGfcacgUfcCfuccausgsu
472

AD-1103857.1
csasuggaGfgAfCfGfugcgcggccu(L96)
336
asGfsgccGfcGfCfacguCfcUfccaugsusc
471

AD-1103861.1
gsasggacGfuGfCfGfcggccgccuu(L96)
340
asAfsggcGfgCfCfgcgcAfcGfuccucscsa
475

AD-1103891.1
cscscgccCfcAfGfCfcguccuccuu(L96)
412
asAfsggaGfgAfCfggcuGfgGfgcgggsgsa
547

AD-1103870.1
gsasgcgcGfgCfCfUfcagcgccauu(L96)
366
asAfsuggCfgCfUfgaggCfcGfcgcucsgsg
501

AD-1103867.1
gsusgcgcGfgCfCfGfccuggugcau(L96)
346
asUfsgcaCfcAfGfgcggCfcGfcgcacsgsu
481

AD-1072433.1
gscsggccGfcCfUfGfgugcaguacu(L96)
347
asGfsuacUfgCfAfccagGfcGfgccgcsasc
482

AD-1103872.1
asgscgccAfuCfCfGfcgagcgccuu(L96)
368
asAfsggcGfcUfCfgcggAfuGfgcgcusgsa
503

AD-1103889.1
gscscuccGfcGfCfAfgccugcagcu(L96)
410
asGfscugCfaGfGfcugcGfcGfgaggcsasg
545

AD-1103864.1
gsascgugCfgCfGfGfccgccugguu(L96)
343
asAfsccaGfgCfGfgccgCfgCfacgucscsu
478

AD-1072464.1
gscscaugCfuCfGfGfccagagcacu(L96)
350
asGfsugcUfcUfGfgccgAfgCfauggcscsu
485

AD-1103862.1
asgsgacgUfgCfGfCfggccgccugu(L96)
341
asCfsaggCfgGfCfcgcgCfaCfguccuscsc
476

AD-1072637.1
cscsagcaGfaUfAfCfgccugcaggu(L96)
383
asCfscugCfaGfGfcguaUfcUfgcuggsgsc
518

AD-1072420.1
csusgggcGfcGfGfAfcauggaggau(L96)
328
asUfsccuCfcAfUfguccGfcGfcccagscsc
463

AD-1072238.1
csasgcgcUfgGfGfAfacuggcacuu(L96)
302
asAfsgugCfcAfGfuuccCfaGfcgcugsgsc
437

AD-1103866.1
csgsugcgCfgGfCfCfgccuggugcu(L96)
345
asGfscacCfaGfGfcggcCfgCfgcacgsusc
480

AD-1103873.1
usgsgggcCfcCfUfGfguggaacagu(L96)
369
asCfsuguUfcCfAfccagGfgGfccccasgsg
504

AD-1103869.1
gsusgcgcCfuCfGfCfcucccaccuu(L96)
353
asAfsgguGfgGfAfggcgAfgGfcgcacscsc
488

AD-1072588.1
gscscuggAfcGfAfGfgugaaggagu(L96)
378
asCfsuccUfuCfAfccucGfuCfcaggcsgsg
513

AD-1072544.1
csusggcaGfuGfUfAfccaggccggu(L96)
365
asCfscggCfcUfGfguacAfcUfgccagsgsc
500

AD-1103859.1
usgsgaggAfcGfUfGfcgcggccgcu(L96)
338
asGfscggCfcGfCfgcacGfuCfcuccasusg
473

AD-1103853.1
csgsgacaUfgGfAfGfgacgugcgcu(L96)
332
asGfscgcAfcGfUfccucCfaUfguccgscsg
467

AD-1103856.1
ascsauggAfgGfAfCfgugcgcggcu(L96)
335
asGfsccgCfgCfAfcgucCfuCfcauguscsc
470

AD-1072607.1
gsgsagguGfcGfCfGfccaagcuggu(L96)
380
asCfscagCfuUfGfgcgcGfcAfccuccsgsc
515

AD-1103860.1
gsgsaggaCfgUfGfCfgcggccgccu(L96)
339
asGfsgcgGfcCfGfcgcaCfgUfccuccsasu
474

AD-1103884.1
gscsgaccCfcAfCfGfccaccccguu(L96)
405
asAfscggGfgUfGfgcguGfgGfgucgcsasu
540

AD-1072551.1
gscscgccAfcUfGfUfgggcucccuu(L96)
372
asAfsgggAfgCfCfcacaGfuGfgcggcscsc
507

AD-1103874.1
cscsccugGfuGfGfAfacagggccgu(L96)
370
asCfsggcCfcUfGfuuccAfcCfaggggscsc
505

AD-1103890.1
cscsugucCfcCfGfCfcccagccguu(L96)
411
asAfscggCfuGfGfggcgGfgGfacaggsgsu
546

AD-1103881.1
ascscagcGfcCfGfCfcccugugccu(L96)
396
asGfsgcaCfaGfGfggcgGfcGfcuggusgsc
531

AD-1103887.1
csgsugccUfcCfUfGfccuccgcgcu(L96)
408
asGfscgcGfgAfGfgcagGfaGfgcacgsgsg
543

AD-1103863.1
gsgsacguGfcGfCfGfgccgccuggu(L96)
342
asCfscagGfcGfGfccgcGfcAfcguccsusc
477

AD-1072509.1
gsgscuccUfcCfGfCfgaugccgauu(L96)
359
asAfsucgGfcAfUfcgcgGfaGfgagccsgsc
494

AD-1103892.1
cscscagcCfgUfCfCfuccugggguu(L96)
413
asAfscccCfaGfGfaggaCfgGfcugggsgsc
548

AD-1103877.1
gscscgcuAfcAfGfGfagcgggcccu(L96)
375
asGfsggcCfcGfCfuccuGfuAfgcggcsusg
510

AD-1103865.1
ascsgugcGfcGfGfCfcgccuggugu(L96)
344
asCfsaccAfgGfCfggccGfcGfcacguscsc
479

AD-1072649.1
gscsaggcCfgAfGfGfccuuccaggu(L96)
385
asCfscugGfaAfGfgccuCfgGfccugcsasg
520

AD-1103880.1
asgsccccUfgGfUfGfgaagacaugu(L96)
391
asCfsaugUfcUfUfccacCfaGfgggcuscsg
526

AD-1103878.1
cscsgaggCfcUfUfCfcaggcccgcu(L96)
386
asGfscggGfcCfUfggaaGfgCfcucggscsc
521

AD-1072163.1
uscsacauUfcCfUfGfgcaggaugcu(L96)
293
asGfscauCfcUfGfccagGfaAfugugascsc
428

AD-1072681.1
gscscgggCfuGfGfUfggagaagguu(L96)
394
asAfsccuUfcUfCfcaccAfgCfccggcscsc
529

AD-1072559.1
gsgsccagCfcGfCfUfacaggagcgu(L96)
374
asCfsgcuCfcUfGfuagcGfgCfuggccsgsg
509

AD-1072538.1
asasgcgcCfuGfGfCfaguguaccau(L96)
364
asUfsgguAfcAfCfugccAfgGfcgcuuscsu
499

AD-1103876.1
cscsuggcCfgGfCfCfagccgcuacu(L96)
373
asGfsuagCfgGfCfuggcCfgGfccaggsgsa
508

TABLE 7

Selected APOE Unmodified Sense and Antisense Strand Sequences From Table 2 Targeting the Pathogenic

APOE4 Allele

SEQ

SEQ

Antisense Strand

Sense Sequence
ID
Antisense Sequence
ID
Sense Strand Target
Target Site in

5′ to 3′
NO:
5′ to 3′
NO:
Site in NM_000041.4
NM_000041.4

CGCGGACAUGGAGGACGUGCU
59
AGCACGUCCUCCAUGUCCGCGCC
194
NM_000041.4_438-
NM_000041.4_436-

458_U20C_G21U_s
458_C1A_A2G_as

GCGGACAUGGAGGACGUGCGU
61
ACGCACGUCCUCCAUGUCCGCGC
196
NM_000041.4_439-
NM_000041.4_437-

459_U19C_C21U_s
459_G1A_A3G_as

CGGACAUGGAGGACGUGCGCU
62
AGCGCACGUCCUCCAUGUCCGCG
197
NM_000041.4_440-
NM_000041.4_438-

460_U18C_G21U_s
460_C1A_A4G_as

GGACAUGGAGGACGUGCGCGU
63
ACGCGCACGUCCUCCAUGUCCGC
198
NM_000041.4_441-
NM_000041.4_439-

461_U17C_G21U_s
461_C1A_A5G_as

GACAUGGAGGACGUGCGCGGU
64
ACCGCGCACGUCCUCCAUGUCCG
199
NM_000041.4_442-
NM_000041.4_440-

462_U16C_C21U_s
462_G1A_A6G_as

ACAUGGAGGACGUGCGCGGCU
65
AGCCGCGCACGUCCUCCAUGUCC
200
NM_000041.4_443-
NM_000041.4_441-

463_U15C_C21U_s
463_G1A_A7G_as

CAUGGAGGACGUGCGCGGCCU
66
AGGCCGCGCACGUCCUCCAUGUC
201
NM_000041.4_444-
NM_000041.4_442-

464_U14C_G21U_s
464_C1A_A8G_as

AUGGAGGACGUGCGCGGCCGU
67
ACGGCCGCGCACGUCCUCCAUGU
202
NM_000041.4_445-
NM_000041.4_443-

465_U13C_C21U_s
465_G1A_A9G_as

UGGAGGACGUGCGCGGCCGCU
68
AGCGGCCGCGCACGUCCUCCAUG
203
NM_000041.4_446-
NM_000041.4_444-

466_U12C_C21U_s
466_G1A_A10G_as

GGAGGACGUGCGCGGCCGCCU
69
AGGCGGCCGCGCACGUCCUCCAU
204
NM_000041.4_447-
NM_000041.4_445-

467_U11C_s
467_AllG_as

GAGGACGUGCGCGGCCGCCUU
70
AAGGCGGCCGCGCACGUCCUCCA
205
NM_000041.4_448-
NM_000041.4_446-

468_U10C_G21U_s
468_C1A_A12G_as

AGGACGUGCGCGGCCGCCUGU
71
ACAGGCGGCCGCGCACGUCCUCC
206
NM_000041.4_449-
NM_000041.4_447-

469_U9C_G21U_s
469_C1A_A13G_as

GGACGUGCGCGGCCGCCUGGU
72
ACCAGGCGGCCGCGCACGUCCUC
207
NM_000041.4_450-
NM_000041.4_448-

470_U8C_s
470_A14G_as

GACGUGCGCGGCCGCCUGGUU
73
AACCAGGCGGCCGCGCACGUCCU
208
NM_000041.4_451-
NM_000041.4_449-

471_U7C_G21U_s
471_C1A_A15G_as

ACGUGCGCGGCCGCCUGGUGU
74
ACACCAGGCGGCCGCGCACGUCC
209
NM_000041.4_452-
NM_000041.4_450-

472_U6C_C21U_s
472_G1A_A16G_as

CGUGCGCGGCCGCCUGGUGCU
75
AGCACCAGGCGGCCGCGCACGUC
210
NM_000041.4_453-
NM_000041.4_451-

473_U5C_A21U_s
473_U1A_A17G_as

GUGCGCGGCCGCCUGGUGCAU
76
AUGCACCAGGCGGCCGCGCACGU
211
NM_000041.4_454-
NM_000041.4_452-

474_U4C_G21U_s
474_C1A_A18G_as

TABLE 8

Selected APOE Modified Sense and Antisense Strand Sequences From Table 2 Targeting the Pathogenic

APOE4 Allele

SEQ

SEQ

SEQ

Sense Sequence
ID
Antisense Sequence
ID
mRNA Target Sequence
ID

5′ to 3′
NO:
5′ to 3′
NO:
5′ to 3′
NO:

csgscggaCfaUfGfGfaggacgugcuL96
329
asGfscacGfuCfCfuccaUfgUfccgcgscsc
464
GGCGCGGACATGGAGGACGTGCG
599

gscsggacAfuGfGfAfggacgugcguL96
331
asCfsgcaCfgUfCfcuccAfuGfuccgcsgsc
466
GCGCGGACATGGAGGACGTGCGC
601

csgsgacaUfgGfAfGfgacgugcgcuL96
332
asGfscgcAfcGfUfccucCfaUfguccgscsg
467
CGCGGACATGGAGGACGTGCGCG
602

gsgsacauGfgAfGfGfacgugcgcguL96
333
asCfsgcgCfaCfGfuccuCfcAfuguccsgsc
468
GCGGACATGGAGGACGTGCGCGG
603

gsascaugGfaGfGfAfcgugcgcgguL96
334
asCfscgcGfcAfCfguccUfcCfaugucscsg
469
CGGACATGGAGGACGTGCGCGGC
604

ascsauggAfgGfAfCfgugcgcggcuL96
335
asGfsccgCfgCfAfcgucCfuCfcauguscsc
470
GGACATGGAGGACGTGCGCGGCC
605

csasuggaGfgAfCfGfugcgcggccuL96
336
asGfsgccGfcGfCfacguCfcUfccaugsusc
471
GACATGGAGGACGTGCGCGGCCG
606

asusggagGfaCfGfUfgcgcggccguL96
337
asCfsggcCfgCfGfcacgUfcCfuccausgsu
472
ACATGGAGGACGTGCGCGGCCGC
607

usgsgaggAfcGfUfGfcgcggccgcuL96
338
asGfscggCfcGfCfgcacGfuCfcuccasusg
473
CATGGAGGACGTGCGCGGCCGCC
608

gsgsaggaCfgUfGfCfgcggccgccuL96
339
asGfsgcgGfcCfGfcgcaCfgUfccuccsasu
474
ATGGAGGACGTGCGCGGCCGCCT
609

gsasggacGfuGfCfGfcggccgccuuL96
340
asAfsggcGfgCfCfgcgcAfcGfuccucscsa
475
TGGAGGACGTGCGCGGCCGCCTG
610

asgsgacgUfgCfGfCfggccgccuguL96
341
asCfsaggCfgGfCfcgcgCfaCfguccuscsc
476
GGAGGACGTGCGCGGCCGCCTGG
611

gsgsacguGfcGfCfGfgccgccugguL96
342
asCfscagGfcGfGfccgcGfcAfcguccsusc
477
GAGGACGTGCGCGGCCGCCTGGT
612

gsascgugCfgCfGfGfccgccugguuL96
343
asAfsccaGfgCfGfgccgCfgCfacgucscsu
478
AGGACGTGCGCGGCCGCCTGGTG
613

ascsgugcGfcGfGfCfcgccugguguL96
344
asCfsaccAfgGfCfggccGfcGfcacguscsc
479
GGACGTGCGCGGCCGCCTGGTGC
614

csgsugcgCfgGfCfCfgccuggugcuL96
345
asGfscacCfaGfGfcggcCfgCfgcacgsusc
480
GACGTGCGCGGCCGCCTGGTGCA
615

gsusgcgcGfgCfCfGfccuggugcauL96
346
asUfsgcaCfcAfGfgcggCfcGfcgcacsgsu
481
ACGTGCGCGGCCGCCTGGTGCAG
616

TABLE 6

10 nM In Vitro Screening Data

Duplex ID
Mean
SD

AD-1072375.1
1.4
0.6

AD-1072352.1
2.4
0.3

AD-1072394.1
2.9
0.3

AD-1072721.1
3.2
0.5

AD-1072254.1
3.2
0.0

AD-1072189.1
3.5
0.3

AD-1072741.1
3.5
0.8

AD-1072382.1
3.7
1.0

AD-1072129.1
4.0
0.5

AD-1072514.1
4.2
0.3

AD-1072124.1
4.2
0.8

AD-1072337.1
4.3
0.6

AD-1072135.1
4.6
0.9

AD-1072745.1
4.7
1.1

AD-1072153.1
5.0
0.3

AD-1072520.1
5.7
1.2

AD-1072389.1
6.5
1.6

AD-1072716.1
6.5
1.3

AD-1072222.1
6.8
0.4

AD-1072367.1
7.1
1.0

AD-1103894.1
9.2
1.3

AD-1072651.1
9.2
0.8

AD-1072260.1
9.4
2.0

AD-1072265.1
9.4
0.9

AD-1072750.1
9.9
1.8

AD-1072142.1
10.1
1.3

AD-1072328.1
10.2
2.3

AD-1072198.1
10.3
1.7

AD-1072361.1
11.2
0.6

AD-1072526.1
11.4
1.5

AD-1072699.1
11.8
1.4

AD-1072711.1
11.8
4.0

AD-1103879.1
11.9
1.6

AD-1103849.1
12.1
0.4

AD-1072662.1
12.6
0.8

AD-1103883.1
12.7
3.2

AD-1072172.1
13.2
1.4

AD-1072158.1
15.4
5.8

AD-1072705.1
15.7
2.5

AD-1072147.1
16.6
0.7

AD-1072593.1
16.8
2.3

AD-1072115.1
17.0
0.4

AD-1072289.1
18.6
6.5

AD-1072283.1
18.9
1.6

AD-1103871.1
19.2
4.2

AD-1072183.1
20.2
0.5

AD-1072667.1
20.3
4.5

AD-1072614.1
20.4
1.7

AD-1072632.1
21.0
1.3

AD-1072211.1
21.2
7.2

AD-1072406.1
21.3
0.4

AD-1103882.1
21.9
0.9

AD-1103855.1
22.0
5.9

AD-1072726.1
22.8
1.5

AD-1103893.1
26.0
2.3

AD-1072736.1
31.5
5.0

AD-1072426.1
32.4
5.5

AD-1072506.1
33.7
6.4

AD-1072248.1
34.2
2.1

AD-1072203.1
35.4
3.7

AD-1103888.1
35.5
11.3

AD-1072243.1
35.8
0.6

AD-1103886.1
38.9
1.2

AD-1072347.1
39.4
3.1

AD-1072411.1
45.5
2.6

AD-1072319.1
53.0
17.3

AD-1103885.1
57.0
1.6

AD-1072488.1
57.3
4.4

AD-1072532.1
60.1
1.8

AD-1072493.1
60.5
5.4

AD-1072686.1
64.8
2.5

AD-1072656.1
66.4
7.3

AD-1103851.1
66.6
5.4

AD-1072216.1
66.6
5.1

AD-1072455.1
67.3
4.3

AD-1072581.1
68.5
9.7

AD-1072499.1
69.5
10.1

AD-1103854.1
70.4
4.7

AD-1072672.1
72.6
4.0

AD-1072644.1
73.6
5.8

AD-1103850.1
74.2
5.0

AD-1103875.1
74.5
2.4

AD-1072401.1
79.5
24.3

AD-1072438.1
79.5
5.7

AD-1072310.1
79.6
3.4

AD-1072277.1
81.9
5.0

AD-1103852.1
82.0
15.0

AD-1072483.1
86.5
3.1

AD-1072569.1
86.6
12.8

AD-1072473.1
87.1
5.6

AD-1103868.1
88.8
4.6

AD-1103858.1
88.9
4.4

AD-1103857.1
89.8
3.4

AD-1103861.1
90.3
6.5

AD-1103891.1
90.5
2.9

AD-1103870.1
92.2
5.7

AD-1103867.1
92.5
6.5

AD-1072433.1
92.5
6.5

AD-1103872.1
93.0
6.5

AD-1103889.1
93.6
3.6

AD-1103864.1
93.7
2.3

AD-1072464.1
94.1
6.3

AD-1103862.1
94.1
4.8

AD-1072637.1
94.7
12.4

AD-1072420.1
95.0
8.6

AD-1072238.1
95.4
5.0

AD-1103866.1
95.9
2.6

AD-1103873.1
96.5
5.7

AD-1103869.1
97.2
3.1

AD-1072588.1
97.8
5.4

AD-1072544.1
98.0
8.7

AD-1103859.1
98.0
6.2

AD-1103853.1
98.3
5.6

AD-1103856.1
99.3
5.1

AD-1072607.1
99.5
6.1

AD-1103860.1
99.6
16.5

AD-1103884.1
100.0
3.0

AD-1072551.1
101.2
3.1

AD-1103874.1
101.3
3.6

AD-1103890.1
103.4
3.4

AD-1103881.1
104.3
5.2

AD-1103887.1
104.9
2.6

AD-1103863.1
105.6
8.2

AD-1072509.1
106.5
19.7

AD-1103892.1
106.6
8.2

AD-1103877.1
106.9
12.2

AD-1103865.1
107.0
1.9

AD-1072649.1
108.5
3.9

AD-1103880.1
109.2
3.3

AD-1103878.1
110.2
5.8

AD-1072163.1
111.3
16.3

AD-1072681.1
114.6
6.8

AD-1072559.1
114.9
7.2

AD-1072538.1
119.3
8.0

AD-1103876.1
120.4
16.4

Example 2. In Vivo Evaluation in Transgenic Mice

This Example describes methods for the in vivo evaluation of APOE RNAi agents in the APPPS1-21 transgenic mouse model of Alzheimer's disease. These mice overexpress human amyloid precursor protein (APP) cDNA with a Swedish mutation (KM670/671NL) and mutant PS1 with the L166P mutation, The endogenous ApoE gene in these mice was replaced with either the human APOE3 allele or the human APOE4 allele (Huynh, et al. (2017) Neuron 96: 1013-1023).

The ability of selected dsRNA agents designed and assayed in Example 1 are assessed for their ability to reduce the level of APOE expression, e.g., APOE2, APOE3, and APOE4 expression, in the brain and the liver of these animals.

Briefly, littermates are intrathecally or subcutaneously administered a single dose of the dsRNA agents of interest, or a placebo. Two weeks after administration, animals are sacrificed, blood and tissue samples, including cerebral cortex, spinal cord, liver, spleen, and cervical lymph nodes, are collected.

To determine the effect of administration of the dsRNA agents targeting APOE on the level APOE mRNA, mRNA levels are determined in cortex and liver samples by qRT-PCR.

The effect of administration of the agents targeting APOE on the pathology of Alzheimer's disease in this mouse model is also assessed as described in Huynh, et al. (supra).

Littermates are intrathecally or subcutaneously administered two doses of the dsRNA agents of interest, or a placebo, at birth and 8 weeks of age. At 16 weeks of age, animals are sacrificed, and blood and tissue samples, including cerebral cortex, spinal cord, liver, spleen, and cervical lymph nodes, are collected and appropriately processed.

The effect of the dsRNA agents on the deposition of Aβ plaques, the accumulation of Aβ, total neuritic dystrophy, the plaque size and the plaque distribution are assessed. Briefly, for immunofluorescence analysis of tissue samples, after fixation and following immersion in sucrose for at least 24 hours, serial coronal sections are collected from frontal cortex to caudal hippocampus (right hemisphere) using a microtome. Three hippocampal-containing sections from the right hemisphere of each brain are stained with X34 dye to visualize fibrillary plaques or with commercially available antibodies against amyloid-β (such as 82E1) and corresponding fluorescently-labeled secondary antibodies. For analysis, stained sections are scanned at 20× magnification with a confocal microscope. Random windows containing clusters of plaques are captured, spanning the same thickness in the z-plane for all sections. Using suitable software, the volume of the markers are quantified under the same threshold. Each data point represents the average value from three separate tissue sections from one single animal.

Example 3. In Vivo Evaluation in Humanized APOE Mice

Humanized ApoE4 knock-in mice (purchased from Jax; stock #027894) for this study were generated by replacing exons 2, 3 and most of exon 4 of the mouse Apoe gene with the human APOE4 gene sequence including exons 2, 3 and 4 (and some 3′ UTR sequence) using standard techniques.

To assess the in vivo efficacy of duplexes of interest, at Day 0, 9-12 week old, male and female, Ketamine/Xylazine anesthetized homozygous humanized APOE knock-in mice were administered a single 300 μg dose of AD-1204704, AD-1204705, AD-1204705, AD-1204706 AD-1204707, AD-1204708, AD-1204709, AD-1204710, AD-1204711, AD-1204712, or AD-1204713, or artificial CSF (aCSF) control by intracerebroventricular injection (ICV) into the right ventricle using a 25 μl Hamilton syringe and a custom angled 3.5 mm needle.

Table 9 provides a detailed list of the unmodified APOE sense and antisense strand sequences of the agents used in this example and Table 10 provides a detailed list of the modified APOE sense and antisense strand sequences of the agents used in this example.

At day 14 post-dose, animals were sacrificed, both hemispheres of the brain and the liver were collected and snap-frozen in liquid nitrogen. mRNA was extracted from the tissue and analyzed by the RT-QPCR method.

The results of this analysis are provided in FIGS. 1A and 1B and demonstrate that a single 300 kg dose of AD-1204704, AD-1204705, AD-1204708, or AD-1204712 potently knocks down APOE expression in the brain (FIG. 1A) with a lesser effect on peripheral APOE expression (FIG. 1B).

FIG. 2 depicts the correlation of the activity of the agents in vitro to the activity of the agents in vivo. Specifically, of the 45 duplexes that exhibited greater than 80% knockdown in Hep3B cells (at 10 nM), the top 4 duplexes identified in that in vitro screen showed the best activity in vivo (agents circled, i.e., AD-1204704, AD-1204705, AD-1204708, or AD-1204712).

TABLE 9

Unodified Sense and Antisense Strand Sequences

SEQ

SEQ

Duplex

ID
Range in

ID
Range n

Name
Sense Sequence 5′ to 3′
NO:
NM_000041.4
Antisense Sequence 5′ to 3′
NO:
NM_000041.4

AD-1204704
CAGGCAGGAAGAUGAAGGUUA
690
59-79
UAACCUUCAUCUUCCUGCCUGUG
700
57-79

AD-1204705
AGGAAGAUGAAGGUUCUGUGA
691
64-84
UCACAGAACCUUCAUCUUCCUGC
701
62-84

AD-1204706
UUCUGUGGGCUGCGUUGCUGA
692
77-97
UCAGCAACGCAGCCCACAGAACC
702
75-97

AD-1204707
GCGUUGCUGGUCACAUUCCUA
693
88-108
UAGGAAUGUGACCAGCAACGCAG
703
86-108

AD-1204708
CACUGGGUCGCUUUUGGGAUA
694
209-229
UAUCCCAAAAGCGACCCAGUGCC
704
207-229

AD-1204709
GUCGCUUUUGGGAUUACCUGA
695
215-235
UCAGGUAAUCCCAAAAGCGACCC
705
213-235

AD-1204710
UUUUGGGAUUACCUGCGCUGA
696
220-240
UCAGCGCAGGUAAUCCCAAAAGC
706
218-240

AD-1204711
CCGCCUCAAGAGCUGGUUCGA
697
900-920
UCGAACCAGCUCUUGAGGCGGGC
707
898-920

AD-1204712
GACCCUAGUUUAAUAAAGAUA
698
1130-1150
UAUCUUUAUUAAACUAGGGUCCA
708
1128-1150

AD-1204713
CGGCCUCAGCGCCAUCCGCGA
699
639-659
UCGCGGAUGGCGCUGAGGCCGCG
709
637-659

TABLE 10

Modified Sense and Antisense Strand Sequences

SEQ

SEQ

SEQ

Duplex

ID

ID
mRNA Target Sequence
ID

Name
Sense Sequence 5′ to 3′
NO:
Antisense Sequence 5′ to 3′
NO:
5′ to 3′
NO:

AD-
csasggc(Ahd)GfgAfAfGfaugaaggu
710
VPusAfsaccUfuCfAfucuuCfcUfgccugs
720
CACAGGCAGGAAGAUGAAG
730

1204704
susa

usg

GUUC

AD-
asgsgaa(Ghd)AfuGfAfAfgguucug
711
VPusCfsacaGfaAfCfcuucAfuCfuuccus
721
GCAGGAAGAUGAAGGUUCU
731

1204705
usgsa

gsc

GUGG

AD-
ususcug(Uhd)GfgGfCfUfgcguugc
712
VPusCfsagcAfaCfGfcagcCfcAfcagaas
722
GGUUCUGUGGGCUGCGUUG
732

1204706
usgsa

csc

CUGG

AD-
gscsguu(Ghd)CfuGfGfUfcacauucc
713
VPusAfsggaAfuGfUfgaccAfgCfaacgcs
723
CUGCGUUGCUGGUCACAUU
733

1204707
susa

asg

CCUG

AD-
csascug(Ghd)GfuCfGfCfuuuuggga
714
VPusAfsuccCfaAfAfagcgAfcCfcagugs
724
GGCACUGGGUCGCUUUUGG
734

1204708
susa

csc

GAUU

AD-
gsuscgc(Uhd)UfuUfGfGfgauuaccu
715
VPusCfsaggUfaAfUfcccaAfaAfgcgacs
725
GGGUCGCUUUUGGGAUUAC
735

1204709
sgsa

csc

CUGC

AD-
ususuug(Ghd)GfaUfUfAfccugcgcu
716
VPusCfsagcGfcAfGfguaaUfcCfcaaaas
726
GCUUUUGGGAUUACCUGCG
736

1204710
sgsa

gsc

CUGG

AD-
cscsgcc(Uhd)CfaAfGfAfgcugguuc
717
VPusCfsgaaCfcAfGfcucuUfgAfggcgg
727
GCCCGCCUCAAGAGCUGGU
737

1204711
sgsa

sgsc

UCGA

AD-
gsasccc(Uhd)AfgUfUfUfaauaaaga
718
VPusAfsucuUfuAfUfuaaaCfuAfggguc
728
UGGACCCUAGUUUAAUAAA
738

1204712
susa

scsa

GAUU

AD-
csgsgcc(Uhd)CfaGfCfGfccauccgc
719
VPusCfsgcgGfaUfGfgcgcUfgAfggccg
729
CGCGGCCUCAGCGCCAUCC
739

1204713
sgsa

scsg

GCGA

Informal Sequence Listing

<210> 1

<211> 1166

<212> DNA

<213> Homo sapiens

<400> 1

ctactcagcc ccagcggagg tgaaggacgt ccttccccag gagccgactg gccaatcaca
60

ggcaggaaga tgaaggttct gtgggctgcg ttgctggtca cattcctggc aggatgccag
120

gccaaggtgg agcaagcggt ggagacagag ccggagcccg agctgcgcca gcagaccgag
180

tggcagagcg gccagcgctg ggaactggca ctgggtcgct tttgggatta cctgcgctgg
240

gtgcagacac tgtctgagca ggtgcaggag gagctgctca gctcccaggt cacccaggaa
300

ctgagggcgc tgatggacga gaccatgaag gagttgaagg cctacaaatc ggaactggag
360

gaacaactga ccccggtggc ggaggagacg cgggcacggc tgtccaagga gctgcaggcg
420

gcgcaggccc ggctgggcgc ggacatggag gacgtgtgcg gccgcctggt gcagtaccgc
480

ggcgaggtgc aggccatgct cggccagagc accgaggagc tgcgggtgcg cctcgcctcc
540

cacctgcgca agctgcgtaa gcggctcctc cgcgatgccg atgacctgca gaagcgcctg
600

gcagtgtacc aggccggggc ccgcgagggc gccgagcgcg gcctcagcgc catccgcgag
660

cgcctggggc ccctggtgga acagggccgc gtgcgggccg ccactgtggg ctccctggcc
720

ggccagccgc tacaggagcg ggcccaggcc tggggcgagc ggctgcgcgc gcggatggag
780

gagatgggca gccggacccg cgaccgcctg gacgaggtga aggagcaggt ggcggaggtg
840

cgcgccaagc tggaggagca ggcccagcag atacgcctgc aggccgaggc cttccaggcc
900

cgcctcaaga gctggttcga gcccctggtg gaagacatgc agcgccagtg ggccgggctg
960

gtggagaagg tgcaggctgc cgtgggcacc agcgccgccc ctgtgcccag cgacaatcac
1020

tgaacgccga agcctgcagc catgcgaccc cacgccaccc cgtgcctcct gcctccgcgc
1080

agcctgcagc gggagaccct gtccccgccc cagccgtcct cctggggtgg accctagttt
1140

aataaagatt caccaagttt cacgca
1166

<210> 2

<211> 1166

<212> DNA

<213> Homo sapiens

<400> 2

tgcgtgaaac ttggtgaatc tttattaaac tagggtccac cccaggagga cggctggggc
60

ggggacaggg tctcccgctg caggctgcgc ggaggcagga ggcacggggt ggcgtggggt
120

cgcatggctg caggcttcgg cgttcagtga ttgtcgctgg gcacaggggc ggcgctggtg
180

cccacggcag cctgcacctt ctccaccagc ccggcccact ggcgctgcat gtcttccacc
240

aggggctcga accagctctt gaggcgggcc tggaaggcct cggcctgcag gcgtatctgc
300

tgggcctgct cctccagctt ggcgcgcacc tccgccacct gctccttcac ctcgtccagg
360

cggtcgcggg tccggctgcc catctcctcc atccgcgcgc gcagccgctc gccccaggcc
420

tgggcccgct cctgtagcgg ctggccggcc agggagccca cagtggcggc ccgcacgcgg
480

ccctgttcca ccaggggccc caggcgctcg cggatggcgc tgaggccgcg ctcggcgccc
540

tcgcgggccc cggcctggta cactgccagg cgcttctgca ggtcatcggc atcgcggagg
600

agccgcttac gcagcttgcg caggtgggag gcgaggcgca cccgcagctc ctcggtgctc
660

tggccgagca tggcctgcac ctcgccgcgg tactgcacca ggcggccgca cacgtcctcc
720

atgtccgcgc ccagccgggc ctgcgccgcc tgcagctcct tggacagccg tgcccgcgtc
780

tcctccgcca ccggggtcag ttgttcctcc agttccgatt tgtaggcctt caactccttc
840

atggtctcgt ccatcagcgc cctcagttcc tgggtgacct gggagctgag cagctcctcc
900

tgcacctgct cagacagtgt ctgcacccag cgcaggtaat cccaaaagcg acccagtgcc
960

agttcccagc gctggccgct ctgccactcg gtctgctggc gcagctcggg ctccggctct
1020

gtctccaccg cttgctccac cttggcctgg catcctgcca ggaatgtgac cagcaacgca
1080

gcccacagaa ccttcatctt cctgcctgtg attggccagt cggctcctgg ggaaggacgt
1140

ccttcacctc cgctggggct gagtag
1166

<210> 3

<211> 1212

<212> DNA

<213> Rattus norvegicus

<400> 3

ataattggac aggtctggga tccggtcccc tgctcagacc ccggaggcta aggagttgtt
60

tcggaaggag ctggtaagac aagcttgggc tggcgattca cccagggggc ttgactggcc
120

aatcacaact gggaagatga aggctctgtg ggccctgctg ttggtcccat tgctgacagg
180

atgcctggcc gagggagagc tggaggtgac agatcagctc ccagggcaaa gcgaccaacc
240

ctgggagcag gccctgaacc gcttctggga ttacctgcgc tgggtgcaga cgctttctga
300

ccaggtccag gaagagctgc agagctccca agtcacacag gaactgacgg tactgatgga
360

ggacactatg acggaagtaa aggcatacaa aaaggagctg gaggaacagc tgggcccagt
420

ggcggaggag acacgggcca ggctggctaa agaggtgcag gcggcacagg cccgtctggg
480

agctgacatg gaggatctac gcaaccgact cgggcagtac cgcaacgagg taaacaccat
540

gctgggccag agcacagagg agctgcggtc gcgcctctcc acacacctgc gcaagatgcg
600

caagcgcctg atgcgggatg cggatgatct gcagaagcgc ctggcggtgt acaaggccgg
660

ggcacaggag ggcgccgagc gcggtgtgag tgctatccgt gagcgcctgg ggccactggt
720

ggagcagggt cgtcagcgca cagccaacct aggcgctggc gccgcccagc ccctgcgcga
780

tcgcgcccag gctttgagtg accgcatccg agggcggctg gaggaagtgg gcaaccaggc
840

ccgagaccgc ctagaggagg tgcgtgagca gatggaggag gtgcgctcca agatggagga
900

gcagacccag cagatacgcc tgcaggccga gatcttccag gcccgcatca agggctggtt
960

cgagccgcta gtggaagaca tgcagcgcca gtgggcaaac ctaatggaga agatacaggc
1020

ctctgtggct accaactcca ttgcctccac cacagtgccc ctggagaatc aatgatcatc
1080

cctcacctac gccctgccgc aacatccatg accagccagg tggccctgtc ccaagcacca
1140

ctctggccct ctggtggccc ttgcttaata aagattctcc aagcaaaaaa aaaaaaaaaa
1200

aaaaaaaaaa aa
1212

<210> 4

<211> 1212

<212> DNA

<213> Rattus norvegicus

<400> 4

tttttttttt tttttttttt ttttttttgc ttggagaatc tttattaagc aagggccacc
60

agagggccag agtggtgctt gggacagggc cacctggctg gtcatggatg ttgcggcagg
120

gcgtaggtga gggatgatca ttgattctcc aggggcactg tggtggaggc aatggagttg
180

gtagccacag aggcctgtat cttctccatt aggtttgccc actggcgctg catgtcttcc
240

actagcggct cgaaccagcc cttgatgcgg gcctggaaga tctcggcctg caggcgtatc
300

tgctgggtct gctcctccat cttggagcgc acctcctcca tctgctcacg cacctcctct
360

aggcggtctc gggcctggtt gcccacttcc tccagccgcc ctcggatgcg gtcactcaaa
420

gcctgggcgc gatcgcgcag gggctgggcg gcgccagcgc ctaggttggc tgtgcgctga
480

cgaccctgct ccaccagtgg ccccaggcgc tcacggatag cactcacacc gcgctcggcg
540

ccctcctgtg ccccggcctt gtacaccgcc aggcgcttct gcagatcatc cgcatcccgc
600

atcaggcgct tgcgcatctt gcgcaggtgt gtggagaggc gcgaccgcag ctcctctgtg
660

ctctggccca gcatggtgtt tacctcgttg cggtactgcc cgagtcggtt gcgtagatcc
720

tccatgtcag ctcccagacg ggcctgtgcc gcctgcacct ctttagccag cctggcccgt
780

gtctcctccg ccactgggcc cagctgttcc tccagctcct ttttgtatgc ctttacttcc
840

gtcatagtgt cctccatcag taccgtcagt tcctgtgtga cttgggagct ctgcagctct
900

tcctggacct ggtcagaaag cgtctgcacc cagcgcaggt aatcccagaa gcggttcagg
960

gcctgctccc agggttggtc gctttgccct gggagctgat ctgtcacctc cagctctccc
1020

tcggccaggc atcctgtcag caatgggacc aacagcaggg cccacagagc cttcatcttc
1080

ccagttgtga ttggccagtc aagccccctg ggtgaatcgc cagcccaagc ttgtcttacc
1140

agctccttcc gaaacaactc cttagcctcc ggggtctgag caggggaccg gatcccagac
1200

ctgtccaatt at
1212

<210> 5

<211> 1358

<212> DNA

<213> Mus musculus

<400> 5

tttcctctgc cctgctgtga agggggagag aacaacccgc ctcgtgacag ggggctggca
60

cagcccgccc tagccctgag gagggggcgg gacaggggga gtcctataat tggaccggtc
120

tgggatccga tcccctgctc agaccctgga ggctaaggac ttgtttcgga aggagctgga
180

gagggagctg gaatttttgg cagcggatcc accccggggt gccgagatag cgaactcggc
240

aaggggagac tggccaatca caattgcgaa gatgaaggct ctgtgggccg tgctgttggt
300

cacattgctg acaggatgcc tagccgaggg agagccggag gtgacagatc agctcgagtg
360

gcaaagcaac caaccctggg agcaggccct gaaccgcttc tgggattacc tgcgctgggt
420

gcagacgctg tctgaccagg tccaggaaga gctgcagagc tcccaagtca cacaagaact
480

gacggcactg atggaggaca ctatgacgga agtaaaggct tacaaaaagg agctggagga
540

acagctgggt ccagtggcgg aggagacacg ggccaggctg ggcaaagagg tgcaggcggc
600

acaggcccga ctcggagccg acatggagga tctacgcaac cgactcgggc agtaccgcaa
660

cgaggtgcac accatgctgg gccagagcac agaggagata cgggcgcggc tctccacaca
720

cctgcgcaag atgcgcaagc gcttgatgcg ggatgccgag gatctgcaga agcgcctagc
780

tgtgtacaag gcaggggcac gcgagggcgc cgagcgcggt gtgagtgcca tccgtgagcg
840

cctggggcct ctggtggagc aaggtcgcca gcgcactgcc aacctaggcg ctggggccgc
900

ccagcctctg cgcgatcgcg cccaggcttt tggtgaccgc atccgagggc ggctggagga
960

agtgggcaac caggcccgtg accgcctaga ggaggtgcgt gagcacatgg aggaggtgcg
1020

ctccaagatg gaggaacaga cccagcaaat acgcctgcag gcggagatct tccaggcccg
1080

cctcaagggc tggttcgagc caatagtgga agacatgcat cgccagtggg caaacctgat
1140

ggagaagata caggcctctg tggctaccaa ccccatcatc accccagtgg cccaggagaa
1200

tcaatgagta tccttctcct gtcctgcaac aacatccata tccagccagg tggccctgtc
1260

tcaagcacct ctctggccct ctggtggccc ttgcttaata aagattctcc gagcacattc
1320

tgagtctctg tgagtgattc caaaaaaaaa aaaaaaaa
1358

<210> 6

<211> 1358

<212> DNA

<213> Mus musculus

<400> 6

tttttttttt tttttttgga atcactcaca gagactcaga atgtgctcgg agaatcttta
60

ttaagcaagg gccaccagag ggccagagag gtgcttgaga cagggccacc tggctggata
120

tggatgttgt tgcaggacag gagaaggata ctcattgatt ctcctgggcc actggggtga
180

tgatggggtt ggtagccaca gaggcctgta tcttctccat caggtttgcc cactggcgat
240

gcatgtcttc cactattggc tcgaaccagc ccttgaggcg ggcctggaag atctccgcct
300

gcaggcgtat ttgctgggtc tgttcctcca tcttggagcg cacctcctcc atgtgctcac
360

gcacctcctc taggcggtca cgggcctggt tgcccacttc ctccagccgc cctcggatgc
420

ggtcaccaaa agcctgggcg cgatcgcgca gaggctgggc ggccccagcg cctaggttgg
480

cagtgcgctg gcgaccttgc tccaccagag gccccaggcg ctcacggatg gcactcacac
540

cgcgctcggc gccctcgcgt gcccctgcct tgtacacagc taggcgcttc tgcagatcct
600

cggcatcccg catcaagcgc ttgcgcatct tgcgcaggtg tgtggagagc cgcgcccgta
660

tctcctctgt gctctggccc agcatggtgt gcacctcgtt gcggtactgc ccgagtcggt
720

tgcgtagatc ctccatgtcg gctccgagtc gggcctgtgc cgcctgcacc tctttgccca
780

gcctggcccg tgtctcctcc gccactggac ccagctgttc ctccagctcc tttttgtaag
840

cctttacttc cgtcatagtg tcctccatca gtgccgtcag ttcttgtgtg acttgggagc
900

tctgcagctc ttcctggacc tggtcagaca gcgtctgcac ccagcgcagg taatcccaga
960

agcggttcag ggcctgctcc cagggttggt tgctttgcca ctcgagctga tctgtcacct
1020

ccggctctcc ctcggctagg catcctgtca gcaatgtgac caacagcacg gcccacagag
1080

ccttcatctt cgcaattgtg attggccagt ctccccttgc cgagttcgct atctcggcac
1140

cccggggtgg atccgctgcc aaaaattcca gctccctctc cagctccttc cgaaacaagt
1200

ccttagcctc cagggtctga gcaggggatc ggatcccaga ccggtccaat tataggactc
1260

cccctgtccc gccccctcct cagggctagg gcgggctgtg ccagccccct gtcacgaggc
1320

gggttgttct ctcccccttc acagcagggc agaggaaa
1358

<210> 7

<211> 1179

<212> DNA

<213> Macaca mulatta

<400> 7

atgagctcag gggcctctag aaagtgtagc tgggacctcg ggaagccctg gcctccagac
60

tggccaatca caggcaggaa gatgaaggtt ctgtgggctg cgttgctggt cacattcctg
120

gcaggatgcc aggccaaggt ggagcaaccg gtggagccag agacggaacc cgagcttcgc
180

cagcaggctg aggggcagag cggccagccc tgggagctgg cactgggtcg cttttgggat
240

tacctgcgct gggtgcagac actgtctgag caggtgcagg aggagctgct cagcccccag
300

gtcacccagg aactgacgac gctgatggat gagaccatga aggagttgaa ggcctacaaa
360

tcggaactgg aggaacagct gagcccggtg gcggaggaga cgcgggcacg gctgtccaag
420

gagctacagg cggcgcaggc ccggctgggt gccgacatgg aggacgtgcg cagccgcctg
480

gtgcagtacc gcagcgaggt gcaggccatg ctgggccaga gtaccgagga gctgcgggcg
540

cgcctcgcct cccacctgcg caagctgcgc aagcggctcc tccgcgatgc tgatgacctg
600

cagaagcgcc tggcagtgta tcaggccggg gcccgcgagg gcgccgagcg cggggtcagc
660

gccatccgcg agcgcctggg acccctggtg gagcagggcc gcgtgcgggc cgccactgtg
720

ggctccctgg ccagccagcc gcttcaggag cgggcccagg ccttgggtga gcggcttcgc
780

gcacggatgg aggagatggg cagccggacc cgcgaccgcc tggacgaggt gaaggagcag
840

gtggcggagg tgcgcgccaa gctggaggaa caggcccagc agataagcct gcaggccgag
900

gccttccagg cccgcctcaa gagctggttc gagcccctgg tggaagatat gcagcgccag
960

tgggctgggc tggtggagaa ggtgcaggct gccgtgggcg ccagcaccgc ccctgtgccc
1020

agcgacaatc actgaacgcc caggcctaca gccatgcgac ccgactccac cccatgcctc
1080

ctctctccgc tcagcctgca gcgggagacc ctgtccccac cccagccgtc ctccaggggt
1140

gggccctagt ttaataaaga ttcgccaagt ttcaccgca
1179

<210> 8

<211> 1179

<212> DNA

<213> Macaca mulatta

<400> 8

tgcggtgaaa cttggcgaat ctttattaaa ctagggccca cccctggagg acggctgggg
60

tggggacagg gtctcccgct gcaggctgag cggagagagg aggcatgggg tggagtcggg
120

tcgcatggct gtaggcctgg gcgttcagtg attgtcgctg ggcacagggg cggtgctggc
180

gcccacggca gcctgcacct tctccaccag cccagcccac tggcgctgca tatcttccac
240

caggggctcg aaccagctct tgaggcgggc ctggaaggcc tcggcctgca ggcttatctg
300

ctgggcctgt tcctccagct tggcgcgcac ctccgccacc tgctccttca cctcgtccag
360

gcggtcgcgg gtccggctgc ccatctcctc catccgtgcg cgaagccgct cacccaaggc
420

ctgggcccgc tcctgaagcg gctggctggc cagggagccc acagtggcgg cccgcacgcg
480

gccctgctcc accaggggtc ccaggcgctc gcggatggcg ctgaccccgc gctcggcgcc
540

ctcgcgggcc ccggcctgat acactgccag gcgcttctgc aggtcatcag catcgcggag
600

gagccgcttg cgcagcttgc gcaggtggga ggcgaggcgc gcccgcagct cctcggtact
660

ctggcccagc atggcctgca cctcgctgcg gtactgcacc aggcggctgc gcacgtcctc
720

catgtcggca cccagccggg cctgcgccgc ctgtagctcc ttggacagcc gtgcccgcgt
780

ctcctccgcc accgggctca gctgttcctc cagttccgat ttgtaggcct tcaactcctt
840

catggtctca tccatcagcg tcgtcagttc ctgggtgacc tgggggctga gcagctcctc
900

ctgcacctgc tcagacagtg tctgcaccca gcgcaggtaa tcccaaaagc gacccagtgc
960

cagctcccag ggctggccgc tctgcccctc agcctgctgg cgaagctcgg gttccgtctc
1020

tggctccacc ggttgctcca ccttggcctg gcatcctgcc aggaatgtga ccagcaacgc
1080

agcccacaga accttcatct tcctgcctgt gattggccag tctggaggcc agggcttccc
1140

gaggtcccag ctacactttc tagaggcccc tgagctcat
1179

<210> 9

<211> 1179

<212> DNA

<213> Macaca fascicularis

<400> 9

atgagctcag gcgcctctag aaagtgtagc tgggacctcg ggaagccctg gcctccagac
60

tggccaatca caggcaggaa gatgaaggtt ctgtgggctg cgttgctggt cacattcctg
120

gcaggatgcc aggccaaggt ggagcaaccg gtggagccag agacggaacc cgagcttcgc
180

cagcaggctg aggggcagag cggccagccc tgggagctgg cactgggtcg cttttgggat
240

tacctgcgct gggtgcagac actgtctgag caggtgcagg aggagctgct cagcccccag
300

gtcacccagg aactgacgac gctgatggat gagaccatga aggagttgaa ggcctacaaa
360

tcggaactgg aggaacagct gagcccggtg gcggaggaga cgcgggcacg gctgtccaag
420

gagctgcagg cggcgcaggc ccggctgggt gccgacatgg aggacgtgcg cagccgcctg
480

gtgcagtacc gcagcgaggt gcaggccatg ctgggccaga gtaccgagga gctgcgggcg
540

cgcctcgcct cccacctgcg caagctgcgc aagcggctcc tccgcgatgc tgatgacctg
600

cagaagcgcc tggcagtgta tcaggccggg gcccgcgagg gcgccgagcg cggggtcagc
660

gccatccgcg agcgcctggg acccctggtg gagcagggcc gcgtgcgggc cgccactgtg
720

ggctccctgg ccagccagcc gcttcaggag cgggcccagg ccttgggtga gcggcttcgc
780

gcacggatgg aggagatggg cagccggacc cgcgaccgcc tggacgaggt gaaggagcag
840

gtggcggagg tgcgcgccaa gctggaggaa caggcccagc agataagcct gcaggccgag
900

gccttccagg cccgcctcaa gagctggttc gagcccctcg tggaagatat gcagcgccag
960

tgggctgggc tggtggagaa ggtgcaggct gccgtgggcg ccagcaccgc ccctgtgccc
1020

agcgacaatc actgaacgcc caggcctaca gccatgcgac ccgactccac cccatgcctc
1080

ctctctccgc tcagcctgca gcgggagacc ctgtccccgc cccagccgtc ctccaggggt
1140

gggccctagt ttaataaaga ttcgccaagt ttcaccgca
1179

<210> 10

<211> 1179

<212> DNA

<213> Macaca fascicularis

<400> 10

tgcggtgaaa cttggcgaat ctttattaaa ctagggccca cccctggagg acggctgggg
60

cggggacagg gtctcccgct gcaggctgag cggagagagg aggcatgggg tggagtcggg
120

tcgcatggct gtaggcctgg gcgttcagtg attgtcgctg ggcacagggg cggtgctggc
180

gcccacggca gcctgcacct tctccaccag cccagcccac tggcgctgca tatcttccac
240

gaggggctcg aaccagctct tgaggcgggc ctggaaggcc tcggcctgca ggcttatctg
300

ctgggcctgt tcctccagct tggcgcgcac ctccgccacc tgctccttca cctcgtccag
360

gcggtcgcgg gtccggctgc ccatctcctc catccgtgcg cgaagccgct cacccaaggc
420

ctgggcccgc tcctgaagcg gctggctggc cagggagccc acagtggcgg cccgcacgcg
480

gccctgctcc accaggggtc ccaggcgctc gcggatggcg ctgaccccgc gctcggcgcc
540

ctcgcgggcc ccggcctgat acactgccag gcgcttctgc aggtcatcag catcgcggag
600

gagccgcttg cgcagcttgc gcaggtggga ggcgaggcgc gcccgcagct cctcggtact
660

ctggcccagc atggcctgca cctcgctgcg gtactgcacc aggcggctgc gcacgtcctc
720

catgtcggca cccagccggg cctgcgccgc ctgcagctcc ttggacagcc gtgcccgcgt
780

ctcctccgcc accgggctca gctgttcctc cagttccgat ttgtaggcct tcaactcctt
840

catggtctca tccatcagcg tcgtcagttc ctgggtgacc tgggggctga gcagctcctc
900

ctgcacctgc tcagacagtg tctgcaccca gcgcaggtaa tcccaaaagc gacccagtgc
960

cagctcccag ggctggccgc tctgcccctc agcctgctgg cgaagctcgg gttccgtctc
1020

tggctccacc ggttgctcca ccttggcctg gcatcctgcc aggaatgtga ccagcaacgc
1080

agcccacaga accttcatct tcctgcctgt gattggccag tctggaggcc agggcttccc
1140

gaggtcccag ctacactttc tagaggcgcc tgagctcat
1179

	Number	Date	Country
Parent	PCT/US2021/029081	Apr 2021	US
Child	17974596		US

APOLIPOPROTEIN E (APOE) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF

Information

Publication Number

Date Filed

Date Published

Inventors

Original Assignees

CPC

International Classifications

Abstract

Description

Claims

RELATED APPLICATIONS

Provisional Applications (1)

Continuations (1)